Bioceres Crop Solutions (BIOX) POS AM 25 Oct 19 Prospectus update (post-effective amendment) Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Jun. 30, 2019
Document and Entity Information [Abstract]
Document Type	POS AM
Entity Registrant Name	Bioceres Crop Solutions Corp.
Entity Central Index Key	0001769484
Amendment Flag	false
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	true
Entity Ex Transition Period	false

CONSOLIDATED STATEMENTS OF FINA

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
CURRENT ASSETS
Cash and cash equivalents	$ 3,450,873	$ 2,215,103	$ 1,679,478
Other financial assets	4,683,508	4,550,847	4,264,792
Trade receivables	59,236,377	52,888,427	41,675,918
Other receivables	1,981,829	4,240,205	7,108,219
Income and minimum presumed income taxes recoverable	1,263,795	2,082,269	1,701,382
Inventories	27,592,582	19,366,001	31,338,034
Total current assets	98,208,964	85,342,852	87,767,823
NON-CURRENT ASSETS
Other financial assets	376,413	243,358	766,999
Other receivables	1,560,310	4,979,507	2,183,244
Income and minimum presumed income taxes recoverable	1,184	126,653	315,565
Deferred tax assets	3,743,709	5,601,821	3,372,101
Investments in joint ventures and associates	25,321,028	19,072,055	32,108,229
Property, plant and equipment	43,834,548	40,177,146	46,218,875
Intangible assets	39,616,426	26,657,345	42,058,891
Goodwill	29,804,715	14,438,027	25,079,324
Total non-current assets	144,258,333	111,295,912	152,103,228
Total assets	242,467,297	196,638,764	239,871,051
CURRENT LIABILITIES
Trade and other payables	40,578,494	27,708,830	22,794,716
Borrowings	66,477,209	65,308,928	34,037,971
Employee benefits and social security	5,357,218	4,411,713	5,047,045
Deferred revenue and advances from customers	1,074,463	1,007,301	1,197,080
Income and minimum presumed income taxes payable	142,028	2,569	29,788
Government grants	2,110	17,695	60,829
Financed payment - Acquisition of business	2,826,611	20,223,590	6,219,980
Total current liabilities	116,458,133	118,680,626	69,387,409
NON-CURRENT LIABILITIES
Trade and other payables	452,654
Borrowings	37,079,521	25,708,205	40,952,164
Government grants	8,098	15,532	57,716
Due to joint ventures and associates	1,970,903	2,012,298	1,527,286
Deferred tax liabilities	21,101,871	13,591,942	25,611,927
Provisions	439,740	845,486	1,415,290
Financed payment - Acquisition of business		2,651,019	21,180,193
Warrants	2,861,511
Puttable instruments			2,500,000
Total non-current liabilities	63,914,298	44,824,482	93,244,576
Total liabilities	180,372,431	163,505,108	162,631,985
EQUITY
Equity attributable to owners of the parent	47,301,863	13,713,484	35,841,621
Non-controlling interests	14,793,003	19,420,172	41,397,445
Total equity	62,094,866	33,133,656	77,239,066
Total equity and liabilities	$ 242,467,297	$ 196,638,764	$ 239,871,051

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)		6 Months Ended	12 Months Ended
		Jun. 30, 2017	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2016
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
Revenue		$ 46,853,369	$ 160,308,979	$ 133,491,118	$ 41,027,474
Government grants		31,941	16,372	51,586	141,775
Initial recognition and changes in the fair value of biological assets			279,945
Cost of sales		(29,613,158)	(86,964,881)	(77,094,551)	(30,598,956)
Research and development expenses		(1,990,268)	(3,689,391)	(3,950,100)	(853,854)
Selling, general and administrative expenses		(15,689,598)	(39,243,800)	(35,263,688)	(8,827,121)
Share of profit or loss of joint ventures and associates		(649,075)	1,012,486	(2,136,801)	(707,042)
Other income or expenses, net		54,252	365,900	613,389	24,765
Operating profit/(loss)		(1,002,537)	32,085,610	15,710,953	207,041
Finance results		(10,193,263)	(41,458,217)	(40,950,716)	(8,249,577)
Loss before income tax		(11,195,800)	(9,372,607)	(25,239,763)	(8,042,536)
Income tax (expense) benefit		2,817,251	(6,986,284)	10,928,517	1,860,647
Loss for the year		(8,378,549)	(16,358,891)	(14,311,246)	(6,181,889)
Profit (loss) for the year attributable to:
Equity holders of the parent		(5,908,927)	(18,369,045)	(11,039,533)	(5,865,870)
Non-controlling interests		(2,469,622)	2,010,154	(3,271,713)	(316,019)
Loss for the year		$ (8,378,549)	$ (16,358,891)	$ (14,311,246)	$ (6,181,889)
LOSS PER SHARE
Basic and diluted loss attributable to ordinary equity holders of the parent (per share)	[1]	$ (0.21)	$ (0.60)	$ (0.39)	$ (0.21)
Weighted average number of shares
Basic	[1]	28,098,117	30,478,390	28,098,117	28,098,117
Loss for the year		$ (8,378,549)	$ (16,358,891)	$ (14,311,246)	$ (6,181,889)
Other comprehensive income (loss)		(2,714,241)	3,904,365	(31,833,554)	(4,579,700)
Items that may be subsequently reclassified to profit and loss		(4,747,113)	5,251,488	(43,710,972)	(4,579,700)
Exchange differences on translation of foreign operations from joint ventures		(1,498,641)	11,337	(13,865,192)	(277,603)
Exchange differences on translation of foreign operations		(3,248,472)	5,240,151	(29,845,780)	(4,302,097)
Items that will not be subsequently reclassified to loss and profit		2,032,872	(1,347,123)	11,877,418
Revaluation of property, plant and equipment, net of tax, of JV and associates (*)	[2]	189,025	94,009	1,679,818
Revaluation of property, plant and equipment, net of tax	[3]	1,843,847	(1,441,132)	8,381,618
Tax rate change over revaluation of property, plant and equipment				1,815,982
Total comprehensive loss		(11,092,790)	(12,454,526)	(46,144,800)	(10,761,589)
Total comprehensive income / (loss) attributable to:
Equity holders of the parent		(8,069,589)	(14,333,037)	(33,927,072)	(9,083,688)
Non-controlling interests		(3,023,201)	1,878,511	(12,217,728)	(1,677,901)
Total comprehensive loss		$ (11,092,790)	$ (12,454,526)	$ (46,144,800)	$ (10,761,589)
[1]	For the years ended June 30, 2019, and 2018, the six-month transition period ended June 30, 2017 and the year ended Decemeber 31, 2016 diluted EPS was the same as basic EPS as the effect of potential ordinary shares would be antidilutive.
[2]	The tax effect of the revalution of property, plant and equipment of JV and associates was $31,336, $559,939, $66,158 and nil for the years ended June 30, 2019 and 2018, the six-month transition period ended June 30,2017 and the year ended December 31, 2016 respectively.
[3]	The tax effect of the revalution of property, plant and equipment was ($480,378), $4,513,179, $1,008,381 and nil for the years ended June 30, 2019 and 2018, the six-month transition period ended June 30,2017 and the year ended December 31, 2016 respectively.

CONSOLIDATED STATEMENTS OF CO_2

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2016
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
Income tax relating to changes in revaluation surplus included in other comprehensive income for Joint Venture and Associates	$ 66,158	$ 31,336	$ 559,939	$ 0
Income tax relating to changes in revaluation surplus included in other comprehensive income	$ 1,008,381	$ (480,378)	$ 4,513,179	$ 0

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY	Equity / (deficit) attributable to owners of the parentUSD ($)	Issued capitalUSD ($)	Share premiumUSD ($)	Stock optionsUSD ($)	Retained deficitUSD ($)	Foreign currency translation reserveUSD ($)	Revaluation of PP&E and effect of tax rate changeUSD ($)	Non-controlling InterestsUSD ($)	USD ($)
Beginning balance at Dec. 31, 2015	$ 1,097,282	$ 2,810	$ 4,426,440	$ 3,285	$ (3,335,253)				$ 1,097,282
Parent company investment	50,470,291		50,470,291						50,470,291
Non-controlling investment								$ 6,481,930	6,481,930
Non-controlling interest in business combination								36,339,002	36,339,002
Stock options	43,827			43,827					43,827
Profit (loss) of the year	(5,865,870)				(5,865,870)			(316,019)	(6,181,889)
Other comprehensive income or loss	(3,217,818)					$ (3,217,818)		(1,361,882)	(4,579,700)
Ending balance at Dec. 31, 2016	42,527,712	2,810	54,896,731	47,112	(9,201,123)	(3,217,818)		41,143,031	83,670,743
Parent company investment	1,357,788		1,357,788						1,357,788
Sale of preferred stocks to non-controlling interest								3,277,615	3,277,615
Stock options	25,710			25,710					25,710
Profit (loss) of the year	(5,908,927)				(5,908,927)			(2,469,622)	(8,378,549)
Other comprehensive income or loss	(2,160,662)					(3,380,262)	$ 1,219,600	(553,579)	(2,714,241)
Ending balance at Jun. 30, 2017	35,841,621	2,810	56,254,519	72,822	(15,110,050)	(6,598,080)	1,219,600	41,397,445	77,239,066
Parent company investment	2,009,385		2,009,385						2,009,385
Purchase of preferred stocks to non-controlling interest	9,759,545		9,759,545					(9,759,545)
Stock options	30,005			30,005					30,005
Profit (loss) of the year	(11,039,533)				(11,039,533)			(3,271,713)	(14,311,246)
Other comprehensive income or loss	(22,887,539)					(30,013,990)	7,126,451	(8,946,015)	(31,833,554)
Ending balance at Jun. 30, 2018	13,713,484	$ 2,810	68,023,449	102,827	(26,149,583)	(36,612,070)	8,346,051	19,420,172	33,133,656
Parent company investment	(14,558,347)		$ (14,558,347)						(14,558,347)
Adjustment of opening balance for the application of IAS 29	19,560,024				22,546,341		(2,986,317)	7,797,295	27,357,319
Reverse Stock Options	$ (102,827)			$ (102,827)					$ (102,827)
Reverse recapitalization	21,906,182	329	21,905,853						21,906,182
Private warrants	$ (3,432,723)		$ (3,432,723)						$ (3,432,723)
Shares issued - Rizobacter call option	21,440,126	$ 474	21,439,652					(14,302,975)	7,137,151
Contribution Semya	3,108,981		3,108,981						3,108,981
Profit (loss) of the year	(18,369,045)				(18,369,045)			2,010,154	(16,358,891)
Other comprehensive income or loss	4,036,008					5,132,487	(1,096,479)	(131,643)	3,904,365
Ending balance at Jun. 30, 2019	$ 47,301,863	$ 3,613	$ 96,486,865		$ (21,972,287)	$ (31,479,583)	$ 4,263,255	$ 14,793,003	$ 62,094,866

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2016
OPERATING ACTIVITIES
Loss for the year	$ (8,378,549)	$ (16,358,891)	$ (14,311,246)	$ (6,181,889)
Adjustments to reconcile loss to net cash flows
Income tax	(2,817,251)	6,986,284	(10,928,517)	(1,860,647)
Finance results	10,193,263	41,458,217	40,950,716	8,249,577
Depreciation of property, plant and equipment	1,254,657	2,450,256	2,230,881	584,293
Amortization of intangible assets	1,418,529	2,376,919	2,141,476	424,179
Inventory purchase price allocation charge	2,436,949		2,257,378	7,516,071
Transaction expenses		4,535,247
Stock options	25,710	(102,827)	30,005	43,827
Share of profit or loss of joint ventures and associates	649,075	(1,012,486)	2,136,801	707,042
Loss of control of subsidiaries		(10,591)
Provisions for contingencies	(248,727)	(246,832)	46,103	293,009
Allowance for impairment of trade debtors	333,490	686,985	1,259,127	125,764
Allowance for obsolescence	148,840	564,873	661,804	982,351
Gain or loss on sale of equipment and intangible assets	155,294	91,762	4,834	(13,760)
Working capital adjustments
Trade receivables	16,744,754	41,488,831	17,316,880	(11,347,636)
Other receivables	3,552,607	5,770,280	513,162	(3,450,565)
Income and minimum presumed income taxes	(2,476,482)	2,778,289	(126,806)	3,582,581
Inventories	(1,123,249)	(8,920,222)	10,355,422	2,977,418
Trade and other payables	(12,932,716)	(33,699,077)	(35,288,368)	(3,170,910)
Employee benefits and social security	1,578,691	931,656	(543,917)	3,757,935
Deferred revenue and advances from customers	351,154	66,178	(162,473)	634,392
Income and minimum presumed income taxes payable	(1,278,038)	(1,705,481)	(71,076)	(5,079,759)
Government grants	(37,374)	(23,019)	(85,318)	3,126
Inflation effects on working capital adjustments		(18,411,538)
Net cash flows generated by (using in) operating activities	9,550,627	29,694,813	18,386,868	(1,223,601)
INVESTMENT ACTIVITIES
Proceeds from sale of property, plant and equipment	130,011	317,953	109,711	13,760
Investment in joint ventures and associates and associates		(129,340)
Purchases of property, plant and equipment	(695,667)	(2,044,102)	(2,791,794)	(608,061)
Net loans granted to shareholders and other related parties	(2,428,076)		(2,621,647)
Capitalized development expenditures	(1,884,289)	(682,530)	(2,301,425)	(175,527)
Purchases of intangible assets	(979,728)	(722,833)	(614,529)	(420,254)
Restricted short-term deposit	(4,222,130)
Acquisition of business				(40,678,146)
Net cash flows used in investing activities	(10,079,879)	(3,260,852)	(8,219,684)	(41,868,228)
FINANCING ACTIVITIES
Proceeds from borrowings	60,338,582	88,693,632	27,745,013	10,548,234
Repayment of borrowings and interest payments	(56,549,534)	(111,084,915)	(37,624,531)	(6,351,924)
(Decrease)/Increase bank overdraft and other short-term borrowings	(1,556,527)	(4,968,813)	1,208,830	(1,332,036)
Other financial proceeds or payments, net	(1,066,102)	(854,731)	(1,787,117)	(883,069)
Reverse Recapitalization		1,268,633
Proceeds from the issuance of preferred shares				42,000,001
Cash dividend distributed by subsidiary				(13,790)
Net cash flows (used in) provided by financing activities	1,166,419	(26,946,194)	(10,457,805)	43,967,416
Net (decrease) increase in cash and cash equivalents	637,167	(512,233)	(290,621)	875,587
Inflation effects on cash and cash equivalents		1,681,113
Cash and cash equivalents as of beginning of the year	982,897	2,215,103	1,679,478	20,524
Effect of exchange rate changes on cash and equivalents	59,414	66,890	826,246	86,786
Cash and cash equivalents as of the end of the year	$ 1,679,478	$ 3,450,873	$ 2,215,103	$ 982,897

GENERAL INFORMATION

GENERAL INFORMATION	12 Months Ended
	Jun. 30, 2019
GENERAL INFORMATION
GENERAL INFORMATION	1. GENERAL INFORMATION On March 14, 2019, Union Acquisition Corp. (“Union” or “UAC”), whose name changed to Bioceres Crop Solutions Corp. (“Bioceres”), consummated the previously announced merger pursuant to a share exchange agreement, dated as of November 8, 2018 (as amended, the “Exchange Agreement”), by and among Union and Bioceres, Inc., a company incorporated under the laws of Delaware, which converted into Bioceres LLC pursuant to the Reorganization (as defined below) on February 28, 2019. This reorganization did not affect the common control structure of the entities forming the Group. The Group is a fully integrated provider of crop productivity solutions, which has developed a multi-discipline and multi-product platform capable of providing solutions throughout the entire crop cycle, from pre-planting to transportation and storage. Description of the merger and reorganization The merger was reflected as a reverse recapitalization (capital transaction) equivalent to the issuance of shares by the private company (Bioceres) for the net monetary assets of the public shell company (Union). Prior to the consummation of the merger on March 14, 2019, the following steps took place among Bioceres, Inc. and certain of its affiliates (collectively the “Reorganization”):  On October 22, 2018, Parent (as defined below), RASA Holding LLC, a Delaware limited liability company and a wholly owned subsidiary of Bioceres, Inc., now a wholly-owned subsidiary of BCS Holding (“RASA Holding”), and Pedro Enrique Mac Mullen, María Marta Mac Mullen and International Property Services Corp., as sellers (collectively, the “Grantors”) entered into an amended and restated option agreement (as may be amended from time to time, the “Rizobacter Call Option Agreement”), pursuant to which the Parent, RASA Holding or any of their nominated affiliates would have the option (the “Rizobacter Call Option”) to purchase from the Grantors all of their 11,916,000 shares of common stock of Rizobacter Argentina S.A., an Argentine corporation and a subsidiary of RASA Holding (“Rizobacter”), representing 29.99% of all outstanding common stock of Rizobacter.  On February 13, 2019, Bioceres, Inc. formed a new subsidiary, BCS Holding Inc. (“BCS Holding”), and contributed its crop business net assets (consisting of certain assets and liabilities, the “Bioceres Inc Crop Business”) to BCS Holding in exchange for 100% equity interest in BCS Holding.  On February 28, 2019, Bioceres, Inc. converted into Bioceres LLC; and  On March 1, 2019, Bioceres S.A., a company organized under the laws of Argentina and our ultimate parent company (“Parent", and jointly with Bioceres LLC, "Parents”), contributed all its equity interest in Bioceres Semillas S.A. to Bioceres LLC in exchange for additional equity interests in Bioceres LLC. Immediately following the consummation of the merger on March 14, 2019, the Rizobacter Call Option (as defined above) was exercised, pursuant to which the total indirect ownership of BCS Holding in Rizobacter increased to 80.00% of all outstanding shares of Rizobacter. Consideration for the Rizobacter Call Option (net of prepayments) was in the form of Union shares. Union shares constituting the in-kind consideration were issued in reliance on an applicable exemption from the registration requirements of the Securities Act of of 1933, as amended (the "Securities Act"). As additional consideration payable to Bioceres LLC in the merger, the original founders of Union have agreed to transfer to Bioceres LLC in the aggregate 862,500 unregistered ordinary shares. As a result of the merger and the other transactions contemplated by the Exchange Agreement, as well as the Reorganization and exercise of the Rizobacter Call Option, Union became the holding company of BCS Holding, its subsidiaries and Bioceres Semillas. Upon the consummation of the merger, Union changed its name to Bioceres Crop Solutions Corp and its fiscal year to June 30. Financial and economic situation The Group has been improving its financial position year over year and has generated positive operating cash flows in the last years. The Group expects to continue generating cash for subsequent years given the Group's plans and projections. This positive operating cash flow allowed the Group to considerably decrease its ratio of operating result over debt during the year ended June 30, 2019 and to decrease the current liabilities over current assets from 1.39x as of June 30, 2018 to 1.16x as of June 30, 2019. Subsequent to June 30, 2019, the Group renewed all its revolving credit facilities that had been expired at the time of issuance of these financial statements for a total capital amount of $17.2 million and paid all the instalments due in a timely manner with resources generated from the business operations or new borrowings. Approximately $33.6 million of the total current borrowings as of June 30, 2019 have this revolving condition. The Group expects to continue renewing the futures installments in similar conditions while working on long-term facilities that allows it to refinance the current debt permanently. In addition, to meet short-term debts, the Group could, if necessary, issue new corporate bonds up to $40 million. This program is already authorized by the regulatory authorities of Argentina and could be allocated to the Group’s needs.

ACCOUNTING STANDARDS AND BASIS

ACCOUNTING STANDARDS AND BASIS OF PREPARATION	12 Months Ended
	Jun. 30, 2019
ACCOUNTING STANDARDS AND BASIS OF PREPARATION
ACCOUNTING STANDARDS AND BASIS OF PREPARATION	2. ACCOUNTING STANDARDS AND BASIS OF PREPARATION 2.1. Statement of compliance with IFRS as issued by IASB The Consolidated financial statements of the Group have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by International Accounting Standard Board (“IASB”) following the accounting policies as set forth and summarized in Note 4. All IFRS issued by the IASB, effective at the time of preparing these Consolidated financial statements have been applied. 2.2. Authorization for the issue of the Consolidated financial statements These Consolidated financial statements of the Group as of June 30, 2019, 2018 and 2017, for the years ended June 30, 2019 and 2018, the six-month transition period ended June 30, 2017 and the year ended December 31, 2016 have been authorized by the Board of Directors of Bioceres Crop Solutions at their meetings held on October 3, 2019. 2.3. Comparative figures In December 2016, Bioceres S.A. and its subsidiaries approved the amendment of its bylaws, thereby changing the fiscal year-end date from December 31 to June 30 of each year. As a result of the change in the fiscal year end, figures presented for the Group in these financial statements in connection with years ended June 30, 2019 and 2018, are not entirely comparable to the six-month transition period ended June 30, 2017. Also, on October 19, 2016, RASA Holding acquired a controlling equity interest in Rizobacter. Therefore, figures presented for the Group in these Combined financial statements in connection with year ended December 31, 2016 are not entirely comparable with the following years presented given the significance of Rizobacter within the Group. 2.4. Retrospectively considerations As the merger took place on March 14, 2019, the 27,116,174 shares issued to Bioceres LLC in exchange of its Bioceres Inc Crop Business and its equity interest in Bioceres Semillas S.A., together with the 119,443 shares issued to exercise the Bioceres Semillas’ tag-along and the 862,500 shares received by Bioceres LLC from the original founders of Union, were considered to have been retrospectively issued and counted in issued capital, and in EPS calculation based on the assumption of those events occurred at the beginning of the earliest period presented. See Note 9. 2.5. Basis of measurement The consolidated financial statements of the Group have been prepared using:  Going concern basis of accounting, considering the conclusion of the assessment made by the Group ’ s Management about the ability of the Group and its subsidiaries to continue as a going concern, in accordance with the requirements of paragraph 25 of IAS 1, “Presentation of Financial Statements”.  Accrual basis of accounting (except for cash flows information). Under this basis of accounting, the effects of transactions and other events are recognized as they occur, even when there are no cash flows. 2.6. Functional currency and presentation currency a) Items included in the financial statements of each of the Group’s entities are measured using the currency of the primary economic market in which the entity operates (i.e., “the functional currency”). IAS 29 “Financial reporting in hyperinflationary economies” requires that the financial statements of an entity whose functional currency is the currency of a hyperinflationary economy with high inflation, whether they are based on the historical cost method or the current cost method, be stated in terms of the measuring unit current at the closing date of the reporting period. For such purpose, the inflation produced from the acquisition date or the revaluation date, as applicable, must be computed in non-monetary items. The standard details a series of factors to be considered for concluding whether an economy is a hyperinflationary economy, including, but not limited to, a cumulative inflation rate over a three-year period that approaches or exceeds 100%. Inflation accumulated in three years, as of June 30, 2018, is over 100%. It is for this reason that, in accordance with IAS 29, the Argentine economy should be considered as high inflation since July 1, 2018. Consequently, the Group should restate its next financial statements to be presented after that date. In an inflationary period, any entity that maintains an excess of monetary assets over monetary liabilities, will lose purchasing power, and any entity that maintains an excess of monetary liabilities on monetary assets, will gain purchasing power, provided that such items are not subject to an adjustment mechanism. The inflation adjustment on the initial balances was calculated by means of conversion factor derived from the Argentine price indexes published by the National Institute of Statistics and the year-over-year change in the index was 1.558. The main procedures for the above-mentioned adjustment are as follows:  Monetary assets and liabilities which are carried at amounts current at the balance sheet date are not restated because they are already expressed in terms of the monetary unit current at the balance sheet date.  Non-monetary assets and liabilities which are not carried at amounts current at the balance sheet date, and components of shareholders' equity are adjusted by applying the relevant conversion factors. (on a monthly basis).  All items in the income statement are restated by applying the relevant conversion factors (on a monthly basis). The company has elected not to segregate the impact of inflation over financial results.  The effect of inflation on the Company’s net monetary position is included in the income statement, in "Other financial results".  The ongoing application of the re-translation of comparative amounts to closing exchanges rates under IAS 21 and the hyperinflation adjustments required by IAS 29 will lead to a difference in addition to the difference arising on the adoption of hyperinflation accounting. The comparative figures in these consolidated financial statements presented in a stable currency are not adjusted for subsequent changes in the price level or exchange rates. This resulted in an initial difference, arising on the adoption of hyperinflation accounting, between the closing equity of the previous year and the opening equity of the current year. The Company recognized this initial difference directly in equity. Presentation currency The consolidated financial statements of the Group are presented in USD, which is the presentation currency. b) Transactions entered into by Group entities in a currency other than their functional currency are recorded at the relevant exchange rates as of the date upon which such transactions occur. Foreign currency monetary assets and liabilities are translated at the prevailing exchanges rates as of the final day of each reporting period. Exchange differences arising on the retranslation of unsettled monetary assets and liabilities are recognized immediately in profit or loss, except for foreign currency borrowings qualifying as a hedge of a net investment in a foreign operation for which exchange differences are recognized in other comprehensive income and accumulated in the foreign exchange reserve along with the exchange differences arising on the retranslation of the foreign operation. Upon the disposal of a foreign operation, the cumulative exchange differences recognized in the foreign exchange reserve relating to such operation up to the date of disposal are transferred to the Consolidated statement of profit or loss and other comprehensive income as part of the profit or loss taking place upon such disposal. 2.7. Subsidiaries Where the Group holds a controlling interest in an entity, such entity is classified as a subsidiary. The Group exercises control over such an entity if all three of the following elements are present: (i) the Group has the power to direct or cause the direction of the management and policies of the entity; (ii) the Group is exposed to the variable returns of such entity; and (iii) the Group has power to affect the variabity of such returns. Control is reassessed whenever facts and circumstances indicate that there may be a change in any of these elements of control. De-facto control exists in situations where the Group has the practical ability to direct the relevant activities of an entity without holding the majority of the voting rights. In determining whether de facto control exists, the Group considers all relevant facts and circumstances, including:  The relative share of the Group’s voting rights with respect both the size and dispersion of other parties who hold voting rights;  Substantive potential voting rights held by the Group and by other parties;  Other contractual arrangements; and  Historic patterns in voting attendance. The subsidiaries of the Group, all of which have been included in the Consolidated financial statements of the Group, are as follows: Country of incorporation and principal place of % Equity interest Name Principal activities business Ref 06/30/2019 06/30/2018 RASA Holding, LLC Investment in subsidiaries United States a 100.00 % 100.00 % Rizobacter Argentina S.A. Microbiology Business Argentina b 80.00 % 60.00 % Rizobacter do Brasil Ltda. Selling of agricultural inputs Brazil c 79.99 % 59.99 % Rizobacter del Paraguay S.A. Selling of agricultural inputs Paraguay c 79.92 % 59.94 % Rizobacter Uruguay Selling of agricultural inputs Uruguay c 80.00 % 60.00 % Rizobacter South Africa Selling of agricultural inputs South Africa c 76.00 % 57.00 % Comer. Agrop. Rizobacter de Bolivia S.A. Selling of agricultural inputs Bolivia c 79.96 % 59.97 % Rizobacter USA, LLC Selling of agricultural inputs United States c 80.00 % 60.00 % Rizobacter India Private Ltd. Selling of agricultural inputs India c 80.00 % 59.99 % Rizobacter Colombia SAS Selling of agricultural inputs Colombia c 80.00 % 60.00 % Indrasa Biotecnología S.A. Research and development Argentina d 31.50 % 52.91 % Rizobacter France SAS Research and development France c 80.00 % 60.00 % Semya S.A. Research and development Argentina e 100.00 % 50.00 % BCS Holding LLC Investment in subsidiaries United States a 100.00 % — Bioceres Semillas Production and commercialization of seeds Argentina a 100.00 % % The Group holds a majority share of the voting rights in all of its subsidiaries. a) The percentage of the voting rights attributable to the Group is the same as the percentage of its equity interest as set forth in the table above. b) Immediately following the consummation of the merger on March 14, 2019, the Rizobacter Call Option was exercised, pursuant to which the total indirect ownership of BCS Holding in Rizobacter increased to 80.00% of all outstanding shares of Rizobacter. See Note 1. c) Indirect interests held through Rizobacter. The indirect equity interest participation included in this table was the 80% of the direct equity interest participation that Rizobacter owns in each entity. d) In September 2018, the participation of Rizobacter S.A. in Indrasa Biotecnología S.A. decreased from 52.50% to 35%, therefore the Group lost the control over this subsidiary. e) In June 2019, Bioceres Crop Solutions signed a share purchase agreement with Bioceres S.A. for the 50% of the ownership in Semya. See Note 4.5.

NEW STANDARDS, AMENDMENTS AND I

NEW STANDARDS, AMENDMENTS AND INTERPRETATIONS ISSUED BY THE IASB	12 Months Ended
	Jun. 30, 2019
NEW STANDARDS, AMENDMENTS AND INTERPRETATIONS ISSUED BY THE IASB
NEW STANDARDS, AMENDMENTS AND INTERPRETATIONS ISSUED BY THE IASB	3. NEW STANDARDS, AMENDMENTS AND INTERPRETATIONS ISSUED BY THE IASB 3.1. New standards and interpretations adopted by the Group The new standards and interpretations adopted by the Group are: IFRS 9 – Financial Instruments (version 2014). IFRS 15 – Revenue from Contracts with Customers. Amendments to IFRS 2 – Classification and measurement of share-based payment transactions. IFRIC 22 – Foreign currency transactions and advance consideration. Amendments to IAS 40 – Transfers of investment. These standards are effective for fiscal years beginning on January 1, 2018 and therefore their impact on the Bioceres Group ruled since the fiscal year started on July 1, 2018 The standards and interpretations issued, but not yet in force at the date of issuance of these Consolidated financial statements, which are or may be applicable to the Group, are: IFRS 16 – Leases. IFRIC 23‑ Uncertainty over Income Tax Treatments. Amendments to IFRS 8‑ Prepayment Features with Negative Compensation Amendments to IAS 28‑ Long-term Interest in Associates and Joint Ventures Annual Improvements to IFRS Standards 2015‑2017 Cycle Amendments to IAS 29‑Plan Amendment, Curtailent or Settlement Amendments to IAS 1 and IAS 8‑ Definition of Material Amendments to IFRS 3‑ Definition of Business Amendments to IFRS 10 and IAS 28 – Sale or Contribution of Assets between an Investor and its Associate or Joint Venture. The Group intends to adopt these standards and interpretations when they become effective, unless otherwise indicated. IFRS 9 – Financial Instruments (version 2014) In July 2014, the IASB issued the final version of “IFRS 9 Financial Instruments” which reflects all phases of the financial instruments project and replaces “IAS 39 Financial Instruments: Recognition and Measurement” and all previous versions of IFRS 9. The standard introduces new requirements for classification and measurement, impairment, and hedge accounting. IFRS 9 is effective for annual periods beginning on or after January 1, 2018, with early application permitted. Retrospective application is required, but comparative information is not compulsory. Early application of previous versions of IFRS 9 (2009, 2010 and 2013) is permitted if the date of initial application is before February 1, 2015. The Group previously elected to adopt IFRS 9 (version 2013) early. The new measurement and classification requirements in IFRS 9 (version 2014) are not applicable to the Group’s business model for managing its financial assets and that model is not expected to change in the foreseeable future. The Group does not use hedge accounting. Regarding the new impairment requirements in IFRS 9 (version 2014), the Group changed its impairment testing methodology for financial assets from an “incurred losses model” to the new “expected losses model.” For the determination of expected credit losses, in accordance with IFRS 9, the Group recognizes the lifetime losses of the instrument by applying an uncollectibility rate (based on historical uncollectibility adjusted by current and projected macroeconomic conditions) to the total amount of the Group’s trade accounts receivable. The analysis is performed by using a forecast matrix based on the age of the balances, including those that are not due at closing. These amendments didn't have a material impact on the Group. IFRS 15 – Revenue from contracts with costumers IFRS 15 was issued in May 2014 and establishes a new five-step model that will apply to revenue arising from contracts with customers. Under IFRS 15 revenue is recognized at an amount that reflects the consideration to which an entity expects to be entitled in exchange for transferring goods or services to a customer. The principles in IFRS 15 provide a more structured approach to measuring and recognizing revenue. The new revenue standard is applicable to all entities and will supersede all current revenue recognition requirements under IFRS. Either a full or modified retrospective application is required for annual periods beginning on or after January 1, 2018 with early adoption permitted. These amendments do not have a material impact on the Group. Amendments to IFRS 2 – Classification and measurement of share-based payment transactions The standard was amended in June 2016 to clarify the measurement basis for cash-settled share-based payments and the accounting for modifications that change an award from cash-settled to equity-settled. It also introduces an exception to IFRS 2 principles by requiring an award to be treated as if it was wholly equity-settled where an employer is obliged to withhold an amount in respect of the employee’s tax obligation associated with a share-based payment and to pay that amount to the relevant tax authority. It is effective for annual periods beginning on or after January 1, 2018. IFRIC 22 – Foreign currency transactions and advance consideration IFRIC 22 was issued in December 2016. The interpretation addresses how to determine the date of the transaction for the purpose of determining the exchange rate to use on initial recognition of the related asset, expense or income related to an entity that has received or paid advance consideration in a foreign currency. The date of the transaction is the date on which an entity initially recognizes the non-monetary asset or non-monetary liability arising from the payment or receipt of such advance consideration. The standard is effective for annual periods beginning on January 1, 2018. Amendments to IAS 40 – Transfers of investment These modifications clarify when an entity must transfer properties, including properties under construction or development, or outside investment property. The modifications establish that a change in use occurs when the property complies with or fails to meet the definition of investment property and there is evidence of change in use. A simple change in Management’s intentions about the use of the property does not provide evidence of change in use. The changes to the standard will become effective for annual periods beginning on January 1, 2018, with advance application permitted. The modifications are applied prospectively to changes in use occurring after the beginning of the annual period in which the modifications are applied for the first time. These amendments are not expected to have material impact on the Group. 3.2. New standards and interpretations not yet adopted by the Group IFRS 16 - Leases IFRS 16 was issued in January 2016. It will result in almost all leases being recognized on the balance sheet, as the distinction between operating and finance leases will be removed. Under the new standard, an asset (the right to use the leased item) and a financial liability to pay rentals are recognized. The only exceptions are short-term and low-value leases. The new standard will be effective for financial years commencing on or after January 1, 2019. At this stage, the Group does not intend to adopt the standard before its effective date. The application of IFRS 16 would imply recognizing assets and liabilities on operating leases of $0.4 million. IFRIC 23‑Uncertainty over Income Tax Treatments In October 2017, the IASB issued IFRC 23. When there is uncertainty about income tax treatments, this interpretation addresses: (i) whether uncertain tax treatments should be considered separately or not; (ii) the assumptions made about the analysis of tax treatments by the tax authorities (it should be considered whether the tax authority is likely to accept an uncertain tax treatment assuming that said tax authority will examine such uncertain tax treatment); (iii) how an entity determines fiscal gain (tax loss), tax bases, unused taxes, unused tax credits and tax rates (probability of occurrence analysis); and (iv) how changes in the relevant facts and circumstances are considered. The new standard is effective for years beginning on January 1, 2019 and early adoption is allowed. The Group does not foresee impacts due to the application of this modification in the statement of financial position, statement of income and statement of cash flow. Amendments to IFRS 9‑ Prepayment Features with Negative Compensation The narrow-scope amendments made to IFRS 9 Financial Instruments in October 2017 enable entities to measure certain prepayable financial assets with negative compensation at amortised cost. These assets which include some loan and debt securities, would otherwise have to be measured at fair value through profit or loss. To qualify for amortised cost measurement, the negative compensation must be “reasonable compensation for early termination of the contract” and the asset must be held within a “held to collect” business model. The new standard is effective for years beginning on January 1, 2019 and early adoption is allowed. The Group does not foresee impacts due to the application of this modification in the statement of financial position, statement of income and statement of cash flow. Amendments to IAS 28‑ Long-term Interests in Associates and Joint Ventures The amendments clarify the accounting for long-term interests in an associate or joint venture, which in substance form a part of the net investment in the associate or joint venture, but to which equity accounting is not applied. Entities must account for such interests under IFRS 9 Financial Instruments before applying the loss allocation and impairment requirements in IAS 28 Investments in Associates and Joint Ventures. The new standard is effective for years beginning on January 1, 2019 and early adoption is allowed. The Group does not foresee impacts due to the application of this modification in the statement of financial position, statement of income and statement of cash flow. Annual Improvements to IFRS Standards 2015‑2017 Cycle The following improvements were finalized in December 2017: IFRS 3 Business Combinations clarified that obtaining control of a business that is a joint operation is a business combination achieved in stages. IFRS 11 Joint Arrangements clarified that the party obtaining joint control of a business that is a joint operation should not remeasure its previously held interest in the joint operation. IAS 12 Disclosure of Interests in Other Entities clarified that the income tax consequences of dividends on financial instruments classified as equity should be recognised according to where the past transactions or events that generated distributable profits were recognised. IAS 23 Borrowing Costs clarified that, if a specific borrowing remains outstanding after the related qualifying asset is ready for ts intended use or sale, it becomes part of general borrowings. The new standard is effective for years beginning on January 1, 2019 and early adoption is allowed. The Group does not foresee impacts due to the application of this modification in the statement of financial position, statement of income and statement of cash flow. Amendments to IAS 19‑Plan Amendment, Curtailment or Settlement The amendments to IAS 19 Employee Benefits clarify the accounting for defined benefit plan amendments, curtailments and settlements. They confirm that entities must: · calculate the current service cost and net interest for the remainder of the reporting period after a plan amendment, curtailment or settlement by using the updated assumptions from the date of the change; · recognise any reduction in a surplus immediately in profit or loss, either as part of past service cost or as a gain or loss on settlement. In other words, a reduction in a surplus must be recognised in profit or loss even if that surplus was not previously recognised because of the impact of the asset ceiling; and · separately recognise any changes in the asset ceiling through other comprehensive income The new standard is effective for years beginning on January 1, 2019 and early adoption is allowed. The Group does not foresee impacts due to the application of this modification in the statement of financial position, statement of income and statement of cash flow. Amendments to IAS 1 and IAS 8‑ Definition of material The IASB has made amendments to IAS 1 Presentation of Financial Statements and IAS 8 Accounting Policies, Changes in Accounting Estimates and Errors which use a consistent definition of materiality throughout International Financial Reporting Standards and the Conceptual Framework for Financial Reporting, clarify when information is material and incorporate some of the guidance in IAS 1 about immaterial information. In particular, the amendments clarify: (i) that the reference to obscuring information addresses situations in which the effect is similar to omitting or misstating that information, and that an entity assesses materiality in the context of the financial statements as a whole, and (ii) the meaning of “primary users of general-purpose financial statements” to whom those financial stataments are directed, by defining them as “existing and potencial investors, lenders and other creditors” that must rely on general purpose financial statements for much of the financial information they need. The new standard is effective for years beginning on January 1, 2019 and early adoption is allowed. The Group does not foresee impacts due to the application of this modification in the statement of financial position, statement of income and statement of cash flow. Amendments to IFRS 3‑ Definition of Business The amended definition of a business requires an acquisition to include an input and a substantive process that together significantly contribute to the ability to create outputs. The definition of the term “outputs” is amended to focus on goods and services provided to customers, generating investment income and other income, and it excludes return in the form of lower costs and other economic benefits. The amendments will likely result in more acquisitions being accounted for as asset acquisitions. The new standard is effective for years beginning on January 1, 2019 and early adoption is allowed. The Group does not foresee impacts due to the application of this modification in the statement of financial position, statement of income and statement of cash flow. Amendments to IFRS 10 and IAS 28 – Sale or contribution of assets between an investor and its associate or joint venture. The IASB has made limited scope amendments to IFRS 10 Consolidated financial statements and IAS 28 Investments in associates and joint ventures. The amendments clarify the accounting treatment for sales or contribution of assets between an investor and its associates or joint ventures. They confirm that the accounting treatment depends on whether the nonmonetary assets sold or contributed to an associate or joint venture constitute a business (as defined in IFRS 3 Business Combinations). Where the non-monetary assets constitute a business, the investor will recognise the full gain or loss on the sale or contribution of assets. If the assets do not meet the definition of a business, the gain or loss is recognised by the the investor only to the extent of the other investor´s is interests in the associate or joint venture. The amendments apply prospectively.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Jun. 30, 2020
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES 4.1. Cash and cash equivalents For the purposes of the statements of financial position and statements of cash flows, cash and cash equivalents include cash on hand and in banks and short-term highly liquid investments (original maturity of less than 90 days). In the consolidated statements of financial position, bank overdrafts are included in borrowings within current liabilities. 4.2. Financial assets The Group previously elected to early adopt IFRS 9 (version 2013). The Group measures its financial assets at initial recognition at fair value. The Group classifies its financial assets as financial assets measured at amortized cost (using the effective interest method) on the basis of both:  The Group’s business model for managing the financial assets; and  The contractual cash flows characteristics of the financial asset. The Group has not irrevocably designated a financial asset as measured at fair value through profit or loss to eliminate or significantly reduce a measurement or recognition inconsistency. Financial assets at fair value through profit or loss are measured at fair value through profit and loss due to the business model used in their negotiation and/or the contractual characteristics of their cash flows. The Group does not apply hedge accounting. Estimates The Group makes estimates of uncollectibility of its recorded receivables. Management analyzes trade account receivables in accordance with conventional criteria, adjusting the amount through a charge of an allowance for bad debts upon recognition of the inability of third parties to afford their financial obligations to the Group. Management specifically analyzes the accounts receivable, the historical bad debts, solvency of customers, current economic trends and the changes to the payment conditions of customers to assess the adequate allowance for bad debts. Offsetting of financial assets with financial liabilities Financial assets and liabitilies are offset and presented for their net amount in the statements of financial position only when the Group has the right, legally enforceable, to compensate the recognized amounts and has the intention to liquidate for the net amount or to settle the asset and cancel the liability simultaneously. 4.3. Inventories Except for agricultural products (biological assets), inventories are recognized at cost initially and subsequently at the lower of cost and net realizable value. Cost comprises all costs of purchase and conversion as well as other costs incurred in bringing the inventories to their present location and condition. Weighted average cost is used to determine the cost of ordinarily interchangeable items. Agricultural products comprise growing crops. Costs are capitalized as agricultural products if, and only if, (a) it is probable that future economic benefits will flow to the entity, and (b) the cost can be measured reliably. The Group capitalizes costs such as: planting, harvesting, weeding, seedlings, irrigation, agrochemicals, fertilizers and a systematic allocation of fixed and variable production overheads that are directly attributable to the management of biological assets, among others. Agricultural products, both at initial recognition and at each subsequent reporting date, are measured at fair value less costs to sell, except where fair value cannot be reliably measured. Cost approximates fair value when little biological transformation has taken place since the costs were originally incurred or the impact of biological transformation on price is not expected to be material. Gains and losses that arise on measuring biological assets at fair value less costs to sell and measuring agricultural produce at the point of harvest at fair value less costs to sell are recognized in the statement of income in the period in which they arise in the line item “Initial recognition and changes in fair value of biological assets”. Estimates The Group assesses the recoverability of inventories considering their sale price, whether the inventories are damaged and whether they have become obsolete in whole or in part. Net realizable value is the sale price estimated to be attained in the ordinary course of business, less costs of completion and other selling expenses. The Group sets up an allowance for obsolescence or slow-moving inventories in relation to finished and in-process products. The allowance for obsolescence or slow-moving inventories is recognized for finished products and in-process products based on an analysis by Management of the aging of inventory stocks. Generally, the estimation of the fair value of biological assets is based on models or inputs that are not observable in the market and the use of unobservable inputs is significant to the overall valuation of the assets. Unobservable inputs are determined based on the best information available. Key assumptions include future market prices, estimated yields at the point of harvest, estimated production cycle, future cash flows, future costs of harvesting and other costs, and estimated discount rate. Market prices are generally determined by reference to observable data in the principal market for the agricultural produce. Harvesting costs and other costs are estimated based on historical and statistical data. Yields are estimated based on several factors including the location of the farmland and soil type, environmental conditions, infrastructure and other restrictions and growth at the time of measurement. Yields are subject to a high degree of uncertainty and may be affected by several factors out of the Group’s control including but not limited to extreme or unusual weather conditions, plagues and other crop diseases, among other factors. 4.4. Business combinations The Group applies the acquisition method to account for business combinations. The acquisition cost is measured as the aggregate of the consideration transferred for the acquisition of a subsidiary, which is measured at fair value at the acquisition date, and the amount of any non-controlling interest in such subsidiary. The Group recognizes any non-controlling interest in a subsidiary at the non-controlling interest’s proportionate share of the recognized amounts of subsidiary’s identifiable net assets. The acquisition related costs are expensed as incurred. Any contingent consideration to be transferred by the Group is recognized at fair value at the acquisition date. The contingent consideration is classified as an asset or liability that is a financial instrument under IFRS 9 is measured at fair value through profit or loss. Goodwill is initially measured at cost, which is the excess of the aggregate of the consideration transferred and the amount of the non-controlling interest and any previous interest carried over the net identifiable assets acquired and liabilities assumed. After initial recognition, goodwill is measured at cost less any accumulated impairment losses. For impairment testing, goodwill acquired in a business combination is, as of the acquisition date, allocated to each of the cash-generating units of the Group that is expected to benefit from the synergies of the combination, without considering whether other assets or liabilities of the subsidiary are allocated to those units. Any impairment in the carrying value is recognized in the consolidated statement of comprehensive income. In the case of acquisitions in stages, prior to the write-off of the previously held equity interest in the subsidiary, said interest is re-measured at fair value as of the date of acquisition of control over the subsidiary. The result of the re-measurement at fair value is recognized in profit or loss. When a seller in a business combination has contractually agreed to indemnify the Group for the result of a contingency or uncertainty related to the entirety or a portion of an asset or liability, the Group recognizes an indemnification asset. The indemnification asset is measured on the same basis as the indemnification item. At the end of each period, the Group measures the indemnification assets recognized at the acquisition date on the same basis as the indemnified liability, subject to any contractual limitation on the amount and, for an indemnification asset that is not periodically measured at fair value, based on Management’s assessment of the recoverability of the indemnification asset. The Group derecognizes the indemnification asset when it collects or sells it, or when it loses the right over it. Judgment On October 19, 2016 the Group signed an option agreement with certain shareholders of Rizobacter to acquire a further 9.99% interest. On October 22, 2018, Parent, RASA Holding LLC, a Delaware limited liability company and a wholly owned subsidiary of Bioceres, Inc., now a wholly-owned subsidiary of BCS Holding (“RASA Holding”), and Pedro Enrique Mac Mullen, María Marta Mac Mullen and International Property Services Corp., as sellers (collectively, the “Grantors”) entered into an amended and restated option agreement (as may be amended from time to time, the “Rizobacter Call Option Agreement”), pursuant to which the Parent, RASA Holding or any of their nominated affiliates would have the option (the “Rizobacter Call Option”) to purchase from the Grantors all of their 11,916,000 shares of common stock of Rizobacter Argentina S.A., representing 29.99% of all outstanding common stock of Rizobacter. As stated in paragraphs B89 and B90 of IFRS 10, the Group must evaluate whether the purchase option grants it, in substance, rights to returns from its involvement with Rizobacter. If the equity interest currently gives the Group rights to returns from its involvement with Rizobacter, then the proportion of returns allocated to the controlling entity should consider the possible exercise of the voting rights that currently entitle the Group to those returns. Otherwise, the possible exercise of the voting rights should not be considered and only the current voting rights are to be considered. To perform this analysis, the Group has considered that the purchase option contract exposes the Group to returns from the change in the value of the shares (due to the fixed price of the option) and that dividends are not significant in relation to the returns from the equity interest, since the Group has the power to restrict dividend payments to equity holders in Rizobacter. Based on this analysis, the Group has concluded that the purchase option contract grants it, in substance, rights to returns from its involvement with Rizobacter and computed those possible voting rights when determining the proportion of returns allocated to the controlling entity. 4.5. Business combination under common control Common control of business combination is excluded from the scope of IFRS 3. There is no other specific guidance on this topic elsewhere in IFRS. Therefore, management needs to use judgement to develop an accounting policy that provides relevant and reliable information in accordance with IAS 8. Management accounting police choice for business combination under common control is “Predecessor value method”. A Predecessor value method involves accounting for the assets and liabilities of the acquired business using existing carrying values. Differences between the carrying value and the amount payable should be accounted as an equity contribution. Semya S.A. combination Semya S.A. (Semya) was a company owned 50% by Bioceres S.A. and 50% by Rizobacter Argentina S.A. It was created as a new proposal for the research, development and commercialization of biological products with high technological value: Semya’s strength consists in the joint and integrated development of biotechnological events, germplasm, biofertilizers and biopesticides to achieve a true synergy in seed treatment. These technologies will increase crop productivity, reduce environmental impact and increase efficiency in the use of resources. Semya’s R&D was being developed by Rizobacter and Bioceres (through Indear) who signed, jointly, a Service Agreement in December 2014. When Group Bioceres acquired control over Rizobacter, it also acquired control over Semya. As required by paragraph 42 of IFRS 3, the Group re-measured the fair value of its previous equity interest in Semya at the acquisition date. The determination of fair value of Semya at the acquisition date is based on the application of a future cash flow present value technique. The main assumptions considered in determining fair value relate to the applicable discount rate and to the projections of revenue from the launch of seed treatment packs. As a result, Ecoseed integrated products have been recorded as intangibles assets. The purpose of those projects is to develop high value-added biological products for the treatment of soybean and wheat seeds, and generate biotechnological, germplasm and bio-inoculants synergies. In June 2019, Bioceres Crop Solutions signed a share purchase agreement (SPA) with Bioceres S.A. for the 50% of ownership in Semya. Concurrently the SPA, Bioceres assigned to Bioceres Crop Solutions the R&D service agreement signed mentioned before. Consideration of the SPA will be in installments equivalent to the 50% of the royalties that Bioceres Crops Solutions will accrue from Semya, up to a total amount of US$ 670,000. 4.6. Impairment of non-financial assets (excluding inventories and deferred tax assets) Impairment tests on goodwill and intangible assets not yet available for use are undertaken annually at the end of the reporting period. Other non-financial assets are subject to impairment tests whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. Where the carrying value of an asset exceeds its recoverable amount (i.e. the higher of value in use and fair value less costs to sell), the asset is written down accordingly. Where it is not possible to estimate the recoverable amount of an individual asset, the impairment test is carried out on the smallest group of assets to which it belongs for which there are separately identifiable cash flows (its Cash Generating Unit or CGU). Goodwill is allocated on initial recognition to each of the Group’s CGUs that are expected to benefit from a business combination that gives rise to the goodwill. Impairment charges are included in profit or loss, except to the extent they reverse gains previously recognized in other comprehensive income. An impairment loss recognized for goodwill is not reversed. Estimate Impairment testing of goodwill and intangible assets not yet available for use requires the use of significant assumptions for the estimation of future cash flows and the determination of discount rates. The significant assumptions and the determination of discount rates for the impairment testing of goodwill are further explained in Note 6.8. 4.7. Joint arrangements An associate is an entity over which the Group exerts significant influence. Significant influence is the power to participate in financial and operating policy decision-making at such entity, but it does not involve control or joint control over those policies. The Group is a party to a joint arrangement when there is a contractual arrangement that confers joint control over the relevant activities of the arrangement to the Group and at least one other party. Joint control is assessed under the same principles as control over subsidiaries. The Group classifies its interests in joint arrangements as either: · Joint ventures : where the group has rights to only the net assets of the joint arrangement. · Joint operations : where the group has both the rights to the assets and obligations for the liabilities of the joint arrangement. In assessing the classification of interests in joint arrangements, the Group considers: · The structure of the joint arrangement; · The legal form of joint arrangements structured through a separate vehicle; · The contractual terms of the joint arrangement agreement; and · Any other facts and circumstances (including any other contractual arrangements). The Group accounts for its interests in joint ventures using the equity method, where the Group’s share of post-acquisition profits and losses and other comprehensive income is recognized in the Consolidated statement of profit and loss and other comprehensive income. Losses in excess of the Group’s investment in the joint venture are recognized only to the extent that the Group has incurred legal or constructive obligations or made payments on behalf of the joint venture. Profits and losses arising on transactions between the Group and its joint ventures are recognized only to the extent of unrelated investors’ interests in the joint venture. The Group’s share in a joint venture’s profits and losses resulting from a transaction is eliminated against the carrying amount of investment in the joint venture through the line “share of profit (or loss) of joint ventures” in the Consolidated statements of profit or loss and other comprehensive income. Any premium paid for an investment in a joint venture above the fair value of the Group’s share of the identifiable assets, liabilities and contingent liabilities acquired is capitalized and included in the carrying amount of the investment in the joint venture. Where there is objective evidence that the investment in a joint venture has been impaired, the carrying amount of the investment is tested for impairment in the same way as other non-financial assets. When the Group loses significant influence in an associate or joint control over a joint venture, it measures and recognizes any investment held at fair value. Any difference between the carrying amount of the associate or joint venture when losing significant influence or joint control and the fair value of the held investment and sale revenue are recognized in profit or loss. The Group accounts for its interests in joint operations by recognizing its share of assets, liabilities, revenues and expenses in accordance with its contractually conferred rights and obligations. For all joint arrangements structured in separate vehicles the Group must assess the substance of the joint arrangement in determining whether it is classified as a joint venture or joint operation. This assessment requires the Group to consider whether it has rights to the joint arrangement’s net assets (in which case it is classified as a joint venture), or rights to and obligations for specific assets, liabilities, expenses, and revenues (in which case it is classified as a joint operation). Upon consideration of the factors mentioned above, the Group has determined that all of its joint arrangements structured through separate vehicles only give it rights to the net assets and are therefore classified as joint ventures (Note 12). Estimates There is considerable uncertainty regarding Management’s estimates of the Group’s ability to recover the carrying amounts of the investments in joint ventures, since such estimates depend on the joint ventures’ ability to generate sufficient funds to complete the development projects, the future outcome of the project deregulation process and the amounts and timing of the cash flows from projects, among other future events. Management assesses whether there are impairment indicators and, if any, it performs a recoverability analysis. Management estimates of the recoverability of these investments represent the best estimate based on available evidence, the existing facts and circumstances, using reasonable and provable assumptions in the cash flow projections. Therefore, the consolidated financial statements do not include adjustments that would be required if the Group were unable to recover the carrying amount of the above-mentioned assets by generating sufficient economic benefits in the future. When the Group acquired control of Rizobacter, it also acquired the joint control of Synertech. Therefore, the investment in Synertech was added at the time of initial recognition of the acquisition at fair value. The determination of the fair value of Synertech at the acquisition date is based on the application of a future cash flow present value technique. The main assumptions considered in determining fair value relate to the applicable discount rate and to the projections of higher revenue from sales of micro-granulated fertilizers. 4.8. Property, plant and equipment Property, plant and equipment items are initially recognized at cost. In addition to the purchase price, cost also includes costs directly attributable to such property, plant and equipment items. There are no unavoidable costs with respect to dismantling and removing items. The cost of property, plant and equipment items acquired in a business combination is their fair value at the acquisition date. Depreciation is calculated using the straight-line method to allocate the property, plant or equipment items’ cost or revalued amounts, net of their residual values, over their estimated useful lives or, in the case of leasehold improvements and certain leased plant and equipment, the shorter lease term as follows: Research instruments: 3 to 10 years Office equipment: 5 to 10 years Vehicles: 5 years Computer equipment and software: 3 years Fixture and fittings: 10 years Machinery and equipment: 5 to 10 years Buildings: 50 years Useful lives and depreciation methods are reviewed every year as required by IAS 16. Assets under items Land and Buildings, are accounted for at fair value arising from the last revaluation performed, applying the revaluation model indicated by IAS 16. This policy was adopted by the Group since the six-month transition period ended June 30, 2017. Revaluations are performed on a regular basis, when there are signs that the book value differs significantly from that to be determined using the fair value at the end of the reporting year. To obtain fair values, the existence of an active market is considered for the assets in their current status. For those assets for which an active market in their current status exists, the fair values were determined based on their market values. For the remaining cases, the market values of comparable new assets are analysed, applying a discount based on the status and wear of each asset and considering the characteristics of each of the revalued assets (for example, improvements made, maintenance status, level of productivity, use, etc. Estimates The Group carries certain classes of property, plant and equipment under the revaluation model under IAS 16. The revaluation model requires that the Group carry property, plant and equipment at revalued amounts, being fair value at the date of revaluation less any subsequent accumulated depreciation and any subsequent accumulated impairment losses. IAS 16 requires that the Group carry out these revaluations with sufficient regularity so that the carrying amounts of its property, plant and equipment do not differ materially from that which would be determined using fair value at the end of a reporting period. The determination of fair value at the date of revaluation requires judgments, estimates and assumptions based on market conditions prevailing at the time of any such revaluation. Changes to any of the Group’s judgments, estimates or assumptions or to the market conditions subsequent to a revaluation will result in changes to the fair value of property, plant and equipment. The Group prepares the corresponding revaluations on a regular basis taking into account the work of independent appraisers. The Group uses different valuation techniques depending on the class of property being valued. Generally, the Group determines the fair value of its industrial buildings and warehouses based on a depreciated replacement cost approach. The Group determines the fair value of its land based on active market prices adjusted, if necessary, for differences in the nature, location or condition of the specific asset. If this information is not available, the Group may use alternative valuation methods, such as recent prices in less active markets. Property valuation is a significant area of estimation uncertainty. Fair values are prepared regularly by Management, taking into account independent valuations. The determination of fair value for the different classes of property, plant and equipment is sensitive to the selection of various significant assumptions and estimates. Changes in those significant assumptions and estimates could materially affect the determination of the revalued amounts of property, plant and equipment. The Group utilizes historical experience, market information and other internal information to determine and/or review the appropriate revalued amounts. The following are the most significant assumptions used in the preparation of the revalued amounts for its classes of property, plant and equipment: a) Land: The Group generally uses the market price of a square meter of land for the same or similar location as the most significant assumption to determine the revalued amount. The Group typically uses comparable land sales in the same location to assess appropriateness of the value of its land. A 10% increase or decrease in the market price of land could have a significant impact on the revalued amount of its land. b) Industrial buildings and warehouses: The Group generally determines the construction cost of a new asset and then the Group adjusts it for normal wear and tear. Construction prices may include, but are not limited to, construction materials, labor costs, installation and assembly costs, site preparation, professional fees and applicable taxes. Construction costs may differ significantly from year to year and are subject to macroeconomic changes in the economy where the Group operates, such as the impact of inflation and foreign exchange rates. The construction cost of its industrial buildings and warehouses is determined on a US dollar per constructed square meter basis, while the construction cost of its mills, facilities and grain storage facilities is determined by reference to their total capacity measured in tons milled or stored, respectively. A 5% increase or decrease in the construction costs relating to such assets could have a significant impact on their revalued amounts. A 5% variation in the estimate of normal wear and tear could also have a significant impact on their revalued amounts. Increases in the carrying amounts arising on revaluation of land and buildings are recognized, net of tax, in other comprehensive income and accumulated in reserves in shareholders’ equity. To the extent that the increase reverses a decrease previously recognized in profit or loss, the increase is first recognized in profit or loss. Decreases that reverse previous increases of the same asset are first recognized in other comprehensive income to the extent of the remaining surplus attributable to the asset; all other decreases are charged to profit or loss. 4.9. Leased assets Where substantially all of the risks and rewards incidental to ownership of a leased asset have been transferred to the Group (a "finance lease"), the asset is treated as if it had been purchased outright. The amount initially recognized as an asset is the lower of the fair value of the leased property and the present value of the minimum lease payments payable over the term of the lease. The corresponding lease commitment is shown as a liability. Lease payments are categorized as capital or interest. The interest element is charged to the Consolidated statement of profit or loss and other comprehensive income over the period of the lease and is calculated so that it represents a constant proportion of the lease liability. The capital element reduces the balance owed to the lessor. Where substantially all of the risks and rewards incidental to ownership are not transferred to the Group (an "operating lease"), the total rentals payable under the lease are charged to the Consolidated statement of profit or loss and other comprehensive income on a straight-line basis over the lease term. The aggregate benefit of lease incentives is recognized as a reduction of the rental expense over the lease term on a straight-line basis. 4.10. Intangible assets a) Externally acquired intangible assets Externally acquired intangible assets are initially recognized at cost and subsequently amortized on a straight-line basis over their useful economic lives. Intangible assets acquired from third parties have an estimated useful life as follows (in years): Software: 3 years Trademarks and patents: 5 years Certification ISO Standards: 3 years Useful lives and amortization methods are reviewed every year as required by IAS 38. b) Internally generated intangible assets (development costs) Expenditure on internally developed products is capitalized if it can be demonstrated that: · It is technically feasible to develop the product for it to be sold; · Adequate resources are available to complete the development; · There is an intention to complete and sell the product; · The Group is able to sell the product; · Sale of the product will generate future economic benefits; and · Expenditure on the project can be measured reliably. Development expenditure not satisfying the above criteria and expenditure on the research phase of internal projects are recognized in the consolidated statement of profit or loss and other comprehensive income as incurred (Note 7.3). Capitalized development costs are amortized using the straight-line method over the periods the Group expects to benefit from selling the products developed (Note 6.7). Useful lives and amortization methods are reviewed every year as required by IAS 38. The research and development process can be divided into several discrete steps or phases, which generally begin with discovery, validation and development and end with regulatory approval and commercial launch. The process for developing seed traits is relatively similar for both GM and non-GM traits. However, the two differ significantly in later phases of development. For example, obtaining regulatory approval for GM seeds is a far more comprehensive and lengthy process than for non-GM seeds. Although breeding programs and industrial biotechnology solutions may have shorter or simpler phases than those described below, the Group has used the industry consensus for seed-trait development phases to characterize its technology portfolios, which is generally divided into the following six phases: i) Discovery: The first phase in the technology development process is the discovery or identification of candidate genes or genetic systems, metabolites, or microorganisms potentially capable of enhancing specified plant characteristics or enabling an agro-industrial biotech solution. In the Group’s experience, the discovery phase typically lasts 18 months, though it may range from as few as six months for microbial solutions to as many as 36 months for plant GM traits. ii) Proof of concept: Upon successful validation of the technologies in model systems ( in vitro or in vivo ), promising technologies graduate from discovery and are advanced to the proof of concept phase. The goal of this phase is to validate a technology within the targeted organism before moving forward with technology escalation activities or extensive field validation. In the Group’s experience, the proof of concept phase typically lasts 36 months, though it may range from as few as six months for a microbial solution to as many as four years for plant GM traits. iii) Early development: In this phase, field tests commenced in the proof of concept phase are expanded to evaluate various permutations of a technology in multiple geographies and growing cycles, as well as other characteristics in order to optimize the technology’s performance in the targeted organisms. The goal of the early development phase is to identify the best mode of use of a technology to define its performance concept. The early development phase typically lasts 24 months. iv) Advanced development and deregulation: In this phase, extensive field tests are used to demonstrate the effectiveness of the technology for its intended purpose. In the case of GM traits, the process of obtaining regulatory approvals from government authorities is also initiated during this phase, and tests are performed to evaluate the potential environmental impact of modified plants. For solutions involving microbial fermentation, industrial-scale runs are conducted. In Argentina and some other countries in South America, the Gro

CRITICAL ACCOUNTING JUDGMENTS A

CRITICAL ACCOUNTING JUDGMENTS AND ESTIMATES	12 Months Ended
	Jun. 30, 2019
CRITICAL ACCOUNTING JUDGMENTS AND ESTIMATES
CRITICAL ACCOUNTING JUDGMENTS AND ESTIMATES	5. CRITICAL ACCOUNTING JUDGMENTS AND ESTIMATES The Group makes certain estimates and assumptions regarding the future. Estimates and judgments are continually evaluated based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. In the future, actual experience may differ from these estimates and assumptions. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below. 5.1. Critical judgments  Determination of the percentage of equity interest in Rizobacter on June 30,2018 (Note 4.4) 5.2. Critical estimates  Estimate of the trade receivables impairment provision (Note 4.2)  Estimate of the inventory obsolescence allowance (Note 4.3)  Capitalization and impairment testing of development costs (Notes 4.6 and 6.7)  Impairment of goodwill (Notes 4.6 and 6.8)  Recoverability of investments in joint ventures (Note 4.7)  Fair value of land and buildings (Note 4.8)  Identification and fair value of identifiable intangible assets arising in a business combination (Note 4.10 y 6.7)  Fair value of financial liabilities measured at fair value through profit or loss (Note 4.11)  Share-based payments (Notes 4.20 and 18)  Recognition and recoverability of deferred tax assets and credit for minimum presumed income tax (Note 4.19 and Note 8)  Fair value of Warrants (Note 6.16)

INFORMATION ABOUT COMPONENTS OF

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION	12 Months Ended
	Jun. 30, 2019
INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION	6. INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION 6.1. Cash and cash equivalents 06/30/2019 06/30/2018 06/30/2017 Cash and banks 3,450,873 2,215,103 1,679,478 3,450,873 2,215,103 1,679,478 6.2. Other financial assets 06/30/2019 06/30/2018 06/30/2017 Current Restricted short-term deposit 4,327,275 4,538,321 4,260,517 Other investments 347,718 — — Other marketable securities 8,515 12,526 4,275 4,683,508 4,550,847 4,264,792 06/30/2019 06/30/2018 06/30/2017 Non-current Shares of Bioceres S.A. 374,685 240,920 676,762 Other marketable securities 1,728 2,438 90,237 376,413 243,358 766,999 Variations in the allowance for uncollectible trade receivables are reported in Note 6.18. The book value is reasonably approximate to the fair value given its short-term nature. 6.3. Trade receivables 06/30/2019 06/30/2018 06/30/2017 Trade debtors 48,910,484 44,641,053 34,121,040 Allowance for impairment of trade debtors (3,360,224) (3,212,170) (2,873,688) Shareholders and other related parties (Note 16) 467,743 571,216 1,025,903 Allowance for impairment of related parties (Note 16) (75,596) (23,126) (205,960) Allowance for return of goods (800,606) (1,517,361) (1,393,059) Trade debtors - Parent company (Note 16) 440,268 361,606 — Trade debtors - Joint ventures and associates (Note 16) 2,369 209,039 217,963 Discounted and deferred checks 13,651,939 11,858,170 10,783,719 59,236,377 52,888,427 41,675,918 The book value is reasonably approximate to the fair value given its short-term nature. 6.4. Other receivables 06/30/2019 06/30/2018 06/30/2017 Current Taxes 584,641 664,926 1,904,592 Other receivables - Other related parties (Note 16) 10,971 119,677 67,753 Other receivables - Parent Company (Note 16) — 103,251 — Other receivables - Joint ventures and associates (Note 16) 250,783 1,962,459 3,085,056 Prepayments to suppliers 496,001 516,742 1,210,070 Reimbursements over exports 366,594 362,815 151,107 Prepaid expenses and other receivables 213,597 — 265,972 Loans receivable — 1,360 5,732 Miscellaneous 59,242 508,975 417,937 1,981,829 4,240,205 7,108,219 06/30/2019 06/30/2018 06/30/2017 Non-Current Taxes 681,168 295,924 484,572 Reimbursements over exports 878,470 346,575 472,276 Other receivables - Joint ventures and associates (Note 16) — 4,337,008 1,213,053 Miscellaneous 672 — 13,343 1,560,310 4,979,507 2,183,244 The book value is reasonably approximate to the fair value given its short-term nature. 6.5. Inventories 06/30/2019 06/30/2018 06/30/2017 Agrochemicals 22,137 94,486 183,822 Seeds and grains 207,519 514,000 1,273,515 Microbiological resale products 13,894,018 8,389,191 13,749,668 Microbiological products produced 8,370,583 6,383,263 8,931,124 Goods in transit 751,737 776,869 482,185 Supplies 4,512,870 3,978,934 7,424,825 Allowance for obsolescence (406,818) (770,742) (707,105) Agricultural product 240,536 — — 27,592,582 19,366,001 31,338,034 The roll-forward of allowance for obsolescence is in Note 6.18. Inventories recognised as an expense during the years ended June 30, 2019,2018 and the six-month transition period ended June 30, 2017 amounted to U$S 80,153,871, U$S 77,797,414 and U$S 26,672,229 respectively. Those expenses were included in cost of sales. 6.6. Property, plant and equipment Property, plant and equipment as of June 30, 2019, June 30, 2018, the six-month transition period ended June 30, 2017 and December 31, 2016, included the following: 06/30/2019 06/30/2018 06/30/2017 12/31/2016 Gross carrying amount 57,059,972 44,764,394 48,520,889 47,276,088 Accumulated depreciation (13,225,424) (4,587,248) (2,302,014) (882,327) Net carrying amount 43,834,548 40,177,146 46,218,875 46,393,761 1. Net carrying amount for each class of assets is as follows: Net carrying Net carrying Net carrying Net carrying amount amount amount amount Class 06/30/2019 06/30/2018 06/30/2017 12/31/2016 Office equipment Vehicles Equipment and computer software 123,472 212,236 308,360 380,386 Fixtures and fittings 4,737,396 3,508,083 4,460,903 4,701,939 Machinery and equipment 6,336,691 4,466,293 8,405,441 9,105,953 Land and buildings 29,969,237 30,513,273 30,103,117 29,584,854 Buildings in progress 668,614 182,839 870,469 420,685 Total 43,834,548 40,177,146 46,218,875 46,393,761 2. Gross carrying amount as of June 30, 2019 is as follows: Gross carrying amount Adjustment of opening net book As of the amount for Foreign beginning application currency As of the Class of year of IAS 29 Additions Transfers Disposals translation Revaluation end of year Office equipment 243,948 333,904 30,621 — (8,493) 29,139 — 629,119 Vehicles 1,660,294 1,054,631 1,093,749 — (297,269) 93,132 — 3,604,537 Equipment and computer software 419,638 416,274 75,152 — (1,685) 46,278 — 955,657 Fixtures and fittings 3,826,665 1,909,115 7,518 213,333 — 481,799 — 6,438,430 Machinery and equipment 5,404,029 3,976,720 98,034 7,863 (31,407) 778,262 — 10,233,501 Land and buildings 33,026,981 1,438,728 125,930 — — 1,994,906 (2,056,431) 34,530,114 Buildings in progress 182,839 75,405 613,098 (221,196) — 18,468 — 668,614 Total 44,764,394 9,204,777 2,044,102 — (338,854) 3,441,984 (2,056,431) 57,059,972 3. Accumulated depreciation as of June 30, 2019 is as follows: Depreciation Adjustment of opening Accumulated net book as of the amount for Foreign Accumulated beginning of application of currency as of the end of Class year IAS 29 Disposals Of the year translation Revaluation year Office equipment 49,129 309,339 (4,007) 39,997 21,224 — 415,682 Vehicles 560,691 750,195 (205,618) 621,974 91,594 — 1,818,836 Equipment and computer software 207,402 486,143 (769) 99,350 40,059 — 832,185 Fixtures and fittings 318,582 912,404 — 397,989 72,059 — 1,701,034 Machinery and equipment 937,736 2,121,816 (16,807) 673,784 180,281 — 3,896,810 Land and buildings 2,513,708 1,343,500 — 617,162 221,428 (134,921) 4,560,877 Total 4,587,248 5,923,397 (227,201) 2,450,256 626,645 (134,921) 13,225,424 4. Gross carrying amount as of June 30, 2018 is as follows: Gross carrying amount As of the Foreign beginning currency As of the Class of year Additions Transfers Disposals translation Revaluation end of year Office equipment 252,220 119,623 — — (127,895) — 243,948 Vehicles 2,223,102 388,856 — (131,746) (819,918) — 1,660,294 Equipment and computer software 426,529 189,094 47,744 (14,726) (229,003) — 419,638 Fixtures and fittings 4,665,074 6,178 1,646,914 (1,632) (2,489,869) — 3,826,665 Machinery and equipment 9,152,269 197,840 — (23,010) (3,923,070) — 5,404,029 Land and buildings 30,931,226 26,017 651,662 — (13,146,785) 14,564,861 33,026,981 Buildings in progress 870,469 1,864,186 (2,346,320) — (205,496) — 182,839 Total 48,520,889 2,791,794 — (171,114) (20,942,036) 14,564,861 44,764,394 5. Accumulated depreciation as of June 30, 2018 is as follows: Depreciation Accumulated as of the Foreign Accumulated beginning of currency as of the end year Disposals Of the year translation Revaluation of year Office equipment 31,522 — 41,740 (24,133) — 49,129 Vehicles 373,215 (42,928) 434,632 (204,228) — 560,691 Equipment and computer software 118,169 (13,641) 195,386 (92,512) — 207,402 Fixtures and fittings 204,171 — 286,024 (171,613) — 318,582 Machinery and equipment 746,828 — 741,508 (550,600) — 937,736 Land and buildings 828,109 — 531,591 (516,056) 1,670,064 2,513,708 Total 2,302,014 (56,569) 2,230,881 (1,559,142) 1,670,064 4,587,248 6. Gross carrying amount as of June 30, 2017 is as follows: Gross carrying amount As of the Foreign beginning Currency As of the Class of year Additions Transfers Disposals Translation Revaluation end of year Office equipment 235,301 32,138 — — (15,219) — 252,220 Vehicles 2,136,823 441,478 — (183,170) (172,029) — 2,223,102 Equipment and computer software 460,518 20,637 — (32,074) (22,552) — 426,529 Fixtures and fittings 4,770,076 — 127,475 — (232,477) — 4,665,074 Machinery and equipment 9,492,852 18,513 73,717 (10,678) (422,135) — 9,152,269 Land and buildings 29,759,833 15,508 (428,844) (197,467) (1,461,403) 3,243,599 30,931,226 Buildings in progress 420,685 167,393 227,652 — 54,739 — 870,469 Total 47,276,088 695,667 — (423,389) (2,271,076) 3,243,599 48,520,889 7. Accumulated depreciation as of June 30, 2017 is as follows: Depreciation Accumulated as of Foreign Accumulated beginning of Currency as of the end of Class year Disposals Of the period Translation Revaluation year Office equipment 27,913 — 5,452 (1,843) — 31,522 Vehicles 144,267 (95,792) 334,019 (9,279) — 373,215 Equipment and computer software 80,132 (31,486) 77,461 (7,938) — 118,169 Fixtures and fittings 68,137 — 145,044 (9,010) — 204,171 Machinery and equipment 386,899 (10,678) 408,975 (38,368) — 746,828 Land and buildings 174,979 — 283,706 (21,947) 391,371 828,109 Total 882,327 (137,956) 1,254,657 (88,385) 391,371 2,302,014 8. Gross carrying amount as of December 31, 2016 is as follows: Gross carrying amount As of the Foreign beginning of Additions Currency As of the Class year Additions por PPA Disposals Translation end of year Office equipment 5,830 4,811 234,221 — (9,561) 235,301 Vehicles 160,895 225,459 1,878,400 (49,179) (78,752) 2,136,823 Equipment and computer software 14,283 13,945 450,785 — (18,495) 460,518 Fixtures and fittings 1,608 118,638 4,848,110 — (198,280) 4,770,076 Machinery and equipment 310,504 35,170 9,533,037 — (385,859) 9,492,852 Land and buildings — 210,038 30,792,604 — (1,242,809) 29,759,833 Buildings in progress — — 430,837 — (10,152) 420,685 Total 493,120 608,061 48,167,994 (49,179) (1,943,908) 47,276,088 9. Accumulated depreciation as of December 31, 2016 is as follows: Depreciation Accumulated as of Foreign Accumulated beginning of Currency as of the end Class year Disposals Of the year Translation of year Office equipment 3,555 — 18,901 5,457 27,913 Vehicles 119,177 (49,179) 75,633 (1,364) 144,267 Equipment and computer software 14,283 — 59,548 6,301 80,132 Fixtures and fittings 1,126 — 153,424 (86,413) 68,137 Machinery and equipment 132,669 — 134,648 119,582 386,899 Land and buildings — — 142,139 32,840 174,979 Total 270,810 (49,179) 584,293 76,403 882,327 The depreciation charge is included in Notes 7.3 and 7.4. The Group has no commitments to purchase property, plant and equipment items. A detail of restricted assets is provided in Note 19. Revaluation of property, plant and equipment At a minimum, the Group updates their assessment of the fair value of its land and buildings at the end of each reporting year (after the revaluation policy was adopted), taking into account the most recent independent valuations and market data. Valuations were performed at June 30, 2019. Management determined the property, plant and equipment’s value within a range of reasonable fair value estimates. All resulting fair value estimates for properties are included in level 3. The following are the carrying amounts that would have been recognized had the assets been carried under the cost model. Value at cost Class of property 06/30/2019 06/30/2018 06/30/2017 Land and buildings 6.7. Intangible assets Intangible assets as of June 30, 2019, June 30,2018, the six-month transition period ended June 30,2017 and December 31, 2016 included the following: 06/30/2019 06/30/2018 06/30/2017 12/31/2016 Gross carrying amount 45,848,737 29,155,315 43,903,217 42,890,018 Accumulated amortization (6,232,311) (2,497,970) (1,844,326) (521,692) Net carrying amount 39,616,426 26,657,345 42,058,891 42,368,326 Seed and integrated products The Group’s seed and integrated product activities concentrate primarily on the development and commercialization of seeds and technologies and products that increase yield per hectare, with a focus on providing seed and integrated crop protection and crop nutrition technologies designed to control weeds, insects or diseases, enhance quality traits of the seeds produced and improve nutritional value and other benefits. The Group has sought to develop integrated products that combine three distinct and complementary components, seed traits, germplasms and seed treatments in order to deliver a superior agronomic experience to customers. The Group’s technologies which are capitalized based on an advanced stage of development (phase 4 or higher), are set forth in the table below: Technologies Crop Germplasm Protection Yield Quality R&D Phase Entity Soybean MG III-VIII(1) GT (2) HB4 — Advanced Develop. BCS Holding Wheat Spring / Winter GluT (2) HB4 — Advanced Develop. Trigall Genetics (3) (Note 12) Notes: (1) Soybean germplasms are categorized by maturity groups (MG) from III to VIII. Non-dormant germplasms are alfalfa elite breeding materials without winter dormancy. A. cruentus germplasms are amaranth varieties of the A. cruentus species. (2) GT means glyphosate tolerance. GluT means glufosinate tolerance. Genuity is the glyphosate tolerance technology developed by Monsanto and Forage Genetics International for alfalfa. ALS means ALS-inhibitor herbicide tolerance. (3) Included in Trigall`s financial statements. Reflected in the Consolidated financial statements through the equity method investment. The soybean HB4 technology was approved by the Argentine Ministry of Agriculture, Livestock and Fishing on October 6, 2015, under Resolution N° 397/15. In the case of HB4 wheat, although favorable opinions have already been obtained from both CONABIA and of SENASA, is awaiting the decision of the National Directorate of Agricultural Markets, that analyzes the commercial impact of being the first country in the world to release a wheat of these characteristics. The U.S. FDA completed its full review of the safety evaluation for HB4 soybeans, clearing it for use in human food and animal food on August 10, 2017. Bioceres Crop received USDA approval of HB4 Drought Tolerant Soybeans on August 2019. Interaction with the regulatory authorities of China continues because the comercialization of the product in Argentina is subject to approval in that country. Specifically, in May 2019, all additional consultations made by the Ministry of Agriculture of the Republic of China (MOA) were answered. Other intangible assets identified in the business combination under common control with Semya (See note 4.5) include the following:  Soybean Ecoseed Pack : This proyect promotes the devolpment of biological products with high added value for soybean seed treatments. The devolpment of these products integrates biotechnological, germoplasm and bio inoculants synergistically.  Wheat Ecoseed Pack : This proyect promotes the devolpment of biological products with high added value for wheat seeds treatments. The devolpment of these products integrates biotechnological, germoplasm and bio inoculants synergistically.  Bio Fungicides : The final objective of the project is to generate biological products with high added value for the treatment of seeds, focusing on the abilitity to bio control diseases in wheat and soybeans crops. Crop nutrition The Group’s crop nutrition activities include the development of and investment in microbiological products that have been incorporated as part of the integration of Rizobacter into the Group, including the following microbiological assets incorporated as intangible assets measured at fair value:  TOP Technologies: The TOP Osmo Protection Technology promotes high metabolic and physiological performance of bacteria and ensures bacterial survival and concentration in seeds and packages, reducing the impact of fungicides and insecticides on bacteria and substantially improving inoculants performance and their incidence in crop yields.  Signum Technologies: Signum bio-inductor generates molecular signals which early activate bacterial and plant metabolic processes, thus maximizing the development of leguminous plants. Furthermore, it stimulates the interrelation with different soil beneficial microorganisms that provide additional advantages to inoculation, activates mechanisms of resistance to abiotic stress factors (low temperatures, droughts and soil acidity), and induces defensive responses in the interaction with harmful microorganisms.  LLI Technologies: This technology marks a turning point in inoculation. The time of disposal to maintain living bacteria on seeds, a prerequisite for an effective nodulation. Ready-to-use (RTU) seed allows to reduce costs, simplify the sowing operation, minimize the risks normally associated with on farm treatments, and achieve the precise positioning of bacteria through the inoculant. This treatment provides for a higher number of healthier plants with outstanding root development to reach the soybean crop’s full yield potential. Other intangible assets Other intangible assets identified in the business combination with Rizobacter:  Product registration: In accordance with regulations set by certain regulatory agencies such as the National Agri-Food Safety and Quality Service (SENASA), Rizobacter has been required to register products with regulatory authorities to be able to sell them both in the domestic and international markets (jointly referred to as "Product Registration"). Some of the registered products have been developed by third parties.  Brand: Rizobacter offers a wide variety of proprietary and third-party products, which are commercialized under the Rizobacter brand name. This intangible has been designated with an indefinite useful life.  Customer loyalty: Rizobacter’s sales to distributors of agrochemicals and to special accounts, mainly large retailers and wholesalers, whether inside or outside the Argentine territory are included. They are recognised at their fair value at the date of acquisition and are subsequently amortised on a straight-line based on the timing of projected cash flows of the clients over their estimated useful lives. 1. Net carrying amount of each class of intangible assets is as follows: Net carrying Net carrying Net Carrying Net Carrying amount amount amount amount Class 06/30/2019 06/30/2018 06/30/2017 12/31/2016 Seed and integrated products Soybean HB4 6,120,336 4,927,853 3,111,253 1,421,707 Ecoseed integrated products 2,627,946 — — — Crop nutrition Microbiology products 2,208,117 2,122,484 3,491,269 3,625,827 Other intangible assets Trademarks and patents 8,063,648 5,574,682 10,402,764 11,265,234 Software 994,723 949,310 1,392,769 799,904 Customer loyalty 19,601,656 13,083,016 23,660,836 25,255,654 Total 39,616,426 26,657,345 42,058,891 42,368,326 2. Gross carrying amount as of June 30, 2019 is as follows: Gross carrying amount Adjustment of opening net book As of the amount for Foreign beginning of application currency As of the Class year of IAS 29 Additions Disposals translation end of year Seed and integrated products Soybean HB4 4,927,853 — 1,192,483 — — 6,120,336 Ecoseed integrated products — — 2,627,946 — — 2,627,946 Crop nutrition Microbiology products 2,505,864 841,753 41,485 (318,949) 197,047 3,267,200 Other intangible assets Trademarks and patents 6,278,706 2,986,739 — — 545,377 9,810,822 Software 1,444,603 438,703 200,600 (40,359) 105,793 2,149,340 Customer loyalty 13,998,289 6,658,894 — — 1,215,910 21,873,093 Total 29,155,315 10,926,089 4,062,514 (359,308) 2,064,127 45,848,737 3. Accumulated amortization as of June 30, 2019 is as follows: Amortization Adjustment of opening Accumulated net book as of amount for Foreign Accumulated beginning of application currency as of the end of Class year of IAS 29 Disposals Of the year translation year Crop nutrition Microbiology products 383,380 202,791 (20,887) 459,287 34,512 1,059,083 Other intangible assets Trademarks and patents 704,024 334,919 — 647,101 61,130 1,747,174 Software 495,293 227,264 (40,359) 429,258 43,161 1,154,617 Customer loyalty 915,273 435,389 — 841,273 79,502 2,271,437 Total 2,497,970 1,200,363 (61,246) 2,376,919 218,305 6,232,311 4. Gross carrying amount as of June 30, 2018 is as follows: Gross carrying amount As of the Foreign beginning of currency As of the end Class year Additions Disposals translation of year Seed and integrated products Soybean HB4 3,111,253 1,816,600 — — 4,927,853 Crop nutrition Microbiology products 3,782,238 484,825 — (1,761,199) 2,505,864 Other intangible assets Trademarks and patents 10,906,317 — — (4,627,611) 6,278,706 Software 1,787,925 614,529 — (957,851) 1,444,603 Customer loyalty 24,315,484 — — (10,317,195) 13,998,289 Total 43,903,217 2,915,954 — (17,663,856) 29,155,315 5. Accumulated amortization as of June 30, 2018 is as follows: Amortization Accumulated as of Foreign Accumulated beginning of currency as of the end Class year Disposals Of the year translation of year Crop nutrition Microbiology products 290,969 — 321,887 (229,476) 383,380 Other intangible assets Trademarks and patents 503,553 — 617,478 (417,007) 704,024 Software 395,156 — 399,311 (299,174) 495,293 Customer loyalty 654,648 — 802,800 (542,175) 915,273 Total 1,844,326 — 2,141,476 (1,487,832) 2,497,970 6. Gross carrying amount as of June 30, 2017 is as follows: Gross carrying amount As of the Foreign beginning of currency As of the end Class year Additions Disposals translation of year Seed and integrated products Soybean HB4 1,421,707 1,689,546 — — 3,111,253 Crop nutrition Microbiology products 3,755,094 194,743 — (167,599) 3,782,238 Other intangible assets Trademarks and patents 11,415,829 — — (509,512) 10,906,317 Software 845,954 979,728 — (37,757) 1,787,925 Customer loyalty 25,451,434 — — (1,135,950) 24,315,484 Total 42,890,018 2,864,017 — (1,850,818) 43,903,217 7. Accumulated amortization as of June 30, 2017 is as follows: Amortization Accumulated as of Foreign Accumulated beginning of currency as of the end Class year Disposals Of the year translation of year Crop nutrition Microbiology products 129,267 — 176,523 (14,821) 290,969 Other intangible assets Trademarks and patents 150,595 — 379,115 (26,157) 503,553 Software 46,050 — 370,018 (20,912) 395,156 Customer loyalty 195,780 — 492,873 (34,005) 654,648 Total 521,692 — 1,418,529 (95,895) 1,844,326 8. Gross carrying amount as of December 31, 2016 is as follows: Gross carrying amount As of the Foreign beginning of Additions currency As of the Class year Additions for P1PA translation end of year Seed and integrated products Soybean HB4 1,421,707 — — — 1,421,707 Crop nutrition Microbiology products — 175,527 3,733,981 (154,414) 3,755,094 Other intangible assets Trademarks and patents — — 11,896,495 (480,666) 11,415,829 Software 9,368 420,254 442,607 (26,275) 845,954 Customer loyalty — — 26,523,073 (1,071,639) 25,451,434 Total 1,431,075 595,781 42,596,156 (1,732,994) 42,890,018 9. Accumulated amortization as of December 31, 2016 is as follows: Amortization Accumulated as of Foreign Accumulated beginning of Of the currency as of the end Class year Disposals year translation of year Crop nutrition Microbiology products — — 21,316 107,951 129,267 Other intangible assets Trademarks and patents — — 153,698 (3,103) 150,595 Software 6,105 — 49,348 (9,403) 46,050 Customer loyalty — — 199,817 (4,037) 195,780 Total 6,105 — 424,179 91,408 521,692 The depreciation charge is included in Notes 7.3 and 7.4. There are no intangibles assets whose use has been restricted or which have been delivered as a guarantee. The Group has not assumed any commitments to acquire new intangibles. Estimates There is an inherent material uncertainty related to Management’s estimation of the ability of the Group to recover the carrying amounts of internally generated intangible assets related to biotechnology projects because it is dependent upon Group`s ability to raise sufficient funds to complete the projects development, the future outcome of the regulatory process, and the timing and amount of the future cash flows generated by the projects, among other future events. Management’s estimations about the demonstrability of the recognition criteria for these assets and the subsequent recoverability represent the best estimate that can be made based on all the available evidence, existing facts and circumstances and using reasonable and supportable assumptions in cash flow projections. Therefore, the Consolidated financial statements do not include any adjustments that would result if the Group were unable to recover the carrying amount of the above-mentioned assets through the generation of enough future economic benefits. 6.8. Goodwill The Group is required to test whether goodwill has suffered any impairment on an annual basis. The recoverable amount is determined based on value in use calculations. The use of this method requires the estimation of future cash flows and the determination of a discount rate in order to calculate the present value of the cash flows. After the business combinations that occurred in 2016, goodwill has been generated for Rizobacter CGU. This CGU is composed of all revenues collected through Rizobacter from the production and sale of proprietary and third-party products, both in the domestic and international markets. Additionally, Rizobacter generates revenue from the formulation, fragmentation and resale of third-party products. Among the main groups of products are i) microbiological products (bio-inductors/inoculants, biological fertilizers and bio-controllers); ii) crop and seed protection (treatments, adjuvants, baits, stored grains and seed treatment); and iii) crop nutrition (fertilizers). Packs are generally a combination of a microbiological product (bio-inductors/inoculants) with a crop and seed protection product (treatments). Also, after the share purchase agreement (SPA) between Bioceres S.A. and Bioceres Crops Solutions Corp for the 50 % of ownership in Semya (see note 4.5.), the Group recognized as goodwill the expected revenues from the commercialization of intensive R&D products of Semya that previously were allocated on the equity participation. The variations in goodwill occurred during the years / period consolidated correspond to translation differences. There have been no goodwill impairment indicators. Carrying amount of goodwill as of June 30, 2019, 2018 and 2017 is as follows: 06/30/2019 06/30/2018 06/30/2017 Rizobacter 23,484,761 14,438,027 25,079,324 Semya 6,319,954 — — 29,804,715 14,438,027 25,079,324 The Rizobacter brand intangible with an indefinite useful life has been allocated to the Rizobacter CGU. Management has made the estimates considering the cash flow projections projected by the management of Rizobacter and third-party valuation reports on the assets, intangible assets and liabilities assumed. The key assumptions utilized are the following: Key assumption Management’s approach Discount rate The discount rate used ranges was 16.71%. The weighted average cost of capital ("WACC") rate has been estimated based on the market capital structure. For the cost of debt, the indebtedness cost of the CGU was taken. For the cost of equity, the discount rate is estimated based on the Capital Asset Pricing Model (CAPM). The value assigned is consistent with external sources of information. Budgeted market share of joint ventures and other customers The projected revenue from the products and services of the CGU has been estimated by Rizobacter´s management based on market penetration data for comparable products and technologies and on future expectations of foreseen economic and market conditions. The value assigned is consistent with external sources of information. Budgeted product prices The prices estimated in the revenue projections are based on current and projected market prices for the products and services of the CGU The value assigned is consistent with external sources of information. Growth rate used to extrapolate future cash flow projections to terminal period The growth rate used to extrapolate the future cash flow projections to terminal period is 2%. The value assigned is consistent with external sources of information. Management believes that any reasonably possible change in any of these key assumptions would not cause the aggregate carrying amount of the CGU to exceed its recoverable amount. 6.9. Trade and other payable 06/30/2019 06/30/2018 06/30/2017 Current Trade creditors 30,489,072 22,222,872 19,779,461 Shareholders and other related parties (Note 16) 1,796,932 365,994 633,700 Trade creditors - Parent company (Note 16) 1,568,036 — 218,744 Trade creditors - Joint ventures and associates (Note 16) 4,805,149 3,493,113 1,649,367 Taxes 1,475,410 35,391 372,990 Consideration payment Semya adquisition (Note 16) 122,950 — — Miscellaneous 320,945 1,591,460 140,454 40,578,494 27,708,830 22,794,716 06/30/2019 06/30/2018 06/30/2017 Non current Consideration payment Semya adquisition (Note 16) 452,654 — — 452,654 — — The book value is reasonably approximate to the fair value given its short-term nature. 6.10. Borrowings 06/30/2019 06/30/2018 06/30/2017 Current Bank overdraft — 532,912 46,511 Bank borrowings 46,467,308 44,061,555 18,594,823 Corporate bonds 8,416,768 3,262,924 4,644,621 BAF Loans — 5,112,222 — Discount checks 5,807,303 10,243,204 9,638,789 Net loans payables-Parents companies and related parties to Parents (Note 16) 5,399,883 1,816,084 646,538 Finance lease 385,947 280,027 466,689 66,477,209 65,308,928 34,037,971 Non-current Bank borrowings 16,239,743 25,253,940 36,383,297 Corporate bonds 8,018,884 — 3,889,874 Net loans payables-Parents companies and related parties to Parents (Note 16) 12,358,024 — — Finance lease 462,870 454,265 678,993 37,079,521 25,708,205 40,952,164 Further information about finance leases is in Note 15.1. The carrying value of some borrowings as of June 30, 2019, 2018 and 2017 are measured at amortized cost differ from their fair value. The following fair values measured are based on discounted cash flows (Level 3) due to the use of unobservable inputs, including own credit risk. 06/30/2019 06/30/2018 06/30/2017 Amortized Amortized Amortized cost Fair value cost Fair value cost Fair value Current Bank borrowings 46,467,308 46,857,879 44,061,555 42,633,227 18,594,823 16,216,748 Discount checks 5,807,303 5,230,123 10,243,204 9,209,508 9,638,789 8,950,197 Corporate Bonds 8,416,768 7,632,806 3,262,924 3,126,570 4,644,621 4,317,658 Non-current Bank borrowings 16,239,743 14,274,547 25,253,940 20,610,018 36,383,297 33,993,312 Corporate Bonds 8,018,884 6,972,332 — — 3,889,874 3,395,857 Net loans payables-Parents companies and related parties to Parents BAF Loans converted into loans payable to Parents companies. Both are debts taken by the Group in connection with the Rizobacter acquisition. On May 7, 2019, Bioceres Crop Solutions Corp., Bioceres LLC and Bioceres SA entered into an agreement for the restructuring of $15 million of the outstanding loans into a facility with a 5-year maturity and an annual rate of 10%. Financial assets (other receivables from Parents and related parties to Parents) and liabilities (Loans payable to Parents companies) are offset and the net amount is reported in the Statement of Financial Position where Bioceres Crop Solutions currently has a legally enforceable right to offset the recognised amounts, and there is an intention to settle on a net basis or realise the asset and settle the liability simultaneously. The following table presents the recognised financial instruments that are offset: Gross amounts set off Net amounts presented in the Statement of in the Statement of Gross amounts Financial Position Financial Position Current other receivables 17,809,676 (15,827,847) 1,981,829 Total current assets 17,809,676 (15,827,847) 1,981,829 Current borrowings (82,305,056) 15,827,847 (66,477,209) Total current liabilities (82,305,056) 15,827,847 (66,477,209) Corporate Bonds a) Issuance of public corporate bonds (Principal Market) On March 31, 2015 the Shareholders’ Meeting of Rizobacter approved the establishment of a global program of corporate bonds (“ CB”) in the Argentine principal market (“the Program”) for the issue of one or more series of simple CB through public offering, for their future listing on stock exchanges and other markets, up to a revolving outstanding amount of USD 40,000,000 or the equivalent in other currencies, or a lower amount to be determined by the Board of Directors, with a maximum term of five years. Series I: On August 13, 2015, CNV approved the Program and the issue of Series I of the Negotiable Obligations for USD 10,000,000 (increasable to a maximum of USD 17,000,000 or the equivalent in Argentine pesos), through Resolution N° 17737, according to the main terms and conditions summarized in the Prospectus Supplement dated August 13, 2015, which Prospectus Supplement was published in the Daily Gazette of the Buenos Aires Stock Exchange and the Rosario Stock Exchange on the same date. Series I (USD) Amount of the Issue: USD 7,786,327 Date of Issue and Subscript

INFORMATION ABOUT COMPONENTS _2

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME	12 Months Ended
	Jun. 30, 2019
INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
INFORMATION ABOUT COMPONENTS OF CONSOLIDTED STATEMENTS OF COMPREHENSIVE INCOME	7. INFORMATION ABOUT COMPONENTS OF CONSOLIDTED STATEMENTS OF COMPREHENSIVE INCOME 7.1. Revenue 06/30/2019 06/30/2018 06/30/2017 12/31/2016 Sale of goods and services 159,198,516 133,048,429 46,751,191 40,677,714 Royalties 1,110,463 442,689 102,178 349,760 160,308,979 133,491,118 46,853,369 41,027,474 Transactions of sales of goods and services with joint ventures and with shareholders and other related parties are reported in Note 16. 7.2. Cost of sales Item 06/30/2019 06/30/2018 06/30/2017 12/31/2016 Inventory as of the beginning of the year 19,366,001 31,338,034 32,677,314 2,835,909 Adjustment of opening net book amount for the application of IAS 29 4,273,416 — — — Combined business — — — 40,846,774 Purchases of the year 88,380,452 65,825,381 25,332,949 17,307,320 Production costs 11,558,513 14,002,049 5,322,615 3,737,400 Foreign currency translation (9,020,919) (14,704,912) (2,381,686) (1,451,133) Subtotal 114,557,463 96,460,552 60,951,192 63,276,270 Inventory as of the end of the year (27,592,582) (19,366,001) (31,338,034) (32,677,314) Cost of sales 86,964,881 77,094,551 29,613,158 30,598,956 7.3. R&D classified by nature Research Research Research Research and and and and development development development development expenses expenses expenses expenses Item 06/30/2019 06/30/2018 06/30/2017 12/31/2016 Amortization intangible assets 1,106,390 943,488 435,577 — Import and export expenses 16,360 21,640 14,165 1,398 Depreciation property, plant and equipment 220,849 223,515 222,446 63,558 Freight and haulage — 30 73,275 136 Employee benefits and social securities 541,025 1,435,028 481,326 360,760 Maintenance 56,395 86,112 42,373 47,055 Energy and fuel 52,919 78,570 49,785 22,703 Supplies and materials 1,175,184 844,372 107,678 107,436 Mobility and travel 48,308 87,628 66,865 29,822 Stock options based incentive — 30,005 25,710 43,827 Professional fees and outsourced services 447,383 121,914 90,206 5,850 Office supplies 3,796 17,932 57,564 38,159 System expenses — 8,851 1,797 211 Insurance 8,593 22,006 18,302 6,646 Miscellaneous 12,189 29,009 303,199 126,293 Total 3,689,391 3,950,100 1,990,268 853,854 7.4. Expenses classified by nature and function Selling, general and Production administrative Total Item costs expenses 06/30/2019 Amortization intangible assets — 1,270,530 1,270,530 Analysis and storage 5,811 904 6,715 Commissions and royalties 751,972 489,301 1,241,273 Bank expenses and commissions — 30,784 30,784 Import and export expenses 95,111 1,396,636 1,491,747 Depreciation property, plant and equipment 1,164,810 1,064,597 2,229,407 Impairment of receivables — 686,985 686,985 Freight and haulage 1,433,867 2,662,715 4,096,582 Employee benefits and social securities 5,313,211 12,969,653 18,282,864 Maintenance 501,699 532,648 1,034,347 Energy and fuel 568,848 195,449 764,297 Supplies and materials 275,378 214,513 489,891 Mobility and travel 12,097 1,306,067 1,318,164 Publicity and advertising — 1,709,552 1,709,552 Contingencies — 67,417 67,417 Professional fees and outsourced services 681,790 7,346,607 8,028,397 Professional fees related parties — 401,005 401,005 Office supplies 31,394 352,167 383,561 Insurance 105,302 802,352 907,654 System expenses — 709,539 709,539 Obsolescence 564,873 — 564,873 Taxes 37,388 4,821,136 4,858,524 Miscellaneous 14,962 213,243 228,205 Total 11,558,513 39,243,800 50,802,313 Selling, general and Production administrative Total Item costs expenses 06/30/2018 Amortization intangible assets — 1,197,988 1,197,988 Analysis and storage 1,225,756 225,462 1,451,218 Commissions and royalties 552,906 671,180 1,224,086 Bank expenses and commissions — 51,471 51,471 Import and export expenses 131,558 725,479 857,037 Depreciation property, plant and equipment 1,208,699 798,667 2,007,366 Impairment of receivables — 1,259,127 1,259,127 Freight and haulage 664,984 2,251,297 2,916,281 Employee benefits and social securities 7,582,440 14,265,650 21,848,090 Maintenance 597,497 408,960 1,006,457 Energy and fuel 419,716 610,376 1,030,092 Supplies and materials 169,674 1,577 171,251 Mobility and travel 48,068 1,373,119 1,421,187 Publicity and advertising — 2,239,505 2,239,505 Contingencies — 84,411 84,411 Telephone and communications — 630 630 Professional fees and outsourced services 195 2,058,787 2,058,982 Professional fees related parties — 759,149 759,149 Office supplies 17,790 549,359 567,149 Insurance 118,610 611,129 729,739 Sistems expenses 19,057 601,955 621,012 Obsolescence 661,804 — 661,804 Taxes 105,104 4,019,515 4,124,619 Miscellaneous 478,191 498,895 977,086 Total 14,002,049 35,263,688 49,265,737 Selling, general and Production administrative Total Item costs expenses 06/30/2017 Amortization intangible assets — 982,952 982,952 Analysis and storage 20,745 46,781 67,526 Commissions and royalties 60,052 258,456 318,508 Bank expenses and commissions — 67,094 67,094 Import and export expenses 76,818 (318,951) (242,133) Depreciation property, plant and equipment 384,019 648,192 1,032,211 Impairment of receivables — 333,490 333,490 Freight and haulage 148,362 903,544 1,051,906 Employee benefits and social securities 3,554,197 6,661,622 10,215,819 Maintenance 426,634 297,924 724,558 Energy and fuel 185,379 258,704 444,083 Supplies and materials 160,069 — 160,069 Mobility and travel 15,980 723,117 739,097 Publicity and advertising — 1,047,653 1,047,653 Contingencies — (248,727) (248,727) Telephone and communications — 1,387 1,387 Professional fees and outsourced services 20,462 888,104 908,566 Professional fees related parties — 447,723 447,723 Office supplies 2,418 466,154 468,572 Insurance 70,320 289,887 360,207 Sistems expenses 10,072 74,084 84,156 Obsolescence 148,840 — 148,840 Taxes 23,850 1,697,783 1,721,633 Miscellaneous 14,398 162,625 177,023 Total 5,322,615 15,689,598 21,012,213 Selling, general and Production administrative Total Item costs expenses 12/31/2016 Amortization intangible assets — 424,179 424,179 Analysis and storage 67,052 71,126 138,178 Commissions and royalties 405,923 92,943 498,866 Bank expenses and commissions — 73,991 73,991 Import and export expenses 21,435 232,402 253,837 Depreciation property, plant and equipment 240,638 280,097 520,735 Impairment of receivables — 125,764 125,764 Freight and haulage 33,638 751,586 785,224 Employee benefits and social securities 1,781,605 2,888,707 4,670,312 Maintenance 3,358 148,583 151,941 Energy and fuel 87,063 126,305 213,368 Supplies and materials 29,885 — 29,885 Mobility and travel 7,540 272,191 279,731 Publicity and advertising — 384,168 384,168 Contingencies — 293,009 293,009 Sistems expenses — 4,633 4,633 Professional fees and outsourced services 14,576 910,145 924,721 Professional fees related parties — 183,393 183,393 Office supplies 5,813 160,938 166,751 Insurance — 86,497 86,497 Obsolescence 982,351 — 982,351 Taxes 11,967 1,072,358 1,084,325 Miscellaneous 44,556 244,106 288,662 Total 3,737,400 8,827,121 12,564,521 7.5. Finance results Finance Income 06/30/2019 06/30/2018 06/30/2017 12/31/2016 Interest generated by assets 1,397,025 909,912 303,513 65,896 Interest generated by assets related parties 90,188 294,577 179,887 73,178 Gain for cancellation of purchase option 6,582,849 — — — Changes in fair value of financial assets or liabilities and other financial results 649,998 67,349 92,820 17,394 8,720,060 1,271,838 576,220 156,468 Finance Costs 06/30/2019 06/30/2018 06/30/2017 12/31/2016 Interest generated by liabilities with the parent (1,386,288) (118,266) (520,959) (1,118,679) Interest generated by liabilities (22,884,366) (16,646,801) (7,422,210) (5,011,139) Financial commissions (1,578,292) (1,628,075) (1,032,366) (885,351) Other financial loss (243,688) — (517,136) (136,792) (26,092,634) (18,393,142) (9,492,671) (7,151,961) Other finance results 06/30/2019 06/30/2018 06/30/2017 12/31/2016 Share based payment cost of listing shares (Note 10.3) (20,893,789) — — — Net gain of inflation effect on monetary items 14,653,335 — — — Exchange differences generated by assets 48,355,784 25,710,957 1,186,264 — Exchange differences generated by liabilities (66,200,973) (49,540,369) (2,463,076) (1,254,084) (24,085,643) (23,829,412) (1,276,812) (1,254,084) Total net finance results (41,458,217) (40,950,716) (10,193,263) (8,249,577)

INCOME TAX AND MINIMUM PRESUMED

INCOME TAX AND MINIMUM PRESUMED INCOME TAX	12 Months Ended
	Jun. 30, 2019
INCOME TAX AND MINIMUM PRESUMED INCOME TAX
INCOME TAX AND MINIMUM PRESUMED INCOME TAX	8. INCOME TAX AND MINIMUM PRESUMED INCOME TAX Tax reform in Argentina On December 29, 2017, the Government promulgated Law 27430 - Income Tax. This law has introduced several changes regarding income tax; its key components are as follows: Income tax rate: The income tax rates for Argentine companies will be gradually reduced from 35% to 30% for fiscal periods beginning from January 1, 2018 until December 31, 2019, and 25% for fiscal periods beginning on or after January 1, 2020, inclusive. Tax on dividends: A tax is introduced on dividends or profits distributed, among others, by Argentine companies or permanent establishments with the following considerations: (i) dividends derived from the profits generated during fiscal years beginning on January 1, 2018 and until December 31, 2019 will be subject to a 7% withholding; and (ii) dividends arising from gains obtained for years beginning on or after January 1, 2020, will be subject to a 13% withholding tax. Dividends arising from benefits obtained up to the year prior to that commenced on or after January 1, 2018 will continue to be subject, for all beneficiaries of the same, to the 35% withholding on the amount that exceeds taxable distributable taxable profits (transition period of the equalization tax). Optional tax revaluation: The regulation establishes that, at the option of the Companies, the tax revaluation of certain assets located in the country and that are affected to the generation of taxable profits may be carried out. The special tax on the amount of the revaluation depends on the nature of the asset, being 8% for buildings that does not have the character of inventories for sale, 15% for the buildings that have the character of inventories for sale, and 10% for the rest of the assets. Once the option for a certain property, plant or equipment is exercised, all other property, plant and equipment in the same category must be revalued. This tax is not deductible from income tax, and tax result that originated through the revaluation is not subject to it. Adjustment of deductions: Acquisitions or investments made in fiscal years beginning on or after January 1, 2018 will be adjusted on the basis of the percentage variations of the Internal Wholesale Price Index (IPIM) provided by the National Institute of Statistics and Census (INDEC), situation that will increase the deductible amortization and its computable cost in case of sale. The balances of income tax and minimum presumed income tax recoverable and payable are as follows: 06/30/2019 06/30/2018 06/30/2017 Current assets Income tax 1,263,795 2,082,269 1,701,382 1,263,795 2,082,269 1,701,382 Non-current assets Income tax — — 95,565 Minimum presumed income tax 1,184 126,653 220,000 1,184 126,653 315,565 06/30/2019 06/30/2018 06/30/2017 Liabilities Income tax 142,028 2,569 29,788 142,028 2,569 29,788 The breakdown of items making up deferred tax assets and liabilities as of June 30, 2019, 2018, 2017 and December 31, 2016 are as follows: Deferred tax assets 06/30/2019 06/30/2018 06/30/2017 12/31/2016 Tax Loss-Carry Forward 2,663,813 3,638,269 1,059,746 753,359 Changes in fair value of financial assets or liabilities 32,062 35,944 96,394 87,467 Trade receivables 374,425 462,756 829,095 804,481 Allowances — 370,930 805,375 935,415 Inventories — 710,391 367,682 519,310 Intangible assets — 15,098 38,241 48,426 Contingencies — — 13,612 — Goverment grants 2,649 9,360 41,616 54,572 Others 670,760 359,073 120,340 1,446,474 Total deferred tax assets 3,743,709 5,601,821 3,372,101 4,649,504 Deferred tax liabilities 06/30/2019 06/30/2018 06/30/2017 12/31/2016 Intangible assets (9,458,239) (5,071,808) (12,633,408) (13,609,901) Property, plant and equipment depreciation (9,618,648) (8,497,756) (12,923,320) (12,738,676) Borrowings (13,170) (19,372) (39,257) (27,482) Contingencies — (2,709) — — Inflation tax adjustment (1,706,092) — — — Allowances (152,159) — — — Inventories (153,563) — — — Others — (297) (15,942) (9,727) Total deferred tax liabilities (21,101,871) (13,591,942) (25,611,927) (26,385,786) Net deferred tax (17,358,162) (7,990,121) (22,239,826) (21,736,282) The roll forward of deferred tax assets and liabilities as of June 30, 2019, 2018, 2017 and December 31, 2016 are as follows: Transfer Adquisition from of control Income deferred Balance of Semya tax tax Charge Conversion Balance Deferred tax assets 06/30/2018 S.A. provision liabilities to OCI difference 06/30/2019 Tax Loss-Carry Forward 3,638,269 113,289 (1,306,198) — — 218,453 2,663,813 Changes in fair value of financial assets or liabilities 35,944 25,868 (33,200) — — 3,450 32,062 Trade receivables 462,756 — (114,765) — — 26,434 374,425 Allowances 370,930 — (555,679) 152,159 — 32,590 — Inventories 710,391 — (119,316) 153,563 — (744,638) — Intangible assets 15,098 (482,387) (22,467) 476,174 — 13,582 — Goverment grants 9,360 — (7,262) — — 551 2,649 Others 359,073 — 290,552 — — 21,135 670,760 Total deferred tax assets 5,601,821 (343,230) (1,868,335) 781,896 — (428,443) 3,743,709 Transfer Adquisition from of control Income deferred Balance of Semya tax tax Charge Conversion Balance Deferred tax liabilities 06/30/2018 S.A. provision assets to OCI difference 06/30/2019 Intangible assets (5,071,808) — (937,962) (476,174) — (2,972,295) (9,458,239) Property, plant and equipment depreciation (8,497,756) — (335,077) — 576,453 (1,362,268) (9,618,648) Borrowings (19,372) — 7,342 — — (1,140) (13,170) Contingencies (2,709) — 2,869 — — (160) — Inflation tax adjustment — — (1,706,092) — — — (1,706,092) Allowances — — — (152,159) — — (152,159) Inventories — — — (153,563) — — (153,563) Others (297) — 314 — — (17) — Total deferred tax liabilities (13,591,942) — (2,968,606) (781,896) 576,453 (4,335,880) (21,101,871) Transfer from deferred Balance Income tax tax Charge Conversion Balance Deferred tax assets 06/30/2017 provision liabilities to OCI difference 06/30/2018 Tax Loss-Carry Forward 1,059,746 3,631,690 — — (1,053,167) 3,638,269 Changes in fair value of financial assets or liabilities 96,394 (27,872) — — (32,578) 35,944 Trade receivables 829,095 (16,762) — — (349,577) 462,756 Allowances 805,375 (143,397) — — (291,048) 370,930 Inventories 367,682 (767,844) — — 1,110,553 710,391 Intangible assets 38,241 (11,570) — — (11,573) 15,098 Contingencies 13,612 — (13,612) — — — Goverment grants 41,616 (21,647) — — (10,609) 9,360 Others 120,340 319,514 12,464 — (93,245) 359,073 Total deferred tax assets 3,372,101 2,962,112 (1,148) — (731,244) 5,601,821 Transfer from Balance Income tax deferred Charge Conversion Balance Deferred tax liabilities 06/30/2017 provision tax assets to OCI difference 06/30/2018 Intangible assets (12,633,408) (1,114,442) — — 8,676,042 (5,071,808) Property, plant and equipment depreciation (12,923,320) 2,811,852 — (4,507,311) 6,121,023 (8,497,756) Borrowings (39,257) 3,720 — — 16,165 (19,372) Contingencies — (15,442) 13,612 — (879) (2,709) Others (15,942) 24,617 (12,464) — 3,492 (297) Total deferred tax liabilities (25,611,927) 1,710,305 1,148 (4,507,311) 14,815,843 (13,591,942) Net deferred tax (22,239,826) 4,672,417 — (4,507,311) 14,084,599 (7,990,121) Transfer from Balance Income tax deferred tax Charge Conversion Balance Deferred tax assets 12/31/2016 provision liabilities to OCI difference 06/30/2017 Tax Loss-Carry Forward 753,359 360,007 — — (53,620) 1,059,746 Changes in fair value of financial assets or liabilities 87,467 13,216 — — (4,289) 96,394 Trade receivables 804,481 60,520 — — (35,906) 829,095 Allowances 935,415 (83,964) — — (46,076) 805,375 Inventories 519,310 (128,450) — — (23,178) 367,682 Intangible assets 48,426 (8,577) — — (1,608) 38,241 Contingencies — 14,301 — — (689) 13,612 Goverment grants 54,572 (11,218) — — (1,738) 41,616 Others 1,446,474 877,016 — — (2,203,150) 120,340 Total deferred tax assets 4,649,504 1,092,851 — — (2,370,254) 3,372,101 Transfer from Balance Income tax deferred tax Charge Conversion Balance Deferred tax liabilities 12/31/2016 provision assets to OCI difference 06/30/2017 Intangible assets (13,609,901) 802,280 — — 174,213 (12,633,408) Property, plant and equipment depreciation (12,738,676) 616,622 — (936,029) 134,763 (12,923,320) Borrowings (27,482) (13,002) — — 1,227 (39,257) Others (9,727) (6,649) — — 434 (15,942) Total deferred tax liabilities (26,385,786) 1,399,251 — (936,029) 310,637 (25,611,927) Net deferred tax (21,736,282) 2,492,102 — (936,029) (2,059,617) (22,239,826) Income Balance tax Business Charge to Conversion Balance Deferred tax assets 12/31/2015 provision combination OCI difference 12/31/2016 Tax Loss-Carry Forward 258,194 520,957 — — (25,792) 753,359 Changes in fair value of financial assets or liabilities 61,913 28,642 — — (3,088) 87,467 Trade receivables — — 804,481 — — 804,481 Allowances 119,651 (9,559) 656,327 — 168,996 935,415 Inventories (246,720) 935,283 (234,278) — 65,025 519,310 Intangible assets 78,956 (41,366) 12,510 — (1,674) 48,426 Goverment grants 53,477 29,362 — — (28,267) 54,572 Others — 32,468 1,394,601 — 19,405 1,446,474 Total deferred tax assets 325,471 1,495,787 2,633,641 — 194,605 4,649,504 Income Balance tax Business Charge to Conversion Balance Deferred tax liabilities 12/31/2015 provision combination OCI difference 12/31/2016 Intangible assets — — (13,609,901) — — (13,609,901) Property, plant and equipment depreciation (53,679) (18,703) (12,699,878) — 33,584 (12,738,676) Borrowings — — (27,482) — — (27,482) Others — 13,696 (17,833) — (5,590) (9,727) Total deferred tax liabilities (53,679) (5,007) (26,355,094) — 27,994 (26,385,786) Net deferred tax 271,792 1,490,780 (23,721,453) — 222,599 (21,736,282) The following table provides a reconciliation of the statutory tax rate to the effective tax rate. As the operations of the Group’s Argentine subsidiaries are the most significant source of profit or loss before tax, the following reconciliation has been prepared using the Argentine statutory tax rate: 06/30/2019 06/30/2018 06/30/2017 12/31/2016 Loss before income tax-rate 0% (21,669,883) — — — Profit before income tax-rate 21% 1,264 — — — Loss before income tax-rate 35% — (21,621,007) (11,195,800) (8,042,536) Profit/(Loss) before income tax-rate 30% 12,296,011 (3,618,756) — — Income tax charge by applying tax rate to profit/(loss) before tax: (3,689,069) 8,652,979 3,918,530 2,814,888 Share of profit or loss of subsidies, joint ventures and associates (44,721) (1,448,925) (571,587) (977,061) Stock options charge 78,681 (8,898) (8,978) (15,339) Rate change adjustment (54,735) 3,768,518 — — Allowance for unused tax losses — (59,879) — (46,553) Non-deductible expenses and untaxed gains (254,201) (732,442) (312,477) 84,712 Representation expenses (136,614) (204,897) — — Foreign investment coverage 233,634 — — — Result por inflation effect on monetary items (3,119,259) — — — Others — 962,061 (208,237) — Income tax (expense) benefit (6,986,284) 10,928,517 2,817,251 1,860,647 The Group did not recognize deferred income tax liabilities of USD 44,721, USD 1,448,925,USD 571,587 and USD 977,061 as of June 30, 2019,2018, 2017 and December 31, 2016, respectively, related to their investments in foreign subsidiaries, associates and joint ventures. In addition, the withholdings and/or similar taxes paid at source may be creditable against the Group’s potential final tax liability. Principal statutory taxes rates in the countries where the Group operates for all of the years presented are: Income tax rate Tax jurisdiction 2019 2018 2017 2016 Argentina 30 % 30% - 35% 35 % 35 % Cayman % — — — United State of America 21 % — — — 06/30/2019 06/30/2018 06/30/2017 12/31/2016 Current tax expense (2,149,343) 6,256,100 325,149 369,867 Deferred tax (4,836,941) 4,672,417 2,492,102 1,490,780 Total (6,986,284) 10,928,517 2,817,251 1,860,647 The charge for income tax charged directly to profit or loss and the amount and expiry date of carry forward tax losses as of June 30, 2019 are as follows: Tax-Loss Tax-Loss Fiscal year Carry forward Carry forward Prescription 2015 125,442 31,389 2020 2016 741,741 185,435 2021 2017 1,149,203 283,096 2022 2018 402,956 104,943 2023 2019 668,458 194,200 2024 2019 8,879,763 1,864,750 2039 Total 11,967,563 2,663,813 The amount of tax losses for the fiscal year ended on June 30, 2019 is an estimate of the amount to be presented in the tax return. The amount and expiry date of unused tax credits of Argentina minimum presumed income tax as of June 30, 2019 is as follows: Fiscal year Amount Prescription 2016 1,184 2026 Total 1,184 Estimates There is an inherent material uncertainty related to Management’s estimation of the ability of the Group to use the deferred tax assets (both carryforward of unused tax losses and deductible temporary differences) and the credit of minimum presumed income tax because their future utilization depends on the generation of enough future taxable income by the entities within the Group during the periods in which those temporary differences are deductible or when the unused tax losses can be used. Based on the projections of future taxable income for the periods in which the deferred tax assets are deductible, the Group’s management estimates that, except for the part of deferred tax asset that were unrecognized, it is probable that the entities within the Group can utilize those deferred tax assets, which depends, among other factors, on the success of the current projects of agricultural biotechnology, the future market price of commodities and the market share of the entities within the Group. The estimates of Management about the demonstrability of the recognition criteria for these deferred tax assets and their subsequent recoverability represent the best estimate that can be made based on all the available evidence, existing facts and circumstances and the use of reasonable and supportable assumptions in the projections of future taxable income. Therefore, the Consolidated financial statements do not include adjustments that could result if the entities within the Group would not be able to recover the deferred tax assets through the generation of enough future taxable income.

LOSS PER SHARE

LOSS PER SHARE	12 Months Ended
	Jun. 30, 2019
LOSS PER SHARE
LOSS PER SHARE	9. LOSS PER SHARE 06/30/2019 06/30/2018 06/30/2017 12/31/2016 Numerator Loss for the year (basic EPS) (1) (18,369,045) (11,039,533) (5,908,927) (5,865,870) Denominator Weighted average number of shares (basic EPS) (1) 30,478,390 28,098,117 28,098,117 28,098,117 Basic loss attributable to ordinary equity holders of the parent (1) (0.60) (0.39) (0.21) (0.21) (1) The 27,116,174 shares issued to Bioceres LLC in exchange of its Bioceres Inc Crop Business and its equity interest in Bioceres Semillas, together with the 119,443 shared issued to exercise the Bioceres Semillas’ tag along and the 862,500 shares received by Bioceres LLC from the original founders of Union, were considered retrospectively in the EPS calculations. The denominators used in the EPS calculation are based on the assumption of those events having occurred at the beginning of the earliest period presented. Warrants outstanding were not included in the EPS calculations for the year ended June 30,2019 and 2018 because they were anti-dilutive securities in those years. There are neither ordinary shares transactions nor potential ordinary shares transactions that have occurred after June 30, 2019 that would have changed significantly the number of ordinary shares or potential ordinary shares outstanding at the end of the reporting period.

INFORMATION ABOUT COMPONENTS _3

INFORMATION ABOUT COMPONENTS OF EQUITY	12 Months Ended
	Jun. 30, 2019
INFORMATION ABOUT COMPONENTS OF EQUITY
INFORMATION ABOUT COMPONENTS OF EQUITY	10. INFORMATION ABOUT COMPONENTS OF EQUITY 10.1. Capital issued The 27,116,174 shares issued to Bioceres LLC in exchange of its Bioceres Inc Crop Business and its equity interest in Bioceres Semillas, together with the 119,443 shares issued to exercise the Bioceres Semillas’ tag-along and the 862,500 shares received by Bioceres LLC from the original founders of Union, were considered retrospectively in issued capital based on the assumption of those events have occurred at the beginning of the earliest period presented. 10.2. Parent company investment The Group has recognized the contribution made by Bioceres S.A. into the combined entity as share premium as follows: 06/30/2019 06/30/2018 06/30/2017 12/31/2016 Capital contributions 294,041 1,572,235 2,585,580 48,083,838 Intangible contributed 623,022 2,105,616 2,049,823 — Preferred shares contributed 3,331,534 (3,277,615) — Incorporation of financial debt (*) (15,475,410) (5,000,000) — 15,569,028 Financed payment to Rizobacter sellers — — — (13,182,575) (14,558,347) 2,009,385 1,357,788 50,470,291 (*) Financial debt taken by the Group in connect with Rizobacter acquisition 10.3. Reverse recapitalization As mentioned in Note 1, the merger was reflected as a reverse recapitalization (capital transaction) equivalent to the issuance of shares by the private company (Bioceres) for the net monetary assets of the public shell company (Union). The difference in the fair value of equity instruments retained by UAC’s former shareholders (shares and public warrants) over the value of the net monetary assets incorporated represents a service for listing the shares and it should be accounted as a shared based payment in accordance to IFRS 2. The cost of the service was recognized as an expense in the line “Share based payment cost of listing shares” for an amount of $20.9 million. In December 2017, Union issued an aggregate of 2,875,000 ordinary shares (“Founder shares”) pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act. 862,500 of those Founder shares were transferred to Bioceres LLC as an additional consideration payable in the merger. On March 2, 2018, Union consummated an IPO of 11,500,000 units. Each unit consisted in one ordinary share, one right exchangeable for one-tenth of one ordinary share, and one redeemable warrant exercisable for one ordinary share at a price of $11.50 per share (Public warrants). On February 27, 2019, Union held an Extraordinary General Meeting of Shareholders, whereby holders voted in favor of the merger with Bioceres and converted 11,500,000 rights into 1,150,000 Union shares. In connection with this vote, the holders of 11,376,836 ordinary shares of UAC exercised their right to redeem their shares and collected a total amount of $117,005,196. Net process from the trust account was incorporated to the Group for a total amount of $1,083,840. The fair value of the shares retained by UAC former shareholders was calculated based on the UAC share price as of the day of the transaction ($5.35). 10.4. Shares issued - Rizobacter Call Option Immediately following the merger, the Rizobacter Call Option was exercised. For the tranche of 9.99% (that was previously accounted as financial liability) consideration of the payment was in $1,265,000 in cash and in the form of UAC shares, pursuant to which 1,334,047 ordinary shares were issued. The difference between the fair value of the consideration paid and the financial liability was recognized in financial results as “Gain for cancellation of purchase option”. For the tranche of an additional 20%, consideration of the payment was in the form of UAC shares, pursuant to which 3,402,688 ordinary shares were issued. The adjustment in the non-controlling interest was recorded as an equity transaction. After the Rizobacter Call Option was exercised, the total indirect ownership of BCS Holding in Rizobacter increased to 80.00% of all outstanding stock of Rizobacter. 10.5. Share capital summary As of the date of this financial statement, the Group had (i) 100,000,000 ordinary shares ($0.0001 par value) authorized, (ii) 36,120,517 ordinary shares issued and outstanding, (iii) 1,000,000 preference shares ($0.0001 par value) authorized, (iv) no preference shares issued and outstanding, (v) 12,700,000 private placement warrants outstanding (5,200,000 of which were issued in connection with Union’s IPO and 7,500,000 of which were issued in connection with the merger) classified as liability (see Note 6.16) and (vi) 11,500,000 public warrants outstanding. Public warrants: simultaneously with the consummation of the IPO, Union consummated the public placement of 11,500,000 public warrants exercisable for one ordinary share at a price of $11.50 per share (Public warrants). Those warrants were purchased by certain of Union initial shareholders. They can be exercised only on a cash basis in a 5-year period and can be redeemed at the option of the company when the stock price is above $18. Public warrants were classified as equity and consideration was included in column “Share Premium”. Holders of the ordinary shares are entitled to one vote for each ordinary share. 10.6. Non-controlling interests The subsidiaries whose non-controlling interest are significant as of June 30, 2019, June 30, 2018 and the six-month transition period ended June 30, 2017 are: a) Rizobacter Argentina Name Country 06/30/2019 06/30/2018 06/30/2017 Rizobacter Argentina S.A. Argentina 20 % 40 % 40 % Below is a detail of the summarized financial information of Rizobacter, prepared in accordance with IFRS, and modified due to fair value adjustments at the acquisition date and differences in accounting policies. The information is presented prior to eliminations between that subsidiary and other Group companies. 06/30/2019 06/30/2018 06/30/2017 Current assets 115,546,951 86,461,071 86,202,115 Non-current assets 47,418,450 48,295,110 113,906,651 Total assets 162,965,401 134,756,181 200,108,766 Current liabilities 100,590,919 88,270,487 60,192,036 Non-current liabilities 34,788,705 29,598,319 65,604,538 Total liabilities 135,379,624 117,868,806 125,796,574 Equity attributable to controlling interest 27,584,666 16,824,251 74,266,985 Equity attributable to non-controlling interest 1,111 63,124 45,207 Total equity 27,585,777 16,887,375 74,312,192 Total liabilities and equity 162,965,401 134,756,181 200,108,766 Period from 10/19/16 - Summary statements of comprehensive income or loss 06/30/2019 06/30/2018 06/30/2017 12/31/2016 Revenues 156,741,933 129,798,271 44,458,442 36,739,496 Cost of sales (85,287,771) (71,699,144) (27,494,324) (26,818,086) Gross margin 71,454,162 58,099,127 16,964,118 9,921,410 Research and development expenses (2,367,727) (2,902,235) (1,711,089) (555,676) Selling, general and administrative expenses (31,316,843) (31,219,784) (14,501,080) (6,936,425) Share of profit or loss of joint ventures and associates 1,071,297 (1,683,949) (610,994) (161,436) Other income 286,626 524,672 53,928 — Operating profit 39,127,515 22,817,831 194,883 2,267,873 Financial results (24,650,359) (37,989,573) (8,619,703) (4,014,402) Loss before taxes 14,477,156 (15,171,742) (8,424,820) (1,746,529) Income tax benefit (expense) (7,729,300) 3,275,077 2,333,310 (1,836,968) Result for the year 6,747,856 (11,896,665) (6,091,510) (3,583,497) Exchange differences on translation of foreign operations 17,197 (8,266,718) 202,981 (898,790) Revaluation of property, plant and equipment, net of tax (1,347,124) 14,079,875 2,032,872 — Total comprehensive result 5,417,929 (6,083,508) (3,855,657) (4,482,287) There were no dividends paid to Rizobacter non-controlling interest (NCI) in the years ended June 30, 2019, 2018, in the six-month transition period ended June 30, 2017 and, in the year ended December 31, 2016. b) RASA Holding preferred shares On October 14, 2016, RASA Holding issued 4,830,000 Class A preferred shares, with a par value of USD 10 per share and a subscription price of USD 8.696 per share, in order to raise USD 42 million to finance the cash payment required for the completion of the acquisition of Rizobacter. The Class A preferred shares in RASA Holding accrue an annual “pay in kind” (PIK) dividend coupon of 12% that accumulates as principal over a maturity term of five years, and carry (i) a mandatory participation right in the subscription to ordinary shares of Bioceres S.A. as part of a qualified public offering (i.e., an offering that is consummated for at least USD 50 million net of the proceeds received from the holders of the RASA Holding Class A preferred shares), and to participate in an optional manner in the case of a non-qualified public offering and/or a private capital increase occurring between December 17, 2017 and October 14, 2021; and (ii) a mandatory conversion right for holders of the RASA Holding Class A preferred shares to convert such preferred shares into common shares of RASA Holding after five years or in the case of a public offering made by RASA Holding or of Rizobacter. In addition, this agreement grants liquidity preference rights to the Class A preferred shares, which give the holders a right to a cash option that can be exercised in the following situations: (i) sale or substantial transfer of the assets of RASA Holding or Rizobacter; (ii) mergers or reorganizations in which RASA Holding is involved; (iii) change of control of RASA Holding; or (iv) liquidation or dissolution of RASA Holding. As of June 30, 2017, there were 1,409,848 preferred shares in the possession of third parties outside the Group. Since there was no contractual obligation to pay cash in any situation, the preferences of liquidity are under the control of the Group and the agreement provides for the delivery of a fixed number of own equity instruments for a fixed amount of cash, preferred shares in possession of third parties outside of Group Bioceres are classified as non-controlling interests in the Consolidated financial statements as of June 30, 2017. After the verification of the financing event that occurred on February 9, 2018 with a capitalization of USD 50.5 million, the holders of RASA Holding’s Preferred Stock, expressed their willingness to exercise the participation rights granted by the Bioceres S.A. on dates October 14, 2016, December 26, 2016 and May 18, 2017. In this way, the holders of Preferred Shares of RASA Holding subscribed new ordinary shares of Bioceres S.A. in exchange for their RASA Holding preferred shares plus the accumulated dividends. At the date of the financing event that occurred on February 9, 2018, there was 1,409,848 Preferred Shares held by third parties, who accumulated an annual dividend payment in kind of 12% and an additional dividend (which allowed them to acquire the same number of shares that they would have otherwise acquired at a subscription price of USD 7.91 for every USD 10 of value of each Preferred Share). This transaction was accounted as an equity contribution for the Consolidated financial statements. Thus, on June 11, 2018, the holders of Preferred Shares subscribed 2,010,170 of new actions of Bioceres S.A. according to his holding as of February 9, 2018, the date of the financing event. As of June 30, 2019, all remaining preferred shares were in property of Group Bioceres and were contributed to BCS Holding in consideration of the business combination with Union.

CASH FLOW INFORMATION

CASH FLOW INFORMATION	12 Months Ended
	Jun. 30, 2019
CASH FLOW INFORMATION
CASH FLOW INFORMATION	11. CASH FLOW INFORMATION Significant non-cash transactions related to investing and financing activities are as follows: 06/30/2019 06/30/2018 06/30/2017 12/31/2016 Investment activities Settlement of liability with loan to joint venture (1) — — — Investment in kind in other related parties (Note 16) 463,511 — — — Non-monetary contributions in joint ventures (Note 12) 94,355 679,510 1,150,259 — 7,521,967 679,510 1,150,259 — Financing activities Purchase option paid by a parent loan (1,265,000) — — — Parent company investment (14,558,347) 2,009,385 1,357,788 50,470,291 Issuanse of shares — — — 15,850,000 Transfer of preferred stocks — 9,759,545 — — Capitalization of financial debt 13,720,000 — — — Reverse recapitalization (3,688,963) — — — Net asstes incorporated of Semya (2) 7,369,168 — — — Acquisition of control of Semya (3,684,585) — — — (2,107,727) 11,768,930 1,357,788 66,320,291 (1) (2) Balance sheet as of May 31, 2019 Total Current assets 67,924 Non-current assets Tax credits 253,655 Intangibles 2,147,199 Goodwill 5,836,268 Total assets 8,305,047 Current liabilities Trade payables 273,442 Borrowings 114,568 Non-current liabilities Deferred tax 547,868 Total liabilities 935,878 Total equity 7,369,169 Disclosure of changes in liabilities arising from financing activities: Financing activities Financed payment - Acquisition of Borrowings business Total As of June 30, 2018 91,017,133 22,874,609 113,891,742 Proceeds from borrowings 88,693,632 — 88,693,632 Decrease bank overdraft and other short-term borrowings (4,968,813) — (4,968,813) Payments (83,777,814) (7,140,000) (90,917,814) Capitalization of financial debt — (13,720,000) (13,720,000) Interest payment (20,167,101) — (20,167,101) Exchange differences and currency translation differences 32,759,693 812,002 33,571,695 As of June 30, 2019 103,556,730 2,826,611 106,383,341

JOINT VENTURES

JOINT VENTURES	12 Months Ended
	Jun. 30, 2019
JOINT VENTURES
JOINT VENTURES	12. JOINT VENTURES In September 2018, the participation of Rizobacter S.A. in Indrasa Biotecnología S.A. decreased from 52.50% to 35%, therefore the Group lost the control over this subsidiary. In June 2019, Bioceres Crop Solutions signed a share purchase agreement with Bioceres S.A. for the 50% of the ownership in Semya. See Note 4.5. Investments in joint ventures and affiliates: 06/30/2019 06/30/2018 06/30/2017 Assets Semya S.A. (1) — 2,972,239 5,263,819 Synertech Industrias S.A. 25,297,376 16,099,816 26,844,410 Indrasa Biotecnología S.A. 23,652 — — 25,321,028 19,072,055 32,108,229 06/30/2019 06/30/2018 06/30/2017 Liabilities Trigall Genetics S.A. 1,970,903 2,012,298 1,527,286 1,970,903 2,012,298 1,527,286 (1) Changes in join ventures investmens and affiliates: 06/30/2019 06/30/2018 06/30/2017 12/31/2016 As of the beginning of the year 17,059,757 30,580,943 31,306,503 (1,188,483) Adjustment of opening net book amount for the application of IAS 29 8,328,794 — — — Monetary contributions 129,340 — — — Non-monetary contributions 94,355 679,510 1,150,259 — Parent company investment 294,041 121,479 82,872 162,012 Loss of control of Indrasa Biotecnología S.A. 10,591 — — Adquisicion of control of Semya S.A. (3,684,585) — — Revaluation of property, plant and equipment 94,009 1,679,818 189,025 — Business combinations - Synertch — — — 29,000,000 Business combinations - Semya — — — 4,317,619 Foreign currency translation 11,337 (13,865,192) (1,498,641) (277,603) Share of profit or loss 1,012,486 (2,136,801) (649,075) (707,042) As of the end of the year 23,350,125 17,059,757 30,580,943 31,306,503 Share of profit or loss of joint ventures and affiliates: 06/30/2019 06/30/2018 06/30/2017 12/31/2016 Trigall Genetics S.A. (2,647) (606,491) (38,081) (545,606) Semya S.A. (1) (22,895) (55,872) (14,140) (6,120) Synertech Industrias S.A. 1,034,818 (1,474,438) (596,854) (155,316) Indrasa Biotecnología S.A. 3,210 — — — 1,012,486 (2,136,801) (649,075) (707,042) Summarized financial information in relation to the joint ventures are presented below: Trigall Genetics (i) Semya (ii) Summarised balance sheet 06/30/2019 06/30/2018 06/30/2017 06/30/2019 (a) 06/30/2018 06/30/2017 Current assets Cash and cash equivalents 13,114 44,937 9,758 489 183 76 Other current assets 323,264 66,077 62,137 77,074 14 — Total current assets 336,379 111,014 71,895 77,563 197 76 Non-current assets Intangible assests 10,214,575 8,681,400 6,819,534 583,936 217,809 — Other non- current assets — — — 362,181 448,942 992,143 Total non-current assets 10,214,575 8,681,400 6,819,534 946,117 666,751 992,143 Current liabilities Financial liabilities 9,476,272 7,878,036 6,378,988 127,074 448,309 220,989 Other current liabilities 1,016,083 1,030,016 607,565 898,623 275,341 440,435 Total current liabilities 10,492,355 8,908,051 6,986,553 1,025,697 723,650 661,424 Non-current liabilities Other non- current liabilities 460,268 295,575 121,656 42,323 — — Total non-current liabilities 460,268 295,575 121,656 42,323 — — Net assets (401,669) (411,212) (216,780) (44,340) (56,701) 330,795 Synertech (iii) Indrasa S.A. (iv) Summarised balance sheet 06/30/2019 06/30/2018 06/30/2017 06/30/2019 06/30/2018 06/30/2017 Current assets Cash and cash equivalents 40,634 39,133 85,654 16,296 28,180 33,986 Other current assets 5,709,650 7,182,862 5,878,527 93,654 45,837 83,400 Total current assets 5,750,284 7,221,995 5,964,181 109,950 74,017 117,386 Non-current assets Property,plan and equipment 15,046,903 8,344,900 15,480,289 18,387 15,243 28,956 Other non- current assets — 1,328,521 1,449,117 — — 3,069 Total non-current assets 15,046,903 9,673,421 16,929,406 18,387 15,243 32,025 Current liabilities Financial liabilities 921,703 705,856 1,428,481 — — 172 Other current liabilities 4,595,906 6,750,220 5,158,724 60,760 42,166 80,435 Total current liabilities 5,517,609 7,456,076 6,587,205 60,760 42,166 80,607 Non-current liabilities Financial liabilities — 1,080,247 2,898,798 — — — Other non- current liabilities 3,974,975 4,801,887 5,378,862 — — — Total non-current liabilities 3,974,975 5,882,134 8,277,660 — — — Net assets 11,304,603 3,557,206 8,028,722 67,577 47,094 68,805 Trigall Genetics (i) Semya (ii) Summarised statements of comprenhensive income 06/30/2019 06/30/2018 06/30/2017 06/30/2019 (a) 06/30/2018 06/30/2017 Revenue 367,646 104,037 21,041 — — Interest income 54,003 14,053 — 29,275 — 41,865 Interest expenses (16,145) (12,213) (31,444) (5,661) (209,966) (75,682) Profit (loss) of the year (33,195) (194,432) (12,986) (218,627) (354,151) (58,356) Other comprenhensive income — — — — (37,036) 163 Total comprenhensive income (loss) (33,195) (194,432) (12,986) (218,627) (391,187) (58,193) Synertech (iii) Indrasa S.A. (iv) Summarised statements of comprenhensive income 06/30/2019 06/30/2018 06/30/2017 06/30/2019 06/30/2018 06/30/2017 Revenue 18,305,953 6,611,384 1,315,857 452,555 232,290 355,499 Interest income 2,434,610 1,758,129 726,519 1,813 756 315 Interest expenses (6,193,963) (5,831,182) (2,331,246) (3,001) (2,516) — Depreciation and amortization (1,074,552) (653,766) (1,714,354) (3,653) — — Profit (loss) of the year 2,278,859 (1,991,754) (1,822,573) 6,548 7,483 53,468 Other comprenhensive income 334,403 — — — — — Total comprenhensive income (loss) 2,613,262 (1,991,754) (1,822,573) 6,548 7,483 53,468 (a) (i) Trigall Genetics S.A. This joint venture was formed in December 2013 with Florimond Desprez (a company from France with an internationally recognized track record in wheat breeding) through Bioceres Inc. Equity interest is equally shared between both participants. Trigall is a separately structured vehicle incorporated and operating in Uruguay. The primary activity of Trigall is being engaged in the development and deregulation of conventional and GM wheat varieties in Latin America, which is in line with the Group’s core business. This joint arrangement provides for each of the joint venture partners to exclusively license its trait and germplasm technologies to Trigall for use in wheat. The Group granted an exclusive, sub licensable license to Trigall for certain of Group`s technologies, including HB4, for use in wheat. Both the Group and Florimond Desprez have agreed to make loans to Trigall in accordance with each party`s ownership interest in the joint venture to provide it funds needed for its operation and growth. The first products in Trigall`s pipeline are conventional wheat varieties that will be sold through Bioceres Semillas, as well as through other Trigall licensees. The first Group`s GM product is HB4, which is now in the advanced development and deregulation phase. Trigall is currently seeking to add other market channel partners in the region. The contractual arrangement provides the Group with only the rights to the net assets of the joint arrangement. The rights to the assets and obligation for liabilities of the joint arrangement rest primarily with Trigall. Under IFRS 11 this joint arrangement is classified as a joint venture and has been included in the Consolidated financial statements using the equity method. The shares of Trigall are not quoted. There are no significant restrictions on the ability of the joint venture to transfer funds to the Group in the form of cash dividends, or to repay loans or advances made by the Group, except for the obligation to establish a legal reserve for 5% of the profit for the year until reaching 20% of the capital (ii) Semya This joint venture was launched in 2012 and formed as a separate vehicle in August 2014 with Rizobacter and Bioceres S.A. Equity interest is equally shared between both participants. The primary activity of Semya is being engaged in the development and deregulation of second generation agricultural biological products, in particular, seed treatments tailored for particular soil environments, which is in line with the Group’s core business. The joint venture agreement provides for each party to render the services required to advance a mutually agreed work plan and which each party agrees to fund in proportion to its equity interest. Under the services agreements, both Bioceres S.A. and Rizobacter agree to provide to Semya the licenses required for product development and commercialization, while results obtained in the provision of the services are owned by Semya. Its creates customized seed treatments based on soil conditions on a given agricultural environment and on specific trait-germplasm combinations. As mentioned in Note 4.5, in June 2019, Bioceres Crop Solutions signed a share purchase agreement with Bioceres S.A. to acquire the remaining 50% interest in Semya. (iii) Synertech Synertech has been included in the Group Bioceres after the acquisition of the majority interest in Rizobacter. This joint venture has arisen from the association between Synertech and De Sangosse, which jointly opened a new fertilizer manufacturing plant in Pergamino, Argentina, on June 28, 2017. Both parties’ equity interest is 50%. Construction and start-up of the new plant required an investment of more than USD 30 million, and was conceived for research, production and commercialization of the Microstar PZ® microgranulated fertilizer, its byproducts and other possible developments in the agricultural fertilization area to supply both the domestic and export markets, such as Brazil, Paraguay, Bolivia, Uruguay, Chile, Central America and North America, among others, accompanying the exponential growth of Rizobacter in the world markets with a strong international insertion. The contractual agreement sets forth that the Group only has rights over the net assets under the joint arrangement. The rights over the assets and obligations for the liabilities assumed under the joint arrangement primarily remain with Synertech. Under IFRS 11, this joint arrangement is classified as a joint venture and has been equity-accounted in the Consolidated financial statements. Synertech shares are not listed for trading in a public offering. There are no significant restrictions on the joint venture’s ability to transfer funds to the Group as cash dividends, or to repay loans or advances made by the Group, except for the obligation to set up a legal reserve for 5% of the profit for the fiscal year until 20% of capital is reached. (iv) Indrasa S.A. This comapany was formed to develope customized solutions, high technology and R&D projects for the creation of innovative products, applying techniques of microbiology, biotechnology, nanotechnology and agronomy. As mentioned before, Rizobacter used to have the 52.913% of the participation. At the end of the period ended September 30, 2018, the participation decreased to 35%, therefore the Group lost the control over this subsidiary. (v) Verdeca LLC This joint venture was formed in February 2012 with Arcadia (an USA based company that develops agricultural biotechnologies) through Bioceres Inc. Equity interest is equally shared between both participants. Verdeca LLC is a separately structured vehicle incorporated and operating in USA. The primary activity of Verdeca is the development and deregulation of soybean traits with second generation technology, which is in line with the Group’s core business. This joint arrangement provides for each of the joint venture partners to license its trait technologies to Verdeca for use in soybeans. The Group will grant an exclusive, worldwide, sub licensable license to Verdeca for its technologies, including HB4, for use in soybeans. Both partners also will grant Verdeca a right of first offer to obtain a license to the intellectual property rights that are owned, licensed to, or acquired by the Group or Arcadia, as applicable, in the future and that are reasonably necessary or useful with respect to soybean traits. The first product in Verdeca pipeline is the Group`s HB4 trait, a drought and salinity tolerance trait that is in the advanced development phase. Verdeca`s pipeline also includes Arcadia`s nutrient use efficiency and water use efficiency technologies, which are combined in a two-trait stack that will be further stacked with HB4. Verdeca has successfully negotiated favorable market access in South America and is growing its partnerships in USA, India and China. The contractual arrangement provides the Group with only the rights to the net assets of the joint arrangement. The rights to the assets and obligation for liabilities of the joint arrangement rest primarily with Verdeca. Under IFRS 11 this joint arrangement is classified as a joint venture and has been included in the Consolidated financial statements using the equity method. The shares of Verdeca are not quoted. There are no significant restrictions on the ability of the joint venture to transfer funds to the Group in the form of cash dividends, or to repay loans or advances made by the Group. As of June 30, 2019, and until the date of issue of these Consolidated financial statements, the license had not been formalized, so the partners (Bioceres LLC and Arcadia) will grant Verdeca an exclusive license for use and commercialization of their HB4 Soybean and other technologies. Therefore, at those dates, Verdeca has not recorded any assets, liabilities or results because it does not have control over those technologies.

SEGMENT INFORMATION

SEGMENT INFORMATION	12 Months Ended
	Jun. 30, 2019
SEGMENT INFORMATION
SEGMENT INFORMATION	13. SEGMENT INFORMATION The Group is organized into three main operating segments:  Seed and integrated products The seed and integrated products segment focuses mainly on the development and commercialization of seed technologies and products that increase yield per hectare, with a focus on the provision of seed technologies and integrated crop protection and crop nutrition products designed to control weeds, insects or diseases, to increase their quality characteristics, to improve nutritional value and other benefits. The segment focuses on the commercialization of integrated products that combine three complementary components biotechnological events, germplasm and seed treatments—in order to increase crop productivity and create value for customers. While each component can increase yield independently, through an integrated technology strategy the segment offers biotechnological events, germplasm and treatments for seeds that complement and integrate with each other to generate higher yields in crops. Currently the segment generates revenue from ordinary activities through the sale of seeds, integrated packs, royalties and licenses charged to third parties, among others.  Crop protection The crop protection segment mainly includes the development, production and marketing of adjuvants, insecticides and fungicides. The adjuvants are used in mixtures to facilitate greater efficiency of the products to be applied (such as fertilizers and agrochemicals). Insecticides and fungicides can significantly reduce disease or insect problems during the germination period. The segment currently generates revenue from ordinary activities through the sale of adjuvants, insecticides, fungicides and baits, among others.  Crop nutrition The crop nutrition segment focuses mainly on the development, production and commercialization of inoculants that allow the biological fixation of nitrogen in the crops, and of fertilizers including biofertilizers and microgranulated fertilizers that optimize the productivity and yield of the crops. Currently the segment generates income from ordinary activities through the sale of inoculants, bio-inductors, biological fertilizers and microgranulated fertilizers, among others. The measurement principles for the Group’s segment reporting structure are based on the IFRS principles adopted in the Consolidated financial statements. Revenue generated by products and services exchanged between segments and entities within the Group are calculated on the basis of market prices. The following tables present information with respect to the Group´s reporting segments: Seed and integrated Crop Crop Year ended June 30, 2019 products protection nutrition Consolidated Revenues Sale of goods and services 24,185,292 89,919,460 45,093,764 159,198,516 Royalties 1,110,463 — — 1,110,463 Others Goverment Grants 16,372 — — 16,372 Initial recognition and changes in the fair value of biological assets. — 279,945 — 279,945 Total 25,312,127 90,199,405 45,093,764 160,605,296 Cost of sales (9,783,737) (53,979,391) (23,201,753) (86,964,881) Gross margin per segment 15,528,390 36,220,014 21,892,011 73,640,415 % % % % % Seed and integrated Crop Crop Year ended June 30, 2018 products protection nutrition Consolidated Revenues Sale of goods and services 26,308,432 77,655,672 29,084,325 133,048,429 Royalties 442,689 — — 442,689 Others Government Grants 51,586 — — 51,586 Total 26,802,707 77,655,672 29,084,325 133,542,704 Cost of sales (13,413,758) (49,453,167) (14,227,626) (77,094,551) Gross margin per segment 13,388,949 28,202,505 14,856,699 56,448,153 % % % % % Seed and integrated Crop Crop Year ended December 31, 2016 products protection nutrition Consolidated Revenues Sale of goods and services 13,956,901 21,493,419 5,227,394 40,677,714 Royalties 349,760 — — 349,760 Others Government Grants 141,775 — — 141,775 Total 14,448,436 21,493,419 5,227,394 41,169,249 Cost of sales (8,953,929) (16,825,572) (4,819,455) (30,598,956) Gross margin per segment 5,494,507 4,667,847 407,939 10,570,293 % 38 % 22 % 8 % 26 % Income by similar group of products or services 06/30/2019 06/30/2018 06/30/2017 12/31/2016 Seed and integrated products 25,295,755 26,751,121 9,021,171 14,306,661 Seeds, royalties & licenses 3,846,991 3,771,579 2,394,927 4,287,978 Packs 21,448,764 22,979,542 6,626,244 10,018,683 Crop protection 89,919,460 77,655,672 31,191,970 21,493,419 Adjuvants 41,854,730 39,931,915 15,008,963 12,526,504 Insecticides & fungicides 12,655,985 14,087,260 9,914,886 2,059,936 Other 35,408,745 23,636,497 6,268,121 6,906,979 Crop nutrition 45,093,764 29,084,325 6,640,228 5,227,394 Inoculants 18,644,673 14,352,761 4,245,712 2,098,826 Fertilizers 26,449,091 14,731,564 2,394,516 3,128,568 Total revenue 160,308,979 133,491,118 46,853,369 41,027,474 Geographical information 06/30/2019 06/30/2018 06/30/2017 12/31/2016 Argentina 124,011,642 106,077,922 41,292,402 37,815,878 Austria 899,045 470,849 8,400 319,237 Bolivia 2,494,216 2,090,758 — 300,084 Brazil 17,338,608 9,450,496 275,545 862,155 China — — 193,911 — Libano (115,927) 376,862 262,428 — United States of America 2,562,376 1,395,438 380,310 16,737 Italia 132,206 10,879 — 80,512 Paraguay 2,506,348 5,584,861 1,052,088 590,176 United Kingdom 137,044 387,859 129,297 220,640 South Africa 3,019,474 3,711,852 1,931,908 8,369 France 711,522 270,878 — — Canada — 3,553 — — Ukraine 611,993 344,401 822,976 145,433 Uruguay 4,684,854 3,197,974 447,248 667,237 Rest of the world 1,315,578 116,536 56,856 1,016 Total revenue 160,308,979 133,491,118 46,853,369 41,027,474 06/30/2019 06/30/2018 06/30/2017 12/31/2016 Non-current assets Argentina 106,056,232 77,860,852 111,743,378 113,739,634 United States 6,136,461 2,411,673 631,063 495,187 Paraguay 722,914 605,491 589,418 538,831 Brazil 305,477 340,144 347,649 188,627 Bolivia 27,487 39,857 22,876 25,325 South Africa 7,080 14,423 22,706 25,442 India 38 78 — — Total 113,255,689 81,272,518 113,357,090 115,013,046

FINANCIAL INSTRUMENTS - RISK MA

FINANCIAL INSTRUMENTS - RISK MANAGEMENT	12 Months Ended
	Jun. 30, 2019
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
FINANCIAL INSTRUMENTS - RISK MANAGEMENT	14. FINANCIAL INSTRUMENTS – RISK MANAGEMENT a. Principal financial instruments The principal financial instruments used by the Group, from which financial instrument risk arise, are as follows:  Cash and cash equivalents  Financial assets at fair value through profit or loss  Trade receivables  Other receivables  Trade and other payables  Bank overdrafts  Other loans  Financed payment for the acquisition of business  Puttable instruments  Warrants The Group is exposed to financial risks: market risk (including currency risk, interest rate risk and fair value risk), credit risk, liquidity risk and capital risk managment that arise from its activities and from its use of financial instruments. This Note provides information on the Group’s exposure to each of the above risks, the Group’s objectives, policies and processes regarding the measurement and management of each risk. The Group does not use derivative financial instruments to hedge any of the above risks. b. Financial instruments by category The following tables show additional information required under IFRS 7 on the financial assets and liabilities recorded as of June 30, 2019,2018 and 2017. Financial assets by category Mandatorily measured at fair Amortized cost value through profit or loss Financial asset 06/30/2019 06/30/2018 06/30/2017 06/30/2019 06/30/2018 06/30/2017 Cash and cash equivalents 3,450,873 2,215,103 1,679,478 — — — Other financial assets 4,703,688 4,781,679 5,027,516 356,233 12,526 4,275 Trade receivables 59,236,377 52,888,427 41,675,918 — — — Other receivables (*) 1,566,732 7,742,120 5,426,257 — — — Total 68,957,670 67,627,329 53,809,169 356,233 12,526 4,275 (*) Financial liabilities by category Mandatorily measured at fair Amortized cost value through profit or loss Financial liability 06/30/2019 06/30/2018 06/30/2017 06/30/2019 06/30/2018 06/30/2017 Trade Payables and other payables 40,578,494 27,708,830 22,794,716 — — — Borrowings 103,556,730 91,017,133 74,990,135 — — — Employee benefits and social security 5,357,218 4,411,713 5,047,045 — — — Financed payment - Acquisition of business 2,826,611 22,874,609 27,400,173 — — — Warrrants — — — 2,861,511 — — Puttable instruments — — — — — 2,500,000 Total 152,319,053 146,012,285 130,232,069 2,861,511 — 2,500,000 c. Financial instruments measured at fair value Fair value by hierarchy According to the requirements of IFRS 7, the Group classifies each class of financial instrument valued at fair value into three levels, depending on the relevance of the judgment associated to the assumptions used for measuring the fair value. Level 1 comprises financial assets and liabilities with fair values determined by reference to quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 comprises inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); Level 3 comprises financial instruments with inputs for estimating fair value that are not based on observable market data. Measurement at fair value at 06/30/2019 Level 1 Level 2 Level 3 Financial assets at fair value Other financial assets 356,233 — — Financial liabilities valued at fair value Private warrants — — 2,861,511 Measurement at fair value at 06/30/2018 Level 1 Level 2 Level 3 Financial assets at fair value Other financial assets 12,526 — — Measurement at fair value at 06/30/2017 Level 1 Level 2 Level 3 Financial assets at fair value Other financial assets 4,275 — — Financial liabilities valued at fair value Puttable Instruments — 2,500,000 — Changes in financial liabilities valued at fair value level 3 are set below: 06/30/2019 As of the beginning of the year — Warrants issued in business combination 3,432,723 Changes in finance results (571,212) As of the end of the year 2,861,511 Estimation of fair value The fair value of marketable securities is calculated using the market approach using quoted prices in active markets for identical assets. The quoted marked price used for financial assets held by the Group is the current bid price. These instruments are included in level 1. The Group’s financial liabilities, which were not traded in an active market were determined using valuation techniques that maximize the use of available market information, and thus rely as little as possible on specific estimates of the entity specific estimates. If all significant inputs required to fair value an instrument are observable, the instruments are included in level 2. If one or more of the significant inputs is not based on observable market data, the instruments are included in level 3. The model and inputs used to value the Private warrants at its fair value is mentioned in Note 2.9. The sensitivity analysis was based on a 5% change in the volatility of instrument. This changes in isolation would have increased or decreased the amount of the financial liability by $1.5 million and $1.2 million if the volatility was 37% or 27%, respectively. The Group’s policy is to recognize transfers between different categories of the fair value hierarchy at the time they occur or when there are changes in the circumstances that cause the transfer. There were no transfers between levels of the fair value hierarchy. There were no changes in economic or business circumstances affecting fair value. d. Financial instruments not measured at fair value The financial instruments not measured at fair value include cash and cash equivalents, trade accounts receivable, other accounts receivable, trade payables and other debts, borrowings, financed payments and instruments with a put option. The carrying value of financial instruments not measured at fair value does not differ significantly from their fair value, except for borrowings (Note 6.10). Management estimates that the carrying value of the financial instruments measured at amortized cost approximates their fair value. e. General objectives, policies and processes The Board of Directors has overall responsibility for establishing and monitoring the Group’s risk management objectives and policies and, whilst retaining ultimate responsibility for them, it has delegated the function to design and operate processes that ensure the effective implementation of the objectives and policies to the Group’s finance function that periodically reports to the Board of Directors on the evolution of the risk management activities and results. The overall objective of the Board of Directors is to set policies that seek to reduce risk as much as possible without unduly affecting the Group’s competitiveness and flexibility. The Group’s risk management policy is established to identify and analyze the risks facing the Group, to set appropriate risk limits and controls and to monitor risks and adherence to limits. The risks and methods for managing the risks are reviewed regularly in order to reflect changes in market conditions and the Group’s activities. The Group, through training and management standards and procedures, aims to develop a disciplined and constructive control environment in which all the employees understand their roles and obligations. The Group seeks to use suitable means of financing to minimize the Group’s capital costs and to manage and control the Group’s financial risks effectively. There have been no substantive changes in the Group’s exposure to financial instrument risks, its objectives, policies and processes for managing those risks or the methods used to measure them from previous periods unless otherwise stated in this Note. The Group adopted a code of ethics applicable to its principal executive, financial and accounting officers and all persons performing similar functions. The principal risks and uncertainties facing the business, set out below, do not appear in any particular order of potential materiality or probability of occurrence. a) Credit risk is the risk of financial loss to the Group if a customer or counterparty fails to meet its contractual obligations, which derives mainly from trade and other receivables, as well as from cash and deposits in financial institutions. The credit risk to which the Group is exposed is mainly defined in the Group’s accounts receivable followed by cash and cash equivalents, with the logical importance of being able to satisfy the Group’s needs in the short term. Trade and other receivables Credit risk is the risk of financial loss to the Group if a customer or counterparty fails to meet its contractual obligations, and derives mainly from trade receivables and other receivables generated by services and product sales, as well as from cash and deposits in financial institutions. The Group is also exposed to political and economic risk events, which may cause nonpayment of local and foreign currency obligations to the Group owed by customers, partners, contractors and suppliers. The Group sells seeds and integrated products, crop protection products, crop nutrition products, and other products and services to a diverse base of customers. Customers include multi-national and local agricultural companies, distributors, research and educational institutions and farmers who purchase the Group’s seed products, integrated products, crop protection products and crop nutrition products. Type and class of customers may differ depending on the Group’s business segments. The Group’s finance function determines concentrations of credit risk by periodically monitoring the credit worthiness rating of existing customers and through a monthly review of the trade receivables’ aging analysis. In monitoring the customers’ credit risk, customers are grouped according to their credit characteristics. The Group’s policy is to manage credit exposure to counterparties through a process of credit rating. The Group performs credit evaluations of existing and new customers, and every new customer is examined thoroughly regarding the quality of its credit before offering the customer transaction terms. The examination made by the Group includes outside credit rating information, if available. Additionally, and even if there is no independent outside rating, the Group assesses the credit quality of the customer taking into account its financial position, past experience, bank references and other factors. A credit limit is prescribed for each customer. These limits are examined annually. Customers that do not meet the Group’s criteria for credit quality may do business with the Group on a prepayment basis or by furnishing collateral satisfactory to the Group. The Group may still seek collateral and guarantees as it may consider appropriate regardless the credit profile of any customer. In monitoring customer credit risk, the customers are grouped according to a characterization of their credit, based on geographical location, industry, aging of receivables, maturity, and existence of past financial difficulties. Customers defined as “high risk” are classified into the restricted customer list and are supervised by management. In a case of a doubtful debt, the Group records a provision for the amount of the debt less the value of the collateral provided and acts to realize the collateral. To cover trade receivables related to Rizobacter, its subsidiaries and Bioceres Semillas, the Group has taken out credit insurance from Grupo Insur SRL, which periodically analyzes its customer portfolio and currently covers 50% of the portfolio. The financial statements contain specific provisions for doubtful debts, which properly reflect, in Management’s estimate, the loss embedded in debts, the collection of which is doubtful. The maximum exposure to credit risk is represented by the carrying amount of each financial asset in the statement of financial position after deducting any impairment allowance On that basis, the loss allowance as at 30, June 2019 was determined as follows: More More More than More than than 120 than 180 More than 15 days 60 days days days 365 days June, 30 2019 Current past due past due past due past due past due Total Expected Loss rate 0.27 % 0.32 % 0.32 % 0.32 % 0.32 % 100.00 % Gross carrying amount-trade receivables 19,253,504 8,221,475 1,762,134 974,658 771,480 3,345,664 34,328,915 Loss allowance 52,913 26,104 5,595 3,095 2,449 3,345,664 3,435,820 Cash and deposits in banks The Group is exposed to counterparty credit risk on cash and cash equivalent balances. The Group holds cash on deposit with a number of financial institutions. The Group manages its credit risk exposure by limiting individual deposits to clearly defined limits. The Group only deposits with high quality banks and financial institutions. The maximum exposure to credit risk is represented by the carrying amount of cash and cash equivalents in the statement of financial position. b) Liquidity risk is the risk that the Group will encounter difficulty in meeting its financial obligations when they come due. The Group’s approach to managing its liquidity risk is to manage the profile of debt maturities and funding sources, maintaining sufficient cash, and ensuring the availability of funding from an adequate amount of committed credit facilities. The Group’s ability to fund its existing and prospective debt requirements is managed by maintaining diversified funding sources with adequate committed funding lines from high quality lenders. The liquidity risk of each of the Group entities is managed centrally by the Group’s finance function. The cash flow forecast is determined at both an entity level and Consolidated level. The forecasts are reviewed by the Board of Directors in advance, enabling the Group’s cash requirements to be anticipated. The Group examines the forecasts of its liquidity requirements in order to ascertain that there is sufficient cash for the operating needs, including the amounts required in order to settle financial liabilities. The following table sets out the contractual maturities of financial liabilities: Between one Between Up to 3 3 to 12 and three three and Subsequent As of June 30, 2019 months months years five years years Trade Payables and other payables 12,854,579 28,987,009 476,482 — — Borrowings 29,051,271 40,097,864 38,524,384 — — Financed payment - Acquisition of business — 2,937,500 — — — Total 41,905,850 72,022,373 39,000,866 — — Between one Between Up to 3 3 to 12 and three three and Subsequent As of June 30, 2018 months months years five years years Trade Payables and other payables 27,352,381 356,449 — — — Borrowings 26,927,533 39,047,778 27,190,055 — — Financed payment - Acquisition of business 2,937,500 17,922,500 2,937,500 — — Total 57,217,414 57,326,727 30,127,555 — — Between one Between Up to 3 3 to 12 and three three and Subsequent As of June 30, 2017 months months years five years years Trade Payables and other payables 16,411,513 6,385,733 151 — — Borrowings 14,581,309 22,418,530 45,088,841 — — Financed payment - Acquisition of business — 6,219,980 21,180,193 — — Total 30,992,822 35,024,243 66,269,185 — — As of June 30, 2019, June 30, 2018 and June 30, 2017 the Group had no exposure to derivative liabilities. c) Foreign currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rate. Currency on foreign exchange risk arises when the Group enters into transactions denominated in a currency other than its functional currency. A significant part of our business activities is conducted in Argentine pesos. However, some of our subsidiaries using the Argentine peso as their functional currency also have significant transactions denominated in U.S. dollars, mainly with respect to sales and financing activities. Our policy is, where possible, to allow the Group entities to settle liabilities denominated in U.S. dollars with the cash generated from their own operations in U.S. dollars. We have liabilities denominated in U.S. dollars in entities utilizing the Argentine peso as functional currency, which expose us to foreign currency exchange risks. Such risks are partially mitigated by our revenues, which are also partly denominated in U.S. dollars (mainly exports) or Argentine pesos but adjusted to reflect changes in U.S. Dollars. We do not use foreign exchange derivatives to hedge our foreign exchange rate exposure. We periodically evaluate the use of derivatives and other financial instruments to hedge our foreign exchange rate exposure, but do not have any exchange rate related financial instruments in place. The table below sets forth our net exposure to currency risk as of June 30,2019,2018 and 2017: Net foreign currency position 06/30/2019 06/30/2018 06/30/2017 Amount expressed in USD (40,513,954) (28,861,129) (17,917,954) Considering only this net currency exposure at June 30, 2019, if an Argentine peso/US dollar revaluation or depreciation in relation to other foreign currencies with the remaining variables remaining constant, would have a positive or a negative impact on comprehensive income as a result of foreign exchange gains or losses. We estimate that a devaluation of the Argentine peso against the U.S. dollar of 20% during the year ended June 30, 2019 would have resulted in a net pre-tax loss of approximately USD 8.3 million. We estimate that an appreciation of the Argentine peso against the U.S. dollar of 20% during the same period would have resulted in a net pre-tax gain of approximately USD 8.3 million. Interest rate risk The Group’s financing costs may be affected by interest rate volatility. Borrowings under the Group’s interest rate management policy may be fixed or floating rate. The Group maintains adequate committed borrowing facilities and holds most of its financial assets primarily in cash or checks collected from customers that are readily convertible into known amounts of cash. The Group’s interest rate risk arises from long-term borrowings. Borrowings issued at floating rates expose the Group to cash flow interest rate risk. Borrowings issued at fixed rates expose the Group to fair value interest rate risk. The Group has not entered into derivative contracts to hedge this exposure. The Group’s debt composition, consisting of the loans and the payment financed for the acquisition of Rizobacter, is set out below. 06/30/2019 06/30/2018 06/30/2017 Carrying Carrying Carrying amount amount amount Fixed-rate instruments Current financial liabilities (69,126,607) (82,888,890) (33,480,167) Non-current financial liabilities (37,006,581) (27,168,905) (61,456,073) Variable-rate instruments Current financial liabilities (177,213) (2,643,628) (6,777,784) Non-current financial liabilities (72,940) (1,190,319) (676,284) Holding all other variables constant, including levels of our external indebtedness, at June 30, 2019 a one percentage point increase in floating interest rates would increase interest payable by less than US$ 0.1 million. The Company does not use derivative financial instruments to hedge its interest rate risk exposure. d) The private warrants classified as financial liability and valued at its fair value expose the Group to market risk derived from fluctuations in the price of shares (Note 6.16.). As of June 30, 2019, their fair value using a share price of $5,30 and risk-free rate of 1.7631 %, decreased to $2.8 million and the Group recognized a gain of $0.6 million. The sensitivity analysis was based on a 5% change in the volatility of instrument. This changes in isolation would have increased or decreased the amount of the financial liability by $1.5 million and $1.2 million if the volatility was 37% or 27%, respectively. e) The Group’s objectives when managing capital are to safeguard the Group’s ability to continue as a going concern, in order to provide returns for shareholders and benefits for other stakeholders, and to maintain an optimal capital structure to reduce the cost of capital. The Group manages its capital structure and makes adjustments to it in the light of changes in economic conditions and the risk characteristics of the underlying assets. In order to maintain or adjust the capital structure, the Group may adjust the amount of any dividends it could pay to shareholders, return capital to shareholders, issue new shares, or sell assets to reduce debt. The current actions that the Group is carrying on for the capital management are detailed in the Note 1. As of June 30, 2019, the subsidiary Rizobacter did not comply with the liabilities to assets ratio covenant related with the syndicated loan. However, Rizobacter received a waiver for the year ended June 30, 2019 from the majority of the banks (See Note 6.10). Covenant compliance is required to be measured annually.

LEASES

LEASES	12 Months Ended
	Jun. 30, 2019
LEASES
LEASES	15. LEASES a. Finance lease - lessee Detail of leased equipment: Such contracts were classified as finance leases as the rental period amounts to the estimated useful economic life of the assets concerned and the Group has the right to purchase the assets outright at the end of the minimum lease term by paying a low nominal amount. The leases are payable in ARS. Number of Present Value leasing of Minimum Giver Object of the contract contracts Payments HP Financial Services Equipment and computer software 7 605,024 Banco Macro Vehicles 10 86,460 Banco Supervielle Machinery and equipment 4 116,126 Banco Galicia Machinery and equipment 1 41,208 Total 848,818 Present value - Minimum payments of financial leases 06/30/2019 06/30/2018 06/30/2017 Less than 1 year 444,999 418,933 701,025 1 year- 5 years 490,088 578,578 961,476 Total 935,087 997,511 1,662,501 Financial charges to be accrued (86,270) (263,219) (516,819) Debt for financial leases 848,817 734,292 1,145,682 There are no contingent rents related to finance leases and no subleases. There are no material restrictions imposed by lease arrangements. b. Operating lease - lessee The Group maintains leased land under operating leases. The total lease payments recognized as expenses during the years ended June 30, 2019 and 2018 and the six-month transition period ended June 30, 2017: Present value - Minimum payments of financial leases 06/30/2019 06/30/2018 06/30/2017 Less than 1 year 385,947 280,038 466,689 1 year- 5 years 462,870 454,254 678,993 Total 848,817 734,292 1,145,682 There are no subleases. There are no material restrictions imposed by lease arrangements.

SHAREHOLDERS AND OTHER RELATED

SHAREHOLDERS AND OTHER RELATED PARTIES BALANCES AND TRANSACTIONS	12 Months Ended
	Jun. 30, 2019
SHAREHOLDERS AND OTHER RELATED PARTIES BALANCES AND TRANSACTIONS
SHAREHOLDERS AND OTHER RELATED PARTIES BALANCES AND TRANSACTIONS	16. SHAREHOLDERS AND OTHER RELATED PARTIES BALANCES AND TRANSACTIONS During the year ended June 30, 2019, June 30,2018, the six-month transition period ended June 30, 2017 and the year ended December 31, 2016, the transactions between the Group and related parties, and the related balances owed by and to them, are as follows: Amount of the transactions of the year ended Party Transaction type 06/30/2019 06/30/2018 06/30/2017 12/31/2016 Joint ventures Sales and services 4,913,254 746,867 — — Joint ventures Purchases of goods and services (17,542,637) (9,809,134) (922,286) — Joint ventures Equity contributions (241,840) 800,989 1,233,131 162,012 Joint ventures Business combination — — — 33,317,619 Joint ventures Net loans granted / (cancelled) (6,964,101) 2,621,647 2,428,076 1,781,389 Key management personnel Salaries, social security benefits and other benefits (3,940,185) (4,703,519) (2,238,908) (649,410) Key management personnel Loans granted 599,984 — — — Key management personnel Interest gain 20,106 — — — Shareholders and other related parties Dividends — (1,450,613) (52,249) — Shareholders and other related parties Sales of goods and services 640,095 1,057,325 781,830 1,761,128 Shareholders and other related parties Purchases of goods and services (1,433,127) (986,217) (875,257) (1,414,998) Shareholders and other related parties Interest gain 90,188 294,577 179,887 73,178 Shareholders and other related parties In-kind contributions 463,511 — — — Parent company Interest lost (1,386,288) (118,266) (520,959) (1,118,679) Parent company Sales of goods and services — 13,505 1,427 2,993 Parent company Purchases of goods and services (120,095) (311,418) (62,500) (135,297) Parent company Equity contributions (14,558,347) — — — Total (39,459,482) (11,844,257) (47,808) 33,779,935 Amounts receivable from related parties Party Transaction type 06/30/2019 06/30/2018 06/30/2017 Parent company Trade debtors 440,268 361,606 — Parent company Other receivables — 103,251 — Shareholders and other related parties Trade receivables 467,743 571,216 1,025,903 Shareholders and other related parties Allowance for impairment (75,596) (23,126) (205,960) Shareholders and other related parties Other receivables 10,971 119,677 67,753 Joint ventures Trade debtors 2,369 209,039 217,963 Joint ventures Other receivables 250,783 6,299,467 4,298,109 Total 1,096,538 7,641,130 5,403,768 Amounts payable to related parties Party Transaction type 06/30/2019 06/30/2018 06/30/2017 Parent company Trade creditors (1,568,036) — (218,744) Parents companies and related parties to Parents Net loans payables (17,757,907) (1,816,084) (646,538) Parent company Consideration payment Semya adquisition (575,604) — — Key management personnel Salaries, social security benefits and other benefits (2,312,253) (1,556,035) (1,614,494) Shareholders and other related parties Trade and other payables (1,796,932) (365,994) (633,700) Joint ventures Trade and other payables (4,805,149) (3,493,113) (1,649,367) Total (28,815,881) (7,231,226) (4,762,843)

KEY MANAGEMENT PERSONNEL COMPEN

KEY MANAGEMENT PERSONNEL COMPENSATION	12 Months Ended
	Jun. 30, 2019
KEY MANAGEMENT PERSONNEL COMPENSATION
KEY MANAGEMENT PERSONNEL COMPENSATION	17. KEY MANAGEMENT PERSONNEL COMPENSATION Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Group. The compensation of directors and other members of key management personnel, including social contributions and other benefits, was as follows for the year ended June 30, 2019, 2018, the six-month transition period ended June 30,2017 and the year ended December 31, 2016. 06/30/2019 06/30/2018 06/30/2017 12/31/2016 Salaries, social security and other benefits 3,940,185 4,703,519 2,238,908 649,410 Total 3,940,185 4,703,519 2,238,908 649,410 The Company entered into indemnification agreements with each of its directors and executive officers. These agreements generally provide that the relevant director or officer will be indemnified by the Company to the fullest extent permitted by law against liability and against all expenses reasonably incurred or paid by him or her in connection with any claim, action, suit or proceeding which he or she becomes involved as a party or otherwise by virtue of his or her being or having been such a director or officer of the Company and against amounts paid or incurred by him or her in the settlement thereof. The agreements are subject to certain exceptions, including that no indemnification will be provided to any director or officer against any liability to the Group or its shareholder (i) by reason of intentional fraudulent conduct, dishonesty, willful misconduct, or gross negligence on the part of the director or officer; or (ii) by reason of payment made under an insurance policy or any third party that has no recourse against the indemnitee director or officer. The compensation of key executives is determined by the Board of Directors of Bioceres S.A. based on the performance of individuals and market trends. The Group currently does not pay any compensation to any of its non-employee board members.

SHARE-BASED PAYMENTS

SHARE-BASED PAYMENTS	12 Months Ended
	Jun. 30, 2019
SHARE-BASED PAYMENTS
SHARE-BASED PAYMENTS	18. SHARE-BASED PAYMENTS On December 17, 2014, the shareholders of the Bioceres S.A. approved the incentive plan based on stocks and options, by issuing: · up to 1,264,000 ordinary shares under the "Options incentive Plan" and subject to the exercise of the option, of which, to date, a total of 808,960 have been granted individually to certain executives and reserved for future authorization a total of 455,040 options; and · Up to 1,264,000 ordinary shares under the "Plan of incentives through shares" of which to date, the granting of up to 902,487 new shares has been approved in favor of certain executives and reserved for future granting a total of 361,513 new shares. Of the total approved, and subject to certain conditions of irrevocability, have been assigned individually 551,148 shares. Both incentive plans are administered by the Compensation Committee of Bioceres S.A. who has the power to grant the incentive plans in accordance with the terms and conditions and approved by the Shareholders’ Meeting and the Board of Directors and perform any action it deems necessary or advisable with respect to these, including, among others, the power to appoint beneficiaries, determine the number of shares and / or options to be granted, determine the price and time to exercise the options and resolve the controversies that involve the incentive plans. Incentive payments based on options On December 16, 2015, purchase options were granted with respect to 31,600 ordinary shares for certain executives of the Bioceres Semillas in accordance with the Capital Market Law of Argentina. The exercise price of the stock options was $ 7.91 and they were consolidated when the beneficiaries have served a period of service since the grant date (December 16, 2015) until the expiration date and under the condition of an initial public offering Successful Company. The beneficiaries should remain in the Company or subsidiary as of the date of exercising the option to exercise it. The stock options could be exercised over a period of 2 years from the date of expiration (that is, until April 1, 2019). The beneficiaries could have request the Company to finance up to 100% of the exercise price of the option, to which end the Company will determine the term of the loan, interest, amortization, the form of payment of interest and amortization, the causes of acceleration of the loan (among which it will include the removal of the beneficiary in the eligible position) and the guarantees (including, without limitation, the issuance of a promissory note, deferred payment checks and / or the constitution of pledge in the first degree of privilege over the shares subject to the option). The fair value of the stock options at the grant date was estimated using the "Black and Scholes" model considering the terms and conditions under which the options on actions were granted and adjusted to consider the possible dilutive effect of the future fiscal year the stock options granted on the estimated fair value at the grant date, in accordance with the provisions of paragraph B41 of IFRS 2. The conditions of service and conditions of performance not related to the market were considered to determine the quantity of the instruments which will be consolidated. There are no cancellation alternatives in cash. The Incentive Option Plan was calculated considering 50-1 split that was authorized by the shareholders of Bioceres S.A. on December 17, 2014. On April 27, 2017, the shareholders approved a modification to the split such that it is now a 100-1 split of the Bioceres S.A. ordinary shares and an increase of 24,000,000 shares of nominal value ARS 1. For the stock purchase options in effect as of June 30, 2019, 2018 and 2017, the exercise price was USD 15.85. The following table shows the fair value of the share options and the factors used for its calculation: Factor Incentive Option Plan Weighted average fair value at measurement date (per option) USD 4.09 Value of the share (per share) USD 15.85 (Split 1:50) Expected dividend rate 0% Expected volatility 47.92% Risk-free interest rate 1,05% Weighted average expected life of stock options 2 years Weighted average exercise price (per share) USD 15.85 (Split 1:50) Model used Black and Scholes (adjusted to consider the possible dilutive effect of the future exercise of options) The expected life of the share options was estimated based on the contractual life of the option adjusted according to the expectations about early exercise of the options. To estimate the effect of early exercise of the options, Management considered the factors mentioned in paragraphs B16 to B21 of IFRS 2 as a whole and put forward the hypothesis that the options would be exercised, on the average, at a time somewhat earlier than the halfway point between the expiration date (April 1, 2017) and the cutoff date for exercising the option (April 1, 2019). Expected volatility was estimated based on the historical volatility in similar public companies. The measure of volatility used is the annualized standard deviation of rates of return on the shares over a period similar to the expected life of the shares, calculated using continuous capitalization. There were no market-related performance conditions or non-vesting conditions that were considered for determining the fair value of options. The following table shows the weighted average amount and exercise price and the movements of the stock options of executives and directors of the Group during the years ended June 30, 2019, June 30, 2018 and the transition period ended June 30, 2017. 06/30/2019 06/30/2018 06/30/2017 Weighted Weighted Weighted Number average Number average Number average of exercise of exercise of exercise options price options price options price At the beginning 31,600 15.85 31,600 15.85 31,600 15.85 Granted during the year/period — — — — — — Annulled during the year/period (31,600) (15.85) — — — — Exercised during the year/period — — — — — — Expired during the year/period — — — — — — Effective at year/period — — 31,600 15.85 31,600 15.85 Before the stock option became exercised, the beneficiary left the subsidiary where he used to work, so the Group has annulled the options outstanding and recovered the charges accounted. Incentive payments based on shares On September 8, 2017, the Board of Directors of the Bioceres S.A. approved the granting of 225.000 shares subject to the incentive plan through actions to Rizobacter teams. At the measurement date, the fair value has been determined based on a market price in transactions of the Company’s equity with independent third parties. There are no conditions of returns referring to the market or conditions other than those of irrevocability of the concession that must be incorporated in the fair value determination of the shares. Expected dividends have not been included in the fair value determination. The Company estimated that 100% of the shares would be delivered, taking into account historical stays in the employment of executives. This estimate was reviewed at each closing of annual or intermediate period. The approved incentive based on shares was subject to the fulfillment of individual objectives and / or economic, as detailed below: “Rizobacter Senior Management”: (i) 225,000 shares in a 3 to 4 year plan conditioned to the fulfillment of between 70% and 100% of the goals and a duty of permanence in the Group for 12 months following the fulfillment of the annual goals of the stretch correspondent; and (ii) 225,000 shares in a three-year plan conditioned between 70% and 100% of the goals and with a duty of permanence in the Group for 4 years following the moment of irrevocability. Out of this total, the Compensation Committee allocated 360,000 shares individually. Half in three annual installments for the years ended June 30, 2017, 2018 and 2019 and conditioned to the fulfillment of goals. The other half in a three-year stretch, according to the exercises mentioned above and conditioned to the achievement of goals. This plan of actions allows the incorporation, at the option of the beneficiary and in consent with the Group, of a new annual installment due to force majeure events that hinder compliance of the annual goals. In this case, this new annual tranche will be considered for the calculation base of the three-year plan. The beneficiaries of this plan have the option of cash settlement. As of June 30, 2019, and 2018, the goals of the third and the second annual tranche have not been met.

CONTINGENCIES, COMMITMENTS AND

CONTINGENCIES, COMMITMENTS AND RESTRICTIONS ON THE DISTRIBUTION OF PROFITS	12 Months Ended
	Jun. 30, 2019
CONTINGENCIES, COMMITMENTS AND RESTRICTIONS ON THE DISTRIBUTION OF PROFITS
CONTINGENCIES, COMMITMENTS AND RESTRICTIONS ON THE DISTRIBUTION OF PROFITS	19. CONTINGENCIES, COMMITMENTS AND RESTRICTIONS ON THE DISTRIBUTION OF PROFITS BAF Loans obtained with BAF Latam Trade Finance Fund B.V. detailed in Note 6.10 have a pledge agreement with RASA Holding and the limitation of distributing dividends to the extent that such distribution will affect or could substantially affect the ability to comply with the loan obligations. Pledged and restricted assets at June 30, 2019 are as follows: Detail Asset value Type of restriction IT equipment 77,760 Leasing Machinery and equipment 528,798 Leasing Machinery and equipment 158,080 Leasing Vehicles 119,728 Leasing Other financial assets 4,327,275 Collateral (a) Unicred S.A. 173,658 Custody checks (b) Macro 573,991 Custody checks (c) Santander Rio 3,093,478 Custody checks (d) Finares SA 176,440 Custody checks (e) Itau 1,594,459 Custody checks (f) Compass Latam & Odisea 16,037,769 Securty Collateral and Mortgage (g) Totals 26,861,436 a) Rizobacter entered into a USD 45 million syndicated loan and signed a guarantee and pledge. On July 3, 2018 Rizobacter granted a pledge of a fixed-term certificate at Banco Galicia for an amount of USD 4,298,101. b) In the months November, December and January, a loan was made by the Unicred Financial for a total amount of USD 1,038,883 guaranteed with third-party checks whose maturity is subsequent to the maturity of the loan. c) In June, loans were made by the Macro Bank for USD 500,000 guaranteed with third-party checks. d) In December, a loan was made by Santander Rio Bank for an amount of USD 3,500,000 guaranteed with third-party checks. e) In January, a loan was made by Finares SA for a value of USD 285,000 guaranteed with third party checks. f) In February, loans were made by Banco Itaú for USD 2,500,000 guaranteed with third-party checks. g) In April, the Group issued Negotiable Obligations worth USD 16,000,000, guaranteeing compliance with a first-degree mortgage of real estate assets of equal value and a p l edge on the shares representing 10% of the holding of Rasa Holding LLC in the capital of Rizobacter Argentina SA

EVENTS OCCURRING AFTER THE REPO

EVENTS OCCURRING AFTER THE REPORTING PERIOD	12 Months Ended
	Jun. 30, 2019
EVENTS OCCURRING AFTER THE REPORTING PERIOD
EVENTS OCCURRING AFTER THE REPORTING PERIOD	20. EVENTS OCCURRING AFTER THE REPORTING PERIOD On August 7, 2019, as a result of the merger with Union that change the Group environment, the Board of Directors of Bioceres S.A., approved the cancellation due to the conditions that were not met of the incentive payment based on shares for Rizobacter Senior Management described in Note 17. At the same date, Bioceres S.A. decided to issue 36,000 ordinary shares and to give USD 399,960 to each of the members of the Rizobacter Senior Management team. 50% of the grant has an instant vesting and it will be paid in twelve installments, and the remaining of 50% of the grant will be vest in one year since grant date and it will be paid in twelve installments. Subsequent to June 30, 2019, there have been no other situations or circumstances that may require significant adjustments or further disclosure in these consolidated financial statements that were not mentioned above.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Jun. 30, 2019
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Cash and cash equivalents	4.1. Cash and cash equivalents For the purposes of the statements of financial position and statements of cash flows, cash and cash equivalents include cash on hand and in banks and short-term highly liquid investments (original maturity of less than 90 days). In the consolidated statements of financial position, bank overdrafts are included in borrowings within current liabilities.
Financial assets	4.2. Financial assets The Group previously elected to early adopt IFRS 9 (version 2013). The Group measures its financial assets at initial recognition at fair value. The Group classifies its financial assets as financial assets measured at amortized cost (using the effective interest method) on the basis of both:  The Group’s business model for managing the financial assets; and  The contractual cash flows characteristics of the financial asset. The Group has not irrevocably designated a financial asset as measured at fair value through profit or loss to eliminate or significantly reduce a measurement or recognition inconsistency. Financial assets at fair value through profit or loss are measured at fair value through profit and loss due to the business model used in their negotiation and/or the contractual characteristics of their cash flows. The Group does not apply hedge accounting. Estimates The Group makes estimates of uncollectibility of its recorded receivables. Management analyzes trade account receivables in accordance with conventional criteria, adjusting the amount through a charge of an allowance for bad debts upon recognition of the inability of third parties to afford their financial obligations to the Group. Management specifically analyzes the accounts receivable, the historical bad debts, solvency of customers, current economic trends and the changes to the payment conditions of customers to assess the adequate allowance for bad debts. Offsetting of financial assets with financial liabilities Financial assets and liabitilies are offset and presented for their net amount in the statements of financial position only when the Group has the right, legally enforceable, to compensate the recognized amounts and has the intention to liquidate for the net amount or to settle the asset and cancel the liability simultaneously.
Inventories	4.3. Inventories Except for agricultural products (biological assets), inventories are recognized at cost initially and subsequently at the lower of cost and net realizable value. Cost comprises all costs of purchase and conversion as well as other costs incurred in bringing the inventories to their present location and condition. Weighted average cost is used to determine the cost of ordinarily interchangeable items. Agricultural products comprise growing crops. Costs are capitalized as agricultural products if, and only if, (a) it is probable that future economic benefits will flow to the entity, and (b) the cost can be measured reliably. The Group capitalizes costs such as: planting, harvesting, weeding, seedlings, irrigation, agrochemicals, fertilizers and a systematic allocation of fixed and variable production overheads that are directly attributable to the management of biological assets, among others. Agricultural products, both at initial recognition and at each subsequent reporting date, are measured at fair value less costs to sell, except where fair value cannot be reliably measured. Cost approximates fair value when little biological transformation has taken place since the costs were originally incurred or the impact of biological transformation on price is not expected to be material. Gains and losses that arise on measuring biological assets at fair value less costs to sell and measuring agricultural produce at the point of harvest at fair value less costs to sell are recognized in the statement of income in the period in which they arise in the line item “Initial recognition and changes in fair value of biological assets”. Estimates The Group assesses the recoverability of inventories considering their sale price, whether the inventories are damaged and whether they have become obsolete in whole or in part. Net realizable value is the sale price estimated to be attained in the ordinary course of business, less costs of completion and other selling expenses. The Group sets up an allowance for obsolescence or slow-moving inventories in relation to finished and in-process products. The allowance for obsolescence or slow-moving inventories is recognized for finished products and in-process products based on an analysis by Management of the aging of inventory stocks. Generally, the estimation of the fair value of biological assets is based on models or inputs that are not observable in the market and the use of unobservable inputs is significant to the overall valuation of the assets. Unobservable inputs are determined based on the best information available. Key assumptions include future market prices, estimated yields at the point of harvest, estimated production cycle, future cash flows, future costs of harvesting and other costs, and estimated discount rate. Market prices are generally determined by reference to observable data in the principal market for the agricultural produce. Harvesting costs and other costs are estimated based on historical and statistical data. Yields are estimated based on several factors including the location of the farmland and soil type, environmental conditions, infrastructure and other restrictions and growth at the time of measurement. Yields are subject to a high degree of uncertainty and may be affected by several factors out of the Group’s control including but not limited to extreme or unusual weather conditions, plagues and other crop diseases, among other factors.
Business combinations	4.4. Business combinations The Group applies the acquisition method to account for business combinations. The acquisition cost is measured as the aggregate of the consideration transferred for the acquisition of a subsidiary, which is measured at fair value at the acquisition date, and the amount of any non-controlling interest in such subsidiary. The Group recognizes any non-controlling interest in a subsidiary at the non-controlling interest’s proportionate share of the recognized amounts of subsidiary’s identifiable net assets. The acquisition related costs are expensed as incurred. Any contingent consideration to be transferred by the Group is recognized at fair value at the acquisition date. The contingent consideration is classified as an asset or liability that is a financial instrument under IFRS 9 is measured at fair value through profit or loss. Goodwill is initially measured at cost, which is the excess of the aggregate of the consideration transferred and the amount of the non-controlling interest and any previous interest carried over the net identifiable assets acquired and liabilities assumed. After initial recognition, goodwill is measured at cost less any accumulated impairment losses. For impairment testing, goodwill acquired in a business combination is, as of the acquisition date, allocated to each of the cash-generating units of the Group that is expected to benefit from the synergies of the combination, without considering whether other assets or liabilities of the subsidiary are allocated to those units. Any impairment in the carrying value is recognized in the consolidated statement of comprehensive income. In the case of acquisitions in stages, prior to the write-off of the previously held equity interest in the subsidiary, said interest is re-measured at fair value as of the date of acquisition of control over the subsidiary. The result of the re-measurement at fair value is recognized in profit or loss. When a seller in a business combination has contractually agreed to indemnify the Group for the result of a contingency or uncertainty related to the entirety or a portion of an asset or liability, the Group recognizes an indemnification asset. The indemnification asset is measured on the same basis as the indemnification item. At the end of each period, the Group measures the indemnification assets recognized at the acquisition date on the same basis as the indemnified liability, subject to any contractual limitation on the amount and, for an indemnification asset that is not periodically measured at fair value, based on Management’s assessment of the recoverability of the indemnification asset. The Group derecognizes the indemnification asset when it collects or sells it, or when it loses the right over it. Judgment On October 19, 2016 the Group signed an option agreement with certain shareholders of Rizobacter to acquire a further 9.99% interest. On October 22, 2018, Parent, RASA Holding LLC, a Delaware limited liability company and a wholly owned subsidiary of Bioceres, Inc., now a wholly-owned subsidiary of BCS Holding (“RASA Holding”), and Pedro Enrique Mac Mullen, María Marta Mac Mullen and International Property Services Corp., as sellers (collectively, the “Grantors”) entered into an amended and restated option agreement (as may be amended from time to time, the “Rizobacter Call Option Agreement”), pursuant to which the Parent, RASA Holding or any of their nominated affiliates would have the option (the “Rizobacter Call Option”) to purchase from the Grantors all of their 11,916,000 shares of common stock of Rizobacter Argentina S.A., representing 29.99% of all outstanding common stock of Rizobacter. As stated in paragraphs B89 and B90 of IFRS 10, the Group must evaluate whether the purchase option grants it, in substance, rights to returns from its involvement with Rizobacter. If the equity interest currently gives the Group rights to returns from its involvement with Rizobacter, then the proportion of returns allocated to the controlling entity should consider the possible exercise of the voting rights that currently entitle the Group to those returns. Otherwise, the possible exercise of the voting rights should not be considered and only the current voting rights are to be considered. To perform this analysis, the Group has considered that the purchase option contract exposes the Group to returns from the change in the value of the shares (due to the fixed price of the option) and that dividends are not significant in relation to the returns from the equity interest, since the Group has the power to restrict dividend payments to equity holders in Rizobacter. Based on this analysis, the Group has concluded that the purchase option contract grants it, in substance, rights to returns from its involvement with Rizobacter and computed those possible voting rights when determining the proportion of returns allocated to the controlling entity.
Business combination under common control	4.5. Business combination under common control Common control of business combination is excluded from the scope of IFRS 3. There is no other specific guidance on this topic elsewhere in IFRS. Therefore, management needs to use judgement to develop an accounting policy that provides relevant and reliable information in accordance with IAS 8. Management accounting police choice for business combination under common control is “Predecessor value method”. A Predecessor value method involves accounting for the assets and liabilities of the acquired business using existing carrying values. Differences between the carrying value and the amount payable should be accounted as an equity contribution. Semya S.A. combination Semya S.A. (Semya) was a company owned 50% by Bioceres S.A. and 50% by Rizobacter Argentina S.A. It was created as a new proposal for the research, development and commercialization of biological products with high technological value: Semya’s strength consists in the joint and integrated development of biotechnological events, germplasm, biofertilizers and biopesticides to achieve a true synergy in seed treatment. These technologies will increase crop productivity, reduce environmental impact and increase efficiency in the use of resources. Semya’s R&D was being developed by Rizobacter and Bioceres (through Indear) who signed, jointly, a Service Agreement in December 2014. When Group Bioceres acquired control over Rizobacter, it also acquired control over Semya. As required by paragraph 42 of IFRS 3, the Group re-measured the fair value of its previous equity interest in Semya at the acquisition date. The determination of fair value of Semya at the acquisition date is based on the application of a future cash flow present value technique. The main assumptions considered in determining fair value relate to the applicable discount rate and to the projections of revenue from the launch of seed treatment packs. As a result, Ecoseed integrated products have been recorded as intangibles assets. The purpose of those projects is to develop high value-added biological products for the treatment of soybean and wheat seeds, and generate biotechnological, germplasm and bio-inoculants synergies. In June 2019, Bioceres Crop Solutions signed a share purchase agreement (SPA) with Bioceres S.A. for the 50% of ownership in Semya. Concurrently the SPA, Bioceres assigned to Bioceres Crop Solutions the R&D service agreement signed mentioned before. Consideration of the SPA will be in installments equivalent to the 50% of the royalties that Bioceres Crops Solutions will accrue from Semya, up to a total amount of US$ 670,000.
Impairment of non-financial assets (excluding inventories and deferred tax assets)	4.6. Impairment of non-financial assets (excluding inventories and deferred tax assets) Impairment tests on goodwill and intangible assets not yet available for use are undertaken annually at the end of the reporting period. Other non-financial assets are subject to impairment tests whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. Where the carrying value of an asset exceeds its recoverable amount (i.e. the higher of value in use and fair value less costs to sell), the asset is written down accordingly. Where it is not possible to estimate the recoverable amount of an individual asset, the impairment test is carried out on the smallest group of assets to which it belongs for which there are separately identifiable cash flows (its Cash Generating Unit or CGU). Goodwill is allocated on initial recognition to each of the Group’s CGUs that are expected to benefit from a business combination that gives rise to the goodwill. Impairment charges are included in profit or loss, except to the extent they reverse gains previously recognized in other comprehensive income. An impairment loss recognized for goodwill is not reversed. Estimate Impairment testing of goodwill and intangible assets not yet available for use requires the use of significant assumptions for the estimation of future cash flows and the determination of discount rates. The significant assumptions and the determination of discount rates for the impairment testing of goodwill are further explained in Note 6.8.
Joint arrangements	4.7. Joint arrangements An associate is an entity over which the Group exerts significant influence. Significant influence is the power to participate in financial and operating policy decision-making at such entity, but it does not involve control or joint control over those policies. The Group is a party to a joint arrangement when there is a contractual arrangement that confers joint control over the relevant activities of the arrangement to the Group and at least one other party. Joint control is assessed under the same principles as control over subsidiaries. The Group classifies its interests in joint arrangements as either: · Joint ventures : where the group has rights to only the net assets of the joint arrangement. · Joint operations : where the group has both the rights to the assets and obligations for the liabilities of the joint arrangement. In assessing the classification of interests in joint arrangements, the Group considers: · The structure of the joint arrangement; · The legal form of joint arrangements structured through a separate vehicle; · The contractual terms of the joint arrangement agreement; and · Any other facts and circumstances (including any other contractual arrangements). The Group accounts for its interests in joint ventures using the equity method, where the Group’s share of post-acquisition profits and losses and other comprehensive income is recognized in the Consolidated statement of profit and loss and other comprehensive income. Losses in excess of the Group’s investment in the joint venture are recognized only to the extent that the Group has incurred legal or constructive obligations or made payments on behalf of the joint venture. Profits and losses arising on transactions between the Group and its joint ventures are recognized only to the extent of unrelated investors’ interests in the joint venture. The Group’s share in a joint venture’s profits and losses resulting from a transaction is eliminated against the carrying amount of investment in the joint venture through the line “share of profit (or loss) of joint ventures” in the Consolidated statements of profit or loss and other comprehensive income. Any premium paid for an investment in a joint venture above the fair value of the Group’s share of the identifiable assets, liabilities and contingent liabilities acquired is capitalized and included in the carrying amount of the investment in the joint venture. Where there is objective evidence that the investment in a joint venture has been impaired, the carrying amount of the investment is tested for impairment in the same way as other non-financial assets. When the Group loses significant influence in an associate or joint control over a joint venture, it measures and recognizes any investment held at fair value. Any difference between the carrying amount of the associate or joint venture when losing significant influence or joint control and the fair value of the held investment and sale revenue are recognized in profit or loss. The Group accounts for its interests in joint operations by recognizing its share of assets, liabilities, revenues and expenses in accordance with its contractually conferred rights and obligations. For all joint arrangements structured in separate vehicles the Group must assess the substance of the joint arrangement in determining whether it is classified as a joint venture or joint operation. This assessment requires the Group to consider whether it has rights to the joint arrangement’s net assets (in which case it is classified as a joint venture), or rights to and obligations for specific assets, liabilities, expenses, and revenues (in which case it is classified as a joint operation). Upon consideration of the factors mentioned above, the Group has determined that all of its joint arrangements structured through separate vehicles only give it rights to the net assets and are therefore classified as joint ventures (Note 12). Estimates There is considerable uncertainty regarding Management’s estimates of the Group’s ability to recover the carrying amounts of the investments in joint ventures, since such estimates depend on the joint ventures’ ability to generate sufficient funds to complete the development projects, the future outcome of the project deregulation process and the amounts and timing of the cash flows from projects, among other future events. Management assesses whether there are impairment indicators and, if any, it performs a recoverability analysis. Management estimates of the recoverability of these investments represent the best estimate based on available evidence, the existing facts and circumstances, using reasonable and provable assumptions in the cash flow projections. Therefore, the consolidated financial statements do not include adjustments that would be required if the Group were unable to recover the carrying amount of the above-mentioned assets by generating sufficient economic benefits in the future. When the Group acquired control of Rizobacter, it also acquired the joint control of Synertech. Therefore, the investment in Synertech was added at the time of initial recognition of the acquisition at fair value. The determination of the fair value of Synertech at the acquisition date is based on the application of a future cash flow present value technique. The main assumptions considered in determining fair value relate to the applicable discount rate and to the projections of higher revenue from sales of micro-granulated fertilizers.
Property, plant and equipment	4.8. Property, plant and equipment Property, plant and equipment items are initially recognized at cost. In addition to the purchase price, cost also includes costs directly attributable to such property, plant and equipment items. There are no unavoidable costs with respect to dismantling and removing items. The cost of property, plant and equipment items acquired in a business combination is their fair value at the acquisition date. Depreciation is calculated using the straight-line method to allocate the property, plant or equipment items’ cost or revalued amounts, net of their residual values, over their estimated useful lives or, in the case of leasehold improvements and certain leased plant and equipment, the shorter lease term as follows: Research instruments: 3 to 10 years Office equipment: 5 to 10 years Vehicles: 5 years Computer equipment and software: 3 years Fixture and fittings: 10 years Machinery and equipment: 5 to 10 years Buildings: 50 years Useful lives and depreciation methods are reviewed every year as required by IAS 16. Assets under items Land and Buildings, are accounted for at fair value arising from the last revaluation performed, applying the revaluation model indicated by IAS 16. This policy was adopted by the Group since the six-month transition period ended June 30, 2017. Revaluations are performed on a regular basis, when there are signs that the book value differs significantly from that to be determined using the fair value at the end of the reporting year. To obtain fair values, the existence of an active market is considered for the assets in their current status. For those assets for which an active market in their current status exists, the fair values were determined based on their market values. For the remaining cases, the market values of comparable new assets are analysed, applying a discount based on the status and wear of each asset and considering the characteristics of each of the revalued assets (for example, improvements made, maintenance status, level of productivity, use, etc. Estimates The Group carries certain classes of property, plant and equipment under the revaluation model under IAS 16. The revaluation model requires that the Group carry property, plant and equipment at revalued amounts, being fair value at the date of revaluation less any subsequent accumulated depreciation and any subsequent accumulated impairment losses. IAS 16 requires that the Group carry out these revaluations with sufficient regularity so that the carrying amounts of its property, plant and equipment do not differ materially from that which would be determined using fair value at the end of a reporting period. The determination of fair value at the date of revaluation requires judgments, estimates and assumptions based on market conditions prevailing at the time of any such revaluation. Changes to any of the Group’s judgments, estimates or assumptions or to the market conditions subsequent to a revaluation will result in changes to the fair value of property, plant and equipment. The Group prepares the corresponding revaluations on a regular basis taking into account the work of independent appraisers. The Group uses different valuation techniques depending on the class of property being valued. Generally, the Group determines the fair value of its industrial buildings and warehouses based on a depreciated replacement cost approach. The Group determines the fair value of its land based on active market prices adjusted, if necessary, for differences in the nature, location or condition of the specific asset. If this information is not available, the Group may use alternative valuation methods, such as recent prices in less active markets. Property valuation is a significant area of estimation uncertainty. Fair values are prepared regularly by Management, taking into account independent valuations. The determination of fair value for the different classes of property, plant and equipment is sensitive to the selection of various significant assumptions and estimates. Changes in those significant assumptions and estimates could materially affect the determination of the revalued amounts of property, plant and equipment. The Group utilizes historical experience, market information and other internal information to determine and/or review the appropriate revalued amounts. The following are the most significant assumptions used in the preparation of the revalued amounts for its classes of property, plant and equipment: a) Land: The Group generally uses the market price of a square meter of land for the same or similar location as the most significant assumption to determine the revalued amount. The Group typically uses comparable land sales in the same location to assess appropriateness of the value of its land. A 10% increase or decrease in the market price of land could have a significant impact on the revalued amount of its land. b) Industrial buildings and warehouses: The Group generally determines the construction cost of a new asset and then the Group adjusts it for normal wear and tear. Construction prices may include, but are not limited to, construction materials, labor costs, installation and assembly costs, site preparation, professional fees and applicable taxes. Construction costs may differ significantly from year to year and are subject to macroeconomic changes in the economy where the Group operates, such as the impact of inflation and foreign exchange rates. The construction cost of its industrial buildings and warehouses is determined on a US dollar per constructed square meter basis, while the construction cost of its mills, facilities and grain storage facilities is determined by reference to their total capacity measured in tons milled or stored, respectively. A 5% increase or decrease in the construction costs relating to such assets could have a significant impact on their revalued amounts. A 5% variation in the estimate of normal wear and tear could also have a significant impact on their revalued amounts. Increases in the carrying amounts arising on revaluation of land and buildings are recognized, net of tax, in other comprehensive income and accumulated in reserves in shareholders’ equity. To the extent that the increase reverses a decrease previously recognized in profit or loss, the increase is first recognized in profit or loss. Decreases that reverse previous increases of the same asset are first recognized in other comprehensive income to the extent of the remaining surplus attributable to the asset; all other decreases are charged to profit or loss.
Leased assets	4.9. Leased assets Where substantially all of the risks and rewards incidental to ownership of a leased asset have been transferred to the Group (a "finance lease"), the asset is treated as if it had been purchased outright. The amount initially recognized as an asset is the lower of the fair value of the leased property and the present value of the minimum lease payments payable over the term of the lease. The corresponding lease commitment is shown as a liability. Lease payments are categorized as capital or interest. The interest element is charged to the Consolidated statement of profit or loss and other comprehensive income over the period of the lease and is calculated so that it represents a constant proportion of the lease liability. The capital element reduces the balance owed to the lessor. Where substantially all of the risks and rewards incidental to ownership are not transferred to the Group (an "operating lease"), the total rentals payable under the lease are charged to the Consolidated statement of profit or loss and other comprehensive income on a straight-line basis over the lease term. The aggregate benefit of lease incentives is recognized as a reduction of the rental expense over the lease term on a straight-line basis.
Intangible assets	4.10. Intangible assets a) Externally acquired intangible assets Externally acquired intangible assets are initially recognized at cost and subsequently amortized on a straight-line basis over their useful economic lives. Intangible assets acquired from third parties have an estimated useful life as follows (in years): Software: 3 years Trademarks and patents: 5 years Certification ISO Standards: 3 years Useful lives and amortization methods are reviewed every year as required by IAS 38. b) Internally generated intangible assets (development costs) Expenditure on internally developed products is capitalized if it can be demonstrated that: · It is technically feasible to develop the product for it to be sold; · Adequate resources are available to complete the development; · There is an intention to complete and sell the product; · The Group is able to sell the product; · Sale of the product will generate future economic benefits; and · Expenditure on the project can be measured reliably. Development expenditure not satisfying the above criteria and expenditure on the research phase of internal projects are recognized in the consolidated statement of profit or loss and other comprehensive income as incurred (Note 7.3). Capitalized development costs are amortized using the straight-line method over the periods the Group expects to benefit from selling the products developed (Note 6.7). Useful lives and amortization methods are reviewed every year as required by IAS 38. The research and development process can be divided into several discrete steps or phases, which generally begin with discovery, validation and development and end with regulatory approval and commercial launch. The process for developing seed traits is relatively similar for both GM and non-GM traits. However, the two differ significantly in later phases of development. For example, obtaining regulatory approval for GM seeds is a far more comprehensive and lengthy process than for non-GM seeds. Although breeding programs and industrial biotechnology solutions may have shorter or simpler phases than those described below, the Group has used the industry consensus for seed-trait development phases to characterize its technology portfolios, which is generally divided into the following six phases: i) Discovery: The first phase in the technology development process is the discovery or identification of candidate genes or genetic systems, metabolites, or microorganisms potentially capable of enhancing specified plant characteristics or enabling an agro-industrial biotech solution. In the Group’s experience, the discovery phase typically lasts 18 months, though it may range from as few as six months for microbial solutions to as many as 36 months for plant GM traits. ii) Proof of concept: Upon successful validation of the technologies in model systems ( in vitro or in vivo ), promising technologies graduate from discovery and are advanced to the proof of concept phase. The goal of this phase is to validate a technology within the targeted organism before moving forward with technology escalation activities or extensive field validation. In the Group’s experience, the proof of concept phase typically lasts 36 months, though it may range from as few as six months for a microbial solution to as many as four years for plant GM traits. iii) Early development: In this phase, field tests commenced in the proof of concept phase are expanded to evaluate various permutations of a technology in multiple geographies and growing cycles, as well as other characteristics in order to optimize the technology’s performance in the targeted organisms. The goal of the early development phase is to identify the best mode of use of a technology to define its performance concept. The early development phase typically lasts 24 months. iv) Advanced development and deregulation: In this phase, extensive field tests are used to demonstrate the effectiveness of the technology for its intended purpose. In the case of GM traits, the process of obtaining regulatory approvals from government authorities is also initiated during this phase, and tests are performed to evaluate the potential environmental impact of modified plants. For solutions involving microbial fermentation, industrial-scale runs are conducted. In Argentina and some other countries in South America, the Group is primarily responsible for undertaking this phase of product development. Similarly, the Group’s strategic partners usually lead the advanced development and deregulation activities in other markets pursuant to the applicable contractual arrangements. The advanced development and deregulation phase typically last about 24 months, with some projects requiring substantial regulatory data lasting as many as three years. For molecular farming projects, where grain production will occur within Argentina, the Group may follow a simplified regulatory approach, which requires less time than traditional GM regulatory approvals. v) Pre-launch: This phase involves finalizing the regulatory approval process and preparing for the launch and commercialization of the technology. The range of activities in this phase includes seed increases, pre-commercial production, and product and solution testing with selected customers. Usually, a more detailed marketing strategy and preparation of marketing materials occur during this phase. The pre-launch phase may last up to 24 months. vi) Product launch: In general, this phase, which is the last milestone of the research and development process, is carried out by the Group, the joint ventures and/or the Group’s technology licensees. When technology is commercialized through the joint ventures or technology licensees, a successful product launch will trigger royalty payments to the Group, which are generally calculated as a percentage of the net sales realized by the technology and captured upon commercialization. Demonstrability of technical feasibility generally occurs when the project reaches the “advanced development and deregulation” phase because at this stage success is considered to be probable. c) Intangible assets acquired in a business combination Intangible assets acquired in a business combination and recognized separately from goodwill are initially recognized at acquisition date fair value (which is considered as their cost). After initial recognition, those assets are measured at cost less accumulated amortization and accumulated impairment losses in the same manner as intangible assets acquired separately.  Product registration: In accordance with regulations set by certain regulatory agencies such as the National Agri-Food Safety and Quality Service (SENASA), Rizobacter has been required to register products with regulatory authorities to be able to sell them both in the domestic and international markets (jointly referred to as "Product Registration"). Some of the registered products have been developed by third parties.  Brand: Rizobacter offers a wide variety of proprietary and third-party products, which are commercialized under the Rizobacter brand name. This intangible has been designated with an indefinite useful life.  Customer loyalty: Rizobacter sales to distributors of agrochemicals and to special accounts, mainly large retailers and wholesalers, whether inside or outside the Argentine territory are included. They are recognised at their fair value at the date of acquisition and are subsequently amortised on a straight-line based on the timing of projected cash flows of the clients over their estimated useful lives. Intangible assets acquired in a business combination have an estimated useful life as follows (in years): Product registration: 5 years Customer loyalty: 26 years Estimates The Group acquired certain intangible assets from Rizobacter in a business combination. To value those intangible assets, valuation techniques generally accepted in the market were applied, based mainly on the revenue approach (such as excess earnings, relief from royalty, and with or without), considering the characteristics of the assets to be valued and available information to estimate their acquisition date fair value. Application of these valuation techniques requires the use of several assumptions related to future cash flows and the discount rate.
Financial liabilities	4.11. Financial liabilities The Group adopted IFRS 9 (version 2013) early. The Group measures its financial liabilities at initial recognition at fair value. The Group classifies all its financial liabilities as financial liabilities measured at amortized cost (using the effective interest rate method), except for the following liabilities that are measured at fair value: (a) Certain hybrid contracts that include embedded derivatives and for which the option of paragraph 4.3.5 of IFRS 9 was used to designate the hybrid contract as a whole at fair value through profit or loss and (b) embedded derivatives. In the case of hybrid contracts that were designated as a whole at fair value through profit or loss, the amount of the change in fair value of the financial liability that is attributable to changes in credit risk attaching to that liability is disclosed in other comprehensive income. The rest of the change in fair value of the liability is recognized in income. In the case of the other financial liabilities measured at fair value, the change in fair value is charged to income. The Group does not apply hedge accounting. Estimates The Group has designated certain hybrid contracts as a whole at fair value. Management of the Group periodically evaluates the appropriate valuation techniques and data used in the fair value measurement and estimation of changes in fair value derived from changes in credit risk. In estimating the fair value of those financial liabilities, the Group uses observable market inputs as far as possible. Information about the valuation techniques and significant assumptions used is detailed in Note 14.
Warrants	4.12. Warrants As part of the merger, the Group incorporated 11,500,000 public warrants (“Public warrants”), 5,200,000 private warrants (“Founder warrants”) and 7,500,000 private warrants (“Bioceres warrants”) that Union issued to Bioceres LLC in exchange of its Bioceres Inc Crop Business and its equity interest in Bioceres Semillas. The warrants are an equity instrument only if (a) the instrument includes no contractual obligation to deliver cash or another financial asset to another entity and (b) if the instrument will or may be settled in the issuer’s own equity instruments, it is either a non-derivative that includes no contractual obligation for the issuer to deliver a variable number of its own equity instruments; or a derivative that will be settled only by the issuer exchanging a fixed amount of cash or another financial asset for a fixed number of its own equity instruments (“fixed-for-fixed’ condition”). Public warrants were classified as equity instrument as they comply with the fixed-for-fixed’ condition. Founder warrants and Bioceres warrants (as a group, the “Private warrants”) instead were classified as financial liabilities (see Note 6.16). Estimates The estimate of the fair value of Private warrants requires a determination of which factors are most appropriate to the pricing model, including the expected life of the option and the expected volatility of the share price upon the basis of which hypotheses are made. The Group measures the fair value of these instruments applying a simulation model of the share price trajectory under the hypothesis of Brownian Motion. The hypotheses used for the estimate of the fair value of these instruments are disclosed in Note 6.16.
Employee benefits	4.13. Employee benefits Employee benefits are expected to be settled wholly within 12 months after the end of the reporting period and are presented as current liabilities. The accounting policies related to incentive payments based on the stock options are detailed in Note 4.20.
Provisions	4.14. Provisions The Group has recognized provisions for liabilities of uncertain timing or amount. The provision is measured at the best estimate of the expenditure required to settle the obligation at the end of the reporting period, discounted at a pre-tax rate reflecting current market assessments of the time value of money and risks specific to the liability.
Parent company investment	4.15. Parent company investment The Group has recognized the contribution made by Bioceres S.A. into the combined entity as Parent company investment. See note 10.2. The Group’s ordinary shares are classified as equity instruments, except for the puttable shares which are compound financial instruments. Puttable shares are segregated into separate components of equity instruments and puttable instruments, the latter of which is classified as a financial liability in accordance with IAS 32. The shares classified as equity instruments are measured at nominal value
Revenue recognition	4.16. Revenue recognition Revenue is measured at fair value of consideration received or receivable. Revenue from ordinary activities from contracts with customers is recognized and measured based on a five-step model, namely:  Identification of the contract with the client. A contract is an agreement between two or more parties, which creates rights and obligations for the parties involved;  Identification of performance obligations, issuing as such a commitment arising from the contract to transfer a good or service.  Determination of the price of the transaction, in reference to the consideration for satisfying each performance obligation.  Assignment of the transaction price between each of the performance obligations identified, based on the methods described in the standard.  Revenue recognition when the performance obligations identified in contracts with customers are met, at any given time or over a period of time. a) Revenue from the sale of goods is recognized when all the following conditions have been satisfied: (i) the Group has transferred to the buyer the significant risks and rewards of ownership of the goods; (ii) the Group retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold; (iii) the amount of revenue can be measured reliably; (iv) it is probable that the economic benefits associated with the transaction will flow to the Group; and (v) the costs incurred or to be incurred in respect of the transaction can be measured reliably. In the case of sales made with where delivery is delayed at the buyer’s request but the buyer assumes ownership and accepts the invoice, revenue is recognized when the buyer assumes ownership, provided that:  It must be probable that delivery will take place;  The goods must be on hand, identified and be ready for delivery to the buyer at the time the sale is recognized  The buyer must specifically acknowledge the deferred delivery instructions; and  The usual payment terms must apply. No revenue is recognized when there is only an intention to purchase or produce the goods in time for delivery. b) When the outcome of a transaction involving the rendering of services can be estimated reliably, revenue associated with the transaction is recognized by reference to the stage of completion of the transaction at the end of the reporting period. The outcome of a transaction can be estimated reliably when all the following conditions are satisfied: (i) the amount of revenue can be measured reliably; (ii) it is probable that the economic benefits associated with the transaction will flow to the entity; (iii) the stage of completion of the transaction at the end of the reporting period can be measured reliably; and (iv) the costs incurred for the transaction and the costs to complete the transaction can be measured reliably. When the outcome of the transaction involving the rendering of services cannot be estimated reliably, revenue is recognized only to the extent of the expenses recognized that are recoverable. The stage of completion for research and development services is generally determined on the basis of internal records of execution of the performed tasks of the respective work plan. For practical purposes, when services are performed by an indeterminate number of acts over a specified period of time, revenue is recognized on a straight-line basis over the specified period unless there is evidence that some other method better represents the stage of completion. When a specific act is much more significant than any other acts, the recognition of revenue is postponed until the significant act is executed. c) Licenses and royalties are recognized when it is probable that the economic benefits associated with the transaction will flow to the Group; and the amount of revenue can be measured reliably. Fees and royalties paid for the use of the Group’s assets are normally recognized in accordance with the substance of the agreement. When a licensee has the right to use certain technology for a specified period of time, revenue is recognized on a straight-line basis over the life of the agreement. An assignment of rights for a fixed fee or non-refundable guarantee under a non-cancellable contract which permits the licensee to exploit those rights freely and the licensor has no remaining obligations to perform is, in substance, a sale. In such cases, revenue is recognized at the time of sale. In some cases, whether or not a license fee or royalty will be received is contingent on the occurrence of a future event. In such cases, revenue is recognized only when it is probable that the fee or royalty will be received, which is normally when the event has occurred.
Government grants	4.17. Government grants Government grants are recognized where there is reasonable assurance that the grant will be received and all attached conditions will be complied with. When the grant relates to an expense item, it is recognized as income on a systematic basis over the periods that the related costs, for which it is intended to compensate, are expensed. When the grant relates to an asset, it is recognized as income in equal amounts over the expected useful life of the related asset. Management elected this accounting policy because the Group determined it better shows the financial effect of government grants in the Consolidated financial statements. When the Group receives grants of non-monetary assets, the asset and the grant are recorded at nominal amounts and released to profit or loss over the expected useful life of the asset. The difference between the money obtained under government loans at subsidized rates and the carrying amount of those loans is treated as a government grant, in accordance with IAS 20.
Borrowing costs	4.18. Borrowing costs Borrowing costs, either generic or specific, attributable to the acquisition, construction or production of assets that necessarily take a substantial period of time to get ready for their intended use or sale (qualifying assets) are included in the cost of the assets until the moment that they are substantially ready for use or sale. Income earned on the temporary investments of funds generated in specific borrowings still pending use in the qualifying assets, are deducted from the total of financing costs potentially eligible for capitalization. All other loan costs are recognized under financial costs, through profit and loss.
Income tax and minimum presumed income tax	4.19. Income tax and minimum presumed income tax Deferred tax assets and liabilities are recognized where the carrying amount of an asset or liability in the Consolidated statement of financial position differs from its tax base, except for differences arising on:  The initial recognition of goodwill;  The initial recognition of an asset or liability in a transaction which is not a business combination and at the time of the transaction affects neither accounting or taxable profit; and Investments in subsidiaries and jointly controlled entities where the Group is able to control the timing of the reversal of the difference and it is probable that the difference will not reverse in the foreseeable future. Recognition of deferred tax assets is restricted to those instances where it is probable that taxable profit will be available against which the difference can be utilized. The amount of the asset or liability is determined using tax rates that have been enacted or substantively enacted by the end of the reporting period and are expected to apply when the deferred tax liabilities / (assets) are settled / (recovered). Deferred tax assets and liabilities are offset when the Group has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority on either:  The same taxable entity within the Group, or  Different entities within the Group which intend either to settle current tax assets and liabilities on a net basis, or to realize the assets and settle the liabilities simultaneously, in each future period in which significant amounts of deferred tax assets or liabilities are expected to be settled or recovered. Minimum presumed income tax applies to assets of the entities domiciled in Argentina. The tax is only applicable if the total value of the assets is above ARS 200,000 at the end of the fiscal year, and is levied at a rate of 1% on the total value of such assets. The amount of the tax paid on minimum presumed income tax is allowed as a credit toward income tax. Furthermore, to the extent that this tax cannot be credited against normal corporate income tax, it may be carried forward as a credit for the following ten years. Shares and other capital participations in the stock capital of entities subject to the minimum presumed income tax are exempted from the tax on minimum presumed income. The Group determined on the basis of current jurisprudence that the aforementioned tax is not applicable in the year ended June 30, 2019, as the Group has both accounting and fiscal losses.
Share-based payments	4.20. Share-based payments Certain executives and directors of the Group were granted incentives in the form of shares and options to purchase Bioceres S.A. shares as consideration for services. The cost of these share-based transactions is determined based on their fair value at the date upon which such incentives are granted using a valuation model that is appropriate in the circumstances. This cost is recognized as an expense together with an increase in equity throughout the period in which the service or performance conditions are satisfied (i.e., the vesting period). The accumulated expense recorded in connection with these transactions at the end of each year until the vesting date reflects the time elapsed between the vesting period and Management’s best estimate of the number of equity instruments that will vest. The charge to income/loss for the period represents the variation in the accumulated expense recorded between the beginning and the end of the year. Non-market related service and performance conditions are not taken into account when determining the grant date fair value of the equity instruments, but the probability that the conditions are fulfilled is assessed as part of Management’s best estimate of the number of equity instruments that will vest. Market-related performance conditions are reflected in the grant date fair value. Any other conditions related to equity-settled share-based payment transactions but without a service requirement are considered as non-vesting conditions. Non-vesting conditions are reflected in the fair value of the equity instruments and are charged to income/loss immediately unless there are service and/or performance conditions as well. No amount is recognized for transactions that will not vest because non-market related performance conditions and/or service conditions were not satisfied. When transactions include market-related conditions or non-vesting conditions, the transactions are considered to be vested, irrespective of whether a market-related condition or the non-vesting condition is satisfied, provided that all the other performance and/or service conditions are met. When the terms and conditions of an equity-settled share-based payment transaction are modified, the minimum expense recognized is the grant date fair value, unmodified, provided that the original terms have been complied with. An additional expense, measured at the date of modification, is recognized for any modification that increases the total fair value of the share-based payment transaction, or is otherwise beneficial to the employee. When the transaction is settled by the Bioceres S.A. or by the counterparty, any remainder of the fair value is charged to income immediately. The dilutive effect of current options is considered in the calculation of the diluted earnings per share. Estimates The estimate of the fair value of equity-settled share-based payment transactions requires a determination to be made of the most adequate option pricing model to apply depending on the terms and conditions of the arrangement. This estimate also requires a determination of those factors most appropriate to the pricing model, including the expected life of the option and the expected volatility of the share price upon the basis of which hypotheses are made. The Group measures the fair value of these transactions at the grant date applying the Black-Scholes formula adjusted to consider the possible dilutive effect of the future exercise of the share options granted on their estimated fair value at grant date, as established in paragraph B41 of IFRS 2. The hypotheses used for the estimate of the fair value of these transactions are disclosed in Note 18 and will not necessarily take place in the future.

ACCOUNTING STANDARDS AND BASI_2

ACCOUNTING STANDARDS AND BASIS OF PREPARATION (Tables)	12 Months Ended
	Jun. 30, 2019
ACCOUNTING STANDARDS AND BASIS OF PREPARATION
Schedule of equity interest in the subsidiaries	Country of incorporation and principal place of % Equity interest Name Principal activities business Ref 06/30/2019 06/30/2018 RASA Holding, LLC Investment in subsidiaries United States a 100.00 % 100.00 % Rizobacter Argentina S.A. Microbiology Business Argentina b 80.00 % 60.00 % Rizobacter do Brasil Ltda. Selling of agricultural inputs Brazil c 79.99 % 59.99 % Rizobacter del Paraguay S.A. Selling of agricultural inputs Paraguay c 79.92 % 59.94 % Rizobacter Uruguay Selling of agricultural inputs Uruguay c 80.00 % 60.00 % Rizobacter South Africa Selling of agricultural inputs South Africa c 76.00 % 57.00 % Comer. Agrop. Rizobacter de Bolivia S.A. Selling of agricultural inputs Bolivia c 79.96 % 59.97 % Rizobacter USA, LLC Selling of agricultural inputs United States c 80.00 % 60.00 % Rizobacter India Private Ltd. Selling of agricultural inputs India c 80.00 % 59.99 % Rizobacter Colombia SAS Selling of agricultural inputs Colombia c 80.00 % 60.00 % Indrasa Biotecnología S.A. Research and development Argentina d 31.50 % 52.91 % Rizobacter France SAS Research and development France c 80.00 % 60.00 % Semya S.A. Research and development Argentina e 100.00 % 50.00 % BCS Holding LLC Investment in subsidiaries United States a 100.00 % — Bioceres Semillas Production and commercialization of seeds Argentina a 100.00 % % The Group holds a majority share of the voting rights in all of its subsidiaries. a) The percentage of the voting rights attributable to the Group is the same as the percentage of its equity interest as set forth in the table above. b) Immediately following the consummation of the merger on March 14, 2019, the Rizobacter Call Option was exercised, pursuant to which the total indirect ownership of BCS Holding in Rizobacter increased to 80.00% of all outstanding shares of Rizobacter. See Note 1. c) Indirect interests held through Rizobacter. The indirect equity interest participation included in this table was the 80% of the direct equity interest participation that Rizobacter owns in each entity. d) In September 2018, the participation of Rizobacter S.A. in Indrasa Biotecnología S.A. decreased from 52.50% to 35%, therefore the Group lost the control over this subsidiary. e) In June 2019, Bioceres Crop Solutions signed a share purchase agreement with Bioceres S.A. for the 50% of the ownership in Semya. See Note 4.5.

INFORMATION ABOUT COMPONENTS _4

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Tables)	12 Months Ended
	Jun. 30, 2019
INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
Schedule of cash and cash equivalents	06/30/2019 06/30/2018 06/30/2017 Cash and banks 3,450,873 2,215,103 1,679,478 3,450,873 2,215,103 1,679,478
Schedule of other financial assets	06/30/2019 06/30/2018 06/30/2017 Current Restricted short-term deposit 4,327,275 4,538,321 4,260,517 Other investments 347,718 — — Other marketable securities 8,515 12,526 4,275 4,683,508 4,550,847 4,264,792 06/30/2019 06/30/2018 06/30/2017 Non-current Shares of Bioceres S.A. 374,685 240,920 676,762 Other marketable securities 1,728 2,438 90,237 376,413 243,358 766,999
Schedule of trade receivables	06/30/2019 06/30/2018 06/30/2017 Trade debtors 48,910,484 44,641,053 34,121,040 Allowance for impairment of trade debtors (3,360,224) (3,212,170) (2,873,688) Shareholders and other related parties (Note 16) 467,743 571,216 1,025,903 Allowance for impairment of related parties (Note 16) (75,596) (23,126) (205,960) Allowance for return of goods (800,606) (1,517,361) (1,393,059) Trade debtors - Parent company (Note 16) 440,268 361,606 — Trade debtors - Joint ventures and associates (Note 16) 2,369 209,039 217,963 Discounted and deferred checks 13,651,939 11,858,170 10,783,719 59,236,377 52,888,427 41,675,918
Schedule of other receivables	06/30/2019 06/30/2018 06/30/2017 Current Taxes 584,641 664,926 1,904,592 Other receivables - Other related parties (Note 16) 10,971 119,677 67,753 Other receivables - Parent Company (Note 16) — 103,251 — Other receivables - Joint ventures and associates (Note 16) 250,783 1,962,459 3,085,056 Prepayments to suppliers 496,001 516,742 1,210,070 Reimbursements over exports 366,594 362,815 151,107 Prepaid expenses and other receivables 213,597 — 265,972 Loans receivable — 1,360 5,732 Miscellaneous 59,242 508,975 417,937 1,981,829 4,240,205 7,108,219 06/30/2019 06/30/2018 06/30/2017 Non-Current Taxes 681,168 295,924 484,572 Reimbursements over exports 878,470 346,575 472,276 Other receivables - Joint ventures and associates (Note 16) — 4,337,008 1,213,053 Miscellaneous 672 — 13,343 1,560,310 4,979,507 2,183,244
Schedule of inventories	06/30/2019 06/30/2018 06/30/2017 Agrochemicals 22,137 94,486 183,822 Seeds and grains 207,519 514,000 1,273,515 Microbiological resale products 13,894,018 8,389,191 13,749,668 Microbiological products produced 8,370,583 6,383,263 8,931,124 Goods in transit 751,737 776,869 482,185 Supplies 4,512,870 3,978,934 7,424,825 Allowance for obsolescence (406,818) (770,742) (707,105) Agricultural product 240,536 — — 27,592,582 19,366,001 31,338,034
Schedule of property plant and equipment	06/30/2019 06/30/2018 06/30/2017 12/31/2016 Gross carrying amount 57,059,972 44,764,394 48,520,889 47,276,088 Accumulated depreciation (13,225,424) (4,587,248) (2,302,014) (882,327) Net carrying amount 43,834,548 40,177,146 46,218,875 46,393,761
Schedule of net carrying amount	Net carrying Net carrying Net carrying Net carrying amount amount amount amount Class 06/30/2019 06/30/2018 06/30/2017 12/31/2016 Office equipment Vehicles Equipment and computer software 123,472 212,236 308,360 380,386 Fixtures and fittings 4,737,396 3,508,083 4,460,903 4,701,939 Machinery and equipment 6,336,691 4,466,293 8,405,441 9,105,953 Land and buildings 29,969,237 30,513,273 30,103,117 29,584,854 Buildings in progress 668,614 182,839 870,469 420,685 Total 43,834,548 40,177,146 46,218,875 46,393,761
Schedule of gross carrying amount	Gross carrying amount as of June 30, 2019 is as follows: Gross carrying amount Adjustment of opening net book As of the amount for Foreign beginning application currency As of the Class of year of IAS 29 Additions Transfers Disposals translation Revaluation end of year Office equipment 243,948 333,904 30,621 — (8,493) 29,139 — 629,119 Vehicles 1,660,294 1,054,631 1,093,749 — (297,269) 93,132 — 3,604,537 Equipment and computer software 419,638 416,274 75,152 — (1,685) 46,278 — 955,657 Fixtures and fittings 3,826,665 1,909,115 7,518 213,333 — 481,799 — 6,438,430 Machinery and equipment 5,404,029 3,976,720 98,034 7,863 (31,407) 778,262 — 10,233,501 Land and buildings 33,026,981 1,438,728 125,930 — — 1,994,906 (2,056,431) 34,530,114 Buildings in progress 182,839 75,405 613,098 (221,196) — 18,468 — 668,614 Total 44,764,394 9,204,777 2,044,102 — (338,854) 3,441,984 (2,056,431) 57,059,972 Gross carrying amount as of June 30, 2018 is as follows: Gross carrying amount As of the Foreign beginning currency As of the Class of year Additions Transfers Disposals translation Revaluation end of year Office equipment 252,220 119,623 — — (127,895) — 243,948 Vehicles 2,223,102 388,856 — (131,746) (819,918) — 1,660,294 Equipment and computer software 426,529 189,094 47,744 (14,726) (229,003) — 419,638 Fixtures and fittings 4,665,074 6,178 1,646,914 (1,632) (2,489,869) — 3,826,665 Machinery and equipment 9,152,269 197,840 — (23,010) (3,923,070) — 5,404,029 Land and buildings 30,931,226 26,017 651,662 — (13,146,785) 14,564,861 33,026,981 Buildings in progress 870,469 1,864,186 (2,346,320) — (205,496) — 182,839 Total 48,520,889 2,791,794 — (171,114) (20,942,036) 14,564,861 44,764,394 Gross carrying amount as of June 30, 2017 is as follows: Gross carrying amount As of the Foreign beginning Currency As of the Class of year Additions Transfers Disposals Translation Revaluation end of year Office equipment 235,301 32,138 — — (15,219) — 252,220 Vehicles 2,136,823 441,478 — (183,170) (172,029) — 2,223,102 Equipment and computer software 460,518 20,637 — (32,074) (22,552) — 426,529 Fixtures and fittings 4,770,076 — 127,475 — (232,477) — 4,665,074 Machinery and equipment 9,492,852 18,513 73,717 (10,678) (422,135) — 9,152,269 Land and buildings 29,759,833 15,508 (428,844) (197,467) (1,461,403) 3,243,599 30,931,226 Buildings in progress 420,685 167,393 227,652 — 54,739 — 870,469 Total 47,276,088 695,667 — (423,389) (2,271,076) 3,243,599 48,520,889 Gross carrying amount as of December 31, 2016 is as follows: Gross carrying amount As of the Foreign beginning of Additions Currency As of the Class year Additions por PPA Disposals Translation end of year Office equipment 5,830 4,811 234,221 — (9,561) 235,301 Vehicles 160,895 225,459 1,878,400 (49,179) (78,752) 2,136,823 Equipment and computer software 14,283 13,945 450,785 — (18,495) 460,518 Fixtures and fittings 1,608 118,638 4,848,110 — (198,280) 4,770,076 Machinery and equipment 310,504 35,170 9,533,037 — (385,859) 9,492,852 Land and buildings — 210,038 30,792,604 — (1,242,809) 29,759,833 Buildings in progress — — 430,837 — (10,152) 420,685 Total 493,120 608,061 48,167,994 (49,179) (1,943,908) 47,276,088
Schedule of accumulated depreciation	Accumulated depreciation as of June 30, 2019 is as follows: Depreciation Adjustment of opening Accumulated net book as of the amount for Foreign Accumulated beginning of application of currency as of the end of Class year IAS 29 Disposals Of the year translation Revaluation year Office equipment 49,129 309,339 (4,007) 39,997 21,224 — 415,682 Vehicles 560,691 750,195 (205,618) 621,974 91,594 — 1,818,836 Equipment and computer software 207,402 486,143 (769) 99,350 40,059 — 832,185 Fixtures and fittings 318,582 912,404 — 397,989 72,059 — 1,701,034 Machinery and equipment 937,736 2,121,816 (16,807) 673,784 180,281 — 3,896,810 Land and buildings 2,513,708 1,343,500 — 617,162 221,428 (134,921) 4,560,877 Total 4,587,248 5,923,397 (227,201) 2,450,256 626,645 (134,921) 13,225,424 Accumulated depreciation as of June 30, 2018 is as follows: Depreciation Accumulated as of the Foreign Accumulated beginning of currency as of the end year Disposals Of the year translation Revaluation of year Office equipment 31,522 — 41,740 (24,133) — 49,129 Vehicles 373,215 (42,928) 434,632 (204,228) — 560,691 Equipment and computer software 118,169 (13,641) 195,386 (92,512) — 207,402 Fixtures and fittings 204,171 — 286,024 (171,613) — 318,582 Machinery and equipment 746,828 — 741,508 (550,600) — 937,736 Land and buildings 828,109 — 531,591 (516,056) 1,670,064 2,513,708 Total 2,302,014 (56,569) 2,230,881 (1,559,142) 1,670,064 4,587,248 Accumulated depreciation as of June 30, 2017 is as follows: Depreciation Accumulated as of Foreign Accumulated beginning of Currency as of the end of Class year Disposals Of the period Translation Revaluation year Office equipment 27,913 — 5,452 (1,843) — 31,522 Vehicles 144,267 (95,792) 334,019 (9,279) — 373,215 Equipment and computer software 80,132 (31,486) 77,461 (7,938) — 118,169 Fixtures and fittings 68,137 — 145,044 (9,010) — 204,171 Machinery and equipment 386,899 (10,678) 408,975 (38,368) — 746,828 Land and buildings 174,979 — 283,706 (21,947) 391,371 828,109 Total 882,327 (137,956) 1,254,657 (88,385) 391,371 2,302,014 Accumulated depreciation as of December 31, 2016 is as follows: Depreciation Accumulated as of Foreign Accumulated beginning of Currency as of the end Class year Disposals Of the year Translation of year Office equipment 3,555 — 18,901 5,457 27,913 Vehicles 119,177 (49,179) 75,633 (1,364) 144,267 Equipment and computer software 14,283 — 59,548 6,301 80,132 Fixtures and fittings 1,126 — 153,424 (86,413) 68,137 Machinery and equipment 132,669 — 134,648 119,582 386,899 Land and buildings — — 142,139 32,840 174,979 Total 270,810 (49,179) 584,293 76,403 882,327
Schedule of carrying amounts if recognized under cost model	Value at cost Class of property 06/30/2019 06/30/2018 06/30/2017 Land and buildings
Schedule of intangible assets	06/30/2019 06/30/2018 06/30/2017 12/31/2016 Gross carrying amount 45,848,737 29,155,315 43,903,217 42,890,018 Accumulated amortization (6,232,311) (2,497,970) (1,844,326) (521,692) Net carrying amount 39,616,426 26,657,345 42,058,891 42,368,326
Schedule of technologies capitalized	Technologies Crop Germplasm Protection Yield Quality R&D Phase Entity Soybean MG III-VIII(1) GT (2) HB4 — Advanced Develop. BCS Holding Wheat Spring / Winter GluT (2) HB4 — Advanced Develop. Trigall Genetics (3) (Note 12) Notes: (1) Soybean germplasms are categorized by maturity groups (MG) from III to VIII. Non-dormant germplasms are alfalfa elite breeding materials without winter dormancy. A. cruentus germplasms are amaranth varieties of the A. cruentus species. (2) GT means glyphosate tolerance. GluT means glufosinate tolerance. Genuity is the glyphosate tolerance technology developed by Monsanto and Forage Genetics International for alfalfa. ALS means ALS-inhibitor herbicide tolerance. (3) Included in Trigall`s financial statements. Reflected in the Consolidated financial statements through the equity method investment.
Schedule of net carrying amount of intangibles	Net carrying Net carrying Net Carrying Net Carrying amount amount amount amount Class 06/30/2019 06/30/2018 06/30/2017 12/31/2016 Seed and integrated products Soybean HB4 6,120,336 4,927,853 3,111,253 1,421,707 Ecoseed integrated products 2,627,946 — — — Crop nutrition Microbiology products 2,208,117 2,122,484 3,491,269 3,625,827 Other intangible assets Trademarks and patents 8,063,648 5,574,682 10,402,764 11,265,234 Software 994,723 949,310 1,392,769 799,904 Customer loyalty 19,601,656 13,083,016 23,660,836 25,255,654 Total 39,616,426 26,657,345 42,058,891 42,368,326
Schedule of gross carrying amounts of intangibles	Gross carrying amount as of June 30, 2019 is as follows: Gross carrying amount Adjustment of opening net book As of the amount for Foreign beginning of application currency As of the Class year of IAS 29 Additions Disposals translation end of year Seed and integrated products Soybean HB4 4,927,853 — 1,192,483 — — 6,120,336 Ecoseed integrated products — — 2,627,946 — — 2,627,946 Crop nutrition Microbiology products 2,505,864 841,753 41,485 (318,949) 197,047 3,267,200 Other intangible assets Trademarks and patents 6,278,706 2,986,739 — — 545,377 9,810,822 Software 1,444,603 438,703 200,600 (40,359) 105,793 2,149,340 Customer loyalty 13,998,289 6,658,894 — — 1,215,910 21,873,093 Total 29,155,315 10,926,089 4,062,514 (359,308) 2,064,127 45,848,737 Gross carrying amount as of June 30, 2018 is as follows: Gross carrying amount As of the Foreign beginning of currency As of the end Class year Additions Disposals translation of year Seed and integrated products Soybean HB4 3,111,253 1,816,600 — — 4,927,853 Crop nutrition Microbiology products 3,782,238 484,825 — (1,761,199) 2,505,864 Other intangible assets Trademarks and patents 10,906,317 — — (4,627,611) 6,278,706 Software 1,787,925 614,529 — (957,851) 1,444,603 Customer loyalty 24,315,484 — — (10,317,195) 13,998,289 Total 43,903,217 2,915,954 — (17,663,856) 29,155,315 Gross carrying amount as of June 30, 2017 is as follows: Gross carrying amount As of the Foreign beginning of currency As of the end Class year Additions Disposals translation of year Seed and integrated products Soybean HB4 1,421,707 1,689,546 — — 3,111,253 Crop nutrition Microbiology products 3,755,094 194,743 — (167,599) 3,782,238 Other intangible assets Trademarks and patents 11,415,829 — — (509,512) 10,906,317 Software 845,954 979,728 — (37,757) 1,787,925 Customer loyalty 25,451,434 — — (1,135,950) 24,315,484 Total 42,890,018 2,864,017 — (1,850,818) 43,903,217 Gross carrying amount as of December 31, 2016 is as follows: Gross carrying amount As of the Foreign beginning of Additions currency As of the Class year Additions for P1PA translation end of year Seed and integrated products Soybean HB4 1,421,707 — — — 1,421,707 Crop nutrition Microbiology products — 175,527 3,733,981 (154,414) 3,755,094 Other intangible assets Trademarks and patents — — 11,896,495 (480,666) 11,415,829 Software 9,368 420,254 442,607 (26,275) 845,954 Customer loyalty — — 26,523,073 (1,071,639) 25,451,434 Total 1,431,075 595,781 42,596,156 (1,732,994) 42,890,018
Schedule of accumulated amortization of intangibles	Accumulated amortization as of June 30, 2019 is as follows: Amortization Adjustment of opening Accumulated net book as of amount for Foreign Accumulated beginning of application currency as of the end of Class year of IAS 29 Disposals Of the year translation year Crop nutrition Microbiology products 383,380 202,791 (20,887) 459,287 34,512 1,059,083 Other intangible assets Trademarks and patents 704,024 334,919 — 647,101 61,130 1,747,174 Software 495,293 227,264 (40,359) 429,258 43,161 1,154,617 Customer loyalty 915,273 435,389 — 841,273 79,502 2,271,437 Total 2,497,970 1,200,363 (61,246) 2,376,919 218,305 6,232,311 Accumulated amortization as of June 30, 2018 is as follows: Amortization Accumulated as of Foreign Accumulated beginning of currency as of the end Class year Disposals Of the year translation of year Crop nutrition Microbiology products 290,969 — 321,887 (229,476) 383,380 Other intangible assets Trademarks and patents 503,553 — 617,478 (417,007) 704,024 Software 395,156 — 399,311 (299,174) 495,293 Customer loyalty 654,648 — 802,800 (542,175) 915,273 Total 1,844,326 — 2,141,476 (1,487,832) 2,497,970 Accumulated amortization as of June 30, 2017 is as follows: Amortization Accumulated as of Foreign Accumulated beginning of currency as of the end Class year Disposals Of the year translation of year Crop nutrition Microbiology products 129,267 — 176,523 (14,821) 290,969 Other intangible assets Trademarks and patents 150,595 — 379,115 (26,157) 503,553 Software 46,050 — 370,018 (20,912) 395,156 Customer loyalty 195,780 — 492,873 (34,005) 654,648 Total 521,692 — 1,418,529 (95,895) 1,844,326 Accumulated amortization as of December 31, 2016 is as follows: Amortization Accumulated as of Foreign Accumulated beginning of Of the currency as of the end Class year Disposals year translation of year Crop nutrition Microbiology products — — 21,316 107,951 129,267 Other intangible assets Trademarks and patents — — 153,698 (3,103) 150,595 Software 6,105 — 49,348 (9,403) 46,050 Customer loyalty — — 199,817 (4,037) 195,780 Total 6,105 — 424,179 91,408 521,692
Schedule of carrying amount of goodwill	06/30/2019 06/30/2018 06/30/2017 Rizobacter 23,484,761 14,438,027 25,079,324 Semya 6,319,954 — — 29,804,715 14,438,027 25,079,324
Schedule of key assumptions for goodwill	Key assumption Management’s approach Discount rate The discount rate used ranges was 16.71%. The weighted average cost of capital ("WACC") rate has been estimated based on the market capital structure. For the cost of debt, the indebtedness cost of the CGU was taken. For the cost of equity, the discount rate is estimated based on the Capital Asset Pricing Model (CAPM). The value assigned is consistent with external sources of information. Budgeted market share of joint ventures and other customers The projected revenue from the products and services of the CGU has been estimated by Rizobacter´s management based on market penetration data for comparable products and technologies and on future expectations of foreseen economic and market conditions. The value assigned is consistent with external sources of information. Budgeted product prices The prices estimated in the revenue projections are based on current and projected market prices for the products and services of the CGU The value assigned is consistent with external sources of information. Growth rate used to extrapolate future cash flow projections to terminal period The growth rate used to extrapolate the future cash flow projections to terminal period is 2%. The value assigned is consistent with external sources of information.
Schedule of trade and other payable	06/30/2019 06/30/2018 06/30/2017 Current Trade creditors 30,489,072 22,222,872 19,779,461 Shareholders and other related parties (Note 16) 1,796,932 365,994 633,700 Trade creditors - Parent company (Note 16) 1,568,036 — 218,744 Trade creditors - Joint ventures and associates (Note 16) 4,805,149 3,493,113 1,649,367 Taxes 1,475,410 35,391 372,990 Consideration payment Semya adquisition (Note 16) 122,950 — — Miscellaneous 320,945 1,591,460 140,454 40,578,494 27,708,830 22,794,716 06/30/2019 06/30/2018 06/30/2017 Non current Consideration payment Semya adquisition (Note 16) 452,654 — — 452,654 — —
Schedule of borrowings	06/30/2019 06/30/2018 06/30/2017 Current Bank overdraft — 532,912 46,511 Bank borrowings 46,467,308 44,061,555 18,594,823 Corporate bonds 8,416,768 3,262,924 4,644,621 BAF Loans — 5,112,222 — Discount checks 5,807,303 10,243,204 9,638,789 Net loans payables-Parents companies and related parties to Parents (Note 16) 5,399,883 1,816,084 646,538 Finance lease 385,947 280,027 466,689 66,477,209 65,308,928 34,037,971 Non-current Bank borrowings 16,239,743 25,253,940 36,383,297 Corporate bonds 8,018,884 — 3,889,874 Net loans payables-Parents companies and related parties to Parents (Note 16) 12,358,024 — — Finance lease 462,870 454,265 678,993 37,079,521 25,708,205 40,952,164
Schedule of carrying value of borrowings	06/30/2019 06/30/2018 06/30/2017 Amortized Amortized Amortized cost Fair value cost Fair value cost Fair value Current Bank borrowings 46,467,308 46,857,879 44,061,555 42,633,227 18,594,823 16,216,748 Discount checks 5,807,303 5,230,123 10,243,204 9,209,508 9,638,789 8,950,197 Corporate Bonds 8,416,768 7,632,806 3,262,924 3,126,570 4,644,621 4,317,658 Non-current Bank borrowings 16,239,743 14,274,547 25,253,940 20,610,018 36,383,297 33,993,312 Corporate Bonds 8,018,884 6,972,332 — — 3,889,874 3,395,857
Schedule of financial instruments that are offset	Gross amounts set off Net amounts presented in the Statement of in the Statement of Gross amounts Financial Position Financial Position Current other receivables 17,809,676 (15,827,847) 1,981,829 Total current assets 17,809,676 (15,827,847) 1,981,829 Current borrowings (82,305,056) 15,827,847 (66,477,209) Total current liabilities (82,305,056) 15,827,847 (66,477,209)
Schedule of employee benefits and social security	06/30/2019 06/30/2018 06/30/2017 Salaries and social security 3,875,834 3,146,583 1,871,710 Staff incentives and vacations 1,481,384 1,265,130 3,175,335 5,357,218 4,411,713 5,047,045
Schedule of deferred revenue and advances from customers	06/30/2019 06/30/2018 06/30/2017 Advances from customers 1,074,463 1,007,301 1,197,080 1,074,463 1,007,301 1,197,080
Schedule of government grants	06/30/2019 06/30/2018 06/30/2017 Current 2,110 17,695 60,829 Non-current 8,098 15,532 57,716 Total 10,208 33,227 118,545
Schedule of government grants rollforward	06/30/2019 06/30/2018 06/30/2017 12/31/2016 At of the beginning of the year 33,227 118,545 155,919 152,792 Adjustement of opening net book amount for application of IAS 29 (27,794) — — — Received during the year 31,785 103,382 64,106 144,902 Currency conversion difference (10,638) (137,114) (69,539) — Released to the statement of profit or loss (16,372) (51,586) (31,941) (141,775) At the end of year 10,208 33,227 118,545 155,919
Schedule of provisions	06/30/2019 06/30/2018 06/30/2017 Provisions for contingencies 439,740 845,486 1,415,290 439,740 845,486 1,415,290
Schedule of financed payment - Acquisition of business	06/30/2019 06/30/2018 06/30/2017 Current Purchase option — 14,605,469 — Financed payment to sellers 2,826,611 5,618,121 6,219,980 2,826,611 20,223,590 6,219,980 Non-current Financed payment to sellers — 2,651,019 7,656,611 Purchase option — — 13,523,582 — 2,651,019 21,180,193
Schedule of puttable instrument	06/30/2019 06/30/2018 06/30/2017 Non-current Puttable preferred shares — — 2,500,000 — — 2,500,000
Schedule of changes in allowances and provisions	Currency Uses and conversion Item 06/30/2018 Additions reversals IAS 29 difference 06/30/2019 DEDUCTED FROM ASSETS Allowance for impairment of trade debtors (3,212,170) (654,991) 87,916 1,220,652 (801,631) (3,360,224) Allowance for impairment of related parties (23,126) (80,913) 12,408 17,396 (1,361) (75,596) Allowance for obsolescence (770,742) (736,372) 615,467 273,252 211,577 (406,818) Total deducted from assets (4,006,038) (1,472,276) 715,791 1,511,300 (591,415) (3,842,638) INCLUDED IN LIABILITIES Provisions for contingencies (845,486) (74,109) 320,941 353,257 (194,343) (439,740) Total included in liabilities (845,486) (74,109) 320,941 353,257 (194,343) (439,740) Total (4,851,524) (1,546,385) 1,036,732 1,864,557 (785,758) (4,282,378) Currency Uses and conversion Item 06/30/2017 Additions reversals difference 06/30/2018 DEDUCTED FROM ASSETS Allowance for impairment of trade debtors (2,873,688) (1,362,720) 76,329 947,909 (3,212,170) Allowance for impairment of related parties (205,960) — 27,264 155,570 (23,126) Allowance for obsolescence (707,105) (822,135) 160,331 598,167 (770,742) Total deducted from assets (3,786,753) (2,184,855) 263,924 1,701,646 (4,006,038) INCLUDED IN LIABILITIES Provisions for contingencies (1,415,290) (84,411) 38,308 615,907 (845,486) Total included in liabilities (1,415,290) (84,411) 38,308 615,907 (845,486) Total (5,202,043) (2,269,266) 302,232 2,317,553 (4,851,524) Currency Uses and conversion Item 12/31/2016 Additions reversals difference 06/30/2017 DEDUCTED FROM ASSETS Allowance for impairment of trade debtors (2,949,214) (154,818) 40,485 189,859 (2,873,688) Allowance for impairment of related parties (8,210) (219,559) 402 21,407 (205,960) Allowance for obsolescence (1,157,997) (289,248) 140,408 599,732 (707,105) Total deducted from assets (4,115,421) (663,625) 181,295 810,998 (3,786,753) INCLUDED IN LIABILITIES Provisions for contingencies (1,909,530) (10,711) 259,438 245,513 (1,415,290) Total included in liabilities (1,909,530) (10,711) 259,438 245,513 (1,415,290) Total (6,024,951) (674,336) 440,733 1,056,511 (5,202,043) Additions Currency for business Uses and conversion Item 12/31/2015 Additions combination reversals difference 12/31/2016 DEDUCTED FROM ASSETS Allowance for impairment of trade debtors (346,515) (490,374) (2,722,575) 373,004 237,246 (2,949,214) Allowance for impairment of related parties — (8,394) — — 184 (8,210) Allowance for obsolescence (167,989) (982,351) (418,498) — 410,841 (1,157,997) Total deducted from assets (514,504) (1,481,119) (3,141,073) 373,004 648,271 (4,115,421) INCLUDED IN LIABILITIES Provisions for contingencies (67,708) (293,009) (1,372,086) — (176,727) (1,909,530) Total included in liabilities (67,708) (293,009) (1,372,086) — (176,727) (1,909,530) Total (582,212) (1,774,128) (4,513,159) 373,004 471,544 (6,024,951)

INFORMATION ABOUT COMPONENTS _5

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Tables)	12 Months Ended
	Jun. 30, 2019
INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
Schedule of revenue	06/30/2019 06/30/2018 06/30/2017 12/31/2016 Sale of goods and services 159,198,516 133,048,429 46,751,191 40,677,714 Royalties 1,110,463 442,689 102,178 349,760 160,308,979 133,491,118 46,853,369 41,027,474
Schedule of cost of sales	Item 06/30/2019 06/30/2018 06/30/2017 12/31/2016 Inventory as of the beginning of the year 19,366,001 31,338,034 32,677,314 2,835,909 Adjustment of opening net book amount for the application of IAS 29 4,273,416 — — — Combined business — — — 40,846,774 Purchases of the year 88,380,452 65,825,381 25,332,949 17,307,320 Production costs 11,558,513 14,002,049 5,322,615 3,737,400 Foreign currency translation (9,020,919) (14,704,912) (2,381,686) (1,451,133) Subtotal 114,557,463 96,460,552 60,951,192 63,276,270 Inventory as of the end of the year (27,592,582) (19,366,001) (31,338,034) (32,677,314) Cost of sales 86,964,881 77,094,551 29,613,158 30,598,956
Schedule of R&D classified by nature	Research Research Research Research and and and and development development development development expenses expenses expenses expenses Item 06/30/2019 06/30/2018 06/30/2017 12/31/2016 Amortization intangible assets 1,106,390 943,488 435,577 — Import and export expenses 16,360 21,640 14,165 1,398 Depreciation property, plant and equipment 220,849 223,515 222,446 63,558 Freight and haulage — 30 73,275 136 Employee benefits and social securities 541,025 1,435,028 481,326 360,760 Maintenance 56,395 86,112 42,373 47,055 Energy and fuel 52,919 78,570 49,785 22,703 Supplies and materials 1,175,184 844,372 107,678 107,436 Mobility and travel 48,308 87,628 66,865 29,822 Stock options based incentive — 30,005 25,710 43,827 Professional fees and outsourced services 447,383 121,914 90,206 5,850 Office supplies 3,796 17,932 57,564 38,159 System expenses — 8,851 1,797 211 Insurance 8,593 22,006 18,302 6,646 Miscellaneous 12,189 29,009 303,199 126,293 Total 3,689,391 3,950,100 1,990,268 853,854
Schedule of expenses classified by nature and function	Selling, general and Production administrative Total Item costs expenses 06/30/2019 Amortization intangible assets — 1,270,530 1,270,530 Analysis and storage 5,811 904 6,715 Commissions and royalties 751,972 489,301 1,241,273 Bank expenses and commissions — 30,784 30,784 Import and export expenses 95,111 1,396,636 1,491,747 Depreciation property, plant and equipment 1,164,810 1,064,597 2,229,407 Impairment of receivables — 686,985 686,985 Freight and haulage 1,433,867 2,662,715 4,096,582 Employee benefits and social securities 5,313,211 12,969,653 18,282,864 Maintenance 501,699 532,648 1,034,347 Energy and fuel 568,848 195,449 764,297 Supplies and materials 275,378 214,513 489,891 Mobility and travel 12,097 1,306,067 1,318,164 Publicity and advertising — 1,709,552 1,709,552 Contingencies — 67,417 67,417 Professional fees and outsourced services 681,790 7,346,607 8,028,397 Professional fees related parties — 401,005 401,005 Office supplies 31,394 352,167 383,561 Insurance 105,302 802,352 907,654 System expenses — 709,539 709,539 Obsolescence 564,873 — 564,873 Taxes 37,388 4,821,136 4,858,524 Miscellaneous 14,962 213,243 228,205 Total 11,558,513 39,243,800 50,802,313 Selling, general and Production administrative Total Item costs expenses 06/30/2018 Amortization intangible assets — 1,197,988 1,197,988 Analysis and storage 1,225,756 225,462 1,451,218 Commissions and royalties 552,906 671,180 1,224,086 Bank expenses and commissions — 51,471 51,471 Import and export expenses 131,558 725,479 857,037 Depreciation property, plant and equipment 1,208,699 798,667 2,007,366 Impairment of receivables — 1,259,127 1,259,127 Freight and haulage 664,984 2,251,297 2,916,281 Employee benefits and social securities 7,582,440 14,265,650 21,848,090 Maintenance 597,497 408,960 1,006,457 Energy and fuel 419,716 610,376 1,030,092 Supplies and materials 169,674 1,577 171,251 Mobility and travel 48,068 1,373,119 1,421,187 Publicity and advertising — 2,239,505 2,239,505 Contingencies — 84,411 84,411 Telephone and communications — 630 630 Professional fees and outsourced services 195 2,058,787 2,058,982 Professional fees related parties — 759,149 759,149 Office supplies 17,790 549,359 567,149 Insurance 118,610 611,129 729,739 Sistems expenses 19,057 601,955 621,012 Obsolescence 661,804 — 661,804 Taxes 105,104 4,019,515 4,124,619 Miscellaneous 478,191 498,895 977,086 Total 14,002,049 35,263,688 49,265,737 Selling, general and Production administrative Total Item costs expenses 06/30/2017 Amortization intangible assets — 982,952 982,952 Analysis and storage 20,745 46,781 67,526 Commissions and royalties 60,052 258,456 318,508 Bank expenses and commissions — 67,094 67,094 Import and export expenses 76,818 (318,951) (242,133) Depreciation property, plant and equipment 384,019 648,192 1,032,211 Impairment of receivables — 333,490 333,490 Freight and haulage 148,362 903,544 1,051,906 Employee benefits and social securities 3,554,197 6,661,622 10,215,819 Maintenance 426,634 297,924 724,558 Energy and fuel 185,379 258,704 444,083 Supplies and materials 160,069 — 160,069 Mobility and travel 15,980 723,117 739,097 Publicity and advertising — 1,047,653 1,047,653 Contingencies — (248,727) (248,727) Telephone and communications — 1,387 1,387 Professional fees and outsourced services 20,462 888,104 908,566 Professional fees related parties — 447,723 447,723 Office supplies 2,418 466,154 468,572 Insurance 70,320 289,887 360,207 Sistems expenses 10,072 74,084 84,156 Obsolescence 148,840 — 148,840 Taxes 23,850 1,697,783 1,721,633 Miscellaneous 14,398 162,625 177,023 Total 5,322,615 15,689,598 21,012,213 Selling, general and Production administrative Total Item costs expenses 12/31/2016 Amortization intangible assets — 424,179 424,179 Analysis and storage 67,052 71,126 138,178 Commissions and royalties 405,923 92,943 498,866 Bank expenses and commissions — 73,991 73,991 Import and export expenses 21,435 232,402 253,837 Depreciation property, plant and equipment 240,638 280,097 520,735 Impairment of receivables — 125,764 125,764 Freight and haulage 33,638 751,586 785,224 Employee benefits and social securities 1,781,605 2,888,707 4,670,312 Maintenance 3,358 148,583 151,941 Energy and fuel 87,063 126,305 213,368 Supplies and materials 29,885 — 29,885 Mobility and travel 7,540 272,191 279,731 Publicity and advertising — 384,168 384,168 Contingencies — 293,009 293,009 Sistems expenses — 4,633 4,633 Professional fees and outsourced services 14,576 910,145 924,721 Professional fees related parties — 183,393 183,393 Office supplies 5,813 160,938 166,751 Insurance — 86,497 86,497 Obsolescence 982,351 — 982,351 Taxes 11,967 1,072,358 1,084,325 Miscellaneous 44,556 244,106 288,662 Total 3,737,400 8,827,121 12,564,521
Schedule of financial results	Finance Income 06/30/2019 06/30/2018 06/30/2017 12/31/2016 Interest generated by assets 1,397,025 909,912 303,513 65,896 Interest generated by assets related parties 90,188 294,577 179,887 73,178 Gain for cancellation of purchase option 6,582,849 — — — Changes in fair value of financial assets or liabilities and other financial results 649,998 67,349 92,820 17,394 8,720,060 1,271,838 576,220 156,468 Finance Costs 06/30/2019 06/30/2018 06/30/2017 12/31/2016 Interest generated by liabilities with the parent (1,386,288) (118,266) (520,959) (1,118,679) Interest generated by liabilities (22,884,366) (16,646,801) (7,422,210) (5,011,139) Financial commissions (1,578,292) (1,628,075) (1,032,366) (885,351) Other financial loss (243,688) — (517,136) (136,792) (26,092,634) (18,393,142) (9,492,671) (7,151,961) Other finance results 06/30/2019 06/30/2018 06/30/2017 12/31/2016 Share based payment cost of listing shares (Note 10.3) (20,893,789) — — — Net gain of inflation effect on monetary items 14,653,335 — — — Exchange differences generated by assets 48,355,784 25,710,957 1,186,264 — Exchange differences generated by liabilities (66,200,973) (49,540,369) (2,463,076) (1,254,084) (24,085,643) (23,829,412) (1,276,812) (1,254,084) Total net finance results (41,458,217) (40,950,716) (10,193,263) (8,249,577)

INCOME TAX AND MINIMUM PRESUM_2

INCOME TAX AND MINIMUM PRESUMED INCOME TAX (Tables)	12 Months Ended
	Jun. 30, 2019
Income tax and minimum presumed income tax
Schedule of income tax and minimum presumed income tax recoverable and payable	06/30/2019 06/30/2018 06/30/2017 Current assets Income tax 1,263,795 2,082,269 1,701,382 1,263,795 2,082,269 1,701,382 Non-current assets Income tax — — 95,565 Minimum presumed income tax 1,184 126,653 220,000 1,184 126,653 315,565 06/30/2019 06/30/2018 06/30/2017 Liabilities Income tax 142,028 2,569 29,788 142,028 2,569 29,788
Schedule of deferred tax assets and liabilities	Deferred tax assets 06/30/2019 06/30/2018 06/30/2017 12/31/2016 Tax Loss-Carry Forward 2,663,813 3,638,269 1,059,746 753,359 Changes in fair value of financial assets or liabilities 32,062 35,944 96,394 87,467 Trade receivables 374,425 462,756 829,095 804,481 Allowances — 370,930 805,375 935,415 Inventories — 710,391 367,682 519,310 Intangible assets — 15,098 38,241 48,426 Contingencies — — 13,612 — Goverment grants 2,649 9,360 41,616 54,572 Others 670,760 359,073 120,340 1,446,474 Total deferred tax assets 3,743,709 5,601,821 3,372,101 4,649,504 Deferred tax liabilities 06/30/2019 06/30/2018 06/30/2017 12/31/2016 Intangible assets (9,458,239) (5,071,808) (12,633,408) (13,609,901) Property, plant and equipment depreciation (9,618,648) (8,497,756) (12,923,320) (12,738,676) Borrowings (13,170) (19,372) (39,257) (27,482) Contingencies — (2,709) — — Inflation tax adjustment (1,706,092) — — — Allowances (152,159) — — — Inventories (153,563) — — — Others — (297) (15,942) (9,727) Total deferred tax liabilities (21,101,871) (13,591,942) (25,611,927) (26,385,786) Net deferred tax (17,358,162) (7,990,121) (22,239,826) (21,736,282) The roll forward of deferred tax assets and liabilities as of June 30, 2019, 2018, 2017 and December 31, 2016 are as follows: Transfer Adquisition from of control Income deferred Balance of Semya tax tax Charge Conversion Balance Deferred tax assets 06/30/2018 S.A. provision liabilities to OCI difference 06/30/2019 Tax Loss-Carry Forward 3,638,269 113,289 (1,306,198) — — 218,453 2,663,813 Changes in fair value of financial assets or liabilities 35,944 25,868 (33,200) — — 3,450 32,062 Trade receivables 462,756 — (114,765) — — 26,434 374,425 Allowances 370,930 — (555,679) 152,159 — 32,590 — Inventories 710,391 — (119,316) 153,563 — (744,638) — Intangible assets 15,098 (482,387) (22,467) 476,174 — 13,582 — Goverment grants 9,360 — (7,262) — — 551 2,649 Others 359,073 — 290,552 — — 21,135 670,760 Total deferred tax assets 5,601,821 (343,230) (1,868,335) 781,896 — (428,443) 3,743,709 Transfer Adquisition from of control Income deferred Balance of Semya tax tax Charge Conversion Balance Deferred tax liabilities 06/30/2018 S.A. provision assets to OCI difference 06/30/2019 Intangible assets (5,071,808) — (937,962) (476,174) — (2,972,295) (9,458,239) Property, plant and equipment depreciation (8,497,756) — (335,077) — 576,453 (1,362,268) (9,618,648) Borrowings (19,372) — 7,342 — — (1,140) (13,170) Contingencies (2,709) — 2,869 — — (160) — Inflation tax adjustment — — (1,706,092) — — — (1,706,092) Allowances — — — (152,159) — — (152,159) Inventories — — — (153,563) — — (153,563) Others (297) — 314 — — (17) — Total deferred tax liabilities (13,591,942) — (2,968,606) (781,896) 576,453 (4,335,880) (21,101,871) Transfer from deferred Balance Income tax tax Charge Conversion Balance Deferred tax assets 06/30/2017 provision liabilities to OCI difference 06/30/2018 Tax Loss-Carry Forward 1,059,746 3,631,690 — — (1,053,167) 3,638,269 Changes in fair value of financial assets or liabilities 96,394 (27,872) — — (32,578) 35,944 Trade receivables 829,095 (16,762) — — (349,577) 462,756 Allowances 805,375 (143,397) — — (291,048) 370,930 Inventories 367,682 (767,844) — — 1,110,553 710,391 Intangible assets 38,241 (11,570) — — (11,573) 15,098 Contingencies 13,612 — (13,612) — — — Goverment grants 41,616 (21,647) — — (10,609) 9,360 Others 120,340 319,514 12,464 — (93,245) 359,073 Total deferred tax assets 3,372,101 2,962,112 (1,148) — (731,244) 5,601,821 Transfer from Balance Income tax deferred Charge Conversion Balance Deferred tax liabilities 06/30/2017 provision tax assets to OCI difference 06/30/2018 Intangible assets (12,633,408) (1,114,442) — — 8,676,042 (5,071,808) Property, plant and equipment depreciation (12,923,320) 2,811,852 — (4,507,311) 6,121,023 (8,497,756) Borrowings (39,257) 3,720 — — 16,165 (19,372) Contingencies — (15,442) 13,612 — (879) (2,709) Others (15,942) 24,617 (12,464) — 3,492 (297) Total deferred tax liabilities (25,611,927) 1,710,305 1,148 (4,507,311) 14,815,843 (13,591,942) Net deferred tax (22,239,826) 4,672,417 — (4,507,311) 14,084,599 (7,990,121) Transfer from Balance Income tax deferred tax Charge Conversion Balance Deferred tax assets 12/31/2016 provision liabilities to OCI difference 06/30/2017 Tax Loss-Carry Forward 753,359 360,007 — — (53,620) 1,059,746 Changes in fair value of financial assets or liabilities 87,467 13,216 — — (4,289) 96,394 Trade receivables 804,481 60,520 — — (35,906) 829,095 Allowances 935,415 (83,964) — — (46,076) 805,375 Inventories 519,310 (128,450) — — (23,178) 367,682 Intangible assets 48,426 (8,577) — — (1,608) 38,241 Contingencies — 14,301 — — (689) 13,612 Goverment grants 54,572 (11,218) — — (1,738) 41,616 Others 1,446,474 877,016 — — (2,203,150) 120,340 Total deferred tax assets 4,649,504 1,092,851 — — (2,370,254) 3,372,101 Transfer from Balance Income tax deferred tax Charge Conversion Balance Deferred tax liabilities 12/31/2016 provision assets to OCI difference 06/30/2017 Intangible assets (13,609,901) 802,280 — — 174,213 (12,633,408) Property, plant and equipment depreciation (12,738,676) 616,622 — (936,029) 134,763 (12,923,320) Borrowings (27,482) (13,002) — — 1,227 (39,257) Others (9,727) (6,649) — — 434 (15,942) Total deferred tax liabilities (26,385,786) 1,399,251 — (936,029) 310,637 (25,611,927) Net deferred tax (21,736,282) 2,492,102 — (936,029) (2,059,617) (22,239,826) Income Balance tax Business Charge to Conversion Balance Deferred tax assets 12/31/2015 provision combination OCI difference 12/31/2016 Tax Loss-Carry Forward 258,194 520,957 — — (25,792) 753,359 Changes in fair value of financial assets or liabilities 61,913 28,642 — — (3,088) 87,467 Trade receivables — — 804,481 — — 804,481 Allowances 119,651 (9,559) 656,327 — 168,996 935,415 Inventories (246,720) 935,283 (234,278) — 65,025 519,310 Intangible assets 78,956 (41,366) 12,510 — (1,674) 48,426 Goverment grants 53,477 29,362 — — (28,267) 54,572 Others — 32,468 1,394,601 — 19,405 1,446,474 Total deferred tax assets 325,471 1,495,787 2,633,641 — 194,605 4,649,504 Income Balance tax Business Charge to Conversion Balance Deferred tax liabilities 12/31/2015 provision combination OCI difference 12/31/2016 Intangible assets — — (13,609,901) — — (13,609,901) Property, plant and equipment depreciation (53,679) (18,703) (12,699,878) — 33,584 (12,738,676) Borrowings — — (27,482) — — (27,482) Others — 13,696 (17,833) — (5,590) (9,727) Total deferred tax liabilities (53,679) (5,007) (26,355,094) — 27,994 (26,385,786) Net deferred tax 271,792 1,490,780 (23,721,453) — 222,599 (21,736,282)
Schedule of reconciliation of the statutory tax rate to the effective tax rate	06/30/2019 06/30/2018 06/30/2017 12/31/2016 Loss before income tax-rate 0% (21,669,883) — — — Profit before income tax-rate 21% 1,264 — — — Loss before income tax-rate 35% — (21,621,007) (11,195,800) (8,042,536) Profit/(Loss) before income tax-rate 30% 12,296,011 (3,618,756) — — Income tax charge by applying tax rate to profit/(loss) before tax: (3,689,069) 8,652,979 3,918,530 2,814,888 Share of profit or loss of subsidies, joint ventures and associates (44,721) (1,448,925) (571,587) (977,061) Stock options charge 78,681 (8,898) (8,978) (15,339) Rate change adjustment (54,735) 3,768,518 — — Allowance for unused tax losses — (59,879) — (46,553) Non-deductible expenses and untaxed gains (254,201) (732,442) (312,477) 84,712 Representation expenses (136,614) (204,897) — — Foreign investment coverage 233,634 — — — Result por inflation effect on monetary items (3,119,259) — — — Others — 962,061 (208,237) — Income tax (expense) benefit (6,986,284) 10,928,517 2,817,251 1,860,647
Schedule of statutory taxes rates	Income tax rate Tax jurisdiction 2019 2018 2017 2016 Argentina 30 % 30% - 35% 35 % 35 % Cayman % — — — United State of America 21 % — — —
Schedule of current tax	06/30/2019 06/30/2018 06/30/2017 12/31/2016 Current tax expense (2,149,343) 6,256,100 325,149 369,867 Deferred tax (4,836,941) 4,672,417 2,492,102 1,490,780 Total (6,986,284) 10,928,517 2,817,251 1,860,647
Schedule of carry forward tax losses	The charge for income tax charged directly to profit or loss and the amount and expiry date of carry forward tax losses as of June 30, 2019 are as follows: Tax-Loss Tax-Loss Fiscal year Carry forward Carry forward Prescription 2015 125,442 31,389 2020 2016 741,741 185,435 2021 2017 1,149,203 283,096 2022 2018 402,956 104,943 2023 2019 668,458 194,200 2024 2019 8,879,763 1,864,750 2039 Total 11,967,563 2,663,813
Argentina
Income tax and minimum presumed income tax
Schedule of carry forward tax losses	The amount and expiry date of unused tax credits of Argentina minimum presumed income tax as of June 30, 2019 is as follows: Fiscal year Amount Prescription 2016 1,184 2026 Total 1,184

LOSS PER SHARE (Tables)

LOSS PER SHARE (Tables)	12 Months Ended
	Jun. 30, 2019
LOSS PER SHARE
Schedule of loss per share	06/30/2019 06/30/2018 06/30/2017 12/31/2016 Numerator Loss for the year (basic EPS) (1) (18,369,045) (11,039,533) (5,908,927) (5,865,870) Denominator Weighted average number of shares (basic EPS) (1) 30,478,390 28,098,117 28,098,117 28,098,117 Basic loss attributable to ordinary equity holders of the parent (1) (0.60) (0.39) (0.21) (0.21) (1)

INFORMATION ABOUT COMPONENTS _6

INFORMATION ABOUT COMPONENTS OF EQUITY (Tables)	12 Months Ended
	Jun. 30, 2019
INFORMATION ABOUT COMPONENTS OF EQUITY
Summary of contributions made by Bioceres S.A.	06/30/2019 06/30/2018 06/30/2017 12/31/2016 Capital contributions 294,041 1,572,235 2,585,580 48,083,838 Intangible contributed 623,022 2,105,616 2,049,823 — Preferred shares contributed 3,331,534 (3,277,615) — Incorporation of financial debt (*) (15,475,410) (5,000,000) — 15,569,028 Financed payment to Rizobacter sellers — — — (13,182,575) (14,558,347) 2,009,385 1,357,788 50,470,291 (*) Financial debt taken by the Group in connect with Rizobacter acquisition
Summary of subsidiaries whose non-controlling interest are significant	Name Country 06/30/2019 06/30/2018 06/30/2017 Rizobacter Argentina S.A. Argentina 20 % 40 % 40 %
Summarized financial information	06/30/2019 06/30/2018 06/30/2017 Current assets 115,546,951 86,461,071 86,202,115 Non-current assets 47,418,450 48,295,110 113,906,651 Total assets 162,965,401 134,756,181 200,108,766 Current liabilities 100,590,919 88,270,487 60,192,036 Non-current liabilities 34,788,705 29,598,319 65,604,538 Total liabilities 135,379,624 117,868,806 125,796,574 Equity attributable to controlling interest 27,584,666 16,824,251 74,266,985 Equity attributable to non-controlling interest 1,111 63,124 45,207 Total equity 27,585,777 16,887,375 74,312,192 Total liabilities and equity 162,965,401 134,756,181 200,108,766 Period from 10/19/16 - Summary statements of comprehensive income or loss 06/30/2019 06/30/2018 06/30/2017 12/31/2016 Revenues 156,741,933 129,798,271 44,458,442 36,739,496 Cost of sales (85,287,771) (71,699,144) (27,494,324) (26,818,086) Gross margin 71,454,162 58,099,127 16,964,118 9,921,410 Research and development expenses (2,367,727) (2,902,235) (1,711,089) (555,676) Selling, general and administrative expenses (31,316,843) (31,219,784) (14,501,080) (6,936,425) Share of profit or loss of joint ventures and associates 1,071,297 (1,683,949) (610,994) (161,436) Other income 286,626 524,672 53,928 — Operating profit 39,127,515 22,817,831 194,883 2,267,873 Financial results (24,650,359) (37,989,573) (8,619,703) (4,014,402) Loss before taxes 14,477,156 (15,171,742) (8,424,820) (1,746,529) Income tax benefit (expense) (7,729,300) 3,275,077 2,333,310 (1,836,968) Result for the year 6,747,856 (11,896,665) (6,091,510) (3,583,497) Exchange differences on translation of foreign operations 17,197 (8,266,718) 202,981 (898,790) Revaluation of property, plant and equipment, net of tax (1,347,124) 14,079,875 2,032,872 — Total comprehensive result 5,417,929 (6,083,508) (3,855,657) (4,482,287)

CASH FLOW INFORMATION (Tables)

CASH FLOW INFORMATION (Tables)	12 Months Ended
	Jun. 30, 2019
CASH FLOW INFORMATION
Schedule of significant non-cash transactions related to investing and financing activities	06/30/2019 06/30/2018 06/30/2017 12/31/2016 Investment activities Settlement of liability with loan to joint venture (1) — — — Investment in kind in other related parties (Note 16) 463,511 — — — Non-monetary contributions in joint ventures (Note 12) 94,355 679,510 1,150,259 — 7,521,967 679,510 1,150,259 — Financing activities Purchase option paid by a parent loan (1,265,000) — — — Parent company investment (14,558,347) 2,009,385 1,357,788 50,470,291 Issuanse of shares — — — 15,850,000 Transfer of preferred stocks — 9,759,545 — — Capitalization of financial debt 13,720,000 — — — Reverse recapitalization (3,688,963) — — — Net asstes incorporated of Semya (2) 7,369,168 — — — Acquisition of control of Semya (3,684,585) — — — (2,107,727) 11,768,930 1,357,788 66,320,291 (1) (2) Balance sheet as of May 31, 2019 Total Current assets 67,924 Non-current assets Tax credits 253,655 Intangibles 2,147,199 Goodwill 5,836,268 Total assets 8,305,047 Current liabilities Trade payables 273,442 Borrowings 114,568 Non-current liabilities Deferred tax 547,868 Total liabilities 935,878 Total equity 7,369,169
Schedule of business combination assets and liabilities	Balance sheet as of May 31, 2019 Total Current assets 67,924 Non-current assets Tax credits 253,655 Intangibles 2,147,199 Goodwill 5,836,268 Total assets 8,305,047 Current liabilities Trade payables 273,442 Borrowings 114,568 Non-current liabilities Deferred tax 547,868 Total liabilities 935,878 Total equity 7,369,169
Schedule of changes in liabilities arising from financing activities	Financing activities Financed payment - Acquisition of Borrowings business Total As of June 30, 2018 91,017,133 22,874,609 113,891,742 Proceeds from borrowings 88,693,632 — 88,693,632 Decrease bank overdraft and other short-term borrowings (4,968,813) — (4,968,813) Payments (83,777,814) (7,140,000) (90,917,814) Capitalization of financial debt — (13,720,000) (13,720,000) Interest payment (20,167,101) — (20,167,101) Exchange differences and currency translation differences 32,759,693 812,002 33,571,695 As of June 30, 2019 103,556,730 2,826,611 106,383,341

JOINT VENTURES (Tables)

JOINT VENTURES (Tables)	12 Months Ended
	Jun. 30, 2019
JOINT VENTURES
Schedule of investments in joint ventures and affiliates	06/30/2019 06/30/2018 06/30/2017 Assets Semya S.A. (1) — 2,972,239 5,263,819 Synertech Industrias S.A. 25,297,376 16,099,816 26,844,410 Indrasa Biotecnología S.A. 23,652 — — 25,321,028 19,072,055 32,108,229 06/30/2019 06/30/2018 06/30/2017 Liabilities Trigall Genetics S.A. 1,970,903 2,012,298 1,527,286 1,970,903 2,012,298 1,527,286 (1)
Schedule of changes in joint ventures investments and affiliates	06/30/2019 06/30/2018 06/30/2017 12/31/2016 As of the beginning of the year 17,059,757 30,580,943 31,306,503 (1,188,483) Adjustment of opening net book amount for the application of IAS 29 8,328,794 — — — Monetary contributions 129,340 — — — Non-monetary contributions 94,355 679,510 1,150,259 — Parent company investment 294,041 121,479 82,872 162,012 Loss of control of Indrasa Biotecnología S.A. 10,591 — — Adquisicion of control of Semya S.A. (3,684,585) — — Revaluation of property, plant and equipment 94,009 1,679,818 189,025 — Business combinations - Synertch — — — 29,000,000 Business combinations - Semya — — — 4,317,619 Foreign currency translation 11,337 (13,865,192) (1,498,641) (277,603) Share of profit or loss 1,012,486 (2,136,801) (649,075) (707,042) As of the end of the year 23,350,125 17,059,757 30,580,943 31,306,503
Schedule of share of profit or loss of joint ventures and affiliates	06/30/2019 06/30/2018 06/30/2017 12/31/2016 Trigall Genetics S.A. (2,647) (606,491) (38,081) (545,606) Semya S.A. (1) (22,895) (55,872) (14,140) (6,120) Synertech Industrias S.A. 1,034,818 (1,474,438) (596,854) (155,316) Indrasa Biotecnología S.A. 3,210 — — — 1,012,486 (2,136,801) (649,075) (707,042) (1) As a result of the share purchase agreement with Bioceres S.A., Semya is a consolidated subsidiary as of June 30, 2019. (See Note 4.5).
Schedule of summarized financial information in joint venture	Trigall Genetics (i) Semya (ii) Summarised balance sheet 06/30/2019 06/30/2018 06/30/2017 06/30/2019 (a) 06/30/2018 06/30/2017 Current assets Cash and cash equivalents 13,114 44,937 9,758 489 183 76 Other current assets 323,264 66,077 62,137 77,074 14 — Total current assets 336,379 111,014 71,895 77,563 197 76 Non-current assets Intangible assests 10,214,575 8,681,400 6,819,534 583,936 217,809 — Other non- current assets — — — 362,181 448,942 992,143 Total non-current assets 10,214,575 8,681,400 6,819,534 946,117 666,751 992,143 Current liabilities Financial liabilities 9,476,272 7,878,036 6,378,988 127,074 448,309 220,989 Other current liabilities 1,016,083 1,030,016 607,565 898,623 275,341 440,435 Total current liabilities 10,492,355 8,908,051 6,986,553 1,025,697 723,650 661,424 Non-current liabilities Other non- current liabilities 460,268 295,575 121,656 42,323 — — Total non-current liabilities 460,268 295,575 121,656 42,323 — — Net assets (401,669) (411,212) (216,780) (44,340) (56,701) 330,795 Synertech (iii) Indrasa S.A. (iv) Summarised balance sheet 06/30/2019 06/30/2018 06/30/2017 06/30/2019 06/30/2018 06/30/2017 Current assets Cash and cash equivalents 40,634 39,133 85,654 16,296 28,180 33,986 Other current assets 5,709,650 7,182,862 5,878,527 93,654 45,837 83,400 Total current assets 5,750,284 7,221,995 5,964,181 109,950 74,017 117,386 Non-current assets Property,plan and equipment 15,046,903 8,344,900 15,480,289 18,387 15,243 28,956 Other non- current assets — 1,328,521 1,449,117 — — 3,069 Total non-current assets 15,046,903 9,673,421 16,929,406 18,387 15,243 32,025 Current liabilities Financial liabilities 921,703 705,856 1,428,481 — — 172 Other current liabilities 4,595,906 6,750,220 5,158,724 60,760 42,166 80,435 Total current liabilities 5,517,609 7,456,076 6,587,205 60,760 42,166 80,607 Non-current liabilities Financial liabilities — 1,080,247 2,898,798 — — — Other non- current liabilities 3,974,975 4,801,887 5,378,862 — — — Total non-current liabilities 3,974,975 5,882,134 8,277,660 — — — Net assets 11,304,603 3,557,206 8,028,722 67,577 47,094 68,805
Schedule of summarized comprehensive income statement of joint venture	Synertech (iii) Indrasa S.A. (iv) Summarised balance sheet 06/30/2019 06/30/2018 06/30/2017 06/30/2019 06/30/2018 06/30/2017 Current assets Cash and cash equivalents 40,634 39,133 85,654 16,296 28,180 33,986 Other current assets 5,709,650 7,182,862 5,878,527 93,654 45,837 83,400 Total current assets 5,750,284 7,221,995 5,964,181 109,950 74,017 117,386 Non-current assets Property,plan and equipment 15,046,903 8,344,900 15,480,289 18,387 15,243 28,956 Other non- current assets — 1,328,521 1,449,117 — — 3,069 Total non-current assets 15,046,903 9,673,421 16,929,406 18,387 15,243 32,025 Current liabilities Financial liabilities 921,703 705,856 1,428,481 — — 172 Other current liabilities 4,595,906 6,750,220 5,158,724 60,760 42,166 80,435 Total current liabilities 5,517,609 7,456,076 6,587,205 60,760 42,166 80,607 Non-current liabilities Financial liabilities — 1,080,247 2,898,798 — — — Other non- current liabilities 3,974,975 4,801,887 5,378,862 — — — Total non-current liabilities 3,974,975 5,882,134 8,277,660 — — — Net assets 11,304,603 3,557,206 8,028,722 67,577 47,094 68,805 Trigall Genetics (i) Semya (ii) Summarised statements of comprenhensive income 06/30/2019 06/30/2018 06/30/2017 06/30/2019 (a) 06/30/2018 06/30/2017 Revenue 367,646 104,037 21,041 — — Interest income 54,003 14,053 — 29,275 — 41,865 Interest expenses (16,145) (12,213) (31,444) (5,661) (209,966) (75,682) Profit (loss) of the year (33,195) (194,432) (12,986) (218,627) (354,151) (58,356) Other comprenhensive income — — — — (37,036) 163 Total comprenhensive income (loss) (33,195) (194,432) (12,986) (218,627) (391,187) (58,193) Synertech (iii) Indrasa S.A. (iv) Summarised statements of comprenhensive income 06/30/2019 06/30/2018 06/30/2017 06/30/2019 06/30/2018 06/30/2017 Revenue 18,305,953 6,611,384 1,315,857 452,555 232,290 355,499 Interest income 2,434,610 1,758,129 726,519 1,813 756 315 Interest expenses (6,193,963) (5,831,182) (2,331,246) (3,001) (2,516) — Depreciation and amortization (1,074,552) (653,766) (1,714,354) (3,653) — — Profit (loss) of the year 2,278,859 (1,991,754) (1,822,573) 6,548 7,483 53,468 Other comprenhensive income 334,403 — — — — — Total comprenhensive income (loss) 2,613,262 (1,991,754) (1,822,573) 6,548 7,483 53,468 (a)

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	12 Months Ended
	Jun. 30, 2019
SEGMENT INFORMATION
Schedule of operating results group's reporting segments	Seed and integrated Crop Crop Year ended June 30, 2019 products protection nutrition Consolidated Revenues Sale of goods and services 24,185,292 89,919,460 45,093,764 159,198,516 Royalties 1,110,463 — — 1,110,463 Others Goverment Grants 16,372 — — 16,372 Initial recognition and changes in the fair value of biological assets. — 279,945 — 279,945 Total 25,312,127 90,199,405 45,093,764 160,605,296 Cost of sales (9,783,737) (53,979,391) (23,201,753) (86,964,881) Gross margin per segment 15,528,390 36,220,014 21,892,011 73,640,415 % % % % % Seed and integrated Crop Crop Year ended June 30, 2018 products protection nutrition Consolidated Revenues Sale of goods and services 26,308,432 77,655,672 29,084,325 133,048,429 Royalties 442,689 — — 442,689 Others Government Grants 51,586 — — 51,586 Total 26,802,707 77,655,672 29,084,325 133,542,704 Cost of sales (13,413,758) (49,453,167) (14,227,626) (77,094,551) Gross margin per segment 13,388,949 28,202,505 14,856,699 56,448,153 % % % % % Seed and integrated Crop Crop Year ended December 31, 2016 products protection nutrition Consolidated Revenues Sale of goods and services 13,956,901 21,493,419 5,227,394 40,677,714 Royalties 349,760 — — 349,760 Others Government Grants 141,775 — — 141,775 Total 14,448,436 21,493,419 5,227,394 41,169,249 Cost of sales (8,953,929) (16,825,572) (4,819,455) (30,598,956) Gross margin per segment 5,494,507 4,667,847 407,939 10,570,293 % 38 % 22 % 8 % 26 %
Schedule of income by similar group of products or services	06/30/2019 06/30/2018 06/30/2017 12/31/2016 Seed and integrated products 25,295,755 26,751,121 9,021,171 14,306,661 Seeds, royalties & licenses 3,846,991 3,771,579 2,394,927 4,287,978 Packs 21,448,764 22,979,542 6,626,244 10,018,683 Crop protection 89,919,460 77,655,672 31,191,970 21,493,419 Adjuvants 41,854,730 39,931,915 15,008,963 12,526,504 Insecticides & fungicides 12,655,985 14,087,260 9,914,886 2,059,936 Other 35,408,745 23,636,497 6,268,121 6,906,979 Crop nutrition 45,093,764 29,084,325 6,640,228 5,227,394 Inoculants 18,644,673 14,352,761 4,245,712 2,098,826 Fertilizers 26,449,091 14,731,564 2,394,516 3,128,568 Total revenue 160,308,979 133,491,118 46,853,369 41,027,474
Schedule of geographical information	06/30/2019 06/30/2018 06/30/2017 12/31/2016 Argentina 124,011,642 106,077,922 41,292,402 37,815,878 Austria 899,045 470,849 8,400 319,237 Bolivia 2,494,216 2,090,758 — 300,084 Brazil 17,338,608 9,450,496 275,545 862,155 China — — 193,911 — Libano (115,927) 376,862 262,428 — United States of America 2,562,376 1,395,438 380,310 16,737 Italia 132,206 10,879 — 80,512 Paraguay 2,506,348 5,584,861 1,052,088 590,176 United Kingdom 137,044 387,859 129,297 220,640 South Africa 3,019,474 3,711,852 1,931,908 8,369 France 711,522 270,878 — — Canada — 3,553 — — Ukraine 611,993 344,401 822,976 145,433 Uruguay 4,684,854 3,197,974 447,248 667,237 Rest of the world 1,315,578 116,536 56,856 1,016 Total revenue 160,308,979 133,491,118 46,853,369 41,027,474 06/30/2019 06/30/2018 06/30/2017 12/31/2016 Non-current assets Argentina 106,056,232 77,860,852 111,743,378 113,739,634 United States 6,136,461 2,411,673 631,063 495,187 Paraguay 722,914 605,491 589,418 538,831 Brazil 305,477 340,144 347,649 188,627 Bolivia 27,487 39,857 22,876 25,325 South Africa 7,080 14,423 22,706 25,442 India 38 78 — — Total 113,255,689 81,272,518 113,357,090 115,013,046

FINANCIAL INSTRUMENTS - RISK _2

FINANCIAL INSTRUMENTS - RISK MANAGEMENT (Tables)	12 Months Ended
	Jun. 30, 2019
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Schedule of financial assets by category	Financial assets by category Mandatorily measured at fair Amortized cost value through profit or loss Financial asset 06/30/2019 06/30/2018 06/30/2017 06/30/2019 06/30/2018 06/30/2017 Cash and cash equivalents 3,450,873 2,215,103 1,679,478 — — — Other financial assets 4,703,688 4,781,679 5,027,516 356,233 12,526 4,275 Trade receivables 59,236,377 52,888,427 41,675,918 — — — Other receivables (*) 1,566,732 7,742,120 5,426,257 — — — Total 68,957,670 67,627,329 53,809,169 356,233 12,526 4,275 (*)
Schedule financial liabilities by category	Financial liabilities by category Mandatorily measured at fair Amortized cost value through profit or loss Financial liability 06/30/2019 06/30/2018 06/30/2017 06/30/2019 06/30/2018 06/30/2017 Trade Payables and other payables 40,578,494 27,708,830 22,794,716 — — — Borrowings 103,556,730 91,017,133 74,990,135 — — — Employee benefits and social security 5,357,218 4,411,713 5,047,045 — — — Financed payment - Acquisition of business 2,826,611 22,874,609 27,400,173 — — — Warrrants — — — 2,861,511 — — Puttable instruments — — — — — 2,500,000 Total 152,319,053 146,012,285 130,232,069 2,861,511 — 2,500,000
Schedule of fair value by hierarchy	Measurement at fair value at 06/30/2019 Level 1 Level 2 Level 3 Financial assets at fair value Other financial assets 356,233 — — Financial liabilities valued at fair value Private warrants — — 2,861,511 Measurement at fair value at 06/30/2018 Level 1 Level 2 Level 3 Financial assets at fair value Other financial assets 12,526 — — Measurement at fair value at 06/30/2017 Level 1 Level 2 Level 3 Financial assets at fair value Other financial assets 4,275 — — Financial liabilities valued at fair value Puttable Instruments — 2,500,000 —
Schedule of changes in financial liabilities valued at fair value level 3	06/30/2019 As of the beginning of the year — Warrants issued in business combination 3,432,723 Changes in finance results (571,212) As of the end of the year 2,861,511
Schedule of contractual maturities of financial liabilities	Between one Between Up to 3 3 to 12 and three three and Subsequent As of June 30, 2019 months months years five years years Trade Payables and other payables 12,854,579 28,987,009 476,482 — — Borrowings 29,051,271 40,097,864 38,524,384 — — Financed payment - Acquisition of business — 2,937,500 — — — Total 41,905,850 72,022,373 39,000,866 — — Between one Between Up to 3 3 to 12 and three three and Subsequent As of June 30, 2018 months months years five years years Trade Payables and other payables 27,352,381 356,449 — — — Borrowings 26,927,533 39,047,778 27,190,055 — — Financed payment - Acquisition of business 2,937,500 17,922,500 2,937,500 — — Total 57,217,414 57,326,727 30,127,555 — — Between one Between Up to 3 3 to 12 and three three and Subsequent As of June 30, 2017 months months years five years years Trade Payables and other payables 16,411,513 6,385,733 151 — — Borrowings 14,581,309 22,418,530 45,088,841 — — Financed payment - Acquisition of business — 6,219,980 21,180,193 — — Total 30,992,822 35,024,243 66,269,185 — —
Credit risk
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Schedule of loss allowances	On that basis, the loss allowance as at 30, June 2019 was determined as follows: More More More than More than than 120 than 180 More than 15 days 60 days days days 365 days June, 30 2019 Current past due past due past due past due past due Total Expected Loss rate 0.27 % 0.32 % 0.32 % 0.32 % 0.32 % 100.00 % Gross carrying amount-trade receivables 19,253,504 8,221,475 1,762,134 974,658 771,480 3,345,664 34,328,915 Loss allowance 52,913 26,104 5,595 3,095 2,449 3,345,664 3,435,820
Currency Risk
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Schedule of net exposure	Net foreign currency position 06/30/2019 06/30/2018 06/30/2017 Amount expressed in USD (40,513,954) (28,861,129) (17,917,954)
Interest Rate Risk
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Schedule of net exposure	06/30/2019 06/30/2018 06/30/2017 Carrying Carrying Carrying amount amount amount Fixed-rate instruments Current financial liabilities (69,126,607) (82,888,890) (33,480,167) Non-current financial liabilities (37,006,581) (27,168,905) (61,456,073) Variable-rate instruments Current financial liabilities (177,213) (2,643,628) (6,777,784) Non-current financial liabilities (72,940) (1,190,319) (676,284)

LEASES (Tables)

LEASES (Tables)	12 Months Ended
	Jun. 30, 2019
LEASES
Schedule of lease payable	Number of Present Value leasing of Minimum Giver Object of the contract contracts Payments HP Financial Services Equipment and computer software 7 605,024 Banco Macro Vehicles 10 86,460 Banco Supervielle Machinery and equipment 4 116,126 Banco Galicia Machinery and equipment 1 41,208 Total 848,818
Schedule of Present value - Minimum payments of financial leases	06/30/2019 06/30/2018 06/30/2017 Less than 1 year 444,999 418,933 701,025 1 year- 5 years 490,088 578,578 961,476 Total 935,087 997,511 1,662,501 Financial charges to be accrued (86,270) (263,219) (516,819) Debt for financial leases 848,817 734,292 1,145,682 Present value - Minimum payments of financial leases 06/30/2019 06/30/2018 06/30/2017 Less than 1 year 385,947 280,038 466,689 1 year- 5 years 462,870 454,254 678,993 Total 848,817 734,292 1,145,682

SHAREHOLDERS AND OTHER RELATE_2

SHAREHOLDERS AND OTHER RELATED PARTIES BALANCES AND TRANSACTIONS (Tables)	12 Months Ended
	Jun. 30, 2019
SHAREHOLDERS AND OTHER RELATED PARTIES BALANCES AND TRANSACTIONS
Schedule of transactions between the group and related parties, and the related balances owed	Amount of the transactions of the year ended Party Transaction type 06/30/2019 06/30/2018 06/30/2017 12/31/2016 Joint ventures Sales and services 4,913,254 746,867 — — Joint ventures Purchases of goods and services (17,542,637) (9,809,134) (922,286) — Joint ventures Equity contributions (241,840) 800,989 1,233,131 162,012 Joint ventures Business combination — — — 33,317,619 Joint ventures Net loans granted / (cancelled) (6,964,101) 2,621,647 2,428,076 1,781,389 Key management personnel Salaries, social security benefits and other benefits (3,940,185) (4,703,519) (2,238,908) (649,410) Key management personnel Loans granted 599,984 — — — Key management personnel Interest gain 20,106 — — — Shareholders and other related parties Dividends — (1,450,613) (52,249) — Shareholders and other related parties Sales of goods and services 640,095 1,057,325 781,830 1,761,128 Shareholders and other related parties Purchases of goods and services (1,433,127) (986,217) (875,257) (1,414,998) Shareholders and other related parties Interest gain 90,188 294,577 179,887 73,178 Shareholders and other related parties In-kind contributions 463,511 — — — Parent company Interest lost (1,386,288) (118,266) (520,959) (1,118,679) Parent company Sales of goods and services — 13,505 1,427 2,993 Parent company Purchases of goods and services (120,095) (311,418) (62,500) (135,297) Parent company Equity contributions (14,558,347) — — — Total (39,459,482) (11,844,257) (47,808) 33,779,935 Amounts receivable from related parties Party Transaction type 06/30/2019 06/30/2018 06/30/2017 Parent company Trade debtors 440,268 361,606 — Parent company Other receivables — 103,251 — Shareholders and other related parties Trade receivables 467,743 571,216 1,025,903 Shareholders and other related parties Allowance for impairment (75,596) (23,126) (205,960) Shareholders and other related parties Other receivables 10,971 119,677 67,753 Joint ventures Trade debtors 2,369 209,039 217,963 Joint ventures Other receivables 250,783 6,299,467 4,298,109 Total 1,096,538 7,641,130 5,403,768 Amounts payable to related parties Party Transaction type 06/30/2019 06/30/2018 06/30/2017 Parent company Trade creditors (1,568,036) — (218,744) Parents companies and related parties to Parents Net loans payables (17,757,907) (1,816,084) (646,538) Parent company Consideration payment Semya adquisition (575,604) — — Key management personnel Salaries, social security benefits and other benefits (2,312,253) (1,556,035) (1,614,494) Shareholders and other related parties Trade and other payables (1,796,932) (365,994) (633,700) Joint ventures Trade and other payables (4,805,149) (3,493,113) (1,649,367) Total (28,815,881) (7,231,226) (4,762,843)

KEY MANAGEMENT PERSONNEL COMP_2

KEY MANAGEMENT PERSONNEL COMPENSATION (Tables)	12 Months Ended
	Jun. 30, 2019
KEY MANAGEMENT PERSONNEL COMPENSATION
Schedule of compensation of directors and other members of key management personnel	06/30/2019 06/30/2018 06/30/2017 12/31/2016 Salaries, social security and other benefits 3,940,185 4,703,519 2,238,908 649,410 Total 3,940,185 4,703,519 2,238,908 649,410

SHARE-BASED PAYMENTS (Tables)

SHARE-BASED PAYMENTS (Tables)	12 Months Ended
	Jun. 30, 2019
SHARE-BASED PAYMENTS
Schedule of fair value of the share options and the factors used for its calculation	Factor Incentive Option Plan Weighted average fair value at measurement date (per option) USD 4.09 Value of the share (per share) USD 15.85 (Split 1:50) Expected dividend rate 0% Expected volatility 47.92% Risk-free interest rate 1,05% Weighted average expected life of stock options 2 years Weighted average exercise price (per share) USD 15.85 (Split 1:50) Model used Black and Scholes (adjusted to consider the possible dilutive effect of the future exercise of options)
Schedule of weighted average amount and exercise price and the movements of the stock options of executives and directors	06/30/2019 06/30/2018 06/30/2017 Weighted Weighted Weighted Number average Number average Number average of exercise of exercise of exercise options price options price options price At the beginning 31,600 15.85 31,600 15.85 31,600 15.85 Granted during the year/period — — — — — — Annulled during the year/period (31,600) (15.85) — — — — Exercised during the year/period — — — — — — Expired during the year/period — — — — — — Effective at year/period — — 31,600 15.85 31,600 15.85

CONTINGENCIES, COMMITMENTS AN_2

CONTINGENCIES, COMMITMENTS AND RESTRICTIONS ON THE DISTRIBUTION OF PROFITS (Tables)	12 Months Ended
	Jun. 30, 2019
CONTINGENCIES, COMMITMENTS AND RESTRICTIONS ON THE DISTRIBUTION OF PROFITS
Schedule of pledged and restricted assets	Pledged and restricted assets at June 30, 2019 are as follows: Detail Asset value Type of restriction IT equipment 77,760 Leasing Machinery and equipment 528,798 Leasing Machinery and equipment 158,080 Leasing Vehicles 119,728 Leasing Other financial assets 4,327,275 Collateral (a) Unicred S.A. 173,658 Custody checks (b) Macro 573,991 Custody checks (c) Santander Rio 3,093,478 Custody checks (d) Finares SA 176,440 Custody checks (e) Itau 1,594,459 Custody checks (f) Compass Latam & Odisea 16,037,769 Securty Collateral and Mortgage (g) Totals 26,861,436 a) Rizobacter entered into a USD 45 million syndicated loan and signed a guarantee and pledge. On July 3, 2018 Rizobacter granted a pledge of a fixed-term certificate at Banco Galicia for an amount of USD 4,298,101. b) In the months November, December and January, a loan was made by the Unicred Financial for a total amount of USD 1,038,883 guaranteed with third-party checks whose maturity is subsequent to the maturity of the loan. c) In June, loans were made by the Macro Bank for USD 500,000 guaranteed with third-party checks. d) In December, a loan was made by Santander Rio Bank for an amount of USD 3,500,000 guaranteed with third-party checks. e) In January, a loan was made by Finares SA for a value of USD 285,000 guaranteed with third party checks. f) In February, loans were made by Banco Itaú for USD 2,500,000 guaranteed with third-party checks. g) In April, the Group issued Negotiable Obligations worth USD 16,000,000, guaranteeing compliance with a first-degree mortgage of real estate assets of equal value and a p l edge on the shares representing 10% of the holding of Rasa Holding LLC in the capital of Rizobacter Argentina SA

GENERAL INFORMATION (Details)

GENERAL INFORMATION (Details)	Mar. 14, 2019USD ($)	Oct. 22, 2018shares	Oct. 19, 2016	Oct. 09, 2016	Jun. 30, 2019	Jun. 30, 2018	Feb. 13, 2019
Rizobacter Argentina
Disclosure of detailed information about business combination
Number of shares to be acquired in option agreement | shares		11,916,000
Voting interest to be acquired in option agreement		29.99%	9.99%	9.99%
Number of instruments or interests issued or issuable	1,334,047
Bioceres LLC
Disclosure of detailed information about business combination
Number of instruments or interests issued or issuable	27,116,174
Rizobacter Argentina
Disclosure of detailed information about business combination
Percentage of ownership interests					80.00%	60.00%
BCS Holding Inc | Rizobacter Argentina
Disclosure of detailed information about business combination
Number of instruments or interests issued or issuable	4,736,736
BCS Holding Inc | Rizobacter Argentina
Disclosure of detailed information about business combination
Percentage of ownership interests	80.00%
Bioceres LLC | BCS Holding Inc
Disclosure of detailed information about business combination
Voting interest to be acquired or acquired							100.00%
Original founders of Union | Bioceres LLC | Founder Shares
Disclosure of detailed information about business combination
Number of instruments or interests issued or issuable	862,500

GENERAL INFORMATION - Financial

GENERAL INFORMATION - Financial and economic situation (Details) $ in Millions	12 Months Ended
	Jun. 30, 2019USD ($)	Jun. 30, 2018	Mar. 31, 2015USD ($)
Borrowings:
Current liabilities over current assets ratio (as a percent)	1.16	1.39
Bonds that maybe issued			$ 40
Revolving credit facility
Borrowings:
Proceeds from renewal of borrowing	$ 17.2
Total borrowings	$ 33.6

ACCOUNTING STANDARDS AND BASI_3

ACCOUNTING STANDARDS AND BASIS OF PREPARATION - Retrospectively consideration and Functional currency and presentation currency (Details)	12 Months Ended
	Jun. 30, 2019	Mar. 14, 2019USD ($)
Acquisition-date fair value of total consideration transferred
Conversion factor to calculate inflation adjustment	1.558
Bioceres LLC
Acquisition-date fair value of total consideration transferred
Number of instruments or interests issued or issuable		27,116,174
Bioceres Semillas
Acquisition-date fair value of total consideration transferred
Number of instruments or interests issued or issuable		119,443
Original founders of Union | Founder Shares | Bioceres LLC
Acquisition-date fair value of total consideration transferred
Number of instruments or interests issued or issuable		862,500

ACCOUNTING STANDARDS AND BASI_4

ACCOUNTING STANDARDS AND BASIS OF PREPARATION - Subsidiaries (Details)	1 Months Ended		12 Months Ended
	Sep. 30, 2018	Aug. 31, 2018	Jun. 30, 2019	Jun. 30, 2018
Bioceres SA | Semya S.A.
DETAILS OF PRINCIPAL SUBSIDIARIES NOW COMPRISING THE GROUP
Percentage of voting equity interests acquired			50.00%
RASA Holding, LLC
DETAILS OF PRINCIPAL SUBSIDIARIES NOW COMPRISING THE GROUP
Proportion of ownership interest in subsidiary			100.00%	100.00%
Rizobacter Argentina
DETAILS OF PRINCIPAL SUBSIDIARIES NOW COMPRISING THE GROUP
Proportion of ownership interest in subsidiary			80.00%	60.00%
Rizobacter do Brasil Ltda.
DETAILS OF PRINCIPAL SUBSIDIARIES NOW COMPRISING THE GROUP
Proportion of ownership interest in subsidiary			79.99%	59.99%
Rizobacter del Paraguay S.A.
DETAILS OF PRINCIPAL SUBSIDIARIES NOW COMPRISING THE GROUP
Proportion of ownership interest in subsidiary			79.92%	59.94%
Rizobacter Uruguay
DETAILS OF PRINCIPAL SUBSIDIARIES NOW COMPRISING THE GROUP
Proportion of ownership interest in subsidiary			80.00%	60.00%
Rizobacter South Africa
DETAILS OF PRINCIPAL SUBSIDIARIES NOW COMPRISING THE GROUP
Proportion of ownership interest in subsidiary			76.00%	57.00%
Comer Agrop Rizobacter de Bolivia S.A.
DETAILS OF PRINCIPAL SUBSIDIARIES NOW COMPRISING THE GROUP
Proportion of ownership interest in subsidiary			79.96%	59.97%
Rizobacter USA, LLC
DETAILS OF PRINCIPAL SUBSIDIARIES NOW COMPRISING THE GROUP
Proportion of ownership interest in subsidiary			80.00%	60.00%
Rizobacter India Private Ltd.
DETAILS OF PRINCIPAL SUBSIDIARIES NOW COMPRISING THE GROUP
Proportion of ownership interest in subsidiary			80.00%	59.99%
Rizobacter Colombia SAS
DETAILS OF PRINCIPAL SUBSIDIARIES NOW COMPRISING THE GROUP
Proportion of ownership interest in subsidiary			80.00%	60.00%
Indrasa Biotecnologia S.A.
DETAILS OF PRINCIPAL SUBSIDIARIES NOW COMPRISING THE GROUP
Proportion of ownership interest in subsidiary			31.50%	52.91%
Rizobacter France SAS
DETAILS OF PRINCIPAL SUBSIDIARIES NOW COMPRISING THE GROUP
Proportion of ownership interest in subsidiary			80.00%	60.00%
Semya S.A.
DETAILS OF PRINCIPAL SUBSIDIARIES NOW COMPRISING THE GROUP
Proportion of ownership interest in subsidiary			100.00%	50.00%
BCS Holding LLC
DETAILS OF PRINCIPAL SUBSIDIARIES NOW COMPRISING THE GROUP
Proportion of ownership interest in subsidiary			100.00%
Bioceres Semillas
DETAILS OF PRINCIPAL SUBSIDIARIES NOW COMPRISING THE GROUP
Proportion of ownership interest in subsidiary			100.00%	8639.00%
Rizobacter Argentina S.A | Indrasa Biotecnologia S.A.
DETAILS OF PRINCIPAL SUBSIDIARIES NOW COMPRISING THE GROUP
Proportion of ownership interest in subsidiary	35.00%	52.50%

ACCOUNTING STANDARDS AND BASI_5

ACCOUNTING STANDARDS AND BASIS OF PREPARATION - Subsidiaries, additional information (Details)	Mar. 14, 2019	Sep. 30, 2018	Aug. 31, 2018	Jun. 30, 2019	Jun. 30, 2018
Semya S.A. | Bioceres SA
Business combinations:
Percentage of voting equity interests acquired				50.00%
Rizobacter Argentina
Business combinations:
Ownership interest in subsidiary (as a percent)				80.00%	60.00%
Indrasa Biotecnologia S.A.
Business combinations:
Ownership interest in subsidiary (as a percent)				31.50%	52.91%
Indirect ownership through Rizobacter
Business combinations:
Ownership interest in subsidiary (as a percent)				80.00%
BCS Holding Inc | Rizobacter Argentina
Business combinations:
Ownership interest in subsidiary (as a percent)	80.00%
Rizobacter Argentina S.A | Indrasa Biotecnologia S.A.
Business combinations:
Ownership interest in subsidiary (as a percent)		35.00%	52.50%

NEW STANDARDS, AMENDMENTS AND_2

NEW STANDARDS, AMENDMENTS AND INTERPRETATIONS ISSUED BY THE IASB - Leases (Details) - IFRS 16 $ in Millions	Jun. 30, 2019USD ($)
Leases
Right of use asset	$ 0.4
Lease liabilities	$ 0.4

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Business combinations (Details) - Rizobacter Argentina - shares	Oct. 22, 2018	Oct. 19, 2016	Oct. 09, 2016
Business combinations:
Voting interest to be acquired in option agreement	29.99%	9.99%	9.99%
Number of shares to be acquired in option agreement	11,916,000

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Business combination under common control (Details) - USD ($)	1 Months Ended		12 Months Ended
	Jun. 30, 2019	Dec. 31, 2014	Jun. 30, 2019
Business combinations
Installments payable			$ 122,950
Bioceres SA | Semya S.A.
Business combinations
Percentage of voting equity interests acquired	50.00%		50.00%
Percentage of royalty to be accrued as payment	50.00%		50.00%
Installments payable	$ 670,000
Bioceres SA | Semya S.A.
Business combinations
Ownership interest (as a percent)		50.00%
Rizobacter Argentina | Semya S.A.
Business combinations
Ownership interest (as a percent)		50.00%

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property, plant and equipment (Details)	12 Months Ended
	Jun. 30, 2019
Land
Property, plant and equipment
Change in market price change that impacts valuation (as a percent)	10.00%
Research instruments | Minimum
Property, plant and equipment
Useful lives (in years)	3 years
Research instruments | Maximum
Property, plant and equipment
Useful lives (in years)	10 years
Office equipment | Minimum
Property, plant and equipment
Useful lives (in years)	5 years
Office equipment | Maximum
Property, plant and equipment
Useful lives (in years)	10 years
Vehicles
Property, plant and equipment
Useful lives (in years)	5 years
Computer equipment and software
Property, plant and equipment
Useful lives (in years)	3 years
Fixture and fittings
Property, plant and equipment
Useful lives (in years)	10 years
Machinery and equipment | Minimum
Property, plant and equipment
Useful lives (in years)	5 years
Machinery and equipment | Maximum
Property, plant and equipment
Useful lives (in years)	10 years
Buildings
Property, plant and equipment
Useful lives (in years)	50 years
Change in construction costs that impacts valuation (as a percent)	5.00%
Variation in wear and tear that impacts valuation (as a percent)	5.00%

SUMMARY OF SIGNIFICANT ACCOUN_6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible assets (Details)	12 Months Ended
	Jun. 30, 2019
Discovery
Intangible assets
Term of seed development phase	18 months
Proof of concept
Intangible assets
Term of seed development phase	36 months
Early development
Intangible assets
Term of seed development phase	24 months
Advanced development and deregulation | Minimum
Intangible assets
Term of seed development phase	24 months
Advanced development and deregulation | Maximum
Intangible assets
Term of seed development phase	3 years
Pre-launch
Intangible assets
Term of seed development phase	24 months
Product registration
Intangible assets
Useful life (in years)	5 years
Customer loyalty
Intangible assets
Useful life (in years)	26 years
Externally acquired | Software
Intangible assets
Useful life (in years)	3 years
Externally acquired | Trademarks and patents
Intangible assets
Useful life (in years)	5 years
Externally acquired | Certification and ISO Standards
Intangible assets
Useful life (in years)	3 years
Microbial solutions | Discovery
Intangible assets
Term of seed development phase	6 months
Microbial solutions | Proof of concept
Intangible assets
Term of seed development phase	6 months
GM traits | Discovery
Intangible assets
Term of seed development phase	36 months
GM traits | Proof of concept
Intangible assets
Term of seed development phase	4 years

SUMMARY OF SIGNIFICANT ACCOUN_7

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Warrants (Details)	Mar. 14, 2019USD ($)
Public warrants
Disclosure of detailed information about business combination
Number of instruments or interests issued or issuable	11,500,000
Founder warrants
Disclosure of detailed information about business combination
Number of instruments or interests issued or issuable	5,200,000
Bioceres warrants
Disclosure of detailed information about business combination
Number of instruments or interests issued or issuable	7,500,000

INFORMATION ABOUT COMPONENTS _7

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Cash and cash equivalents (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
Cash and banks	$ 3,450,873	$ 2,215,103	$ 1,679,478
Total cash and cash equivalents	$ 3,450,873	$ 2,215,103	$ 1,679,478

INFORMATION ABOUT COMPONENTS _8

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Other financial assets (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Current
Restricted short-term deposit	$ 4,327,275	$ 4,538,321	$ 4,260,517
Other investments	347,718
Other marketable securities	8,515	12,526	4,275
Other financial assets	4,683,508	4,550,847	4,264,792
Non-current
Shares of Bioceres S.A.	374,685	240,920	676,762
Other marketable securities	1,728	2,438	90,237
Other financial assets	$ 376,413	$ 243,358	$ 766,999

INFORMATION ABOUT COMPONENTS _9

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Trade receivables (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Components of Consolidated Statement of Financial Position
Trade debtors	$ 48,910,484	$ 44,641,053	$ 34,121,040
Allowance for impairment of trade debtors	(3,360,224)	(3,212,170)	(2,873,688)
Allowance for return of goods	(800,606)	(1,517,361)	(1,393,059)
Discounted and deferred checks	13,651,939	11,858,170	10,783,719
Trade receivables	59,236,377	52,888,427	41,675,918
Shareholders and other related parties
Components of Consolidated Statement of Financial Position
Trade debtors	467,743	571,216	1,025,903
Allowance for impairment of related parties	(75,596)	(23,126)	(205,960)
Parent company
Components of Consolidated Statement of Financial Position
Trade debtors	440,268	361,606
Trade receivables	59,236,377	52,888,427	41,675,918
Joint ventures and associates
Components of Consolidated Statement of Financial Position
Trade debtors	$ 2,369	$ 209,039	$ 217,963

INFORMATION ABOUT COMPONENTS_10

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Other receivables (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Current
Taxes	$ 584,641	$ 664,926	$ 1,904,592
Prepayments to suppliers	496,001	516,742	1,210,070
Reimbursements over exports	366,594	362,815	151,107
Prepaid expenses and other receivables	213,597		265,972
Loans receivable		1,360	5,732
Miscellaneous	59,242	508,975	417,937
Other receivables	1,981,829	4,240,205	7,108,219
Non-current
Taxes	681,168	295,924	484,572
Reimbursements over exports	878,470	346,575	472,276
Miscellaneous	672		13,343
Other receivables	1,560,310	4,979,507	2,183,244
Shareholders and other related parties
Current
Other receivables	10,971	119,677	67,753
Parent company
Current
Other receivables		103,251
Joint ventures and associates
Current
Other receivables	$ 250,783	1,962,459	3,085,056
Non-current
Other receivables		$ 4,337,008	$ 1,213,053

INFORMATION ABOUT COMPONENTS_11

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Inventories (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2019	Jun. 30, 2018
Inventory
Goods in transit	$ 482,185	$ 751,737	$ 776,869
Supplies	7,424,825	4,512,870	3,978,934
Agricultural product		240,536
Inventories	31,338,034	27,592,582	19,366,001
Inventory recognized as expense	26,672,229	80,153,871	77,797,414
Agrochemicals
Inventory
Inventories	183,822	22,137	94,486
Seeds and Grains
Inventory
Inventories	1,273,515	207,519	514,000
Microbiological resale products
Inventory
Inventories	13,749,668	13,894,018	8,389,191
Microbiological products produced
Inventory
Inventories	8,931,124	8,370,583	6,383,263
Allowance for obsolescence
Inventory
Inventories	$ (707,105)	$ (406,818)	$ (770,742)

INFORMATION ABOUT COMPONENTS_12

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Property, plant and equipment (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Property, plant and equipment
Property, plant and equipment	$ 43,834,548	$ 40,177,146	$ 46,218,875	$ 46,393,761
Gross carrying amount
Property, plant and equipment
Property, plant and equipment	57,059,972	44,764,394	48,520,889	47,276,088	$ 493,120
Accumulated depreciation/amortization
Property, plant and equipment
Property, plant and equipment	$ (13,225,424)	$ (4,587,248)	$ (2,302,014)	$ (882,327)	$ (270,810)

INFORMATION ABOUT COMPONENTS_13

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Property, plant and equipment - net carrying amount (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2016
Property, plant and equipment
Property, plant and equipment	$ 43,834,548	$ 40,177,146	$ 46,218,875	$ 46,393,761
Office equipment
Property, plant and equipment
Property, plant and equipment	213,437	194,819	220,698	207,388
Vehicles
Property, plant and equipment
Property, plant and equipment	1,785,701	1,099,603	1,849,887	1,992,556
Computer equipment and software
Property, plant and equipment
Property, plant and equipment	123,472	212,236	308,360	380,386
Fixture and fittings
Property, plant and equipment
Property, plant and equipment	4,737,396	3,508,083	4,460,903	4,701,939
Machinery and equipment
Property, plant and equipment
Property, plant and equipment	6,336,691	4,466,293	8,405,441	9,105,953
Land and buildings
Property, plant and equipment
Property, plant and equipment	29,969,237	30,513,273	30,103,117	29,584,854
Buildings in progress
Property, plant and equipment
Property, plant and equipment	$ 668,614	$ 182,839	$ 870,469	$ 420,685

INFORMATION ABOUT COMPONENTS_14

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Property, plant and equipment - gross carrying amounts (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2016
Property, plant and equipment
As of the beginning of period	$ 46,393,761	$ 40,177,146	$ 46,218,875
As of the end of period	46,218,875	43,834,548	40,177,146	$ 46,393,761
Office equipment
Property, plant and equipment
As of the beginning of period	207,388	194,819	220,698
As of the end of period	220,698	213,437	194,819	207,388
Vehicles
Property, plant and equipment
As of the beginning of period	1,992,556	1,099,603	1,849,887
As of the end of period	1,849,887	1,785,701	1,099,603	1,992,556
Computer equipment and software
Property, plant and equipment
As of the beginning of period	380,386	212,236	308,360
As of the end of period	308,360	123,472	212,236	380,386
Fixture and fittings
Property, plant and equipment
As of the beginning of period	4,701,939	3,508,083	4,460,903
As of the end of period	4,460,903	4,737,396	3,508,083	4,701,939
Machinery and equipment
Property, plant and equipment
As of the beginning of period	9,105,953	4,466,293	8,405,441
As of the end of period	8,405,441	6,336,691	4,466,293	9,105,953
Land and buildings
Property, plant and equipment
As of the beginning of period	29,584,854	30,513,273	30,103,117
As of the end of period	30,103,117	29,969,237	30,513,273	29,584,854
Buildings in progress
Property, plant and equipment
As of the beginning of period	420,685	182,839	870,469
As of the end of period	870,469	668,614	182,839	420,685
Gross carrying amount
Property, plant and equipment
As of the beginning of period	47,276,088	44,764,394	48,520,889	493,120
Adjustment of opening net book amount for application of IAS 29		9,204,777
Additions	695,667	2,044,102	2,791,794	608,061
Additions for PPA				48,167,994
Disposals	(423,389)	(338,854)	(171,114)	(49,179)
Foreign currency translation	(2,271,076)	3,441,984	(20,942,036)	(1,943,908)
Revaluation	3,243,599	(2,056,431)	14,564,861
As of the end of period	48,520,889	57,059,972	44,764,394	47,276,088
Gross carrying amount | Office equipment
Property, plant and equipment
As of the beginning of period	235,301	243,948	252,220	5,830
Adjustment of opening net book amount for application of IAS 29		333,904
Additions	32,138	30,621	119,623	4,811
Additions for PPA				234,221
Disposals		(8,493)
Foreign currency translation	(15,219)	29,139	(127,895)	(9,561)
As of the end of period	252,220	629,119	243,948	235,301
Gross carrying amount | Vehicles
Property, plant and equipment
As of the beginning of period	2,136,823	1,660,294	2,223,102	160,895
Adjustment of opening net book amount for application of IAS 29		1,054,631
Additions	441,478	1,093,749	388,856	225,459
Additions for PPA				1,878,400
Disposals	(183,170)	(297,269)	(131,746)	(49,179)
Foreign currency translation	(172,029)	93,132	(819,918)	(78,752)
As of the end of period	2,223,102	3,604,537	1,660,294	2,136,823
Gross carrying amount | Computer equipment and software
Property, plant and equipment
As of the beginning of period	460,518	419,638	426,529	14,283
Adjustment of opening net book amount for application of IAS 29		416,274
Additions	20,637	75,152	189,094	13,945
Additions for PPA				450,785
Transfers			47,744
Disposals	(32,074)	(1,685)	(14,726)
Foreign currency translation	(22,552)	46,278	(229,003)	(18,495)
As of the end of period	426,529	955,657	419,638	460,518
Gross carrying amount | Fixture and fittings
Property, plant and equipment
As of the beginning of period	4,770,076	3,826,665	4,665,074	1,608
Adjustment of opening net book amount for application of IAS 29		1,909,115
Additions		7,518	6,178	118,638
Additions for PPA				4,848,110
Transfers	127,475	213,333	1,646,914
Disposals			(1,632)
Foreign currency translation	(232,477)	481,799	(2,489,869)	(198,280)
As of the end of period	4,665,074	6,438,430	3,826,665	4,770,076
Gross carrying amount | Machinery and equipment
Property, plant and equipment
As of the beginning of period	9,492,852	5,404,029	9,152,269	310,504
Adjustment of opening net book amount for application of IAS 29		3,976,720
Additions	18,513	98,034	197,840	35,170
Additions for PPA				9,533,037
Transfers	73,717	7,863
Disposals	(10,678)	(31,407)	(23,010)
Foreign currency translation	(422,135)	778,262	(3,923,070)	(385,859)
As of the end of period	9,152,269	10,233,501	5,404,029	9,492,852
Gross carrying amount | Land and buildings
Property, plant and equipment
As of the beginning of period	29,759,833	33,026,981	30,931,226
Adjustment of opening net book amount for application of IAS 29		1,438,728
Additions	15,508	125,930	26,017	210,038
Additions for PPA				30,792,604
Transfers	(428,844)		651,662
Disposals	(197,467)
Foreign currency translation	(1,461,403)	1,994,906	(13,146,785)	(1,242,809)
Revaluation	3,243,599	(2,056,431)	14,564,861
As of the end of period	30,931,226	34,530,114	33,026,981	29,759,833
Gross carrying amount | Buildings in progress
Property, plant and equipment
As of the beginning of period	420,685	182,839	870,469
Adjustment of opening net book amount for application of IAS 29		75,405
Additions	167,393	613,098	1,864,186
Additions for PPA				430,837
Transfers	227,652	(221,196)	(2,346,320)
Foreign currency translation	54,739	18,468	(205,496)	(10,152)
As of the end of period	$ 870,469	$ 668,614	$ 182,839	$ 420,685

INFORMATION ABOUT COMPONENTS_15

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Property, plant and equipment - accumulated depreciation (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2016
Property, plant and equipment
As of the beginning of period	$ 46,393,761	$ 40,177,146	$ 46,218,875
As of the end of period	46,218,875	43,834,548	40,177,146	$ 46,393,761
Office equipment
Property, plant and equipment
As of the beginning of period	207,388	194,819	220,698
As of the end of period	220,698	213,437	194,819	207,388
Vehicles
Property, plant and equipment
As of the beginning of period	1,992,556	1,099,603	1,849,887
As of the end of period	1,849,887	1,785,701	1,099,603	1,992,556
Computer equipment and software
Property, plant and equipment
As of the beginning of period	380,386	212,236	308,360
As of the end of period	308,360	123,472	212,236	380,386
Fixture and fittings
Property, plant and equipment
As of the beginning of period	4,701,939	3,508,083	4,460,903
As of the end of period	4,460,903	4,737,396	3,508,083	4,701,939
Machinery and equipment
Property, plant and equipment
As of the beginning of period	9,105,953	4,466,293	8,405,441
As of the end of period	8,405,441	6,336,691	4,466,293	9,105,953
Land and buildings
Property, plant and equipment
As of the beginning of period	29,584,854	30,513,273	30,103,117
As of the end of period	30,103,117	29,969,237	30,513,273	29,584,854
Accumulated depreciation/amortization
Property, plant and equipment
As of the beginning of period	(882,327)	(4,587,248)	(2,302,014)	(270,810)
Adjustment of opening net book amount for application of IAS 29		(5,923,397)
Disposals	(137,956)	(227,201)	(56,569)	(49,179)
Additions	(1,254,657)	(2,450,256)	(2,230,881)	(584,293)
Foreign currency translation	88,385	(626,645)	1,559,142	(76,403)
Revaluation	391,371	(134,921)	1,670,064
As of the end of period	(2,302,014)	(13,225,424)	(4,587,248)	(882,327)
Accumulated depreciation/amortization | Office equipment
Property, plant and equipment
As of the beginning of period	(27,913)	(49,129)	(31,522)	(3,555)
Adjustment of opening net book amount for application of IAS 29		(309,339)
Disposals		(4,007)
Additions	(5,452)	(39,997)	(41,740)	(18,901)
Foreign currency translation	1,843	(21,224)	24,133	(5,457)
As of the end of period	(31,522)	(415,682)	(49,129)	(27,913)
Accumulated depreciation/amortization | Vehicles
Property, plant and equipment
As of the beginning of period	(144,267)	(560,691)	(373,215)	(119,177)
Adjustment of opening net book amount for application of IAS 29		(750,195)
Disposals	(95,792)	(205,618)	(42,928)	(49,179)
Additions	(334,019)	(621,974)	(434,632)	(75,633)
Foreign currency translation	9,279	(91,594)	204,228	1,364
As of the end of period	(373,215)	(1,818,836)	(560,691)	(144,267)
Accumulated depreciation/amortization | Computer equipment and software
Property, plant and equipment
As of the beginning of period	(80,132)	(207,402)	(118,169)	(14,283)
Adjustment of opening net book amount for application of IAS 29		(486,143)
Disposals	(31,486)	(769)	(13,641)
Additions	(77,461)	(99,350)	(195,386)	(59,548)
Foreign currency translation	7,938	(40,059)	92,512	(6,301)
As of the end of period	(118,169)	(832,185)	(207,402)	(80,132)
Accumulated depreciation/amortization | Fixture and fittings
Property, plant and equipment
As of the beginning of period	(68,137)	(318,582)	(204,171)	(1,126)
Adjustment of opening net book amount for application of IAS 29		(912,404)
Additions	(145,044)	(397,989)	(286,024)	(153,424)
Foreign currency translation	9,010	(72,059)	171,613	86,413
As of the end of period	(204,171)	(1,701,034)	(318,582)	(68,137)
Accumulated depreciation/amortization | Machinery and equipment
Property, plant and equipment
As of the beginning of period	(386,899)	(937,736)	(746,828)	(132,669)
Adjustment of opening net book amount for application of IAS 29		(2,121,816)
Disposals	(10,678)	(16,807)
Additions	(408,975)	(673,784)	(741,508)	(134,648)
Foreign currency translation	38,368	(180,281)	550,600	(119,582)
As of the end of period	(746,828)	(3,896,810)	(937,736)	(386,899)
Accumulated depreciation/amortization | Land and buildings
Property, plant and equipment
As of the beginning of period	(174,979)	(2,513,708)	(828,109)
Adjustment of opening net book amount for application of IAS 29		(1,343,500)
Additions	(283,706)	(617,162)	(531,591)	(142,139)
Foreign currency translation	21,947	(221,428)	516,056	(32,840)
Revaluation	391,371	(134,921)	1,670,064
As of the end of period	$ (828,109)	$ (4,560,877)	$ (2,513,708)	$ (174,979)

INFORMATION ABOUT COMPONENTS_16

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Property, plant and equipment - revaluation (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
Carrying amount of land and buildings recognized if under cost model	$ 14,330,892	$ 18,244,100	$ 11,694,646

INFORMATION ABOUT COMPONENTS_17

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Intangible assets (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Intangible assets
Intangible assets	$ 39,616,426	$ 26,657,345	$ 42,058,891	$ 42,368,326
Gross carrying amount
Intangible assets
Intangible assets	45,848,737	29,155,315	43,903,217	42,890,018	$ 1,431,075
Accumulated depreciation/amortization
Intangible assets
Intangible assets	$ (6,232,311)	$ (2,497,970)	$ (1,844,326)	$ (521,692)	$ (6,105)

INFORMATION ABOUT COMPONENTS_18

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Intangible assets, net carrying amount (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2016
Intangible assets
Intangible assets	$ 39,616,426	$ 26,657,345	$ 42,058,891	$ 42,368,326
Soybean HB4
Intangible assets
Intangible assets	6,120,336	4,927,853	3,111,253	1,421,707
Ecoseed integrated products
Intangible assets
Intangible assets	2,627,946
Microbiology product
Intangible assets
Intangible assets	2,208,117	2,122,484	3,491,269	3,625,827
Trademarks and patents
Intangible assets
Intangible assets	8,063,648	5,574,682	10,402,764	11,265,234
Software
Intangible assets
Intangible assets	994,723	949,310	1,392,769	799,904
Customer loyalty
Intangible assets
Intangible assets	$ 19,601,656	$ 13,083,016	$ 23,660,836	$ 25,255,654

INFORMATION ABOUT COMPONENTS_19

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Intangible assets, gross carrying amount (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2016
Intangible assets
Balance at beginning of the year	$ 42,368,326	$ 26,657,345	$ 42,058,891
Balance at end of the year	42,058,891	39,616,426	26,657,345	$ 42,368,326
Gross carrying amount
Intangible assets
Balance at beginning of the year	42,890,018	29,155,315	43,903,217	1,431,075
Adjustment of opening net book amount for application of IAS 29		10,926,089
Additions	2,864,017	4,062,514	2,915,954	595,781
Additions for PPA				42,596,156
Disposals		(359,308)
Foreign currency translation	(1,850,818)	2,064,127	(17,663,856)	(1,732,994)
Balance at end of the year	43,903,217	45,848,737	29,155,315	42,890,018
Soybean HB4
Intangible assets
Balance at beginning of the year	1,421,707	4,927,853	3,111,253
Balance at end of the year	3,111,253	6,120,336	4,927,853	1,421,707
Soybean HB4 | Gross carrying amount
Intangible assets
Balance at beginning of the year	1,421,707	4,927,853	3,111,253	1,421,707
Additions	1,689,546	1,192,483	1,816,600
Balance at end of the year	3,111,253	6,120,336	4,927,853	1,421,707
Ecoseed integrated products
Intangible assets
Balance at end of the year		2,627,946
Ecoseed integrated products | Gross carrying amount
Intangible assets
Additions		2,627,946
Balance at end of the year		2,627,946
Microbiology product
Intangible assets
Balance at beginning of the year	3,625,827	2,122,484	3,491,269
Balance at end of the year	3,491,269	2,208,117	2,122,484	3,625,827
Microbiology product | Gross carrying amount
Intangible assets
Balance at beginning of the year	3,755,094	2,505,864	3,782,238
Adjustment of opening net book amount for application of IAS 29		841,753
Additions	194,743	41,485	484,825	175,527
Additions for PPA				3,733,981
Disposals		(318,949)
Foreign currency translation	(167,599)	197,047	(1,761,199)	(154,414)
Balance at end of the year	3,782,238	3,267,200	2,505,864	3,755,094
Trademarks and patents
Intangible assets
Balance at beginning of the year	11,265,234	5,574,682	10,402,764
Balance at end of the year	10,402,764	8,063,648	5,574,682	11,265,234
Trademarks and patents | Gross carrying amount
Intangible assets
Balance at beginning of the year	11,415,829	6,278,706	10,906,317
Adjustment of opening net book amount for application of IAS 29		2,986,739
Additions for PPA				11,896,495
Foreign currency translation	(509,512)	545,377	(4,627,611)	(480,666)
Balance at end of the year	10,906,317	9,810,822	6,278,706	11,415,829
Software
Intangible assets
Balance at beginning of the year	799,904	949,310	1,392,769
Balance at end of the year	1,392,769	994,723	949,310	799,904
Software | Gross carrying amount
Intangible assets
Balance at beginning of the year	845,954	1,444,603	1,787,925	9,368
Adjustment of opening net book amount for application of IAS 29		438,703
Additions	979,728	200,600	614,529	420,254
Additions for PPA				442,607
Disposals		(40,359)
Foreign currency translation	(37,757)	105,793	(957,851)	(26,275)
Balance at end of the year	1,787,925	2,149,340	1,444,603	845,954
Customer loyalty
Intangible assets
Balance at beginning of the year	25,255,654	13,083,016	23,660,836
Balance at end of the year	23,660,836	19,601,656	13,083,016	25,255,654
Customer loyalty | Gross carrying amount
Intangible assets
Balance at beginning of the year	25,451,434	13,998,289	24,315,484
Adjustment of opening net book amount for application of IAS 29		6,658,894
Additions for PPA				26,523,073
Foreign currency translation	(1,135,950)	1,215,910	(10,317,195)	(1,071,639)
Balance at end of the year	$ 24,315,484	$ 21,873,093	$ 13,998,289	$ 25,451,434

INFORMATION ABOUT COMPONENTS_20

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Intangible assets, accumulated amortization (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2016
Intangible assets
Balance at beginning of the year	$ 42,368,326	$ 26,657,345	$ 42,058,891
Balance at end of the year	42,058,891	39,616,426	26,657,345	$ 42,368,326
Accumulated depreciation/amortization
Intangible assets
Balance at beginning of the year	(521,692)	(2,497,970)	(1,844,326)	(6,105)
Adjustment of opening net book amount for application of IAS 29		(1,200,363)
Disposals		(61,246)
Additions	(1,418,529)	(2,376,919)	(2,141,476)	(424,179)
Foreign currency translation	95,895	(218,305)	1,487,832	(91,408)
Balance at end of the year	(1,844,326)	(6,232,311)	(2,497,970)	(521,692)
Microbiology product
Intangible assets
Balance at beginning of the year	3,625,827	2,122,484	3,491,269
Balance at end of the year	3,491,269	2,208,117	2,122,484	3,625,827
Microbiology product | Accumulated depreciation/amortization
Intangible assets
Balance at beginning of the year	(129,267)	(383,380)	(290,969)
Adjustment of opening net book amount for application of IAS 29		(202,791)
Disposals		(20,887)
Additions	(176,523)	(459,287)	(321,887)	(21,316)
Foreign currency translation	14,821	(34,512)	229,476	(107,951)
Balance at end of the year	(290,969)	(1,059,083)	(383,380)	(129,267)
Trademarks and patents
Intangible assets
Balance at beginning of the year	11,265,234	5,574,682	10,402,764
Balance at end of the year	10,402,764	8,063,648	5,574,682	11,265,234
Trademarks and patents | Accumulated depreciation/amortization
Intangible assets
Balance at beginning of the year	(150,595)	(704,024)	(503,553)
Adjustment of opening net book amount for application of IAS 29		(334,919)
Additions	(379,115)	(647,101)	(617,478)	(153,698)
Foreign currency translation	26,157	(61,130)	417,007	3,103
Balance at end of the year	(503,553)	(1,747,174)	(704,024)	(150,595)
Software
Intangible assets
Balance at beginning of the year	799,904	949,310	1,392,769
Balance at end of the year	1,392,769	994,723	949,310	799,904
Software | Accumulated depreciation/amortization
Intangible assets
Balance at beginning of the year	(46,050)	(495,293)	(395,156)	(6,105)
Adjustment of opening net book amount for application of IAS 29		(227,264)
Disposals		(40,359)
Additions	(370,018)	(429,258)	(399,311)	(49,348)
Foreign currency translation	20,912	(43,161)	299,174	9,403
Balance at end of the year	(395,156)	(1,154,617)	(495,293)	(46,050)
Customer loyalty
Intangible assets
Balance at beginning of the year	25,255,654	13,083,016	23,660,836
Balance at end of the year	23,660,836	19,601,656	13,083,016	25,255,654
Customer loyalty | Accumulated depreciation/amortization
Intangible assets
Balance at beginning of the year	(195,780)	(915,273)	(654,648)
Adjustment of opening net book amount for application of IAS 29		(435,389)
Additions	(492,873)	(841,273)	(802,800)	(199,817)
Foreign currency translation	34,005	(79,502)	542,175	4,037
Balance at end of the year	$ (654,648)	$ (2,271,437)	$ (915,273)	$ (195,780)

INFORMATION ABOUT COMPONENTS_21

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Goodwill (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Goodwill
Goodwill	$ 29,804,715	$ 14,438,027	$ 25,079,324
Rizobacter Argentina
Goodwill
Goodwill	23,484,761	$ 14,438,027	$ 25,079,324
Semya S.A.
Goodwill
Goodwill	$ 6,319,954

INFORMATION ABOUT COMPONENTS_22

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Goodwill, key assumptions (Details)	Jun. 30, 2019
INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
Discount rate	16.71%
Growth rate	2.00%

INFORMATION ABOUT COMPONENTS_23

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Trade and other payable (Details) - USD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Current
Trade creditors	$ 30,489,072	$ 22,222,872	$ 19,779,461
Taxes	1,475,410	35,391	372,990
Consideration payment Semya acquisition	122,950
Miscellaneous	320,945	1,591,460	140,454
Trade and other payable	40,578,494	27,708,830	22,794,716
Non current
Consideration payment Semya acquisition	452,654
Trade and other payables	452,654
Shareholders and other related parties
Current
Trade payable, related party	1,796,932	365,994	633,700
Parent company
Current
Trade payable, related party	1,568,036		218,744
Joint ventures and associates
Current
Trade payable, related party	$ 4,805,149	$ 3,493,113	$ 1,649,367

INFORMATION ABOUT COMPONENTS_24

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Borrowings (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Current
Corporate bonds	$ 8,416,768	$ 3,262,924	$ 4,644,621
Borrowings	66,477,209	65,308,928	34,037,971
Finance lease	385,947	280,027	466,689
Non-current
Corporate bonds	8,018,884		3,889,874
Finance lease	462,870	454,265	678,993
Borrowings	37,079,521	25,708,205	40,952,164
Bank overdraft
Current
Borrowings		532,912	46,511
Bank borrowings
Current
Borrowings	46,467,308	44,061,555	18,594,823
Non-current
Borrowings	16,239,743	25,253,940	36,383,297
BAF Loans
Current
Borrowings		5,112,222
Discount checks
Current
Borrowings	5,807,303	10,243,204	9,638,789
Parents companies and related parties
Current
Borrowings	5,399,883	$ 1,816,084	$ 646,538
Non-current
Borrowings	$ 12,358,024

INFORMATION ABOUT COMPONENTS_25

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Borrowings, carrying amount (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Current
Borrowings	$ 66,477,209	$ 65,308,928	$ 34,037,971
Corporate bonds	8,416,768	3,262,924	4,644,621
Non-current
Corporate bonds	8,018,884		3,889,874
Borrowings	37,079,521	25,708,205	40,952,164
Amortized cost
Current
Corporate bonds	8,416,768	3,262,924	4,644,621
Non-current
Corporate bonds	8,018,884		3,889,874
Fair value
Current
Corporate bonds	7,632,806	3,126,570	4,317,658
Non-current
Corporate bonds	6,972,332		3,395,857
Bank borrowings
Current
Borrowings	46,467,308	44,061,555	18,594,823
Non-current
Borrowings	16,239,743	25,253,940	36,383,297
Bank borrowings | Amortized cost
Current
Borrowings	46,467,308	44,061,555	18,594,823
Non-current
Borrowings	16,239,743	25,253,940	36,383,297
Bank borrowings | Fair value
Current
Borrowings	46,857,879	42,633,227	16,216,748
Non-current
Borrowings	14,274,547	20,610,018	33,993,312
Discount checks
Current
Borrowings	5,807,303	10,243,204	9,638,789
Discount checks | Amortized cost
Current
Borrowings	5,807,303	10,243,204	9,638,789
Discount checks | Fair value
Current
Borrowings	$ 5,230,123	$ 9,209,508	$ 8,950,197

INFORMATION ABOUT COMPONENTS_26

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Borrowings, parent company loans (Details) - USD ($)	May 07, 2019	Jun. 30, 2019
Current borrowings
Borrowings:
Gross amounts		$ (82,305,056)
Gross amounts set off in the Statement of Financial Position		15,827,847
Net amounts presented in the Statement of Financial Position		(66,477,209)
Total current liabilities
Borrowings:
Gross amounts		(82,305,056)
Gross amounts set off in the Statement of Financial Position		15,827,847
Net amounts presented in the Statement of Financial Position		(66,477,209)
Current other receivables
Borrowings:
Gross amounts		17,809,676
Gross amounts set off in the Statement of Financial Position		(15,827,847)
Net amounts presented in the Statement of Financial Position		1,981,829
Total current assets
Borrowings:
Gross amounts		17,809,676
Gross amounts set off in the Statement of Financial Position		(15,827,847)
Net amounts presented in the Statement of Financial Position		$ 1,981,829
Parent company loans
Borrowings:
Notional amount	$ 15,000,000
Term	5 years
Borrowings, interest rate	10.00%

INFORMATION ABOUT COMPONENTS_27

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Borrowings, corporate bonds (Details)	Apr. 05, 2019USD ($)installment	Apr. 04, 2019USD ($)installment	Aug. 31, 2015ARS ($)installment	Mar. 31, 2015USD ($)	Jun. 30, 2019USD ($)	Apr. 25, 2017USD ($)	Mar. 15, 2017USD ($)	Aug. 31, 2015USD ($)	Aug. 13, 2015USD ($)
Tranche A
Borrowings:
Notional amount							$ 22,000,000
Tranche B
Borrowings:
Notional amount						$ 23,000,000
Issuance of public corporate bonds
Borrowings:
Notional amount		$ 16,000,000		$ 40,000,000
Term				5 years
Series I
Borrowings:
Notional amount								$ 7,786,327	$ 10,000,000
Interest rate (as a percent)			6.00%					6.00%
Initial exchange rate			9.28					9.28
Number of installments | installment			5
Series I | Tranche A
Borrowings:
Number of installments | installment			4
Percentage of total debt			17.50%
Series I | Tranche B
Borrowings:
Percentage of total debt			30.00%
Series I | Maximum
Borrowings:
Notional amount									$ 17,000,000
Series I Class I
Borrowings:
Notional amount			$ 84,115,789					$ 5,592,805
Interest rate (as a percent)			26.50%					26.50%
Number of installments | installment			5
Borrowings, adjustment to interest rate basis			5.50%					5.50%
Series I Class I | Tranche A
Borrowings:
Number of installments | installment			4
Percentage of total debt			17.50%
Series I Class I | Tranche B
Borrowings:
Percentage of total debt			30.00%
Series I Class I | Maximum | Fixed rate
Borrowings:
Interest rate (as a percent)			35.00%					35.00%
Series I Class I | Maximum | Variable rate
Borrowings:
Interest rate (as a percent)			32.00%					32.00%
Series I Class I | Minimum | Variable rate
Borrowings:
Interest rate (as a percent)			16.00%					16.00%
Series I Class II
Borrowings:
Notional amount			$ 1,377,882					$ 91,614
Interest rate (as a percent)			27.00%					27.00%
Number of installments | installment			5
Series I Class II | Tranche A
Borrowings:
Number of installments | installment			4
Percentage of total debt			17.50%
Series I Class II | Tranche B
Borrowings:
Percentage of total debt			30.00%
Series I Inversiones Odisea
Borrowings:
Notional amount		$ 13,000,000
Interest rate (as a percent)		1055.00%
Number of installments | installment		4
Percentage of total debt		25.00%
Owned capital					$ 13,000,000
Series II Compas Latam High Yield
Borrowings:
Notional amount	$ 3,000,000
Interest rate (as a percent)	1055.00%
Number of installments | installment	4
Percentage of total debt	25.00%
Owned capital					$ 3,000,000

INFORMATION ABOUT COMPONENTS_28

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Borrowings, syndicated loan (Details)	6 Months Ended
	Jun. 30, 2017USD ($)multipleinstallment	Apr. 25, 2017USD ($)	Mar. 15, 2017USD ($)
Tranche A
Borrowings:
Notional amount | $			$ 22,000,000
Tranche B
Borrowings:
Notional amount | $		$ 23,000,000
Bank borrowings
Borrowings:
Notional amount | $	$ 45,000,000
Number of installments | installment	13
Interest rate (as a percent)	6.50%
Net debt to EBITA ratio	3
Bank borrowings | Year 2017
Borrowings:
EBITDA to interest ratio	1.2
Liabilities to assets ratio	0.85
Bank borrowings | Year 2018
Borrowings:
EBITDA to interest ratio	1.5
Liabilities to assets ratio	0.825
Bank borrowings | Year 2019
Borrowings:
EBITDA to interest ratio	2
Liabilities to assets ratio	0.8
Bank borrowings | Year 2020
Borrowings:
EBITDA to interest ratio	2
Liabilities to assets ratio	0.8

INFORMATION ABOUT COMPONENTS_29

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Employee benefits and social security (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
Salaries and social security	$ 3,875,834	$ 3,146,583	$ 1,871,710
Staff incentives and vacations	1,481,384	1,265,130	3,175,335
Employee benefits and social security	$ 5,357,218	$ 4,411,713	$ 5,047,045

INFORMATION ABOUT COMPONENTS_30

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Deferred revenue and advances from customers (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
Advances from customers	$ 1,074,463	$ 1,007,301	$ 1,197,080
Deferred revenue and advances from customers	$ 1,074,463	$ 1,007,301	$ 1,197,080

INFORMATION ABOUT COMPONENTS_31

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Government grants (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
Current	$ 2,110	$ 17,695	$ 60,829
Non-current	8,098	15,532	57,716
Government grants	$ 10,208	$ 33,227	$ 118,545	$ 155,919	$ 152,792

INFORMATION ABOUT COMPONENTS_32

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Government grants, rollforward (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2016
INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
At the beginning of the year	$ 155,919	$ 33,227	$ 118,545	$ 152,792
Adjustment of net book amount for application of IAS 29		(27,794)
Received during the year	64,106	31,785	103,382	144,902
Currency conversion differences	(69,539)	(10,638)	(137,114)
Released to the statement of profit or loss	(31,941)	(16,372)	(51,586)	(141,775)
At the end of year	$ 118,545	$ 10,208	$ 33,227	$ 155,919

INFORMATION ABOUT COMPONENTS_33

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Provisions (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Provisions
Provision	$ 4,282,378	$ 4,851,524	$ 5,202,043	$ 6,024,951	$ 582,212
Total included in liabilities
Provisions
Provision	439,740	845,486	1,415,290	1,909,530	67,708
Provisions for contingencies
Provisions
Provision	$ 439,740	$ 845,486	$ 1,415,290	$ 1,909,530	$ 67,708

INFORMATION ABOUT COMPONENTS_34

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Acquisition of business (Details)	Mar. 14, 2019USD ($)	Oct. 22, 2018	Oct. 19, 2016USD ($)	Oct. 09, 2016USD ($)	Jun. 30, 2019USD ($)installment	Jun. 30, 2018USD ($)	Apr. 30, 2019USD ($)	Oct. 31, 2018USD ($)	Apr. 30, 2018USD ($)	Oct. 31, 2017USD ($)	Jun. 30, 2017USD ($)
Current
Purchase option						$ 14,605,469
Financed payment to sellers					$ 2,826,611	5,618,121					$ 6,219,980
Current					2,826,611	20,223,590					6,219,980
Financed payment to sellers						2,651,019					7,656,611
Purchase option											13,523,582
Non-current						$ 2,651,019					$ 21,180,193
Gain for cancellation of purchase option					$ 6,582,849
Rizobacter Argentina
Current
Number of installments | installment					4
Cash transferred							$ 2,900,000	$ 2,900,000	$ 2,900,000	$ 3,500,000
Voting interest to be acquired in option agreement		29.99%	9.99%	9.99%
Consideration of additional interest to be acquired in option agreement				$ 14,900,000
Number of instruments or interests issued or issuable	1,334,047
Price per share on the day of the transaction			$ 5.35
Gain for cancellation of purchase option			$ 6,582,849
Acquisition of 9.99% Ownership of Rizobacter Argentina
Current
Cash transferred	$ 1,265,000
Percentage of voting equity interests acquired			9.99%
Number of instruments or interests issued or issuable	1,334,047
BCS Holding Inc | Rizobacter Argentina
Current
Cash transferred	$ 1,265,000
Number of instruments or interests issued or issuable	4,736,736
Rizobacter Argentina
Current
Proportion of ownership interest in subsidiary					80.00%	60.00%
Rizobacter Argentina | BCS Holding Inc
Current
Proportion of ownership interest in subsidiary	80.00%

INFORMATION ABOUT COMPONENTS_35

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Private Warrants (Details)	Jun. 30, 2019USD ($)$ / shares	Mar. 14, 2019USD ($)$ / shares	Mar. 02, 2018$ / sharesshares
Private warrants
INFORMATION ABOUT COMPONENTS OF EQUITY
Warrant exercise period		5 years
Warrants incorporate in the reverse capitalization as reduction of equity		$ 1,589,548
Financial liabilities, at fair value	$ 2,800,000	$ 3,400,000
Gain recognized from change in fair value	$ 600,000
Private warrants | Volatility
INFORMATION ABOUT COMPONENTS OF EQUITY
Assumption used in estimating fair value | $ / shares		32
Private warrants | Share price
INFORMATION ABOUT COMPONENTS OF EQUITY
Assumption used in estimating fair value | $ / shares	5.30	5.35
Private warrants | Risk-free rate
INFORMATION ABOUT COMPONENTS OF EQUITY
Assumption used in estimating fair value	1.7631	2.43
Private warrants, strike price $15.00
INFORMATION ABOUT COMPONENTS OF EQUITY
Warrant exercise price | $ / shares		$ 15
Number of instruments or interests issued or issuable		2,500,000
Private warrants, strike price $18.00
INFORMATION ABOUT COMPONENTS OF EQUITY
Warrant exercise price | $ / shares		$ 18
Number of instruments or interests issued or issuable		2,500,000
Founder warrants
INFORMATION ABOUT COMPONENTS OF EQUITY
Warrants incorporate in the reverse capitalization as reduction of equity		$ 1,843,175
Number of instruments or interests issued or issuable		5,200,000
Bioceres warrants
INFORMATION ABOUT COMPONENTS OF EQUITY
Number of instruments or interests issued or issuable		7,500,000
UAC
INFORMATION ABOUT COMPONENTS OF EQUITY
Number of warrants issued in IPO | shares			5,200,000
Warrant exercise price | $ / shares			$ 11.50
Warrant exercise period			5 years
UAC | Private warrants, strike price $11.50
INFORMATION ABOUT COMPONENTS OF EQUITY
Warrant exercise price | $ / shares		$ 11.50
Number of instruments or interests issued or issuable		2,500,000
Share price at which warrants become exercisable | $ / shares		$ 15
Number of trading days of shares at $15.00 for the warrants to vest		20
Continuous trading period at the warrant strike price for the warrants to vest		30 days

INFORMATION ABOUT COMPONENTS_36

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Puttable instrument (Details) - USD ($)	Jun. 11, 2018	Feb. 09, 2018	Oct. 14, 2016	Jun. 30, 2017	Jun. 30, 2019
Ordinary shares
Puttable instrument
Par value per share					$ 0.0001
Number of shares outstanding					36,120,517
Number of shares issued					36,120,517
Preference shares
Puttable instrument
Par value per share					$ 0.0001
Number of shares outstanding					0
Number of shares issued					0
Puttable instruments
Puttable instrument
Financial liabilities, at fair value				$ 2,500,000
Puttable instruments | Preference shares
Puttable instrument
Financial liabilities, at fair value				$ 2,500,000
Loss on remeasurement of the liability of Puttable preferred shares	$ 831,534
RASA Holding, LLC | Preference shares
Puttable instrument
Maturity term			5 years	5 years
Par value per share			$ 10	$ 10
Number of shares outstanding		1,409,848		1,409,848
Dividend rate in kind (as a percent)		12.00%	12.00%
Subscription price (in USD per share)			$ 8.696
Number of shares issued			4,830,000
Bioceres SA | Holders Of Preferred Shares | Ordinary shares
Puttable instrument
Subscription price (in USD per share)		$ 7.91
Shares subscribed	2,010,170	2,010,170
Number of shares issued	2,010,170
Shares issued on puttable preferred shares	421,180

INFORMATION ABOUT COMPONENTS_37

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Changes in allowance and provisions (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2016
Changes in allowances and provisions
Beginning	$ (6,024,951)	$ (4,851,524)	$ (5,202,043)	$ (582,212)
Additions	(674,336)	(1,546,385)	(2,269,266)	(1,774,128)
Additions for business combination				(4,513,159)
Uses and reversals	440,733	1,036,732	302,232	373,004
IAS 29		1,864,557
Currency conversion difference	1,056,511	(785,758)	2,317,553	471,544
Ending	(5,202,043)	(4,282,378)	(4,851,524)	(6,024,951)
Allowance deducted from assets
Changes in allowances and provisions
Beginning	(4,115,421)	(4,006,038)	(3,786,753)	(514,504)
Additions	(663,625)	(1,472,276)	(2,184,855)	(1,481,119)
Additions for business combination				(3,141,073)
Uses and reversals	181,295	715,791	263,924	373,004
IAS 29		1,511,300
Currency conversion difference	810,998	(591,415)	1,701,646	648,271
Ending	(3,786,753)	(3,842,638)	(4,006,038)	(4,115,421)
Allowance for impairment of trade debtors
Changes in allowances and provisions
Beginning	(2,949,214)	(3,212,170)	(2,873,688)	(346,515)
Additions	(154,818)	(654,991)	(1,362,720)	(490,374)
Additions for business combination				(2,722,575)
Uses and reversals	40,485	87,916	76,329	373,004
IAS 29		1,220,652
Currency conversion difference	189,859	(801,631)	947,909	237,246
Ending	(2,873,688)	(3,360,224)	(3,212,170)	(2,949,214)
Allowance for impairment of related parties
Changes in allowances and provisions
Beginning	(8,210)	(23,126)	(205,960)
Additions	(219,559)	(80,913)		(8,394)
Uses and reversals	402	12,408	27,264
IAS 29		17,396
Currency conversion difference	21,407	(1,361)	155,570	184
Ending	(205,960)	(75,596)	(23,126)	(8,210)
Allowance for obsolescence
Changes in allowances and provisions
Beginning	(1,157,997)	(770,742)	(707,105)	(167,989)
Additions	(289,248)	(736,372)	(822,135)	(982,351)
Additions for business combination				(418,498)
Uses and reversals	140,408	615,467	160,331
IAS 29		273,252
Currency conversion difference	599,732	211,577	598,167	410,841
Ending	(707,105)	(406,818)	(770,742)	(1,157,997)
Total included in liabilities
Changes in allowances and provisions
Beginning	(1,909,530)	(845,486)	(1,415,290)	(67,708)
Additions	(10,711)	(74,109)	(84,411)	(293,009)
Additions for business combination				(1,372,086)
Uses and reversals	259,438	320,941	38,308
IAS 29		353,257
Currency conversion difference	245,513	(194,343)	615,907	(176,727)
Ending	(1,415,290)	(439,740)	(845,486)	(1,909,530)
Provisions for contingencies
Changes in allowances and provisions
Beginning	(1,909,530)	(845,486)	(1,415,290)	(67,708)
Additions	(10,711)	(74,109)	(84,411)	(293,009)
Additions for business combination				(1,372,086)
Uses and reversals	259,438	320,941	38,308
IAS 29		353,257
Currency conversion difference	245,513	(194,343)	615,907	(176,727)
Ending	$ (1,415,290)	$ (439,740)	$ (845,486)	$ (1,909,530)

INFORMATION ABOUT COMPONENTS_38

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - Revenue (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2016
Revenue
Royalties	$ 102,178	$ 1,110,463	$ 442,689	$ 349,760
Revenue	46,853,369	160,308,979	133,491,118	41,027,474
Sale of goods and services
Revenue
Revenue	$ 46,751,191	$ 159,198,516	$ 133,048,429	$ 40,677,714

INFORMATION ABOUT COMPONENTS_39

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - Cost of Sales (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2016
INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
Inventory as of the beginning of the year	$ 32,677,314	$ 19,366,001	$ 31,338,034	$ 2,835,909
Adjustment of opening net book amount for the application of IAS 29		4,273,416
Combine business				40,846,774
Purchases of the period	25,332,949	88,380,452	65,825,381	17,307,320
Production costs	5,322,615	11,558,513	14,002,049	3,737,400
Foreign currency translation	(2,381,686)	(9,020,919)	(14,704,912)	(1,451,133)
Subtotal	60,951,192	114,557,463	96,460,552	63,276,270
Inventory as of the end of the year	31,338,034	27,592,582	19,366,001	32,677,314
Cost of sales	$ 29,613,158	$ 86,964,881	$ 77,094,551	$ 30,598,956

INFORMATION ABOUT COMPONENTS_40

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - R&D classified by nature (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2016
R&D classified by nature
Amortization intangible assets	$ 982,952	$ 1,270,530	$ 1,197,988	$ 424,179
Import and export expenses	(242,133)	1,491,747	857,037	253,837
Depreciation property, plant and equipment	1,032,211	2,229,407	2,007,366	520,735
Employee benefits and social securities	10,215,819	18,282,864	21,848,090	4,670,312
Maintenance	724,558	1,034,347	1,006,457	151,941
Energy and fuel	444,083	764,297	1,030,092	213,368
Supplies and materials	160,069	489,891	171,251	29,885
Stock options based incentive		20,893,789
Mobility and travel	739,097	1,318,164	1,421,187	279,731
Professional fees and outsourced services	908,566	8,028,397	2,058,982	924,721
Office supplies	468,572	383,561	567,149	166,751
Systems expenses	84,156	709,539	621,012	4,633
Insurance	360,207	907,654	729,739	86,497
Miscellaneous	177,023	228,205	977,086	288,662
Research and development expenses	1,990,268	3,689,391	3,950,100	853,854
Research and development expenses
R&D classified by nature
Amortization intangible assets	435,577	1,106,390	943,488
Import and export expenses	14,165	16,360	21,640	1,398
Depreciation property, plant and equipment	222,446	220,849	223,515	63,558
Freight and haulage	73,275		30	136
Employee benefits and social securities	481,326	541,025	1,435,028	360,760
Maintenance	42,373	56,395	86,112	47,055
Energy and fuel	49,785	52,919	78,570	22,703
Supplies and materials	107,678	1,175,184	844,372	107,436
Stock options based incentive	25,710		30,005	43,827
Mobility and travel	66,865	48,308	87,628	29,822
Professional fees and outsourced services	90,206	447,383	121,914	5,850
Office supplies	57,564	3,796	17,932	38,159
Systems expenses	1,797		8,851	211
Insurance	18,302	8,593	22,006	6,646
Miscellaneous	303,199	12,189	29,009	126,293
Research and development expenses	$ 1,990,268	$ 3,689,391	$ 3,950,100	$ 853,854

INFORMATION ABOUT COMPONENTS_41

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - Expenses Classified by Nature and Function (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2016
Production costs
Analysis and storage	$ 20,745	$ 5,811	$ 1,225,756	$ 67,052
Commissions and royalties	60,052	751,972	552,906	405,923
Import and export expenses	76,818	95,111	131,558	21,435
Depreciation property, plant and equipment	384,019	1,164,810	1,208,699	240,638
Freight and haulage	148,362	1,433,867	664,984	33,638
Employee benefits and social securities	3,554,197	5,313,211	7,582,440	1,781,605
Maintenance	426,634	501,699	597,497	3,358
Energy and fuel	185,379	568,848	419,716	87,063
Supplies and materials	160,069	275,378	169,674	29,885
Mobility and travel	15,980	12,097	48,068	7,540
Professional fees and outsourced services	20,462	681,790	195	14,576
Office supplies	2,418	31,394	17,790	5,813
Insurance	70,320	105,302	118,610
Systems expenses	10,072		19,057
Allowance for obsolescence	148,840	564,873	661,804	982,351
Taxes	23,850	37,388	105,104	11,967
Miscellaneous	14,398	14,962	478,191	44,556
Production costs	5,322,615	11,558,513	14,002,049	3,737,400
Selling, general and administrative expenses
Amortization intangible assets	982,952	1,270,530	1,197,988	424,179
Analysis and storage	46,781	904	225,462	71,126
Commissions and royalties	258,456	489,301	671,180	92,943
Bank expenses and commissions	67,094	30,784	51,471	73,991
Import and export expenses	(318,951)	1,396,636	725,479	232,402
Depreciation property, plant and equipment	648,192	1,064,597	798,667	280,097
Impairment of receivables	333,490	686,985	1,259,127	125,764
Freight and haulage	903,544	2,662,715	2,251,297	751,586
Employee benefits and social securities	6,661,622	12,969,653	14,265,650	2,888,707
Maintenance	297,924	532,648	408,960	148,583
Energy and fuel	258,704	195,449	610,376	126,305
Supplies and materials		214,513	1,577
Mobility and travel	723,117	1,306,067	1,373,119	272,191
Publicity and advertising	1,047,653	1,709,552	2,239,505	384,168
Contingencies	(248,727)	67,417	84,411	293,009
Telephone and communications	1,387		630
Professional fees and outsourced services	888,104	7,346,607	2,058,787	910,145
Professional fees related parties	447,723	401,005	759,149	183,393
Office supplies	466,154	352,167	549,359	160,938
Insurance	289,887	802,352	611,129	86,497
System expenses	74,084	709,539	601,955	4,633
Taxes	1,697,783	4,821,136	4,019,515	1,072,358
Miscellaneous	162,625	213,243	498,895	244,106
Total selling, general and administrative expense	15,689,598	39,243,800	35,263,688	8,827,121
Production costs and selling, general and administrative expenses
Amortization intangible assets	982,952	1,270,530	1,197,988	424,179
Analysis and Storage	67,526	6,715	1,451,218	138,178
Commissions and royalties	318,508	1,241,273	1,224,086	498,866
Bank expenses and commissions	67,094	30,784	51,471	73,991
Import and export expenses	(242,133)	1,491,747	857,037	253,837
Depreciation, property, plant and equipment	1,032,211	2,229,407	2,007,366	520,735
Impairment of receivables	333,490	686,985	1,259,127	125,764
Freight and haulage	1,051,906	4,096,582	2,916,281	785,224
Employee benefits and social securities	10,215,819	18,282,864	21,848,090	4,670,312
Maintenance	724,558	1,034,347	1,006,457	151,941
Energy and fuel	444,083	764,297	1,030,092	213,368
Supplies and materials	160,069	489,891	171,251	29,885
Mobility and travel	739,097	1,318,164	1,421,187	279,731
Publicity and advertising	1,047,653	1,709,552	2,239,505	384,168
Contingencies	(248,727)	67,417	84,411	293,009
Telephone and communications	1,387		630
Professional fees and outsourced services	908,566	8,028,397	2,058,982	924,721
Professional fees related parties	447,723	401,005	759,149	183,393
Office supplies	468,572	383,561	567,149	166,751
Insurance	360,207	907,654	729,739	86,497
System expenses	84,156	709,539	621,012	4,633
Obsolescence	148,840	564,873	661,804	982,351
Taxes	1,721,633	4,858,524	4,124,619	1,084,325
Miscellaneous	177,023	228,205	977,086	288,662
Total	$ 21,012,213	$ 50,802,313	$ 49,265,737	$ 12,564,521

INFORMATION ABOUT COMPONENTS_42

INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - Finance results (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2016
Finance Income
Interest generated by assets	$ 303,513	$ 1,397,025	$ 909,912	$ 65,896
Interest generated by assets related parties	179,887	90,188	294,577	73,178
Gain for cancellation of purchase option		6,582,849
Changes in fair value of financial assets or liabilities and other financial results	92,820	649,998	67,349	17,394
Finance Income	576,220	8,720,060	1,271,838	156,468
Finance Costs
Interest generated by liabilities with the parent	(520,959)	(1,386,288)	(118,266)	(1,118,679)
Interest generated by liabilities	(7,422,210)	(22,884,366)	(16,646,801)	(5,011,139)
Financial commissions	(1,032,366)	(1,578,292)	(1,628,075)	(885,351)
Other financial loss	(517,136)	(243,688)		(136,792)
Finance Costs	(9,492,671)	(26,092,634)	(18,393,142)	(7,151,961)
Other finance results
Share based payment cost of listing shares		(20,893,789)
Net gain of inflation effect on monetary items		14,653,335
Exchange differences generated by assets	1,186,264	48,355,784	25,710,957
Exchange differences generated by liabilities	(2,463,076)	(66,200,973)	(49,540,369)	(1,254,084)
Other finance results	(1,276,812)	(24,085,643)	(23,829,412)	(1,254,084)
Total net finance results	$ (10,193,263)	$ (41,458,217)	$ (40,950,716)	$ (8,249,577)

INCOME TAX AND MINIMUM PRESUM_3

INCOME TAX AND MINIMUM PRESUMED INCOME TAX (Details)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2020	Dec. 31, 2019	Jun. 30, 2019	Dec. 31, 2018	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
INCOME TAX AND MINIMUM PRESUMED INCOME TAX
Income tax rate (as a percent)	35.00%	25.00%	30.00%	30.00%	30.00%	35.00%	35.00%	35.00%
Dividends tax (as a percent)		13.00%	7.00%				35.00%
Optional tax - buildings (as a percent)			8.00%
Optional tax - inventory (as a percent)			15.00%
Optional tax - remaining assets (as a percent)			10.00%

INCOME TAX AND MINIMUM PRESUM_4

INCOME TAX AND MINIMUM PRESUMED INCOME TAX - Tax recoverable and payable (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Current assets
Income tax	$ 1,263,795	$ 2,082,269	$ 1,701,382
Non-current assets
Income tax	0	0	95,565
Minimum presumed income tax	1,184	126,653	220,000
Total	1,184	126,653	315,565
Liabilities
Income tax	$ 142,028	$ 2,569	$ 29,788

INCOME TAX AND MINIMUM PRESUM_5

INCOME TAX AND MINIMUM PRESUMED INCOME TAX - Deferred tax assets and liabilities (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Deferred tax assets and liabilities
Total deferred tax assets	$ 3,743,709	$ 5,601,821	$ 3,372,101	$ 4,649,504
Total deferred tax liabilities	(21,101,871)	(13,591,942)	(25,611,927)	(26,385,786)
Net deferred tax	(17,358,162)	(7,990,121)	(22,239,826)	(21,736,282)	$ (271,792)
Tax Loss-Carry Forward
Deferred tax assets and liabilities
Total deferred tax assets	2,663,813	3,638,269	1,059,746	753,359
Net deferred tax	(2,663,813)	(3,638,269)	(1,059,746)	(753,359)	(258,194)
Changes in fair value of financial assets or liabilities
Deferred tax assets and liabilities
Total deferred tax assets	32,062	35,944	96,394	87,467
Net deferred tax	(32,062)	(35,944)	(96,394)	(87,467)	(61,913)
Trade receivables
Deferred tax assets and liabilities
Total deferred tax assets	374,425	462,756	829,095	804,481
Net deferred tax	(374,425)	(462,756)	(829,095)	(804,481)
Allowances
Deferred tax assets and liabilities
Total deferred tax assets		370,930	805,375	935,415
Total deferred tax liabilities	(152,159)
Inventories
Deferred tax assets and liabilities
Total deferred tax assets		710,391	367,682	519,310
Total deferred tax liabilities	(153,563)
Intangible assets
Deferred tax assets and liabilities
Total deferred tax assets		15,098	38,241	48,426
Total deferred tax liabilities	(9,458,239)	(5,071,808)	(12,633,408)	(13,609,901)
Contingencies
Deferred tax assets and liabilities
Total deferred tax assets			13,612
Total deferred tax liabilities		(2,709)
Net deferred tax		(2,709)
Government grants
Deferred tax assets and liabilities
Total deferred tax assets	2,649	9,360	41,616	54,572
Net deferred tax	(2,649)	(9,360)	(41,616)	(54,572)	(53,477)
Others
Deferred tax assets and liabilities
Total deferred tax assets	670,760	359,073	120,340	1,446,474
Total deferred tax liabilities		(297)	(15,942)	(9,727)
Accumulated depreciation/amortization
Deferred tax assets and liabilities
Total deferred tax liabilities	(9,618,648)	(8,497,756)	(12,923,320)	(12,738,676)
Net deferred tax	(9,618,648)	(8,497,756)	12,923,320	12,738,676	$ 53,679
Borrowings
Deferred tax assets and liabilities
Total deferred tax liabilities	(13,170)	(19,372)	(39,257)	(27,482)
Net deferred tax	(13,170)	$ (19,372)	$ 39,257	$ 27,482
Inflation tax adjustment
Deferred tax assets and liabilities
Total deferred tax liabilities	(1,706,092)
Net deferred tax	$ (1,706,092)

INCOME TAX AND MINIMUM PRESUM_6

INCOME TAX AND MINIMUM PRESUMED INCOME TAX - Deferred tax assets and liabilities rollforward (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2016
Deferred tax assets and liabilities
Deferred tax liability (asset) at beginning of period	$ 21,736,282	$ 7,990,121	$ 22,239,826	$ 271,792
Acquisition of control through Business combination				(23,721,453)
Income tax provision	2,492,102		(4,672,417)	1,490,780
Charge to OCI	(936,029)		(4,507,311)
Conversion difference	2,059,617		(14,084,599)	222,599
Deferred tax liability (asset) at end of period	22,239,826	17,358,162	7,990,121	21,736,282
Deferred Tax Asset [Member]
Deferred tax assets and liabilities
Deferred tax liability (asset) at beginning of period	4,649,504	5,601,821	3,372,101	325,471
Acquisition of control through Business combination		(343,230)		2,633,641
Income tax provision	1,092,851	(1,868,335)	2,962,112	1,495,787
Transfer from deferred tax liabilities		781,896	(1,148)
Conversion difference	(2,370,254)	(428,443)	(731,244)	194,605
Deferred tax liability (asset) at end of period	3,372,101	3,743,709	5,601,821	4,649,504
Tax Loss-Carry Forward
Deferred tax assets and liabilities
Deferred tax liability (asset) at beginning of period	753,359	3,638,269	1,059,746	258,194
Acquisition of control through Business combination		113,289
Income tax provision	360,007	(1,306,198)	3,631,690	520,957
Conversion difference	(53,620)	218,453	(1,053,167)	(25,792)
Deferred tax liability (asset) at end of period	1,059,746	2,663,813	3,638,269	753,359
Changes in fair value of financial assets or liabilities
Deferred tax assets and liabilities
Deferred tax liability (asset) at beginning of period	87,467	35,944	96,394	61,913
Acquisition of control through Business combination		25,868
Income tax provision	13,216	(33,200)	(27,872)	28,642
Conversion difference	(4,289)	3,450	(32,578)	(3,088)
Deferred tax liability (asset) at end of period	96,394	32,062	35,944	87,467
Trade receivables
Deferred tax assets and liabilities
Deferred tax liability (asset) at beginning of period	804,481	462,756	829,095
Acquisition of control through Business combination				804,481
Income tax provision	60,520	(114,765)	(16,762)
Conversion difference	(35,906)	26,434	(349,577)
Deferred tax liability (asset) at end of period	829,095	374,425	462,756	804,481
Allowances
Deferred tax assets and liabilities
Deferred tax liability (asset) at beginning of period	935,415	370,930	805,375	119,651
Acquisition of control through Business combination				656,327
Income tax provision	(83,964)	(555,679)	(143,397)	(9,559)
Transfer from deferred tax liabilities		152,159
Conversion difference	(46,076)	32,590	(291,048)	168,996
Deferred tax liability (asset) at end of period	805,375		370,930	935,415
Inventories, Tax Asset [Member]
Deferred tax assets and liabilities
Deferred tax liability (asset) at beginning of period	519,310	710,391	367,682	(246,720)
Acquisition of control through Business combination				(234,278)
Income tax provision	(128,450)	(119,316)	(767,844)	935,283
Transfer from deferred tax liabilities		153,563
Conversion difference	(23,178)	(744,638)	1,110,553	65,025
Deferred tax liability (asset) at end of period	367,682		710,391	519,310
Intangible Assets, Tax Asset [Member]
Deferred tax assets and liabilities
Deferred tax liability (asset) at beginning of period	48,426	15,098	38,241	78,956
Acquisition of control through Business combination		(482,387)		12,510
Income tax provision	(8,577)	(22,467)	(11,570)	(41,366)
Transfer from deferred tax liabilities		476,174
Conversion difference	(1,608)	13,582	(11,573)	(1,674)
Deferred tax liability (asset) at end of period	38,241		15,098	48,426
Contingencies, Tax Asset [Member]
Deferred tax assets and liabilities
Deferred tax liability (asset) at beginning of period			13,612
Income tax provision	14,301
Transfer from deferred tax liabilities			(13,612)
Conversion difference	(689)
Deferred tax liability (asset) at end of period	13,612
Government grants
Deferred tax assets and liabilities
Deferred tax liability (asset) at beginning of period	54,572	9,360	41,616	53,477
Income tax provision	(11,218)	(7,262)	(21,647)	29,362
Conversion difference	(1,738)	551	(10,609)	(28,267)
Deferred tax liability (asset) at end of period	41,616	2,649	9,360	54,572
Other, Tax Asset [Member]
Deferred tax assets and liabilities
Deferred tax liability (asset) at beginning of period	1,446,474	359,073	120,340
Acquisition of control through Business combination				1,394,601
Income tax provision	877,016	290,552	319,514	32,468
Transfer from deferred tax liabilities			12,464
Conversion difference	(2,203,150)	21,135	(93,245)	19,405
Deferred tax liability (asset) at end of period	120,340	670,760	359,073	1,446,474
Deferred Tax Liability [Member]
Deferred tax assets and liabilities
Deferred tax liability (asset) at beginning of period	(26,385,786)	13,591,942	(25,611,927)	(53,679)
Acquisition of control through Business combination				(26,355,094)
Income tax provision	1,399,251	(2,968,606)	1,710,305	(5,007)
Transfer from deferred tax liabilities		(781,896)	1,148
Charge to OCI	(936,029)	576,453	(4,507,311)
Conversion difference	(310,637)	(4,335,880)	14,815,843	27,994
Deferred tax liability (asset) at end of period	(25,611,927)	21,101,871	13,591,942	(26,385,786)
Intangibles, Tax Liability [Member]
Deferred tax assets and liabilities
Deferred tax liability (asset) at beginning of period	(13,609,901)	5,071,808	(12,633,408)
Acquisition of control through Business combination				(13,609,901)
Income tax provision	802,280	(937,962)	(1,114,442)
Transfer from deferred tax liabilities		(476,174)
Conversion difference	(174,213)	(2,972,295)	8,676,042
Deferred tax liability (asset) at end of period	(12,633,408)	9,458,239	5,071,808	(13,609,901)
Accumulated depreciation/amortization
Deferred tax assets and liabilities
Deferred tax liability (asset) at beginning of period	(12,738,676)	8,497,756	(12,923,320)	(53,679)
Acquisition of control through Business combination				(12,699,878)
Income tax provision	616,622	(335,077)	2,811,852	(18,703)
Charge to OCI	(936,029)	576,453	(4,507,311)
Conversion difference	(134,763)	(1,362,268)	6,121,023	33,584
Deferred tax liability (asset) at end of period	(12,923,320)	9,618,648	8,497,756	(12,738,676)
Borrowings
Deferred tax assets and liabilities
Deferred tax liability (asset) at beginning of period	(27,482)	19,372	(39,257)
Acquisition of control through Business combination				(27,482)
Income tax provision	(13,002)	7,342	3,720
Conversion difference	(1,227)	(1,140)	16,165
Deferred tax liability (asset) at end of period	(39,257)	13,170	19,372	(27,482)
Contingencies
Deferred tax assets and liabilities
Deferred tax liability (asset) at beginning of period		2,709
Income tax provision		2,869	(15,442)
Transfer from deferred tax liabilities			13,612
Conversion difference		(160)	(879)
Deferred tax liability (asset) at end of period			2,709
Inflation tax adjustment
Deferred tax assets and liabilities
Income tax provision		(1,706,092)
Deferred tax liability (asset) at end of period		1,706,092
Allowances, Tax Liability [Member]
Deferred tax assets and liabilities
Transfer from deferred tax liabilities		(152,159)
Deferred tax liability (asset) at end of period		152,159
Inventories, Tax Liability [Member]
Deferred tax assets and liabilities
Transfer from deferred tax liabilities		(153,563)
Deferred tax liability (asset) at end of period		153,563
Other, Tax Liability [Member]
Deferred tax assets and liabilities
Deferred tax liability (asset) at beginning of period	(9,727)	297	(15,942)
Acquisition of control through Business combination				(17,833)
Income tax provision	(6,649)	314	24,617	13,696
Transfer from deferred tax liabilities			(12,464)
Conversion difference	(434)	$ (17)	3,492	(5,590)
Deferred tax liability (asset) at end of period	$ (15,942)		$ 297	$ (9,727)

INCOME TAX AND MINIMUM PRESUM_7

INCOME TAX AND MINIMUM PRESUMED INCOME TAX - Reconciliation of the statutory tax rate (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2020	Dec. 31, 2019	Jun. 30, 2019	Dec. 31, 2018	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Reconciliation of the statutory tax rate
2019 First tax rate tax				0.00%
2019 Second tax rate				21.00%
Income tax rate (as a percent)	35.00%	25.00%	30.00%	30.00%	30.00%	35.00%	35.00%	35.00%
Loss before income tax-rate 0%				$ (21,669,883)
Profit before income tax-rate 21%				1,264
Loss before income tax-rate 35%	$ (11,195,800)					$ (21,621,007)		$ (8,042,536)
Profit/(Loss) before income tax-rate 30%				12,296,011		(3,618,756)
Income tax charge by applying tax rate to profit/(loss) before tax:	3,918,530			(3,689,069)		8,652,979		2,814,888
Share of profit or loss of subsidies, joint ventures and associates	(571,587)			(44,721)		(1,448,925)		(977,061)
Stock options charge	(8,978)			78,681		(8,898)		(15,339)
Rate change adjustment				(54,735)		3,768,518
Allowance for unused tax losses						(59,879)		(46,553)
Non-deductible expenses and untaxed gains	(312,477)			(254,201)		(732,442)		84,712
Representation expenses				(136,614)		(204,897)
Foreign investment coverage				233,634
Result por inflation effect on monetary items				(3,119,259)
Others	(208,237)					962,061
Total income tax (expense) credit	2,817,251			(6,986,284)		10,928,517		1,860,647
Deferred income tax liabilities not recognized	$ 571,587			$ 44,721		$ 1,448,925		$ 977,061

INCOME TAX AND MINIMUM PRESUM_8

INCOME TAX AND MINIMUM PRESUMED INCOME TAX - Schedule of Principal statutory taxes rates and current tax (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2020	Dec. 31, 2019	Jun. 30, 2019	Dec. 31, 2018	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
INCOME TAX AND MINIMUM PRESUMED INCOME TAX
Current tax expense	$ 325,149			$ (2,149,343)		$ 6,256,100		$ 369,867
Deferred tax	2,492,102			(4,836,941)		4,672,417		1,490,780
Total income tax (expense) credit	$ 2,817,251			$ (6,986,284)		$ 10,928,517		$ 1,860,647
Applicable tax rate	35.00%	25.00%	30.00%	30.00%	30.00%	35.00%	35.00%	35.00%
Argentina
INCOME TAX AND MINIMUM PRESUMED INCOME TAX
Applicable tax rate	35.00%			30.00%				35.00%
CAYMAN ISLANDS
INCOME TAX AND MINIMUM PRESUMED INCOME TAX
Applicable tax rate				0.00%
United States of America
INCOME TAX AND MINIMUM PRESUMED INCOME TAX
Applicable tax rate				21.00%
Maximum | Argentina
INCOME TAX AND MINIMUM PRESUMED INCOME TAX
Applicable tax rate						35.00%
Minimum | Argentina
INCOME TAX AND MINIMUM PRESUMED INCOME TAX
Applicable tax rate						30.00%

INCOME TAX AND MINIMUM PRESUM_9

INCOME TAX AND MINIMUM PRESUMED INCOME TAX - Tax loss carryforward (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Tax loss carryforward
Deferred tax assets	$ 3,743,709	$ 5,601,821	$ 3,372,101
Minimum amount of presumed income tax	1,184
Argentina | 2016
Tax loss carryforward
Minimum amount of presumed income tax	1,184
Tax Loss-Carry Forward
Tax loss carryforward
Tax-Loss Carry forward	11,967,563
Deferred tax assets	2,663,813
Tax Loss-Carry Forward | 2015
Tax loss carryforward
Tax-Loss Carry forward	125,442
Deferred tax assets	31,389
Tax Loss-Carry Forward | 2016
Tax loss carryforward
Tax-Loss Carry forward	741,741
Deferred tax assets	185,435
Tax Loss-Carry Forward | 2017
Tax loss carryforward
Tax-Loss Carry forward	1,149,203
Deferred tax assets	283,096
Tax Loss-Carry Forward | 2018
Tax loss carryforward
Tax-Loss Carry forward	402,956
Deferred tax assets	104,943
Tax Loss-Carry Forward | 2019
Tax loss carryforward
Tax-Loss Carry forward	668,458
Deferred tax assets	194,200
Tax Loss-Carry Forward | 2019
Tax loss carryforward
Tax-Loss Carry forward	8,879,763
Deferred tax assets	$ 1,864,750

LOSS PER SHARE (Details)

LOSS PER SHARE (Details) - USD ($)		6 Months Ended	12 Months Ended
		Jun. 30, 2017	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2016
Numerator
Loss for the year (basic EPS)		$ (5,908,927)	$ (18,369,045)	$ (11,039,533)	$ (5,865,870)
Denominator
Weighted average number of shares (basic EPS)	[1]	28,098,117	30,478,390	28,098,117	28,098,117
Basic loss attributable to ordinary equity holders of the parent		$ (0.21)	$ (0.60)	$ (0.39)	$ (0.21)
[1]	For the years ended June 30, 2019, and 2018, the six-month transition period ended June 30, 2017 and the year ended Decemeber 31, 2016 diluted EPS was the same as basic EPS as the effect of potential ordinary shares would be antidilutive.

LOSS PER SHARE - Capital issued

LOSS PER SHARE - Capital issued (Details)	Mar. 14, 2019USD ($)
Bioceres LLC
Disclosure of detailed information about business combination
Number of shares issued	27,116,174
Bioceres Semillas
Disclosure of detailed information about business combination
Number of shares issued	119,443
Original founders of Union | Founder Shares | Bioceres LLC
Disclosure of detailed information about business combination
Number of shares issued	862,500

INFORMATION ABOUT COMPONENTS_43

INFORMATION ABOUT COMPONENTS OF EQUITY - Capital issued (Details)	Mar. 14, 2019USD ($)
Bioceres LLC
Capital issued
Number of instruments or interests issued or issuable	27,116,174
Bioceres Semillas
Capital issued
Number of instruments or interests issued or issuable	119,443
Original founders of Union | Founder Shares | Bioceres LLC
Capital issued
Number of instruments or interests issued or issuable	862,500

INFORMATION ABOUT COMPONENTS_44

INFORMATION ABOUT COMPONENTS OF EQUITY - Parent company investment (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2016
INFORMATION ABOUT COMPONENTS OF EQUITY
Capital contributions	$ 2,585,580	$ 294,041	$ 1,572,235	$ 48,083,838
Intangible contributed	2,049,823	623,022	2,105,616
Preferred shares contributed	(3,277,615)		3,331,534
Incorporation of financial debt		(15,475,410)	(5,000,000)	15,569,028
Financed payment to Rizobacter sellers				(13,182,575)
Recognized contribution	$ 1,357,788	$ (14,558,347)	$ 2,009,385	$ 50,470,291

INFORMATION ABOUT COMPONENTS_45

INFORMATION ABOUT COMPONENTS OF EQUITY - Reverse recapitalization (Details)	Mar. 14, 2019USD ($)	Feb. 27, 2019USD ($)shares	Mar. 02, 2018$ / sharesshares	Jun. 30, 2019shares	Dec. 31, 2017shares
INFORMATION ABOUT COMPONENTS OF EQUITY
Excess of fair value of equity instruments over the net monetary assets acquired | $	$ 20,900,000
Trust account proceeds incorporated to the Group | $		$ 1,083,840
Bioceres LLC
INFORMATION ABOUT COMPONENTS OF EQUITY
Number of instruments or interests issued or issuable | $	27,116,174
Public warrants
INFORMATION ABOUT COMPONENTS OF EQUITY
Number of shares issued				11,500,000
Warrants exercise price (USD per share) | $ / shares			$ 11.50
UAC
INFORMATION ABOUT COMPONENTS OF EQUITY
Number of units sold in IPO			11,500,000
Number of ordinary share in a unit sold in IPO			1
Number of exchange right ordinary share in a unit sold in IPO			1
Exchange ratio of exchange right ordinary share in a unit sold in IPO			0.10
Number of warrants in a unit sold in IPO			1
Number shares the warrants can be exercise to			1
Warrants exercise price (USD per share) | $ / shares			$ 11.50
Number of rights converted to ordinary shares		11,500,000
Number of shares issued for the 11,500,000 rights		1,150,000
Number ordinary share redeemed		11,376,836
Redemption payment | $		$ 117,005,196
Price per share on the day of the transaction | $		$ 5.35
UAC | Founder Shares
INFORMATION ABOUT COMPONENTS OF EQUITY
Number of shares issued					2,875,000
Original founders of Union | Founder Shares | Bioceres LLC
INFORMATION ABOUT COMPONENTS OF EQUITY
Number of instruments or interests issued or issuable | $	862,500

INFORMATION ABOUT COMPONENTS_46

INFORMATION ABOUT COMPONENTS OF EQUITY - Rizobacter Call Option (Details) - USD ($)	Mar. 14, 2019	Jun. 30, 2019	Jun. 30, 2018	Oct. 19, 2016
Rizobacter Argentina
Capital issued
Ownership interest in subsidiary (as a percent)		80.00%	60.00%
Acquisition of 9.99% Ownership of Rizobacter Argentina
Capital issued
Percentage of voting equity interests acquired				9.99%
Cash transferred	$ 1,265,000
Number of instruments or interests issued or issuable	1,334,047
Acquisition of 20% Ownership of Rizobacter Argentina
Capital issued
Percentage of voting equity interests acquired	20.00%
Number of instruments or interests issued or issuable	3,402,688
BCS Holding Inc | Rizobacter Argentina
Capital issued
Ownership interest in subsidiary (as a percent)	80.00%

INFORMATION ABOUT COMPONENTS_47

INFORMATION ABOUT COMPONENTS OF EQUITY - Shares summary (Details)	Mar. 14, 2019shares	Mar. 02, 2018$ / sharesshares	Jun. 30, 2019Vote$ / sharesshares
INFORMATION ABOUT COMPONENTS OF EQUITY
Warrants outstanding			12,700,000
Ordinary shares
INFORMATION ABOUT COMPONENTS OF EQUITY
Number of shares authorised			100,000,000
Par value per share | $ / shares			$ 0.0001
Number of shares issued			36,120,517
Number of shares outstanding			36,120,517
Vote per share | Vote			1
Preference shares
INFORMATION ABOUT COMPONENTS OF EQUITY
Number of shares authorised			1,000,000
Par value per share | $ / shares			$ 0.0001
Number of shares issued			0
Number of shares outstanding			0
Public warrants
INFORMATION ABOUT COMPONENTS OF EQUITY
Number of shares issued			11,500,000
Warrants exercise price (USD per share) | $ / shares		$ 11.50
Founder warrants
INFORMATION ABOUT COMPONENTS OF EQUITY
Issue of convertible instruments in shares	5,200,000
Bioceres warrants
INFORMATION ABOUT COMPONENTS OF EQUITY
Issue of convertible instruments in shares	7,500,000
UAC
INFORMATION ABOUT COMPONENTS OF EQUITY
Number shares the warrants can be exercise to		1
Warrants exercise price (USD per share) | $ / shares		$ 11.50
Warrant exercise period		5 years
UAC | Public warrants
INFORMATION ABOUT COMPONENTS OF EQUITY
Issue of convertible instruments in shares		11,500,000
Warrant exercise period		5 years
Stock price above which the company can redeem the warrants (USD per share) | $ / shares		$ 18

INFORMATION ABOUT COMPONENTS_48

INFORMATION ABOUT COMPONENTS OF EQUITY - Rizobacter Argentina (Details) - USD ($)		2 Months Ended	6 Months Ended	12 Months Ended
		Dec. 31, 2016	Jun. 30, 2017	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2016	Dec. 31, 2015
Financial position
Current assets			$ 87,767,823	$ 98,208,964	$ 85,342,852
Non-current assets			152,103,228	144,258,333	111,295,912
Total assets			239,871,051	242,467,297	196,638,764
Current liabilities			69,387,409	116,458,133	118,680,626
Non-current liabilities			93,244,576	63,914,298	44,824,482
Total liabilities			162,631,985	180,372,431	163,505,108
Equity attributable to controlling interest			35,841,621	47,301,863	13,713,484
Equity attributable to non-controlling interest			41,397,445	14,793,003	19,420,172
Total equity		$ 83,670,743	77,239,066	62,094,866	33,133,656	$ 83,670,743	$ 1,097,282
Total liabilities and equity			239,871,051	242,467,297	196,638,764
Summary statements of comprehensive income or loss
Revenues				160,605,296	133,542,704	41,169,249
Cost of sales			(29,613,158)	(86,964,881)	(77,094,551)	(30,598,956)
Gross margin				73,640,415	56,448,153	10,570,293
Research and development expenses			(1,990,268)	(3,689,391)	(3,950,100)	(853,854)
Selling, general and administrative expenses			(15,689,598)	(39,243,800)	(35,263,688)	(8,827,121)
Share of profit or loss of joint ventures and associates			(649,075)	1,012,486	(2,136,801)	(707,042)
Operating profit/(loss)			(1,002,537)	32,085,610	15,710,953	207,041
Finance results			(10,193,263)	(41,458,217)	(40,950,716)	(8,249,577)
Loss before income tax			(11,195,800)	(9,372,607)	(25,239,763)	(8,042,536)
Income tax benefit (expense)			2,817,251	(6,986,284)	10,928,517	1,860,647
Result for the year			(8,378,549)	(16,358,891)	(14,311,246)	(6,181,889)
Exchange differences on translation of foreign operations			(3,248,472)	5,240,151	(29,845,780)	(4,302,097)
Revaluation of property, plant and equipment, net of tax	[1]		1,843,847	(1,441,132)	8,381,618
Total comprehensive loss			$ (11,092,790)	$ (12,454,526)	$ (46,144,800)	$ (10,761,589)
Rizobacter Argentina
Summarized financial information
Proportion of ownership interests held by non-controlling interests			40.00%	20.00%	40.00%
Financial position
Current assets			$ 86,202,115	$ 115,546,951	$ 86,461,071
Non-current assets			113,906,651	47,418,450	48,295,110
Total assets			200,108,766	162,965,401	134,756,181
Current liabilities			60,192,036	100,590,919	88,270,487
Non-current liabilities			65,604,538	34,788,705	29,598,319
Total liabilities			125,796,574	135,379,624	117,868,806
Equity attributable to controlling interest			74,266,985	27,584,666	16,824,251
Equity attributable to non-controlling interest			45,207	1,111	63,124
Total equity			74,312,192	27,585,777	16,887,375
Total liabilities and equity			200,108,766	162,965,401	134,756,181
Summary statements of comprehensive income or loss
Revenues		36,739,496	44,458,442	156,741,933	129,798,271
Cost of sales		(26,818,086)	(27,494,324)	(85,287,771)	(71,699,144)
Gross margin		9,921,410	16,964,118	71,454,162	58,099,127
Research and development expenses		(555,676)	(1,711,089)	(2,367,727)	(2,902,235)
Selling, general and administrative expenses		(6,936,425)	(14,501,080)	(31,316,843)	(31,219,784)
Share of profit or loss of joint ventures and associates		(161,436)	(610,994)	1,071,297	(1,683,949)
Other income			53,928	286,626	524,672
Operating profit/(loss)		2,267,873	194,883	39,127,515	22,817,831
Finance results		(4,014,402)	(8,619,703)	(24,650,359)	(37,989,573)
Loss before income tax		(1,746,529)	(8,424,820)	14,477,156	(15,171,742)
Income tax benefit (expense)		(1,836,968)	2,333,310	(7,729,300)	3,275,077
Result for the year		(3,583,497)	(6,091,510)	6,747,856	(11,896,665)
Exchange differences on translation of foreign operations		(898,790)	202,981	17,197	(8,266,718)
Revaluation of property, plant and equipment, net of tax			2,032,872	(1,347,124)	14,079,875
Total comprehensive loss		$ (4,482,287)	$ (3,855,657)	$ 5,417,929	$ (6,083,508)
[1]	The tax effect of the revalution of property, plant and equipment was ($480,378), $4,513,179, $1,008,381 and nil for the years ended June 30, 2019 and 2018, the six-month transition period ended June 30,2017 and the year ended December 31, 2016 respectively.

INFORMATION ABOUT COMPONENTS_49

INFORMATION ABOUT COMPONENTS OF EQUITY - RAZA Holding preferred shares (Details) $ / shares in Units, $ in Millions	Jun. 11, 2018shares	Feb. 09, 2018USD ($)$ / sharesshares	Oct. 14, 2016USD ($)$ / sharesshares	Jun. 30, 2017$ / sharesshares	Jun. 30, 2019Vote$ / sharesshares	Mar. 02, 2018$ / shares
INFORMATION ABOUT COMPONENTS OF EQUITY
Warrants outstanding					12,700,000
Ordinary shares
INFORMATION ABOUT COMPONENTS OF EQUITY
Number of shares issued					36,120,517
Par value per share | $ / shares					$ 0.0001
Number of shares authorised					100,000,000
Number of shares outstanding					36,120,517
Vote per share | Vote					1
Preference shares
INFORMATION ABOUT COMPONENTS OF EQUITY
Number of shares issued					0
Par value per share | $ / shares					$ 0.0001
Number of shares authorised					1,000,000
Number of shares outstanding					0
Public warrants
INFORMATION ABOUT COMPONENTS OF EQUITY
Number of shares issued					11,500,000
Warrants exercise price (USD per share) | $ / shares						$ 11.50
RASA Holding, LLC
INFORMATION ABOUT COMPONENTS OF EQUITY
Capitalization amount | $		$ 50.5
RASA Holding, LLC | Preference shares
INFORMATION ABOUT COMPONENTS OF EQUITY
Number of shares issued			4,830,000
Par value per share | $ / shares			$ 10	$ 10
Subscription price (in USD per share) | $ / shares			$ 8.696
Proceeds from issuing shares | $			$ 42
Dividend rate in kind (as a percent)		12.00%	12.00%
Maturity term			5 years	5 years
Consummated offering that carrys mandatory participation right the subscription to ordinary shares | $			$ 50
Number of shares outstanding		1,409,848		1,409,848
Bioceres SA | Holders Of Preferred Shares | Ordinary shares
INFORMATION ABOUT COMPONENTS OF EQUITY
Number of shares issued	2,010,170
Subscription price (in USD per share) | $ / shares		$ 7.91
Shares subscribed	2,010,170	2,010,170

CASH FLOW INFORMATION (Details)

CASH FLOW INFORMATION (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2016
Investment activities
Settlement of liability with loan to joint venture		$ 6,964,101
Investment in kind in other related parties (Note 16)		463,511
Non-monetary contributions in joint ventures (Note 12)	$ 1,150,259	94,355	$ 679,510
Investing activities	1,150,259	7,521,967	679,510
Non Cash Financing Activities
Purchase option paid by a parent loan		(1,265,000)
Parent company investment	(1,357,788)	14,558,347	(2,009,385)	$ (50,470,291)
Issuance of shares				15,850,000
Transfer of preferred stocks			(9,759,545)
Capitalization of financial debt		13,720,000
Reverse recapitalization		3,688,963
Net assets incorporated of Semya		7,369,168
Acquisition of control of Semya S.A.		3,684,585
Acquisition of control of Semya	$ (1,357,788)	$ 2,107,727	$ (11,768,930)	$ (66,320,291)

CASH FLOW INFORMATION - Busines

CASH FLOW INFORMATION - Business combination of assets and liabilities (Details) - Semya S.A.	May 31, 2019USD ($)
Business Combination Assets And Liabilities
Current assets	$ 67,924
Non-current assets
Tax credits	253,655
Intangibles	2,147,199
Goodwil	5,836,268
Total assets	8,305,047
Current liabilities
Trade payables	273,442
Borrowings	114,568
Non-current liabilities
Deferred tax	547,868
Total liabilities	935,878
Total equity	$ 7,369,169

CASH FLOW INFORMATION - Changes

CASH FLOW INFORMATION - Changes in liabilities arising from financing activities (Details)	12 Months Ended
	Jun. 30, 2019USD ($)
Changes in liabilities arising from financing activities
As of June 30, 2018	$ 113,891,742
Proceeds from borrowings	88,693,632
Decrease bank overdraft and other short-term borrowings	(4,968,813)
Payments	(90,917,814)
Capitalization of financial debt	(13,720,000)
Interest payment	(20,167,101)
Exchange differences and currency translation differences	(33,571,695)
As of June 30, 2019	106,383,341
Borrowings
Changes in liabilities arising from financing activities
As of June 30, 2018	91,017,133
Proceeds from borrowings	88,693,632
Decrease bank overdraft and other short-term borrowings	(4,968,813)
Payments	(83,777,814)
Interest payment	(20,167,101)
Exchange differences and currency translation differences	(32,759,693)
As of June 30, 2019	103,556,730
Financed payment - Acquisition of business
Changes in liabilities arising from financing activities
As of June 30, 2018	22,874,609
Payments	(7,140,000)
Capitalization of financial debt	(13,720,000)
Exchange differences and currency translation differences	(812,002)
As of June 30, 2019	$ 2,826,611

JOINT VENTURES - Equity Interes

JOINT VENTURES - Equity Interest in Joint Venture (Details)	Aug. 31, 2018	Jun. 30, 2019	Sep. 30, 2018	Jun. 28, 2018
Semya S.A.
JOINT VENTURES
Percentage of equity interest		50.00%
Synertech Industrias S.A.
JOINT VENTURES
Percentage of equity interest				50.00%
Indrasa Biotecnologia S.A.
JOINT VENTURES
Percentage of equity interest	52.50%		35.00%

JOINT VENTURES - Investment in

JOINT VENTURES - Investment in Joint Venture and affiliates (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
JOINT VENTURES
Investments in joint ventures and affiliates, Assets	$ 25,321,028	$ 19,072,055	$ 32,108,229
Investments in joint ventures and affiliates, Liabilities	1,970,903	2,012,298	1,527,286
Semya S.A.
JOINT VENTURES
Investments in joint ventures and affiliates, Assets	0	2,972,239	5,263,819
Synertech Industrias S.A.
JOINT VENTURES
Investments in joint ventures and affiliates, Assets	25,297,376	16,099,816	26,844,410
Indrasa Biotecnologia S.A.
JOINT VENTURES
Investments in joint ventures and affiliates, Assets	23,652		0
Trigall Genetics S.A.
JOINT VENTURES
Investments in joint ventures and affiliates, Liabilities	$ 1,970,903	$ 2,012,298	$ 1,527,286

JOINT VENTURES - Changes in joi

JOINT VENTURES - Changes in joint ventures investments and affiliates (Details) - USD ($)		6 Months Ended	12 Months Ended
		Jun. 30, 2017	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2016
JOINT VENTURES
As of the beginning of the year		$ 31,306,503	$ 17,059,757	$ 30,580,943	$ (1,188,483)
Adjustment of opening net book amount for the application of IAS 29			8,328,794
Monetary contributions			129,340
Non-monetary contributions		1,150,259	94,355	679,510
Parent company investment		82,872	294,041	121,479	162,012
Loss of control of Indrasa Biotecnolog?a S.A.			10,591
Acquisition of control of Semya S.A.			(3,684,585)
Revaluation of property, plant and equipment	[1]	189,025	94,009	1,679,818
Foreign currency translation		(1,498,641)	11,337	(13,865,192)	(277,603)
Share of profit or loss		(649,075)	1,012,486	(2,136,801)	(707,042)
As of the end of the year		30,580,943	23,350,125	17,059,757	31,306,503
Synertech Industrias S.A.
JOINT VENTURES
Business combinations					29,000,000
Share of profit or loss		(596,854)	1,034,818	(1,474,438)	(155,316)
Semya S.A.
JOINT VENTURES
Business combinations					4,317,619
Share of profit or loss		$ (14,140)	$ (22,895)	$ (55,872)	$ (6,120)
[1]	The tax effect of the revalution of property, plant and equipment of JV and associates was $31,336, $559,939, $66,158 and nil for the years ended June 30, 2019 and 2018, the six-month transition period ended June 30,2017 and the year ended December 31, 2016 respectively.

JOINT VENTURES - Share of profi

JOINT VENTURES - Share of profit or loss of joint ventures and affiliates (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2016
JOINT VENTURES
Share of profit or loss of joint ventures and affiliates	$ (649,075)	$ 1,012,486	$ (2,136,801)	$ (707,042)
Trigall Genetics S.A.
JOINT VENTURES
Share of profit or loss of joint ventures and affiliates	(38,081)	(2,647)	(606,491)	(545,606)
Semya S.A.
JOINT VENTURES
Share of profit or loss of joint ventures and affiliates	(14,140)	(22,895)	(55,872)	(6,120)
Synertech Industrias S.A.
JOINT VENTURES
Share of profit or loss of joint ventures and affiliates	(596,854)	1,034,818	(1,474,438)	(155,316)
Indrasa Biotecnologia S.A.
JOINT VENTURES
Share of profit or loss of joint ventures and affiliates	$ 0	$ 3,210	$ 0	$ 0

JOINT VENTURES - Summarized bal

JOINT VENTURES - Summarized balance sheet (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2016
Summarised balance sheet
Cash and cash equivalents	$ 3,450,873	$ 2,215,103	$ 1,679,478
Total current assets	98,208,964	85,342,852	87,767,823
Intangible assets	39,616,426	26,657,345	42,058,891	$ 42,368,326
Property, plant and equipment	43,834,548	40,177,146	46,218,875	$ 46,393,761
Total non-current assets	144,258,333	111,295,912	152,103,228
Total current liabilities	116,458,133	118,680,626	69,387,409
Total non-current liabilities	63,914,298	44,824,482	93,244,576
Trigall Genetics S.A.
Summarised balance sheet
Cash and cash equivalents	13,114	44,937	9,758
Other current assets	323,264	66,077	62,137
Total current assets	336,379	111,014	71,895
Intangible assets	10,214,575	8,681,400	6,819,534
Other non- current assets	0		0
Total non-current assets	10,214,575	8,681,400	6,819,534
Financial liabilities	9,476,272	7,878,036	6,378,988
Other current liabilities	1,016,083	1,030,016	607,565
Total current liabilities	10,492,355	8,908,051	6,986,553
Other non- current liabilities	460,268	295,575	121,656
Total non-current liabilities	460,268	295,575	121,656
Net assets	(401,669)	(411,212)	(216,780)
Semya S.A.
Summarised balance sheet
Cash and cash equivalents	489	183	76
Other current assets	77,074	14	0
Total current assets	77,563	197	76
Intangible assets	583,936	217,809	0
Other non- current assets	362,181	448,942	992,143
Total non-current assets	946,117	666,751	992,143
Financial liabilities	127,074	448,309	220,989
Other current liabilities	898,623	275,341	440,435
Total current liabilities	1,025,697	723,650	661,424
Other non- current liabilities	42,323		0
Total non-current liabilities	42,323		0
Net assets	(44,340)	(56,701)	330,795
Synertech Industrias S.A.
Summarised balance sheet
Cash and cash equivalents	40,634	39,133	85,654
Other current assets	5,709,650	7,182,862	5,878,527
Total current assets	5,750,284	7,221,995	5,964,181
Property, plant and equipment	15,046,903	8,344,900	15,480,289
Other non- current assets		1,328,521	1,449,117
Total non-current assets	15,046,903	9,673,421	16,929,406
Financial liabilities	921,703	705,856	1,428,481
Other current liabilities	4,595,906	6,750,220	5,158,724
Total current liabilities	5,517,609	7,456,076	6,587,205
Financial liabilities		1,080,247	2,898,798
Other non- current liabilities	3,974,975	4,801,887	5,378,862
Total non-current liabilities	3,974,975	5,882,134	8,277,660
Net assets	11,304,603	3,557,206	8,028,722
Indrasa Biotecnologia S.A.
Summarised balance sheet
Cash and cash equivalents	16,296	28,180	33,986
Other current assets	93,654	45,837	83,400
Total current assets	109,950	74,017	117,386
Property, plant and equipment	18,387	15,243	28,956
Other non- current assets			3,069
Total non-current assets	18,387	15,243	32,025
Financial liabilities			172
Other current liabilities	60,760	42,166	80,435
Total current liabilities	60,760	42,166	80,607
Net assets	$ 67,577	$ 47,094	$ 68,805

JOINT VENTURES - Summarized sta

JOINT VENTURES - Summarized statements of comprehensive income (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2016
Summarised statements of comprehensive income
Revenue	$ 46,853,369	$ 160,308,979	$ 133,491,118	$ 41,027,474
Profit (loss) of the year	(8,378,549)	(16,358,891)	(14,311,246)	(6,181,889)
Other comprehensive income	(2,714,241)	3,904,365	(31,833,554)	(4,579,700)
Total comprehensive income (loss)	11,092,790	12,454,526	46,144,800	$ 10,761,589
Trigall Genetics S.A.
Summarised statements of comprehensive income
Revenue	21,041	367,646	104,037
Interest income	0	54,003	14,053
Interest expenses	(31,444)	(16,145)	(12,213)
Profit (loss) of the year	(12,986)	(33,195)	(194,432)
Other comprehensive income	0	0
Total comprehensive income (loss)	(12,986)	(33,195)	(194,432)
Semya S.A.
Summarised statements of comprehensive income
Revenue	0	0
Interest income	41,865	29,275
Interest expenses	(75,682)	(5,661)	(209,966)
Profit (loss) of the year	(58,356)	(218,627)	(354,151)
Other comprehensive income	163	0	(37,036)
Total comprehensive income (loss)	(58,193)	(218,627)	(391,187)
Synertech Industrias S.A.
Summarised statements of comprehensive income
Revenue	1,315,857	18,305,953	6,611,384
Interest income	726,519	2,434,610	1,758,129
Interest expenses	(2,331,246)	(6,193,963)	(5,831,182)
Depreciation and amortisation expense	(1,714,354)	(1,074,552)	(653,766)
Profit (loss) of the year	(1,822,573)	2,278,859	(1,991,754)
Other comprehensive income		334,403
Total comprehensive income (loss)	(1,822,573)	2,613,262	(1,991,754)
Indrasa Biotecnologia S.A.
Summarised statements of comprehensive income
Revenue	355,499	452,555	232,290
Interest income	315	1,813	756
Interest expenses		(3,001)	(2,516)
Depreciation and amortisation expense		(3,653)
Profit (loss) of the year	53,468	6,548	7,483
Total comprehensive income (loss)	$ 53,468	$ 6,548	$ 7,483

JOINT VENTURES - Additional Inf

JOINT VENTURES - Additional Information (Details) - USD ($) $ in Millions	Aug. 31, 2018	Jun. 30, 2019	Sep. 30, 2018	Jun. 28, 2018	Jun. 30, 2019	Jun. 30, 2018
Trigall Genetics S.A.
JOINT VENTURES
Percentage of profit					5.00%
Maximum percentage of capital					20.00%
Semya S.A.
JOINT VENTURES
Percentage of equity interest		50.00%
Synertech Industrias S.A.
JOINT VENTURES
Percentage of profit						5.00%
Maximum percentage of capital						20.00%
Percentage of equity interest				50.00%
Minimum investment construction and start-up of the new plant		$ 30			$ 30
Indrasa Biotecnologia S.A.
JOINT VENTURES
Percentage of equity interest	52.50%		35.00%

SEGMENT INFORMATION - Number of

SEGMENT INFORMATION - Number of segments (Details)	Jun. 30, 2019USD ($)
SEGMENT INFORMATION
Number of main operating segments	3
Number of complementary components	3

SEGMENT INFORMATION - Group's r

SEGMENT INFORMATION - Group's reporting segments (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2016
Revenues
Sale of goods and services	$ 46,853,369	$ 160,308,979	$ 133,491,118	$ 41,027,474
Royalties	102,178	1,110,463	442,689	349,760
Initial recognition and changes in the fair value of biological assets		279,945
Grants	31,941	16,372	51,586	141,775
Total revenue		160,605,296	133,542,704	41,169,249
Cost of sales	29,613,158	86,964,881	77,094,551	30,598,956
Gross margin per segment		$ 73,640,415	$ 56,448,153	$ 10,570,293
Gross margin and total revenue (as a percent)		46.00%	42.00%	26.00%
Seed and integrated products
Revenues
Sale of goods and services	9,021,171	$ 25,295,755	$ 26,751,121	$ 14,306,661
Royalties		1,110,463	442,689	349,760
Grants		16,372	51,586	141,775
Total revenue		25,312,127	26,802,707	14,448,436
Cost of sales		9,783,737	13,413,758	8,953,929
Gross margin per segment		$ 15,528,390	$ 13,388,949	$ 5,494,507
Gross margin and total revenue (as a percent)		61.00%	50.00%	38.00%
Crop protection
Revenues
Sale of goods and services	31,191,970	$ 89,919,460	$ 77,655,672	$ 21,493,419
Initial recognition and changes in the fair value of biological assets		279,945
Total revenue		90,199,405	77,655,672	21,493,419
Cost of sales		53,979,391	49,453,167	16,825,572
Gross margin per segment		$ 36,220,014	$ 28,202,505	$ 4,667,847
Gross margin and total revenue (as a percent)		40.00%	36.00%	22.00%
Crop nutrition
Revenues
Sale of goods and services	6,640,228	$ 45,093,764	$ 29,084,325	$ 5,227,394
Total revenue		45,093,764	29,084,325	5,227,394
Cost of sales		23,201,753	14,227,626	4,819,455
Gross margin per segment		$ 21,892,011	$ 14,856,699	$ 407,939
Gross margin and total revenue (as a percent)		49.00%	51.00%	8.00%
Sale of goods and services
Revenues
Sale of goods and services	$ 46,751,191	$ 159,198,516	$ 133,048,429	$ 40,677,714
Sale of goods and services | Seed and integrated products
Revenues
Sale of goods and services		24,185,292	26,308,432	13,956,901
Sale of goods and services | Crop protection
Revenues
Sale of goods and services		89,919,460	77,655,672	21,493,419
Sale of goods and services | Crop nutrition
Revenues
Sale of goods and services		$ 45,093,764	$ 29,084,325	$ 5,227,394

SEGMENT INFORMATION - Income by

SEGMENT INFORMATION - Income by similar group of products or services (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2016
SEGMENT INFORMATION
Revenue	$ 46,853,369	$ 160,308,979	$ 133,491,118	$ 41,027,474
Seed and integrated products
SEGMENT INFORMATION
Revenue	9,021,171	25,295,755	26,751,121	14,306,661
Crop protection
SEGMENT INFORMATION
Revenue	31,191,970	89,919,460	77,655,672	21,493,419
Crop nutrition
SEGMENT INFORMATION
Revenue	6,640,228	45,093,764	29,084,325	5,227,394
Seeds, royalties & licenses | Seed and integrated products
SEGMENT INFORMATION
Revenue	2,394,927	3,846,991	3,771,579	4,287,978
Packs | Seed and integrated products
SEGMENT INFORMATION
Revenue	6,626,244	21,448,764	22,979,542	10,018,683
Adjuvants | Crop protection
SEGMENT INFORMATION
Revenue	15,008,963	41,854,730	39,931,915	12,526,504
Insecticides & fungicides | Crop protection
SEGMENT INFORMATION
Revenue	9,914,886	12,655,985	14,087,260	2,059,936
Other | Crop protection
SEGMENT INFORMATION
Revenue	6,268,121	35,408,745	23,636,497	6,906,979
Inoculants | Crop nutrition
SEGMENT INFORMATION
Revenue	4,245,712	18,644,673	14,352,761	2,098,826
Fertilizers | Crop nutrition
SEGMENT INFORMATION
Revenue	$ 2,394,516	$ 26,449,091	$ 14,731,564	$ 3,128,568

SEGMENT INFORMATION - Geographi

SEGMENT INFORMATION - Geographical information (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2016
SEGMENT INFORMATION
Revenue	$ 46,853,369	$ 160,308,979	$ 133,491,118	$ 41,027,474
Total non-current assets	113,357,090	113,255,689	81,272,518	115,013,046
Argentina
SEGMENT INFORMATION
Revenue	41,292,402	124,011,642	106,077,922	37,815,878
Total non-current assets	111,743,378	106,056,232	77,860,852	113,739,634
Austria
SEGMENT INFORMATION
Revenue	8,400	899,045	470,849	319,237
Bolivia
SEGMENT INFORMATION
Revenue		2,494,216	2,090,758	300,084
Total non-current assets	22,876	27,487	39,857	25,325
Brazil
SEGMENT INFORMATION
Revenue	275,545	17,338,608	9,450,496	862,155
Total non-current assets	347,649	305,477	340,144	188,627
CHINA
SEGMENT INFORMATION
Revenue	193,911
Libano
SEGMENT INFORMATION
Revenue	262,428		376,862
Revenue		(115,927)
United States of America
SEGMENT INFORMATION
Revenue	380,310	2,562,376	1,395,438	16,737
Total non-current assets	631,063	6,136,461	2,411,673	495,187
Italia
SEGMENT INFORMATION
Revenue		132,206	10,879	80,512
Paraguay
SEGMENT INFORMATION
Revenue	1,052,088	2,506,348	5,584,861	590,176
Total non-current assets	589,418	722,914	605,491	538,831
United Kingdom
SEGMENT INFORMATION
Revenue	129,297	137,044	387,859	220,640
South Africa
SEGMENT INFORMATION
Revenue	1,931,908	3,019,474	3,711,852	8,369
Total non-current assets	22,706	7,080	14,423	25,442
France
SEGMENT INFORMATION
Revenue		711,522	270,878
Canada
SEGMENT INFORMATION
Revenue			3,553
Ukraine
SEGMENT INFORMATION
Revenue	822,976	611,993	344,401	145,433
Uruguay
SEGMENT INFORMATION
Revenue	447,248	4,684,854	3,197,974	667,237
India
SEGMENT INFORMATION
Total non-current assets		38	78
Rest of the world
SEGMENT INFORMATION
Revenue	$ 56,856	$ 1,315,578	$ 116,536	$ 1,016

FINANCIAL INSTRUMENTS - RISK _3

FINANCIAL INSTRUMENTS - RISK MANAGEMENT - Financial assets by category (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Amortized cost
Financial assets by category
Financial assets.	$ 68,957,670	$ 67,627,329	$ 53,809,169
Fair value
Financial assets by category
Financial assets.	356,233	12,526	4,275
Cash and cash equivalents | Amortized cost
Financial assets by category
Financial assets.	3,450,873	2,215,103	1,679,478
Other financial assets | Amortized cost
Financial assets by category
Financial assets.	4,703,688	4,781,679	5,027,516
Other financial assets | Fair value
Financial assets by category
Financial assets.	356,233	12,526	4,275
Trade receivables | Amortized cost
Financial assets by category
Financial assets.	59,236,377	52,888,427	41,675,918
Other receivables | Amortized cost
Financial assets by category
Financial assets.	$ 1,566,732	$ 7,742,120	$ 5,426,257

FINANCIAL INSTRUMENTS - RISK _4

FINANCIAL INSTRUMENTS - RISK MANAGEMENT - Financial liabilities by category (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Financial liabilities by category
Financial liabilities		$ 146,012,285
Amortized cost
Financial liabilities by category
Financial liabilities	$ 152,319,053		$ 130,232,069
Fair value
Financial liabilities by category
Financial liabilities	2,861,511		2,500,000
Trade Payables and other payables
Financial liabilities by category
Financial liabilities		27,708,830
Trade Payables and other payables | Amortized cost
Financial liabilities by category
Financial liabilities	40,578,494		22,794,716
Borrowings
Financial liabilities by category
Financial liabilities		91,017,133
Borrowings | Amortized cost
Financial liabilities by category
Financial liabilities	103,556,730		74,990,135
Employee benefits and social security
Financial liabilities by category
Financial liabilities		4,411,713
Employee benefits and social security | Amortized cost
Financial liabilities by category
Financial liabilities	5,357,218		5,047,045
Financed payment - Acquisition of business
Financial liabilities by category
Financial liabilities		$ 22,874,609
Financed payment - Acquisition of business | Amortized cost
Financial liabilities by category
Financial liabilities	2,826,611		27,400,173
Private warrants | Fair value
Financial liabilities by category
Financial liabilities	$ 2,861,511
Puttable instruments | Fair value
Financial liabilities by category
Financial liabilities			$ 2,500,000

FINANCIAL INSTRUMENTS - RISK _5

FINANCIAL INSTRUMENTS - RISK MANAGEMENT - Fair value by hierarchy (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Private warrants | Level 3
Fair value by hierarchy
Financial liabilities, at fair value	$ 2,861,511
Puttable instruments | Level 2
Fair value by hierarchy
Financial liabilities, at fair value			$ 2,500,000
Other financial assets | Level 1
Fair value by hierarchy
Financial assets, at fair value	$ 356,233	$ 12,526	$ 4,275

FINANCIAL INSTRUMENTS - RISK _6

FINANCIAL INSTRUMENTS - RISK MANAGEMENT - Changes in financial liabilities values at fair value level 3 (Details) - Level 3 - Private warrants	12 Months Ended
	Jun. 30, 2019USD ($)
Fair value
Warrants issued in business combination	$ 3,432,723
Changes in finance results	(571,212)
As of the end of the year	$ 2,861,511

FINANCIAL INSTRUMENTS - RISK _7

FINANCIAL INSTRUMENTS - RISK MANAGEMENT - Estimation of fair value (Details) - Fair value - Private warrants - Simulation method	12 Months Ended
	Jun. 30, 2019USD ($)
Fair value
Assumed increase in volatility (as a percent)	5.00%
Assumed decrease in volatility (as a percent)	5.00%
Increase in liability if volatility were 37%	$ 1,500,000
Decrease in liability if volatility were 27%	$ 1,200,000
Volatility | Minimum
Fair value
Assumed volatility (as a percent)	27
Volatility | Maximum
Fair value
Assumed volatility (as a percent)	37

FINANCIAL INSTRUMENTS - RISK _8

FINANCIAL INSTRUMENTS - RISK MANAGEMENT - Credit risk (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Loss allowance	$ 3,360,224	$ 3,212,170	$ 2,873,688
Trade and other receivables
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Financial assets.	34,328,915
Loss allowance	$ 3,435,820
Trade and other receivables | Current
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Expected loss rate	0.27%
Financial assets.	$ 19,253,504
Loss allowance	$ 52,913
Trade and other receivables | More Than 15 Days Past Due
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Expected loss rate	0.32%
Financial assets.	$ 8,221,475
Loss allowance	$ 26,104
Trade and other receivables | More Than 60 Days Past Due
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Expected loss rate	0.32%
Financial assets.	$ 1,762,134
Loss allowance	$ 5,595
Trade and other receivables | More Than 120 Days Past Due
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Expected loss rate	0.32%
Financial assets.	$ 974,658
Loss allowance	$ 3,095
Trade and other receivables | More Than 180 Days Past Due
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Expected loss rate	0.32%
Financial assets.	$ 771,480
Loss allowance	$ 2,449
Trade and other receivables | More Than 365 Days Past Due
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Expected loss rate	100.00%
Financial assets.	$ 3,345,664
Loss allowance	$ 3,345,664
Credit risk
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Customer portfolio insurance coverage (as a percent)	50.00%

FINANCIAL INSTRUMENTS - RISK _9

FINANCIAL INSTRUMENTS - RISK MANAGEMENT - Liquidity risk (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Financial liabilities		$ 146,012,285
Up to 3 months
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Financial liabilities	$ 41,905,850
3 to 12 months
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Financial liabilities	72,022,373
Between one and three years
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Financial liabilities	39,000,866
Trade Payables and other payables
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Financial liabilities		27,708,830
Trade Payables and other payables | Up to 3 months
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Financial liabilities	12,854,579
Trade Payables and other payables | 3 to 12 months
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Financial liabilities	28,987,009
Trade Payables and other payables | Between one and three years
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Financial liabilities	476,482
Borrowings
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Financial liabilities		91,017,133
Borrowings | Up to 3 months
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Financial liabilities	29,051,271
Borrowings | 3 to 12 months
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Financial liabilities	40,097,864
Borrowings | Between one and three years
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Financial liabilities	38,524,384
Financed payment - Acquisition of business
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Financial liabilities		22,874,609
Financed payment - Acquisition of business | 3 to 12 months
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Financial liabilities	$ 2,937,500
Liquidity risk | Up to 3 months
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Financial liabilities		57,217,414	$ 30,992,822
Liquidity risk | 3 to 12 months
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Financial liabilities		57,326,727	35,024,243
Liquidity risk | Between one and three years
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Financial liabilities		30,127,555	66,269,185
Liquidity risk | Trade Payables and other payables | Up to 3 months
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Financial liabilities		27,352,381	16,411,513
Liquidity risk | Trade Payables and other payables | 3 to 12 months
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Financial liabilities		356,449	6,385,733
Liquidity risk | Trade Payables and other payables | Between one and three years
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Financial liabilities			151
Liquidity risk | Borrowings | Up to 3 months
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Financial liabilities		26,927,533	14,581,309
Liquidity risk | Borrowings | 3 to 12 months
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Financial liabilities		39,047,778	22,418,530
Liquidity risk | Borrowings | Between one and three years
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Financial liabilities		27,190,055	45,088,841
Liquidity risk | Financed payment - Acquisition of business | Up to 3 months
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Financial liabilities		2,937,500
Liquidity risk | Financed payment - Acquisition of business | 3 to 12 months
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Financial liabilities		17,922,500	6,219,980
Liquidity risk | Financed payment - Acquisition of business | Between one and three years
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Financial liabilities		$ 2,937,500	$ 21,180,193

FINANCIAL INSTRUMENTS - RISK_10

FINANCIAL INSTRUMENTS - RISK MANAGEMENT - Currency risk (Details) - Currency Risk - Amount expressed in USD - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
FINANCIAL INSTRUMENTS - RISK MANAGEMENT
Risk exposure associated with instruments sharing characteristic	$ (40,513,954)	$ (28,861,129)	$ (17,917,954)
Estimate of devaluation of Argentine peso (as a percent)	20.00%
Result in pre-tax loss	$ 8,300,000
Estimate of appreciation of Argentine peso	20.00%
Result in pre-tax gain	$ 8,300,000

FINANCIAL INSTRUMENTS - RISK_11

FINANCIAL INSTRUMENTS - RISK MANAGEMENT - Interest rate risk (Details) - Interest Rate Risk - USD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Debt composition
Percentage point increase in interest point	1.00%
Maximum
Debt composition
Increase in interest payable	$ 100,000
Fixed-rate instruments
Debt composition
Current financial liabilities	(69,126,607)	$ (82,888,890)	$ (33,480,167)
Non-current financial liabilities	(37,006,581)	(27,168,905)	(61,456,073)
Variable-rate instruments
Debt composition
Current financial liabilities	(177,213)	(2,643,628)	(6,777,784)
Non-current financial liabilities	$ (72,940)	$ (1,190,319)	$ (676,284)

FINANCIAL INSTRUMENTS - RISK_12

FINANCIAL INSTRUMENTS - RISK MANAGEMENT - Market risk (Details) - Fair value - Private warrants - Simulation method	12 Months Ended
	Jun. 30, 2019USD ($)$ / shares
Fair value
Financial liabilities, at fair value	$ 2,800,000
Gain recognized from change in fair value	$ 600,000
Assumed increase in volatility (as a percent)	5.00%
Assumed decrease in volatility (as a percent)	5.00%
Increase in liability if volatility were 37%	$ 1,500,000
Decrease in liability if volatility were 27%	$ 1,200,000
Share price
Fair value
Assumption used in estimating fair value | $ / shares	5.30
Risk-free rate
Fair value
Assumption used in estimating fair value	1.7631
Volatility | Minimum
Fair value
Assumption used in estimating fair value	27
Volatility | Maximum
Fair value
Assumption used in estimating fair value	37

LEASES - Payables (Details)

LEASES - Payables (Details)	Jun. 30, 2019USD ($)contract	Jun. 30, 2018USD ($)	Jun. 30, 2017USD ($)
LEASES
Leases payable	$ 848,817	$ 734,292	$ 1,145,682
HP Financial Services
LEASES
Number of leasing contracts | contract	7
Leases payable	$ 605,024
Banco Macro
LEASES
Number of leasing contracts | contract	10
Leases payable	$ 86,460
Banco Supervielle
LEASES
Number of leasing contracts | contract	4
Leases payable	$ 116,126
Banco Galicia
LEASES
Number of leasing contracts | contract	1
Leases payable	$ 41,208

LEASES - Minimum payments of fi

LEASES - Minimum payments of finance leases (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
LEASES
Minimum finance lease payments payable	$ 935,087	$ 997,511	$ 1,662,501
Future finance charge on finance lease	(86,270)	(263,219)	(516,819)
Minimum finance lease payments payable, at present value	848,817	734,292	1,145,682
Less than 1 year
LEASES
Minimum finance lease payments payable	444,999	418,933	701,025
1 year- 5 years
LEASES
Minimum finance lease payments payable	$ 490,088	$ 578,578	$ 961,476

LEASES - Operating leases (Deta

LEASES - Operating leases (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
LEASES
Minimum payments	$ 848,817	$ 734,292	$ 1,145,682
Less than 1 year
LEASES
Minimum payments	385,947	280,038	466,689
1 year- 5 years
LEASES
Minimum payments	$ 462,870	$ 454,254	$ 678,993

SHAREHOLDERS AND OTHER RELATE_3

SHAREHOLDERS AND OTHER RELATED PARTIES BALANCES AND TRANSACTIONS - Transactions (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2016
Trade and other payable
Interest gain	$ 179,887	$ 90,188	$ 294,577	$ 73,178
In-kind contributions		463,511
Total	(47,808)	(39,459,482)	(11,844,257)	33,779,935
Joint ventures
Trade and other payable
Sales of goods and services		4,913,254	746,867	0
Purchases of goods and services	922,286	17,542,637	9,809,134	0
Equity contributions	1,233,131	(241,840)	800,989	162,012
Business combination		0	0	33,317,619
Net loans granted / (cancelled)	2,428,076	(6,964,101)	2,621,647	1,781,389
Key management personnel
Trade and other payable
Salaries, social security benefits and other benefits	2,238,908	3,940,185	4,703,519	649,410
Loans granted		599,984	0	0
Interest gain		20,106	0	0
Shareholders and other related parties
Trade and other payable
Sales of goods and services	781,830	640,095	1,057,325	1,761,128
Purchases of goods and services	875,257	1,433,127	986,217	1,414,998
Interest gain	179,887	90,188	294,577	73,178
Dividends	(52,249)	0	(1,450,613)	0
In-kind contributions		463,511	0	0
Parent company
Trade and other payable
Sales of goods and services	1,427	0	13,505	2,993
Purchases of goods and services	62,500	120,095	311,418	135,297
Equity contributions		(14,558,347)	0	0
Interest lost	$ (520,959)	$ (1,386,288)	$ (118,266)	$ (1,118,679)

SHAREHOLDERS AND OTHER RELATE_4

SHAREHOLDERS AND OTHER RELATED PARTIES BALANCES AND TRANSACTIONS - Receivable (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Trade and other payable
Other receivables	$ 1,981,829	$ 4,240,205	$ 7,108,219
Parent company
Trade and other payable
Trade receivables	440,268	361,606
Other receivables		103,251
Shareholders and other related parties
Trade and other payable
Trade receivables	467,743	571,216	1,025,903
Other receivables	10,971	119,677	67,753
Allowance for impairment	(75,596)	(23,126)	(205,960)
Joint ventures
Trade and other payable
Trade receivables	2,369	209,039	217,963
Other receivables	250,783	6,299,467	4,298,109
Amounts receivable from related parties	$ 1,096,538	$ 7,641,130	$ 5,403,768

SHAREHOLDERS AND OTHER RELATE_5

SHAREHOLDERS AND OTHER RELATED PARTIES BALANCES AND TRANSACTIONS - Payables (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2019	Jun. 30, 2018
Trade and other payable
Borrowings	$ (34,037,971)	$ (66,477,209)	$ (65,308,928)
Amounts payable to related parties	(4,762,843)	(28,815,881)	(7,231,226)
Parent company
Trade and other payable
Trade payables	(218,744)	(1,568,036)
Borrowings		(575,604)
Parents companies and related parties to Parents
Trade and other payable
Loans payables	(646,538)	(17,757,907)	(1,816,084)
Key management personnel
Trade and other payable
Salaries, social security benefits and other benefits	(1,614,494)	(2,312,253)	(1,556,035)
Shareholders and other related parties
Trade and other payable
Trade payables	(633,700)	(1,796,932)	(365,994)
Joint ventures
Trade and other payable
Trade payables	$ (1,649,367)	$ (4,805,149)	$ (3,493,113)

KEY MANAGEMENT PERSONNEL COMP_3

KEY MANAGEMENT PERSONNEL COMPENSATION - Summary of compensation of directors and other members (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2016
KEY MANAGEMENT PERSONNEL COMPENSATION
Salaries, social security and other benefits	$ 2,238,908	$ 3,940,185	$ 4,703,519	$ 649,410
Total	$ 2,238,908	$ 3,940,185	$ 4,703,519	$ 649,410

SHARE-BASED PAYMENTS (Details)

SHARE-BASED PAYMENTS (Details) - shares	Jun. 30, 2019	Dec. 17, 2014
Options incentive Plan
SHARE-BASED PAYMENTS
Approved ordinary shares		1,264,000
Number of awards granted to date	808,960
Shares available for future awards	455,040
Plan of incentives through shares
SHARE-BASED PAYMENTS
Approved ordinary shares		1,264,000
Number of awards granted to date	902,487
Shares available for future awards	361,513
Number of shares assigned individually	551,148

SHARE-BASED PAYMENTS - Options

SHARE-BASED PAYMENTS - Options (Details) - Options incentive Plan	Apr. 27, 2017shares	Dec. 16, 2015USD ($)	Dec. 17, 2014	Jun. 30, 2019USD ($)	Jun. 30, 2018USD ($)	Jun. 30, 2017USD ($)	Dec. 31, 2016USD ($)
SHARE-BASED PAYMENTS
Number of options, granted during the year/period		31,600
Exercise price of the stock options		$ 7.91		$ 15.85
Vesting period		2 years
Percentage to finance in respect of exercise price		100.00%
Option Split	0.01		0.02
Increase in shares of nominal value | shares	24,000,000
Weighted average exercise price (per share)				$ 15.85	$ 15.85	$ 15.85	$ 15.85

SHARE-BASED PAYMENTS - Fair val

SHARE-BASED PAYMENTS - Fair value of share options (Details) - Options incentive Plan	Dec. 16, 2015USD ($)	Jun. 30, 2019USD ($)Y	Jun. 30, 2018USD ($)	Jun. 30, 2017USD ($)	Dec. 31, 2016USD ($)
SHARE-BASED PAYMENTS
Weighted average fair value at measurement date (per option)		$ 4.09
Value of the share (per share)	$ 7.91	$ 15.85
Expected dividend rate		0.00%
Expected volatility		47.92%
Risk-free interest rate		105.00%
Weighted average expected life of stock options | Y		2
Weighted average exercise price (per share)		$ 15.85	$ 15.85	$ 15.85	$ 15.85

SHARE-BASED PAYMENTS - Option a

SHARE-BASED PAYMENTS - Option activity (Details) - Options incentive Plan - USD ($)	Dec. 16, 2015	Jun. 30, 2017	Jun. 30, 2019	Jun. 30, 2018
SHARE-BASED PAYMENTS
Number of options, at the beginning		31,600	31,600	31,600
Number of options, granted during the year/period	31,600
Number of options, annulled during the year/period		0	(31,600)	0
Number of options, effective at year/period end		31,600		31,600
Weighted average exercise price, at the beginning		$ 15.85	$ 15.85	$ 15.85
Weighted average exercise price, annulled during the year/period			(15.85)
Weighted average exercise price, effective at year/period end		$ 15.85	$ 15.85	$ 15.85

SHARE-BASED PAYMENTS - Incentiv

SHARE-BASED PAYMENTS - Incentive payments based on shares (Details)	Sep. 08, 2017EquityInstrumentsinstallmentshares
Plan of incentives through shares
SHARE-BASED PAYMENTS
Number of other equity instruments granted in share-based payment arrangement | EquityInstruments	225
Percentage of shares that would be delivered	100.00%
Shares allocated individually | shares	360,000
Plan Of Incentives Through Shares, Three To Four Year Plan
SHARE-BASED PAYMENTS
Minimum fulfillment of goals (as a percent)	70.00%
Maximum fulfillment of goals (as a percent)	100.00%
Period of duty of permanence	12 months
Plan Of Incentives Through Shares, Three Year Plan
SHARE-BASED PAYMENTS
Minimum fulfillment of goals (as a percent)	70.00%
Maximum fulfillment of goals (as a percent)	100.00%
Period of duty of permanence	4 years
Plan Of Incentives Through Shares, 360,000 Shares
SHARE-BASED PAYMENTS
Portion in installment (as a percent)	50.00%
Plan Of Incentives Through Shares, First Half Of 360,000 Shares
SHARE-BASED PAYMENTS
Number of installments | installment	3
Plan Of Incentives Through Shares, Second Half Of 360,000 Shares
SHARE-BASED PAYMENTS
Period of achievement of condition	3 years

CONTINGENCIES, COMMITMENTS AN_3

CONTINGENCIES, COMMITMENTS AND RESTRICTIONS ON THE DISTRIBUTION OF PROFITS - Summary of Pledged and restricted assets (Details)	Jun. 30, 2019USD ($)
Pledged and restricted assets
Pledged and restricted assets	$ 26,861,436
Other financial assets
Pledged and restricted assets
Pledged and restricted assets	4,327,275
Unicred S.A.
Pledged and restricted assets
Pledged and restricted assets	173,658
Macro
Pledged and restricted assets
Pledged and restricted assets	573,991
Santander Rio
Pledged and restricted assets
Pledged and restricted assets	3,093,478
Finares SA
Pledged and restricted assets
Pledged and restricted assets	176,440
Itau
Pledged and restricted assets
Pledged and restricted assets	1,594,459
Compass Latam & Odisea
Pledged and restricted assets
Pledged and restricted assets	16,037,769
IT equipment
Pledged and restricted assets
Pledged and restricted assets	77,760
Machinery and equipment
Pledged and restricted assets
Pledged and restricted assets	528,798
Machinery and equipment II
Pledged and restricted assets
Pledged and restricted assets	158,080
Vehicles
Pledged and restricted assets
Pledged and restricted assets	$ 119,728

CONTINGENCIES, COMMITMENTS AN_4

CONTINGENCIES, COMMITMENTS AND RESTRICTIONS ON THE DISTRIBUTION OF PROFITS - Additional (Details) - USD ($)	1 Months Ended
	Apr. 30, 2019	Jun. 30, 2019	Feb. 28, 2019	Jan. 31, 2019	Dec. 31, 2018	Nov. 30, 2018	Jul. 03, 2018
Unicred S.A.
Pledged and restricted assets
Amount of loan taken				$ 1,038,883	$ 1,038,883	$ 1,038,883
Macro
Pledged and restricted assets
Amount of loan taken		$ 500,000
Santander Rio
Pledged and restricted assets
Amount of loan taken					$ 3,500,000
Finares SA
Pledged and restricted assets
Amount of loan taken				$ 285,000
Itau
Pledged and restricted assets
Amount of loan taken			$ 2,500,000
Compass Latam & Odisea
Pledged and restricted assets
Amount of negotiable instruments issued	$ 16,000,000
Percentage of shares pledged	10.00%
Other financial assets
Pledged and restricted assets
Syndicated loan entered by Rizobacter		$ 45,000,000
Other financial assets | Banco Galicia
Pledged and restricted assets
Amount of Pledge granted in fixed term certificate							$ 4,298,101

EVENTS OCCURRING AFTER THE RE_2

EVENTS OCCURRING AFTER THE REPORTING PERIOD (Details) - Issuance of ordinarly shares to Rizobacter Management team - Bioceres SA	Aug. 07, 2019USD ($)installment
EVENTS OCCURRING AFTER THE REPORTING PERIOD
Cash paid to beneficiaries | $	$ 399,960
Percentage of cash transferred instantly	50.00%
Percentage of cash transferred in twelve installments	50.00%
Ordinary shares
EVENTS OCCURRING AFTER THE REPORTING PERIOD
Number of shares granted | $	36,000
First 50%
EVENTS OCCURRING AFTER THE REPORTING PERIOD
Number of installments | installment	12
Second 50%
EVENTS OCCURRING AFTER THE REPORTING PERIOD
Number of installments | installment	12
Vesting period	1 year